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 Characterization of Two Radical S-Adenosyl-L-methionine Enzymes in 
the Biosynthesis of Aminoglycosides 
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Supervisor: Hung-wen Liu 
 
Biosynthetic studies of natural products are essential to the discovery and 
development of new drugs, because by understanding biosynthetic pathways and the 
enzymes that characterize them, new pathways can be engineered for the production of 
new compounds with improved clinical properties. Aminoglycosides have traditionally 
been used as important antibiotics, but resistance against aminoglycosides is well known. 
This has resulted in a need to better understand the biosynthesis of aminoglycosides. 
Besides the practical value, the discovery of new enzymes with unprecedented functions 
in the biosynthesis of aminoglycosides can expand our knowledge and advance our 
understanding of enzyme catalysis.  
The work described in this dissertation focuses on the in vitro characterization of 
two radical S-adenosyl-L-methionine (SAM) enzymes in the biosynthesis of 
aminoglycosides. First, GenK is a cobalamin (Cbl)-dependent radical SAM enzyme that 
is responsible for catalyzing the methylation of gentamicin X2 to produce G418. In vitro 
assays of purified and reconstituted GenK from Micromonospora echinospora showed 
that this enzyme is a radical SAM enzyme with one [4Fe-4S] cluster. Assays of GenK 
 ix 
with SAM, gentamicin X2 and Cbl confirmed that the methylation reaction occurs at an 
unactivated carbon during gentamicin biosynthesis. Isotope labeling experiments strongly 
suggested that SAM is the preliminary methyl donor to cobalamin, followed by 
secondary transfer from Me-Cbl to gentamicin X2. It was demonstrated that GenK also 
accepts alternative aminoglycoside substrates besides gentamicin X2. Second, three 
possible mechanisms for the GenK reaction were suggested and tested. Experiments 
investigating the stoichiometry of the GenK reaction revealed 5'-deoxyadenosine (5'-
dAdo), S-adenoxylhomocysteine (SAH), and G418 were produced in equal proportion 
and one-to-one with each methylation reaction catalyzed by GenK. The experiment with 
labeled substrates indicated that the 6'-pro-R-hydrogen atom of gentamicin X2 is 
abstracted by 5'-dAdo• and that methylation occurs with retention of configuration at C6'. 
Several substrate derivatives were synthesized to investigate the manner of methyl 
transfer from cobalamin to the substrate. Finally, the in vitro characterization of AprD4 
and AprD3 in the biosynthesis of C3'-deoxyaminoglycoside was also conducted. Purified 
and reconstituted AprD4 from Streptomyces tenebrarius is a radical SAM enzyme, 
catalyzing homolysis of SAM to 5'-dAdo in the presence of paromamine to produce 4-
oxolividamine. AprD3 from the same strain is shown to be a dehydrogenase acting as the 
reductase counterpart to AprD4 to catalyze the reduction of 4-oxolividamine to generate 
lividamine. The experiments with labeled compounds confirmed the regiochemistry of 
hydrogen atom abstraction by 5'-dAdo• and the stereochemical course of C3'-
deoxygenation of paromamine.      
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 1 
Chapter 1:  Radical S-adenosyl-L-methionine (SAM) Enzymes in 
Aminoglycoside Biosynthesis 
1.1. AMINOGLYCOSIDE BIOSYNTHESIS 
1.1.1. Introduction 
 Aminoglycosides belong to a long-standing and important class of antibiotics.
1-2
 
Waksman reported the first aminoglycoside streptomycin from the soil bacteria, 
Streptomyces griseus, in 1943 and showed that it possesses antituberculosis activity.
 3
 
However, antibiotic resistance against aminoglycosides has been more common, and this 
has led investigators to search for new aminoglycosides. Consequently, several 
aminoglycosides like gentamicin,
4
 tobramycin,
5
 apramycin,
6
 lividomycin
7
 and others
8
 
were subsequently discovered and shown to be clinically useful in the treatment of 
infections by Gram-negative and selective Gram-positive bacterial, fungi, and 
Pseudomonas spp. Also semisynthetic derivatives like dibekacin,
9
 amikacin,
10
 
arbekacin,
11
 isepamicin,
12
 and netilmicin
13
 were introduced during the 1970s when 
modifications of aminoglycosides such as N-acetylation, O-phosphorylation, and O-
adenylation were recognized as resistance mechanisms that reduce the affinity of the 
drugs for rRNAs.
3
  
The mode of action of aminoglycoside antibiotics has been thoroughly studied.
3
 
Aminoglycosides contain several hydroxyl and amino groups that are important for the 
binding interactions with bacterial ribosomal RNAs. Such binary complex formation 
prevents translocation or proofreading during translation resulting in the death of the 
bacteria.
14
 In general, the amino groups of aminoglycosides are positively charged at 
 2 
neutral pH and thus interact favorably with the negatively charged phosphate backbone of 
RNAs. Also crystal structure analysis of rRNA complexes with aminoglycoside 
antibiotics showed the specific interactions that promote binding of aminoglycosides to 
RNAs.
15-16
 Although most aminoglycosides have different binding interactions, they all 
adversely affect translation. The details as to how their effects on translation lead to the 
bacterial death are not clear. One possibility is that aminoglycosides combine with 
ribosomal RNA leading to misread proteins.
17-18
 These abnormal proteins combine with 
the inner membrane and lead to destabilization. Another possibility is that 
aminoglycosides inhibit ribosomal activity.
19
 Another model proposes that binding with 
aminoglycosides perturbs metabolism and respiration of bacteria which results in 
oxidative stress due to the increased formation of highly toxic hydroxyl radicals and 
superoxide production.
20
   
 
1.1.2. Aminoglycoside Structure 
 The general structure of aminoglycosides consists of an aminocyclitol linked to at 
least one amino sugar. Aminoglycosides thus contain a number of free hydroxyl groups 
and at least two amino groups. Based on the structure of the aminocyclitol, the 
aminoglycosides can be divided into four different groups: a) myo-inositol-derived, b) 2-
deoxy-scyllo-inose-derived, c) 2-epi-5-epi-valiolone-derived, and d) cyclopentitol-
derived aminoglycosides (Figure 1-1). Figure 1-1 shows examples of theses 
aminoglycosides.
21
  
myo-Inositol-derived aminoglycosides include streptomycin, bluensomycin, 
spectinomycin, the fortimicins, and kasugamycin. These molecules play critical roles in 
many cellular processes and are involved in cell wall biogenesis, stress response, and 
signal transduction pathways.
22-24
 These aminoglycosides are derived from myo-inositol 
 3 
1-phosphate (MIP) which is biosynthesized from D-glucose 6-phosphate (G6P) by myo-
inositol-1-phosphate synthase found in both prokaryote and eukaryotes.
25
 MIP is 
converted into aminoinositols via a series of reactions catalyzed by phosphatases, 
dehydrogenases, and aminotransferases.  
2-Deoxy-scyllo-inose-derived aminoglycosides commonly contain 2-
deoxystreptamine (2-DOS) as a core scaffold and are decorated with several 
monosaccharides at the C4, C5 and C6 positions. These aminoglycosides include the 
kanamycins, neomycins, gentamicins, apramycin and butirosins. They are 
biosynthetically derived from paromamine. Clinically important aminoglycosides in this 
group are further subclassified according to the substitution pattern of DOS with 
aminosugars. Thus, neomycin and paromomycin are 4,5-disubstituted aminoglycosides, 
whereas gentamicin, kanamycin, and tobramycin are 4,6-disubstituted aminoglycosides. 
The details regarding the biosynthesis of 2-DOS containing aminoglycosides are 
described below.  
The third class of aminoglycosides is characterized by a C7N aminocyclitol core 
structure. These aminoglycosides include acarbose, the oligostatins, the trestatins, 
validamycin A, pyralomycin 1a, and cetoniacytone.
21
 Their chemical structures 
commonly contain an unsaturated aminocyclitol unit, valienamine, although some 
compounds contain modified forms of valienamine. The biosynthetic origin of 
valienamine in these aminoglycosides was established to be 2-epi-5-epi-valiolone by 
isotope-labeling experiments.
26-28
   
The final class of aminoglycosides is relatively rare in nature. These 
aminoglycosides include pactamycin,
29
 an antibiotic antitumor agent from Streptomyces 
pactum, and allosamidin, a chitinase inhibitor isolated from Streptomyces sp. No 1713.
30
 
These aminoglycosides contain a unique cyclopentitol moiety. Pactamicin consists of 
 4 
three cyclic units, the cyclopentitol, a 6-methylsalicyclic acid functionality, and an m-
aminoacetophenone moiety which are derived from different biosynthetic pathways. The 
cyclopentitol moiety is derived from glucose, while the other two are generated via 
polyketide synthase (PKS) chemistry and a pathway reminiscent of shikimate 
biosynthesis.
31
 Allosamidin has a distinctive structure consisting of a cyclopentitol 
moiety called allosamizoline and two monosaccharide units of N-acetyl-D-allosamine. 
Cyclopentitol moieties are also found in carbocyclic nucleotides like neplanocin A, 
aristeromycin, adecypenol, queuosine, and epoxyqueuosine, and bacterial derived 
hopanoids.
21
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Figure 1-1. Structures of selected aminoglycoside antibiotics 
 6 
1.1.3. Biosynthesis of Aminoglycosides 
 This section focuses on the biosynthesis of aminoglycosides and 2-DOS. 
Biosynthetic studies of other aminoglycosides are covered by several reviews.
8,21,32
 Many 
laboratories are involved to characterize the biosynthetic genes and enzymes for 
aminoglycoside biosynthesis and their biotechnological applications. As aminoglycoside 
biosynthetic genes are often reported with different names, the set of gene annotations 
use by Piepersberg
8
 and Eguchi
33 
will also be used consistently here. 
Early feeding experiments with radioisotope- and stable-isotope primary 
metabolites such as glucose and glucosamine showed that the majority of aminoglycoside 
components are derived from sugars.
34
 Mutant studies were also used to elucidate the 
structures of biosynthetic intermediates
35
 and to determine the order of the biosynthetic 
steps.
36
 However, the mechanisms of the enzymatic reactions and the timing of 
modifications in the biosynthesis of aminoglycosides were not fully elucidated until now.   
 The first genetic analysis of aminoglycoside biosynthesis was performed in 1987 
and only a portion of the complete gene cluster for streptomycin was identified.
37
 Several 
biosynthetic genes located both up- and downstream of the identified portion were 
discovered later using hybridization studies, and determining the nucleotide sequences.
38
 
Since then, analyses of more than 30 aminoglycoside biosynthetic gene clusters have 
been accomplished and deposited in the public gene data bank. The discovery of 2-
deoxy-scyllo-inose (2-DOS) synthases from the butirosin producing strain Bacillus 
circulans in 1999
39
 boosted the identification of additional 2-DOS-containing 
aminoglycoside biosynthetic gene clusters such as butirosin, neomycin, ribostamycin, 
paromamine, lividomycin, kanamycin, tobramycin, gentamicin, sisomycin, istamycin, 
apramycin and hygromycin B.  
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Comparison of the gene clusters has led to speculation that some conserved 
biosynthetic enzymes encoded in different aminoglycoside gene clusters are responsible 
for the biosynthesis of the common intermediates. There are also many cases of gene 
clusters encoding aminoglycosides that have mixed structures of other aminoglycosides, 
such as gentamicin gene cluster that shares modification patterns and subunits with 
kanamycin and fortimicin gene cluster. Under such situation, the information from 
biosynthetic gene cluster from one aminoglycoside predicts the modification of the 
intermediates step by step in the biosynthetic pathway of another aminoglycoside with 
similar gene cluster.  
 
1.1.3.1. Biosynthesis of 2-Deoxystreptamine (DOS) 
2-DOS, also known as 1,3-diamino-4,5,6-trihydroxycyclohexane, is found in the 
majority of aminoglycosides as a central moiety and plays a critical role in their 
biological function by interacting directly with the 16S ribosomal RNA subunit.
1,40-41
 The 
biosynthesis of 2-DOS has been investigated in detail.
42-44
 Early studies using 
13
C-labeled 
substrate in neomycin isolated from the culture of Streptomyces fradiae demonstrated 
that 2-DOS originates from D-glucose, with C-1 and C-2 carbons of 2-DOS 
corresponding respectively to the C-1 and C-6 carbons of glucose (Scheme 1-1).
45
 The  
nitrogen from glucosamine is not incorporated into 2-DOS.
34
 Experiments with 6,6-
dideuterated glucose in ribostamycin from Streptomyces ribosidificus demonstrated that 
both deuteriums at C-6 are retained in 2-DOS and rearrangement proceeded with 
retention of stereochemistry.
46-47
 Labeling experiments showed that the C-4 proton of 
glucose is lost during the biosynthesis of 2-DOS.
48-49
 The in vitro assay with cell-free 
extracts of S. fradiae demonstrated that the conversion of glucose-6-phsophate to 2-DOS 
is NAD
+
-dependent.
50-51
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Scheme 1-1. Biosynthesis of 2-DOS 
BtrC, 2-deoxy-scyllo-inosose (2-DOI) synthase, was purified from the butirosin-
producing bacterium Bacillus circulans, and shown to be dependent on both cobalt and 
NAD
+
.
52-54
 Enzymes homologous to BtrC have been identified in all 2-DOS-containing 
aminoglycoside biosynthetic pathways (Scheme 1-1).
55
 The mechanism of BtrC was 
proposed based on its X-ray crystal structure and compared to that of 5-dehydroquinate 
(DHQ) synthase, because they have moderately similar amino acid sequences (26–34%) 
(Scheme 1-2).
56
 The two enzymes have different conserved amino acids at positions 243 
and 239: asparagine and arginine in DHQ vs glutamate and glycine in 2-DOI synthase. 
Also 2-DOI synthase has an additional conserved glutamate residue at 235. In the DHQ 
synthase reaction (Scheme 1-2), oxidation at C4 occurs in the first step. Asn268 is not 
directly involved in the abstraction of a proton at C5, but the substrate phosphate group 
can abstract a proton to provide an α,β-unsaturated ketone intermediate.57 After reduction 
of the carbonyl group at C-4 and ring opening of the hemi acetal, the stereoselective 
intramolecular aldol condensation gives DHQ. The proposed mechanism of BtrC 
catalysis is similar to that of DHQ synthase. The difference between them is the acid-base 
chemistry during proton abstraction at C5 (the second step).
58
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Scheme 1-2. Proposed mechanisms of DHQ synthase and 2-DOI synthases. The amino 
acid position numbers derived from Aspergillus nidulans DHQ and BtrC from 2-DOI 
synthase are indicated. 
 
The conversion of 2-DOI to 2-deoxy-scyllo-inosamine (2-DOIA) is catalyzed by a 
PLP-dependent aminotransferase BtrS.
30
 This enzyme was also found to catalyze the 
conversion of 2-deoxy-3-keto-scyllo-inosamine (keto-2-DOIA) to 2-deoxystreptamine (2-
DOS), suggesting that this enzyme play a dual role. This phenomenon is also found in the 
biosynthesis of other aminoglycosides including neomycin, gentamicin, and kanamycin.
26
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The next step from 2-DOIA to keto-2-DOIA is catalyzed by the radical SAM enzyme 
BtrN (this enzyme is described in detail in Section 1.3.1).
29
 During 2-DOS biosynthesis, 
only the butirosin biosynthetic pathway involves a radical SAM enzyme for oxidation of 
hydroxyl group at C1. Other biosynthetic pathways involve the NADP
+
-dependent 
enzymes for this step.  
 
1.1.3.2. Biosynthesis of Paromamine 
Paromamine is the most common intermediate during biosynthesis of the 2-DOS-
based aminoglycosides besides neamine. The biosynthesis of paromamine consists of two 
steps: glycosylation of 2-DOS with N-acetylglucosamine (GlcNAc) and deacetylation 
(Scheme 1-3). BtrM identified in the butirosin biosynthetic gene cluster and its 
homologues, NeoD in neomycin biosynthesis, GenM1 in gentamicin biosynthesis, 
KanM1 in kanamycin biosynthesis, RibM in ribostamycin biosynthesis, and TobM1 in 
tobramycin biosynthesis, were suggested to catalyze transfer of NDP-D-glucosamine to 
2-DOS.
55
 It was demonstrated with cell-free extracts of E. coli expressing neoM that 
NeoM catalyzes the glycosylation reaction.
59
 The function of BtrD in the butirosin gene 
cluster is to catalyze 2'-N-acetylparomamine deacetylation, and was shown by studying 
the recombinant BtrD and 2'-N-acetylparomamine.
60
 Also GenD in gentamicin, KanN in 
kanamycin, and RibD in ribostamycin were demonstrated to be 2'-N-acetylparomamine 
deacetylases by heterologous expression of the respective genes to produce paromamine 
in S. venezuelae.
60
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Scheme 1-3. Biosynthesis of paromamine from 2-DOS 
1.1.3.3. Biosynthesis of Ribostamycin, Neomycin C, and Neomycin B 
 Ribostamycin is an intermediate in the production of 4,5-disubstituted 
aminoglycosides, including butirosin and neomycin. The transformation of paromamine 
to neamine is catalyzed by the FAD-dependent dehydrogenase NeoQ and the PLP-
dependent aminotransferase NeoB (Scheme 1-4).
61
 The formation of ribostamycin, a 
common intermediate fin the biosynthesis of neomycins and butirosin, from neamine 
occurs in two steps: ribosylation by BtrL using 5-phosphoribosyl-1-pyrophosphate 
(PRPP) as a ribosyl donor to form 5''-phosphoribostamycin and subsequent hydrolysis by 
BtrP.
62
 BtrL and BtrP also catalyze the ribosylation of paromamine to provide 6'-
deamino-6'-hydroxyribostamycin.
62
 RibL and RibP in the ribostamycin producer S. 
ribosidificus have the same functions as BtrL and BtrP.
63
 
 The last glycosylation in neomycin biosynthesis to attach the fourth ring is 
catalyzed by NeoF which transfers UDP-N-acetylglucosamine onto ribostamicin to 
generate 2''-N-acetyl-neomycin Y2.
59
 The function of NeoF was also confirmed by an in 
vivo in-frame gene deletion of neoF in S. fradiae, resulting in the accumulation of 
ribostamycin.
64
 The deacetylation of 2''-N-acetyl-neomycin Y2 to provide neomycin Y2 is 
catalyzed by NeoD, which also recognizes the pseudodisaccharide 2-acetylparomamine 
(Scheme 1-3 and Scheme 1-4).
59
 In the gene cluster of neomycin, only one BtrD-
homologous deacetylase, NeoD, is present. From the result that the neoD S. fradiae 
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mutant still produces neomycin from neamine, the second deacetylase in S. fradiae 
should exist for the deacetylation of tetrapseudosaccharide.
64
 The aminotransfer at C6'' is 
catalyzed by two enzymes, the dehydrogenase NeoQ and aminotransferase NeoB.
65-66
 
NeoQ and NeoB can also recognize the pseudodisaccharide paromamine to provide 
neamine (Scheme 1-5).
67
 The final epimerization is catalyzed by a radical SAM enzyme 
NeoN. NeoN is described in detail in section 1.3.2. 
 
 
Scheme 1-4. Biosynthetic pathway for neomycin B 
 
1.1.3.4. Biosynthesis of Kanamycins 
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 Compared to 4,5-disubstituted aminoglycosides such as ribostamycin and 
neomycin, kanamycins isolated from S. kanamyceticus are 4,6-disubstituted 
pseudotrisaccharides with a 3-aminosugar moiety at the C6-hydroxyl group of 2-DOS. 
The Yoon group proposed parallel biosynthetic pathways based on heterologous gene 
expression of kanamycin genes in S. venezuelae (Scheme 1-5).
68
 KanM1 is able to accept 
both UDP-glucosamine and UDP-glucose as the glycosyl donor to provide respectively 
paromamine and 2'-deamino-2'-hydroxyparomamine.
68
 The glycosyltransferase KanM2 
can use four different substrates such as paromamine, neamine, 2'-deamino-2'-
hydroxyparomamine, and 2'-deamino-2'-hydroxyneamine as glycosyl acceptors. Also 
KanM2 can accept two glycosyl donors such as UDP-glucose and UDP-kanosamine (the 
biosynthetic step using UDP-glucose is not shown in Scheme 1-5. After UDP-glucose is 
accepted by KanM2 to give 3'-deamino-3'-hydroxykanamycin C,
69
 subsequent amino 
group introduction at C3'' to produce kanamycin C is unclear even though KanD2 and 
KanS2 are assigned to this step from the gene analysis of kanamycin biosynthesis). The 
dehydrogenase KanQ and aminotransferase KanB also show substrate flexibility. They 
accept both pseudodisaccharides such as paromamine and 2'-deamino-2'-
hydroxyparomamine as well as pseudotrisaccharides such as kanamycin C and 
kanamycin X.
68
 An α-ketoglutarate-dependent non-heme iron dioxygenase, KanJ, and a 
oxidoreductase, KanK, catalyze the deamination of kanamycin B to kanamycin A.
70
 KanJ 
catalyzes the hydroxylation at C2' to provide a hemiaminal intermediate which is 
converted into 2'-oxokanamycin B by the release of ammonia. Then a NADH-dependent 
reductase KanK reduces the carbonyl group of 2'-oxokanamycin B to produce kanamycin 
A.    
 
 
 14 
 
Scheme 1-5. Biosynthetic pathway for kanamycin A 
 
 1.1.3.5. Biosynthesis of Gentamicins 
Gentamicins are aminoglycoside antibiotics produced by Micromonospora 
echinispora.
4
 Gentamicins are composed of a 2-deoxystraptamine (2-DOS) core 
substituted at C4 with a purpurosamine moiety and at C-6 with a garosamine moiety.  
Biosynthetic studies of gentamicin had been carried out involving isolation of 
gentamicin-related compounds from the wild type producers as well as mutants to 
identify the biosynthetic intermediates. The major components which compose 
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approximately 80% of gentamicin include gentamicin C1, C1a and C2, and the minor ones 
include gentamicin A, A1, A2, A3, B, X2,
71-73 
and antibiotics JI-20A and JI-20B.
74
 Using 
these compounds, Tilley et al carried out biosynthetic studies of gentamicin and showed 
interconversion of gentamicin-related components using biological catalysts and 
extracts.
75
 They used M. purpurea Paro 346, a mutant that produces paromamine but 
none of the gentamicin C's. Since gentamicin C1a was not converted into gentamicin C2 or 
gentamicin C1, the C-methyl transferase responsible for methylation at the C6' position 
apparently could not recognize gentamicin C1a as a substrate. Using the mutant, they also 
showed the transformation of JI-20A to gentamicin C1a and gentamicin C2b whereas JI-
20B and G418 were converted to gentamicin C2 and gentamicin C1. These results 
supported the hypothesis that two different pathways are operant for the production of 
different gentamicin C's. Furthermore, gentamicin A and gentamicin X2 were 
transformed by the mutant into gentamicin C1a, gentamicin C2 and gentamicin C1, thus it 
appears that these species serve as precursors to the gentamicins C's before the branch 
point. From these data, a biosynthetic pathway was proposed (Scheme 1-6). 
 The gene cluster of gentamicin was sequenced by the Sohng group
76
 and 
Wellington group
77
 in 2004 and the Piepersberg group
8
 in 2006, all from 
Micromonospora echinospora ATCC 15835 (Figure 1-2). Homology search results for 
each genes in the cluster are summarized in Table 1-1. The majority of the genes in the  
gentamicin gene cluster show high similarity with those in the fortimicin,
8
 sisomicin,
78
 
Frankia Ccl3,
33
 and istamicin
33
 clusters (structures are shown in Figure 1-1). GenC, 
GenS1, GenE, GenM1, and GenD were assigned to be responsible for paromamine 
formation, similar to the butirosin biosynthetic pathway (Scheme 1-2 and Scheme 1-3). 
GenD1, GenD2, GenX, GenU, GenV, GenN, GenS2, and GenM2 were expected to be 
involved in the biosynthesis of the garosamine moiety. GenM2, GenD2, and GenS2 were 
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expected to be responsible for xylose transfer. GenD1 and GenN were estimated to be 
involved in the modification of the xylose moiety. GenK, GenB2, GenB4 and GenG are 
conserved in the gentamicin and fortimicin biosynthetic gene clusters. GenK may 
catalyze C-methylation of the purpurosamine moiety. GenH, GenI, GenQ, and GenB1 (or 
GenB3) are conserved in the gentamicin, sisomycin, fortimicin, and istamycin 
biosynthetic gene clusters. They seem to be responsible for the biosynthesis of the 
common characters of the purpurosamine moiety. GenX, GenU and GenV remain 
uncharacterized.  
Another interesting finding is that the gentamicin, fortimicin, and Frankia clusters 
have queuosine biosynthetic genes such as GenO, GenW, GenA, and GenF, and a radical 
SAM enzyme like GenF. Blast search against known Streptomyces genomes (S. griseus, 
S. avermitilis, S. coelicolor, and S. acabiei) shows Streptomyces does not have queuosine 
biosynthetic genes. Furthermore, the Flankia CCl3 aminoglycoside (fortimicin) 
biosynthetic gene cluster has queuosine biosynthetic genes (Table 1-1). Considering 
queuosine biosynthetic genes are missing in known genomes of hi-GC Gram-positive 
bacteria, all gentamicin/fortimicin clusters have a set of genes for queuosine biosynthesis 
(QueD, QueE, QueC, QueF, and TGT) in the cluster. Moreover, other aminoglycoside 
biosynthetic gene clusters do not have those homologues. Since these genes are not 
present in the istamycin cluster, it is less likely that those genes are important for 3,4-
dideoxygenation steps. One possible scenario is that homologues of QueD, QueE, QueC, 
and QueF produce preA1 and the TGT homologue catalyzes the transfer of proQ1 to 
rRNA for gentamicin/fortimicin self-resistance mechanism.    
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Piepersberg and Wellington group 
 
Sohng group 
 
Figure 1-2. Gene cluster of gentamicin 
 
Proposed Function 
Piepers-
berg 
Welling-
ton 
Sohng 
Siso-
micin 
cluster 
Forti-
micin 
cluster 
Frankia 
Ccl3 
cluster 
Ista-
mycin 
cluster 
hypothetical protein  GntT GacN     
putative Trp-tRNA ligase  GntU GacM     
queuosine/archaeosine 
tRNA-ribosyltransferase 
GenO GntV GacL Sis3 FosA 3378  
putative ribosomal 
methyltransferase 
GmrB GrmO GacL Sis4    
gentamicin (hexosaminyl-
6-) aminotransferase 
GenB1 GntW GacK 
Sis5 
Sis18 
ForB 3369 IstB 
GenB2 GntL GacE 
GenB3 GntJ GacB 
GenB4 GntH GacC 
hexose-6'-dehydrogenase GenQ GntX GacJ Sis6 ForQ 3360 IstQ 
SDR/putative gentamicin 
oxidoreductase 
GenD3 GntY GtmH Sis7    
(N-acetyl)hexos-
aminyltransferase 
GenM1 GntZ GtmG Sis8 ForM 3362 IstM 
putative ribosomal 
methyltransferase 
GmrA GrmA GtmF Sis9    
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putative L-
glutamine:ketocyclitol 
aminotransferase 
GenS1 GntA GtmB 
Sis10 
Sis15 
ForS 3363 IstS 
GenS2 GntF GtmD 
2-deoxy-scyllo-inose 
synthase 
GenC GntB GtmA Sis11   IstC 
NAD(P) dependent 
oxidoreductase 
GenD2 GntC GtmC Sis12    
gentamicin 
glycosyltransferase II 
GenM2 GntD GtmE Sis13    
B12 radical SAM 
dependent oxidoreductase/ 
methyltransferase 
GenD1 GntE GtmI Sis14    
GTP cyclohydrolase 
/NADPH dependent 7-
cyclo-7-deazaguanine 
reductase 
GenW GntG GacA Sis16 FosC 3383  
biosynthetic 
aminoglycoside 3'-
phosphotransferase 
GenP GntI GtmJ Sis17 ForP 3368  
B12 radical SAM 
dependent C-
methyltransferase 
GenK GntK GtmJ  ForK 3370  
hypothetical protein GenX GntM GacF Sis19    
hypothetical protein GenU GntN GacG Sis20    
deoxyinosamine 
dehydrogenase 
GenE GntP GacH Sis22 ForE 3364 IstE 
putative cation antiporter  GenY GntQ GacI Sis23 ForY   
ATP utilize enzyme 
(QueC) 
GenA GntR  Sis24 FosE 3379  
radical SAM enzyme 
(QueE)  
GenF GntS  Sis25 FosF 3380  
Que homologue GenG    FosG 3381  
export protein 
GenV 
GenH 
GenI 
GntO 
 
 
GtmK 
 
 
Sis21 
Sis26 
ForI 
ForH 
ForJ 
ForV 
 
 
3359 
3358 
IstI 
IstH 
IstJ 
SAM-dependent 
methyltransferase 
GenT   Sis28 ForT 3373  
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putative N-
acetylhexosaminyl 
deacetylase 
GenD  GtmM Sis29 ForD 3367 IstD 
putative gentamicin 
methyltransferase  
GenN   Sis30    
hypothetical     ForW 3361 IstW 
putative fortimicin O-
methyltransferase 
    ForO 3365 IstO 
radical SAM family 
protein 
    ForL2 3366 IstL2 
fortimicin A N-
fortimidoyltransferase 
    ForZ 3371 IstZ 
putative fortimicin 
production protein 
    ForX 3376 IstX 
putative myo-inositol 3-
dehydrogenase 
    ForG 3374  
fortimicin N-
methyltransferase 
    ForN 3373 IstN 
inositol-1-
monophosphatase 
    ForA   
radical SAM protein     ForL 
3357 IstL 
3375 IstL3 
Table 1-1. Gene analysis of gentamicin 
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Scheme 1-6. Biosynthetic pathway for gentamicins. The activity of the enzymes with red 
colors has already been demonstrated. 
Many biotransformations in the biosynthetic pathway of gentamicin have been 
demonstrated. The Yoon group confirmed that GenM2 is required for the glycosylation 
that forms the pseudotrisaccharide from paromamine and UDP-xylose.
79
 They used an 
engineered paromamine-producing strain of S. venezuelae to generate gentamicin A2. 
However, it was noted that the amount of gentamicin A2 produced with S. 
venezuelae/pYJ505 was 4.5 μg/L, and could only be detected by LC-MS analysis. This 
was mainly due to limited amount of NDP-xylose present in S. venezuelae host cells. 
When cell free extracts of S. venezuelae/pYJ505 were supplied with UDP-xylose, 
gentamicin A2 production was enhanced up to 8-fold, supporting that the glycosyl donor 
is UDP-xylose. Two oxidation and amination reactions occur in the biosynthetic pathway 
of gentamicins. One is the conversion of gentamicin A2 to gentamicin A, and the other is 
the conversion of gentamicin X2 to JI-20A or G-418 to JI-20B. Leadlay and Sun et al 
demonstrated through gene mutation experiments that the first oxidation and amination 
are catalyzed respectively by GenD2 and GenS2,
80
 and the second transformations are 
catalyzed by GenB1 and GenQ.
81
 For the two N-methyltransfer reactions from 
gentamicin A2 to gentamicin A and from gentamicin C1a to gentamicin C2b or from 
gentamicin C2 to gentamicin C1, only the methylation reaction at N3'' has been 
established to be catalyzed by GenN.
80,82
 Two C-methyltransfer reactions have now been 
shown to be catalyzed by cobalamin-dependent radical SAM enzymes (GenD1 and 
GenK). GenD1 catalyzes the methylation at C4'' of garosamine,
80
 and is described in 
detail in Sections 2.1 and 2.2. GenK catalyzes the methylation at C6' and is discussed in 
Chapters 2 and 3. Two epimerization reactions are also required for gentamicin 
biosynthesis: the first is from JI-20B to JI-20Ba,
81
 and the second is from gentamicin C2a 
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to gentamicin C2.
83
 These two epimerizations are both catalyzed only by GenB2 and are 
reversible.    
The remaining uncharacterized steps are the deoxygenation at C3' and C4' and N-
methylation at the end to complete the biosynthesis of gentamicins. While GenP is known 
to catalyze phosphorylation of the hydroxyl group at C3',
84
 the remaining enzymatic 
reactions are enigmatic. From comparison of the genes in the gentamicin and fortimicin 
clusters, several genes could be involved in the dideoxygenation reaction, such as GenV, 
GenH, and GenI. These genes have been assigned as membrane associated exporters. 
However, these proteins do not resemble membrane proteins, and homologues of these 
enzymes are not present in any other organisms based on BLAST analysis.  
 
1.1.3.6. Biosynthesis of Other Aminoglycosides 
 Biosynthetic studies of other aminoglycosides with 2-DOS like tobramycin, 
apramycin, and lividomycin have not been successful so far. Conserved biosynthetic 
enzymes are expected to be responsible for the construction of the common biosynthetic 
intermediate, 2-DOS and paromamine based on the gene analysis.
8,33
   
Tobramycin (3'-deoxykanamycin B) has been identified from two strains, 
Streptoalloteichus hindustanus and Streptomyces tenebrarius (Figure 1-1).
8
 Both 
microorganisms produce apramycin as well, indicating that the biosynthesis of 
tobramycin and apramycin share some biosynthetic genes. The biosynthesis of 
tobramycin includes deoxygenation of paromamine or kanamycin C. Comparison of the  
tobramycin/apramycin, kanamycin and lividomycin biosynthetic gene clusters has 
suggested that AprD3 and AprD4 catalyze deoxygenation reaction during the 
biosynthesis of tobramycin and apramycin.
8,33
 AprD3 and AprD4 are described in detail 
in Chapter 4.  
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1.2. RADICAL S-ADENOSYL-L-METHIONINE (SAM) ENZYME 
 S-Adenosyl-L-methionine (SAM) is a versatile compound in nature. This 
compound is primarily known for its electrophilic methyl that is used to methylate 
nucleotides, amino acids, or other molecules containing sulfur, amino, and hydroxyl 
nucleophiles. However, in the early 1970s, lysine 2,3-aminomutase is shown to use SAM 
in a novel way.
85-86
 This enzyme is sensitive to air and its activity depends on the 
presence of dithionite and SAM. Further studies showed that the 5'-deoxyadenosyl 
moiety of SAM is homolytically cleaved and the resulting 5'-deoxyadenosyl radical 
facilitates hydrogen abstraction from the substrate of lysine 2,3-aminomutase,
87
 which is 
similar to the reactions catalyzed by adenosylcobalamin-dependent mutases using the 5'-
deoxyadenosyl radical. EPR analysis revealed the presence of a [4Fe-4S] cluster.
88-89
 
Studies of several other enzymes such as pyruvate formate-lyase activase,
90-94
 biotin 
synthase,
91 
and ribonucleotide triphosphate reductase III,
95-96
 led to the characterization of 
a new class of enzymes that utilize a reduced iron-sulfur cluster and SAM to initiate their 
catalyses. This class enzymes, which has grown to approximately 64000 based on 
bioinformatics analysis,
97
 are across all phylogenetic kingdoms and are now referred as 
the radical SAM superfamily.
98
  
Radical SAM enzymes have a characteristic Cx3Cx2C sequence motif conserved 
in most of superfamily members, although enzymes exhibiting variations of this motif are 
also known (see in Section 4.1). In the active site of a typical radical SAM enzyme, the 
three cysteine residues coordinate three of the four irons of a [4Fe-4S] cluster, and one of 
the four iron atoms is coordinated by the amino and carboxylate moieties of SAM (Figure 
1-3).
99-100
 Reducing agents such as flavodoxin or dithionite can provide one electron to 
reduce the [4Fe-4S]
2+
 cluster to generate the catalytically active [4Fe-4S]
+
. The reduced 
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[4Fe-4S]
+
 cluster can reduce SAM leading to homolysis of the S-C5' bond to give the a 
5'-deoxyadenosyl radical (5'-dAdo•) and methionine. The 5'-dAdo• s then used to abstract 
a hydrogen atom from the substrate in a stereo- and regiospecific manner to generate a 
substrate radical which can undergo further reaction such as methylation, sulfur insertion, 
oxidation, dehydrogenation, methylthiolation, and complex carbon skeleton 
rearrangements.
101
 In most radical SAM enzymes, SAM is consumed during catalysis, 
and methionine and 5'-dAdo along with the product are produced in a 1:1:1 ratio 
(pathway A in Figure 1-3). However, when SAM is used catalytically, the product radical 
abstracts a hydrogen atom from 5'-dAdo to afford the product and 5'-dAdo•. The latter 
recombines with methionine to regenerate SAM (pathway B in Figure 1-3).  
A second auxiliary iron-sulfur cluster has been found in many radical SAM 
enzymes. In some cases, the second cluster is involved in the reaction (Figure 1-4). For 
example, in the biosynthesis of biotin, one sulfur atom in the second cluster is inserted 
between C6 and C9 of dethiobiotin to generate biotin (Figure 1-4A).
101
 In the cases of 
MiaB and RimO, the nucleophilic persulfide-bound moiety of the second cluster accepts 
the methyl group from SAM (Figure 1-4B).
102
 The resulting methylated sulfur atom of 
the polysulfide chain reacts with the substrate radical to yield the methylthiolated product 
and a [4Fe-4S] cluster with a terminal persulfide. HydG has another auxiliary [4Fe-4S] 
cluster coordinated with a Cx2Cx22C motif (Figure 1-4C).
103
 A tyrosine bound to an 
auxiliary C-terminal [4Fe-4S] cluster reacts with 5'-dAdo• generated by SAM and an N-
terminal [4Fe-4S] cluster to provide a tyrosine radical. Heterolytic cleavage of this 
tyrosine radical at the Cα–Cβ bond forms a transient 4-oxidobenzyl (4OB) radical and the 
dehydroglycine bond to the C-terminal [4Fe-4S] cluster, which has been detected by EPR 
spectroscopy.
104
 Other secondary [4Fe-4S] clusters are expected to act as electron 
donors.
105
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Figure 1-3. Mechanism for radical SAM cleavage 
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Figure 1-4. Roles of the secondary [4Fe-4S] clusters in selected radical SAM enzymes. 
A) BioB in biotin biosynthesis, B) RimO in the methylthiolation of aspartate89 of the 
ribosomal S12 protein, C) HydG in the biosynthesis of the H-cluster of the [FeFe]-
hydrogenase 
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1.3. RADICAL SAM ENZYMES IN AMINOGLYCOSIDE BIOSYNTHESIS 
 In the biosynthetic pathways of aminoglycosides, several enzymes have been 
assigned as radical SAM enzymes such as BtrN in the butirosin pathway, NeoN in the 
neomycin pathway, RibN in the ribostamycin pathway, ParN in the paromomycin 
pathway, LivN and LivW in the lividomycin pathway, GenD1, GenK and GenF in the 
gentamicin pathway, IstL2, IstL, and IstL3 in the istamycin pathway, ForK, FosF, ForL2, 
and FosL in the fortimicin pathway, AprD4 in the apramycin/tobramycin pathway, HygY 
in the hygromycin pathway, and SpcY in the spectinomycin pathway,
8,33
 but only a few 
radical SAM enzymes (i.e. BtrN, NeoN, and GenD1) in aminoglycoside biosynthesis 
have been characterized in vitro. GenD1 is discussed in detail in Section 2.1 and Section 
3.1. The in vitro characterizations of GenK and AprD4 are presented in this dissertation 
in detail.  
 
1.3.1. BtrN 
During the biosynthesis of 2-deoxystreptamine (2-DOS) in the butirosin producer 
B. circulans, BtrN catalyzes the oxidation of the alcohol at C1 of 2-deoxy-scyllo-
inosamine (2-DOIA) to form keto-2-deoxy-scyllo-inosamine (keto-2-DOIA) (another 
named 3-amino-2,3-dideoxy-scyllo-inosose (amino-DOI)) under anaerobic conditions 
(Scheme 1-1).
106
 From analysis of the butirosin biosynthetic gene cluster, BtrN has been 
shown to possess canonical the CxxxCxxC motif in its primary sequence, indicating that 
this enzyme is a radical SAM enzyme.
106
 Electron paramagnetic resonance (EPR) studies 
performed at 50 °K with reconstituted BtrN but without SAM and 2-DOIA showed 
characteristic g values of 1.92 and 2.04 for the [4Fe-4S] cluster of radical SAM enzymes. 
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These g values can be compared with reconstituted BtrN in the presence of dithionite  
and SAM (g = 1.83, 1.99) or with additional SAM and 2-DOIA (g = 1.87, 1.96, 2.05).
107
  
Gene analysis of BtrN showed the existence of eight cysteine residues, suggesting 
that a second [4Fe-4S] cluster may exist.
108
 Mutagenesis studies indicated that 
reconstituted BtrN contains two [4Fe-4S] clusters. When the three cysteine residues of 
the CxxxCxxC motif were changed to alanine, the enzyme was found to still contain a 
single [4Fe-4S] cluster based on iron/sulfur titration and Mössbauer spectroscopy.
108
 
Generation of variants in which the remaining cysteine residues were changed to alanines 
showed that the C69A mutant provided similar activity as the wild type, but the C235A 
mutant displayed reduced solubility and low activity. Mutation of Cys169, C187 and 
C232 produced insoluble proteins. These results led to the proposal that the three latter 
residues serve as ligands to bind the second [4Fe-4S] cluster.  
Kinetics analysis revealed that BtrN proceeds with an ordered mechanism because 
uncompetitive substrate inhibition was observed with amino-DOI, but not with SAM.
106
 
In BtrN catalysis, one equivalent of SAM versus 2-DOIA is consumed and an equal 
number of moles of  5'-dAdo, methionine, and amino-DOI are generated. Assays of 
BtrN with [3-
2
H]-2-DOIA generated a mixture of unlabeled, monodeuterated, and 
dideuterated 5'-dAdo, while incubation of nonlabeled 2-DOIA in the deuterium buffer did 
not provide incorporation of deuterium at all. These results indicate that 5'-dAdo radical 
abstracts a hydrogen atom from the C3 position of 2-DOIA.  
Determination of the X-ray structure of this enzyme with and without substrate 
further clarified the mechanism and role of the auxiliary cluster.
109
 The auxiliary cluster 
is fully ligated both in the presence and in the absence of the substrate, which excludes 
the possibility that this cluster coordinates the substrate. In addition, 2-DOIA is bound in 
a hydrophilic pocket between SAM and the auxiliary clusters. Based on the observation 
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that 2-DOIA binds in an equatorial chair conformation and hydrogen bonding 
interactions with the functional group of the substrate, the auxiliary cluster in BtrN is 
suggested to function as an electron acceptor during the dehydrogenation reaction. Also 
the putative base, Arg152, involved in the BtrN catalysis was identified. Formation of the 
α-hydroxyalkyl radical after H-atom abstraction by 5'-dAdo radical promotes 
deprotonation of the C3-hydroxy functional group by decreasing its pKa. The proposed 
mechanism of the BtrN reaction is shown in Figure 1-5. 
 
 
Figure 1-5. Proposed mechanism of the BtrN reaction 
The substrate flexibility of BtrN was examined using several cyclitol and sugar 
compounds (Figure 1-6).
106
 Only three substrate analogues such as DOS, scyllo-inositol, 
and myo-inositol showed activity with BtrN in terms of the formation of 5'-dAdo. These 
results indicate that BtrN exhibits strict specificity for cyclitols and not for sugars.  
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Figure 1-6. Substrate specificity of BtrN 
    
1.3.2. NeoN 
 In the neomycin biosynthetic pathway, NeoN was assigned to catalyze the 
epimerization at C5''' of neomycin C to generate neomycin B.
8,33
 ParN in paromomycin, 
and LivN in lividomycin are also assigned to have analogous functions because they have 
similar structures (Figure 1-1). These enzymes contain the canonical CxxxCxxC motif 
that is present in most radical SAM enzymes. The reconstituted and reduced NeoN with 
SAM and neomycin C under anaerobic conditions provided neomycin B.
110
 NeoN also 
catalyzes the conversion of  neomycin Y2 to neomycin Y1, indicating that the amino 
group at C6''' is not necessarily involved in substrate recognition (Scheme 1-7). In the 
NeoN catalytic cycle, SAM is not utilized catalytically based on the observation that one 
equivalent each of SAM and the substrate are consumed, while equal amounts of 5'-dAdo 
and neomycin B are generated.
110
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Scheme 1-7. Epimerization of NeoN      
 The NeoN reaction carried out in a buffer prepared with deuterium oxide was 
analyzed by LC-ESI-MS and NMR, demonstrating the incorporation of a single 
deuterium atom at the C-5''' of neomycin B.  Mutation studies of NeoN with a triple 
cysteine mutant for the radical SAM motif (C26/30/33A) did not show epimerization 
activity, indicating that these cysteine residues are critical for catalysis. The assay of 
NeoN with C249A provided a new product, a five-membered carbocyclic structure with 
an aminomethyl group confirmed by 2D NMR analysis (Figure 1-7B). This result 
suggests that the C249 thiol provides the hydrogen atom at C5''' position in which 5'-
dAdo• abstracts to complete the epimerization of neomycin C. EPR spectroscopic studies 
performed at 10K with reduced and reconstituted NeoN showed characteristic g values of 
2.03 and 1.92. However, in the presence of SAM, the g values changed to 2.00, 1.90, and  
1.86, indicating the coordination of SAM to the [4Fe-4S]
+
 cluster. Addition of neomycin 
C did not affect the shape of the signal and this result suggests that neomycin C does not 
coordinate directly with the [4Fe-4S]
+
 cluster even though the substrate may be located 
close to the cluster. EPR analysis with the reduced C249A variant, neomycin C and SAM 
at 10 K revealed almost the same signals compared to the wild type, but at 50 K a 
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hyperfine-coupled EPR signal was observed. This observation indicated trapping of an 
organic radical generated at the C-5''' position of neomycin.  
 The iron and sulfur atom contents in NeoN were estimated respectively at 6.6 ± 
0.9 and 5.8 ± 0.9 equivalents per protein monomer, which indicates that NeoN has a 
second [4Fe-4S] cluster.
107
 UV spectroscopic analysis of the C26/30/33A mutants 
showed an absorption around 420 nm, which is characteristic for [4Fe-4S] clusters. Other 
mutation studies showed that the C226/246/271/274A mutants led to self-degradation of 
NeoN during protein purification. Sequence alignment of NeoN with BtrN
109
 and 
anaerobic sulfatase maturating enzyme (anSME)
111
 indicated that a putative second [4Fe-
4S] cluster might coordinate a set of C226, C247, C271, and C274. Also it is also 
expected that C249 is located close to the second [4Fe-4S] cluster and might be able to 
interact with C247. From these analyses, catalytic mechanism was proposed for NeoN as 
shown in Figure 1-7A.   
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Figure 1-7. NeoN catalysis. A) Proposed mechanism of NeoN reaction. B) Reaction of 
C249A mutant of NeoN with neomycin C 
 
1.4. DISSERTATION STATEMENT 
 Biosynthetic studies of natural products have become essential to the discovery 
and development of new drugs, because understanding the biosynthetic pathways and the 
chemical mechanisms of each enzyme in the pathways can facilitate efforts in pathway 
engineering to produce new compounds with improved clinical properties. 
Aminoglycosides  are well known and important antibiotics, but antibiotic resistance to 
aminoglycosides is increasing. This has led to renewed interest in the biosynthesis of 
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aminoglycosides. Radical SAM enzymes catalyze novel and miscellaneous reactions in 
the biosynthesis of natural products. Even though several enzymes in the biosynthesis of 
aminoglycosides are assigned to be radical SAM enzymes based on the gene analysis, 
only a few radical SAM enzymes have been characterized  in vitro. This dissertation 
focuses on the in vitro characterization of two radical SAM enzymes in the biosynthesis 
of aminoglycosides.  
 Chapter 2 describes the in vitro characterization of a Cbl-dependent radical SAM 
methyltransferase, GenK. This enzyme catalyzes the methylation of an unactivated sp
3
 
carbon of gentamicin X2 to produce G418 during the biosynthesis of gentamicin. 
Experiments to investigate the stoichiometry of GenK reaction showed that an equal 
number of equivalents of 5'-dAdo, SAH, and G418 are produced. Isotope-labeling 
experiments demonstrated that the S-methyl group from SAM is transferred via Cbl to the 
aminoglycoside product during the course of the reaction. Experiments with other 
aminoglycosides in the biosynthetic pathway of gentamicin demonstrated the promiscuity 
of GenK substrate recognition.  
Chapter 3 describes efforts to elucidate the mechanism of the GenK reaction. 
From the results of Chapter 2, three mechanisms are proposed and examined using 
chemically synthesized substrate analogs. The GenK assays with stereospecifically 
labeled (R)- and (S)-[6'-
2
H]-gentamicin X2 demonstrated the stereochemical course of the 
hydrogen atom abstraction by 5'-Ado• and the overall stereochemistry of the GenK 
catalyzed reaction. Various substrate derivatives of gentamicin X2 modified at C6' were 
tested to investigate the manner of methyl transfer from methylcobalamin to the substrate 
to produce the methylated product.   
Chapter 4 describes the in vitro characterization of a radical SAM enzyme AprD4 
and its reductase partner AprD3. AprD4/D3 from Streptomyces tenebrarius were purified 
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following heterologous expression in E. coli and examined in vitro. The C3'-
deoxygenation reaction of paromamine catalyzed by AprD4/D3 was confirmed by 
comparison of chemically synthesized lividamine. Mass spectroscopy experiments 
confirmed the function of AprD4 by the detection of 4'-oxolividamine. Experiments with 
isotope-labeled substrates showed the position of hydrogen atom abstraction by 5'-dAdo• 
and stereochemical course of proton transfer at C3'-deoxygenation of paromamine. 
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Chapter 2: Characterization of GenK, a Cobalamin-Dependent Radical 
SAM Methyltransferase Enzyme 
2.1. INTRODUCTION 
 Methylation is a recurrent and significant reaction in biological processes.
112
 
Various biological molecules including natural products, metabolites, and 
macromolecules such as nucleic acids, proteins, and polysaccharides can all serve as 
substrates in methylation reaction whereupon their biological properties may be 
modified. For example, DNA methylation is a critical feature in the control of gene 
expression as methylated DNA sequences are subjected to transcriptional repression.
113
 
One of the key molecules that serves as methyl donor in these reactions is S-adenosyl-L-
methionine (SAM).
114
 In such reactions, attack at the electrophilic methyl group of SAM  
by a nucleophile such as amino, alkoxide and thiolate functionality of the substrate  
results in methyl transfer to the substrate and concomitant production of S-adenosyl-L-
homocysteine (SAH). However, a number of methyltransferases that are mechanistically 
unique compared the standard paradigm involving Lewis acid-base chemistry have 
recently been described.
115
 The catalytic cycles of these enzymes instead involve radical 
chemistry and result in the methylation of non-nucleophilic carbon or phosphrous 
centers.
116
 These enzymes are members of radical SAM superfamily and thus catalyze the 
reductive homolysis of SAM via single electron transfer form an active site [4Fe-4S] 
cluster to produce methionine and a 5'-deoxyadenosyl radical (5'-dAdo•) that serves as a 
radical initiator in the subsequent transformation.
117
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 In a recent review, Booker et al
116 
divided the radical SAM methyltransferase 
(RSMT) into four classes (i.e. classes A, B, C, and D) organized by protein architecture, 
expected enzymatic mechanism, and cofactor dependence (Table 2-1). Catalysis by class 
A RSMTs involves the generation of a methylene radical on two strictly conserved 
cysteines and results in the methylation of sp
2
-hybridized carbon centers. Representative 
enzymes in this class are RlmN
118-120
 and Cfr
121-126
, which contribute to the modification 
of rRNA in various organisms. Class B RSMTs are characterized by distinctive protein 
architecture that includes a cobalamin-binding domain at the N-terminus and a radical 
SAM domain at the C-terminus. These enzymes methylate unactivated sp
2
- or sp
3
-
hybrized carbons or phosphinates. While class B is the largest and most diverse to date, 
only five enzymes (TsrM
127-129
, Fom3
130-131
, GenD1
81
, ThnK
132
 and PhpK
133-135
) have 
been studied in vitro. These enzymes are described in detail below. Class C RSMTs 
demonstrate significant sequence similarity with coproporpyphyrinogen III oxidase  
(HemN) and methylate sp
2
-hybridized carbons. These enzymes do not have the two 
conserved cysteines that are characteristic of the class A enzymes and are frequently part 
of the biosynthetic pathways responsible for complex secondary metabolites with 
antitumor and antibiotic behavior such as nosiheptide (NosN
136
 and NocN
137
), 
yatakemycin (YtkY
138-139
) and jawsamycin (Jaw5
140-141
). Finally, in the more recently 
discovered class D radical SAM methyltransferases, which includes MJ0619.
142
 
Methylenetetrahydrofolate is proposed to serve as the methyl donor rather than SAM.  
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Class Enzyme Function Substrate 
A 
 
RlmN 
Cfr 
 
rRNA and tRNA modification 
rRNA modification 
 
B 
Fom3 
Fms7 
GenD1 and GenK 
ThnK, L, and P 
PacJ, N, and O 
Cndl 
Swb9 
HpnP 
BchQ, BchR 
PoyB and C 
 
CloN6 
CouN6 
 
TsrM 
SioT 
 
BcpD/PhpK 
Forsfomycin biosynthesis 
Fortimicin A biosynthesis 
Gentamicin biosynthesis 
Thienamycin biosynthesis 
Pactamycin biosynthesis 
Chondrochlorens biosynthesis 
Quinomycin biosynthesis 
2-Methylhopanoid biosynthesis 
Chlorophyll biosynthesis 
Polytheonamide biosynthesis 
 
Clorobiocin biosynthesis 
Cooumermycin biosynthesis 
 
Thiostrepton biosynthesis 
Siomycin biosynthesis 
 
Bialaphos biosynthesis 
 
 
 
 
 
 
 
 
 
 
 
 
C 
NosN 
NocN 
 
TpdI 
TpdL and U 
 
Blm-Orf8 
Tlm-Orf11 
Zpm-Orf26 
 
 
YtkT 
 
 
Jaw5 
Nosiheptide biosynthesis 
Nocathiacin biosynthesis 
 
Thiomuracin biosynthesis 
GE2270 biosynthesis 
 
Bleomycin biosynthesis 
Tallysomycin biosynthesis 
Zorbamycin biosynthesis 
 
 
Yatakemycin biosynthesis 
 
 
Jawsamycin biosynthesis 
 
 
 
 
 
 
D MJ0619 Methanopterin modification 
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Table 2-1. The four classes of radical SAM methylases
5 
Among the four classes of radical SAM methylases, class B is of particular 
interest, because it includes GenK, which is the topic of this chapter. Other members of 
this class include PhpK, TsrM, Fom3, GenD1, and ThnK.  
PhpK is isolated from the phosalacin producer Kitasatospora phosalacinea, and 
was the first class B RSMT to be purified and characterized in vitro.
133
 PhpK catalyzes 
the methylation of the phosphinate group of 2-acetylamino-4-hydroxyphosphinyl 
butanoate (N-acetyldemethylphosphinothricin, NAcDMPT) to produce 2-acetylamino-4-
hydroxymethylphosphinylbutanoate (N-acetylphosphinothricin, NAcPT) which possesses 
the only carbon-phosphorus-carbon linkage currently known in nature (Scheme 2-1). 
PhpK overexpressed from E. coli was not soluble and found only in inclusion bodies.  
After refolding and purification of the enzyme by anionic exchange chromatography, its 
Fe/S cluster was anaerobically reconstituted. Reconstituted PhpK coordinates a single 
[4Fe-4S] cluster, which was confirmed by EPR spectroscopy at 10 K. Assays containing 
reconstituted PhpK, SAM, methylcobalamin, NAcDMPT and dithionite enable 
observation of formation of NAcPT. Two dimensional 
1
H-
31
P gradient heteronuclear 
single-quantum correlation (gHSQC) spectroscopy displayed a strong H-P cross-peak 
indicative a methylated phosphorus center. However, the NAcPT-associated gHSQC 
cross peak was not found in the absence of dithionite, which is required for the reduction 
of the [4Fe-4S] cluster. When 
13
CH3-methyl-Cbl(III) was used in PhpK reactions, H-P 
cross peaks from the passive couplings of 
1
H and 
31
P to the attached 
13
C nuclei were 
found. This experiment demonstrated that MeCbl(III) is a methyl source for NAcPT. 
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Scheme 2-1. P-Methyl transfer reactions catalyzed by PhpK 
 TsrM from Streptomyces laurentii catalyzes the methylation of sp
2
-
hybridized C2 carbon in tryptophan to produce 2-methyltryptophan during the 
biosynthesis of thiostrepton A (Scheme 2-2).
127-129
 This reaction is the first step in the 
conversion of tryptophan to the quinaldic acid moiety of thiostrepton A. Early feeding 
experiments using chirally labeled methionine showed that the methyl group is 
transferred with net retention of configuration. This observation suggested a double 
displacement mechanism that involves two SN2 type reactions, which differs from the 
typical methionine-dependent methylations.
143
 Berteau et al purified TsrM as a strep-tag 
fusion protein in E. coli. The purified protein has one mol of iron and one mol of sulfur 
per polypeptide.
127
 When the reconstituted enzyme was incubated in the presence of 
tryptophan, SAM and sodium dithionite, there was no detectable formation of 5'-dAdo, 
which is a typical harbinger of radical-SAM chemistry. However, after methylcobalamin 
was included in the previous assay mixture, methyltryptophan and SAH were produced in 
a constant ratio. Furthermore, isotope-tracer experiments demonstrated that the methyl 
group ultimately comes from SAM while cobalamin acts as an intermediate methyl 
carrier. When 11 tryptophan derivatives with different substitution at C5 (5-Me-, 5-OH-, 
5-F-Trp) or without the α-carboxy group of tryptophan or with other changes were 
evaluated as potential substrates for TsrM, all compounds that were substituted on the 
indole ring were found to be susceptible to the methyl transfer reaction.
128
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Scheme 2-2. Methylation of tryptophan catalyzed by TsrM 
Fom3 isolated from Streptomyces wedmorensis catalyzes methylation of 2-
hydroxyethylphosphonate (2-HEP) to produce 2-hydroxypropylphosphonate (2-HPP) in 
the biosynthetic pathway of fosfomycin (Scheme 2-3).
131
 Early mutation studies showed 
that a mutant strain with a block in the vitamin B12 biosynthetic pathway could not 
produce fosfomycin, but converted HPP to fosfomycin.
144
 Feeding experiments with 
14
C-
labled MeCbl and this mutant showed the formation of 
14
C-labeld fosfomycin from 
HPP.
145
 Isotope labeling experiments indicated that methyl transfer occurs at pro-(R) 
hydrogen position.
146
 An in vitro study of wild type (WT) Fom3 was conducted by Wang 
et al.
130
 WT Fom3 overexpressed from E. coli was not soluble and found exclusively in 
the inclusion bodies. After refolding, however, the enzyme could be isolated and 
reconstituted with additional ion and sulfide. N-terminal hexahistidine tagged WT His-
Fom3 was also prepared. WT Fom3 has a single [4Fe-4S] cluster and His6-Fom3 has four 
[4Fe-4S] clusters. In low-temperature EPR experiments, WT Fom3 and His6-Fom3 
showed signals of the [4Fe-4S] cluster. Cysteines 282, 286, and 289 in the conserved 
radical SAM CX3CX2C motif were shown to be essential for cluster binding by mutation 
studies. 
31
P NMR spectroscopic data with His-Fom3, dithionite, 2-HEP, and MeCbl 
exhibited signals corresponding to HPP. However, no product formation has been 
detected due to the instability of the enzyme.     
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Scheme 2-3. Fosfomycin biosynthetic pathway 
GenD1 is another putative radical SAM enzyme in the gentamicin biosynthetic 
pathway.
81
 GenD1 catalyzes the C-methylation at C-4'' of gentamicin A to produce 
gentamicin X2 (Scheme 2-4). GenD1 has a noncanonical Cx4Cx2C motif instead of the 
highly conserved Cx3Cx2C binding motif for the [4Fe-4S] cluster found in most radical 
SAM enzymes. In vitro studies of GenD1 were conducted by Leadlay and Sun et al.
81
 In 
contrast to other radical SAM methyltransferase, GenD1 could be expressed and isolated 
as the N-His6-tagged protein in E. coli in soluble form and in excellent yield. After 
reconstitution of the iron-sulfur cluster, assays with GenA, SAM, dithiothreitol (DTT), 
methylcobalamin, methyl viologen and NADPH showed production of GenX2 and 5'-
deoxyadenosine (5'-dAdo) which were confirmed by HPLC and mass spectroscopy. As 
expected, no activity was observed with non-reconstituted enzyme or under aerobic 
conditions. 
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Scheme 2-4. GenD1 catalyzed methylation reaction 
Townsend et al found that ThnK from Streptomyces cattleya in the biosynthetic 
pathway of thienamycin catalyzes sequential methylations to build out the C6-ethyl side 
chain in a stereocontrolled manner (Scheme 2-5).
132
 ThnK was expressed with a C-
terminal His6-tag in E. coli Rosetta 2(DE3) and enzyme production was conducted in 
ethanolamine-M9 medium, which facilitates uptake of externally supplied HOCbl into E. 
coli. Without further reconstitution of iron and sulfur, the as-isolated ThnK has 7.4 ± 1.4 
equivalents of iron and 3.7 ± 0.8 equivalents of sulfide per polypeptide. Assays of ThnK 
with SAM, methyl viologen, NADPH and (2R,3R,5R)-carbapenam showed the formation 
of 5'-deoxyadenosine (5'-dAdo), S-adenosylhomocysteine (SAH) and an ethylated 
product. Labeling experiments and mass spectrometry using S-adenosyl-[CD3]-methyl-
methionine (d3-SAM) demonstrated an M+3 m/z shift for the methylated product and an 
M+5 m/z shift for the twice-methylated product, consistent with the formation of an ethyl 
side chain at C6 of the substrate by successive methyl transfers.  
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Scheme 2-5. Double methylation catalyzed by ThnK  
The class B radical SAM methyltransferases characterized in vitro so far are 
summarized in Table 2-2. TsrM and GenD1 gave different products from SAM. TsrM 
gave only SAH, not 5'-dAdo, but GenD1 gave opposite results. Most enzymes used 
MeCbl or HOCbl, indicating that Cbl plays a role as an a methyl carrier for the methyl 
transfer process. Reducing systems required to reduce the [4Fe-4S] cluster to the active 
+1 redox state were different. PhpK and Fom3 were reduced by dithionite. The GenD1 
and ThnK reactions used methyl viologen (MV) or benzyl viologen (BV) and NADPH. 
However, TsrM used dithiothreitol (DTT) as the sole reductant. 
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Enzymes PhpK TsrM Fom3 GenD1 ThnK 
Fe 
S 
5.9 
4.4 
5.0 ± 0.3 
3.0 ± 0.2 
5.7 ± 0.7 
7.5 ± 1.0 
No 
information 
7.4 ± 1.4 
3.7 ± 0.8 
Substrate P sp
2
 C sp
3
 C sp
3
 C sp
3
 C 
SAM 
amount 
used 
2-5 1 0.5-1 4 1 
5'-dAdo 
formation 
No 
information 
No 
No 
information 
Yes Yes 
SAH 
formation 
No 
information 
Yes 
No 
information 
No Yes 
Cbl 
used 
MeCbl 
MeCbl 
HOCbl 
CNCbl 
AdoCbl 
MeCbl 
MeCbl 
HOCbl 
MeCbl 
HOCbl 
Reducing 
systems 
dithionite DTT dithionite 
NADPH/MV 
NADPH/BV 
NADPH/MV 
Table 2-2. Class B radical SAM methyltransferses characterized in vitro.    
The biosynthesis of gentamicins is already described in the Chapter 1. Sequence 
analysis of the gentamicin C1 biosynthetic gene cluster suggested that the methylation 
step at C-6' of gentamicin X2 (GenX2) to yield the clinically useful geneticin (G418)
75, 147
 
is likely catalyzed by a Cbl-dependent radical SAM enzyme, GenK (Scheme 2-6).
77
 
GenK belongs to class B of the radical SAM dependent methyltransferases. Recently 
gene mutation experiments showed that knock-out of the genK gene blocked the 
production of gentamicin C1 or C2, while production of gentamicin C1a was increased 
significantly.
148
 The vitro activity of GenK and results of product stoichiometry, 
mechanism of methyl transfer, and alternative substrates are reported herein.  
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Scheme 2-6. GenK catalysis 
 
2.2. EXPERIMENTAL PROCEDURES 
2.2.1. Materials and Equipment 
All chemicals were purchased from Fisher Science (Pittsburgh, PA) or Sigma-
Aldrich (St. Louise, MO) and used without further purification unless otherwise 
specified. DNA gel extraction and spin minipreps were obtained from Qiagen (Valencia, 
CA). All reagents for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Amicon and Microcon YM-10 filtration products were purchased from Bio-
Rad (Hercules, CA) and Millipore (Billerica, MA), respectively. Escherichia coli DH5a 
cells were bought from Bethesda Research Laboratories (Muskegon, MI). The vector 
pET24b (+) and enzyme KOD DNA polymerase were purchased from Novagen 
(Madison, WI). DNA modifying enzymes (for restriction digestion and ligation), PCR 
primers, and the overexpression host E. coli BL21 star (DE3) were acquired from 
Invitrogen (Carlsbad, CA) and New England Biolabs (NEB, Beverly, MA). Luria Bertani 
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(LB) media are products of Difco (Detroit, MI) or Fisher Scientific (Pittsburgh, PA). Pre-
stained protein markers were purchased from NEB. Protein concentrations were 
determined by Bradford Assay
149
 using bovine serum albumin as the standard. The 
relative molecular mass and purity of enzyme samples were determined using SDS-
PAGE. The general methods and protocols for recombinant DNA manipulations were as 
described by Sambrook et al.
150
 DNA sequencing was performed at the Core Facilities of 
the Institute of Cellular and Molecular Biology, University of Texas at Austin. All 
reactions involving GenK were performed in a Coy Anaerobic Chamber (glovebox) 
under an atmosphere of approximately 97.5% N2 and 2.5% H2 with less than 1 ppm O2. 
All solutions used for GenK assays were deaerated by bubbling with nitrogen gas before 
they were transferred into the glovebox. The solvents in the glove box were stirred open 
to the anaerobic atmosphere overnight to allow equilibration before use. Gentamicin X2, 
G-418, and GenA were purchased from TOKU-E (Bellingham, WA). Tetrahydrofuran 
(THF) was distilled from sodium benzophenone and dichloromethane (CH2Cl2) was 
distilled over calcium hydride under a nitrogen atmosphere. Other anhydrous solvents 
were purchased from Acros Organics (Pittsburgh, PA). Analytic thin layer 
chromatography (TLC) was performed on pre-coated TLC glass plates (silica gel, grade 
60, F254, 0.25 mm layer thickness) purchased from EMD Chemicals (Madison, WI). 
Flash column chromatography was carried out on silica gel (230-400 mesh, grade 60) 
from Sorbent Technologies (Atlanta, GA) by eluting with the specified solvents. 
1
H and 
13
C NMR spectra were recorded at 400, 500, 600 MHz and 100, 125, 150 MHz with a 
Varian Gemini Spectrometer. Chemical shifts are reported as parts per million (ppm) 
relative to deuteriochloroform (CDCl3), 7.26 ppm for 
1
H NMR and 77.16 ppm for 
13
C 
NMR, respectively. Visualization in TLC was effected with p-phosphoryl molybdic acid 
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solution.  MS analyses were carried out at the Mass Spectrometry and Proteomics 
Facility of the Department of Chemistry, University of Texas at Austin. 
 
2.2.2. Cloning and Expression of Micromonospora echinospora GenK 
The gentamicin producer M. echinospora (NRRL 2953) was obtained from the 
Agricultural Research Service of the US Department of Agriculture as a lyophilized 
sample. It was inoculated into 10 mL of tryptic soybroth (TSB) starter culture,
151
 which 
was incubated overnight at 30 °C with shaking at 250 rpm. The following day, 0.1 mL of 
starter culture was inoculated into 10 mL of fresh TSB, and the resulting culture was 
inoculated at 30 °C for 72 hr. Chromosomal DNA was extracted from 1.5 mL of this 
culture using a Qiagen DNeasy tissue kit. The genK gene was PCR amplified from the 
isolated M. echinospora DNA with the following primers:  
5-CAACATATGAACGCGCTGGTGGCAGC (forward), 
5-TAACGAATTCAGTGGGAAACCGCCTCGG (reverse), 
and cloned into a pCR:blunt vector (Invitrogen) prior to excision with NdeI and EcoRI 
and ligation into the pET24 vector (Invitrogen). The resulting expression plasmid, 
pET24:genK, was used to transform E. coli Rosetta DE3 cells (Novagen) for expression 
of native and, recombinant GenK. Transformants were grown in 3 L of LB medium at 18 
°C with shaking at 200 rpm. GenK expression was induced with 1 mM IPTG when the 
cells had reached an optical density of 0.6 at 600 nm. Cells were harvested by 
centrifugation 20 h after induction (5000  g, 15 min), resuspended in 50 mM TrisHCl 
buffer (pH 8.0) containing 10% glycerol, and 1 mM PMSF, and lysed by sonication. Cell 
lysate was centrifuged at 25,000  g for 30 min to pellet the insoluble material. 
Preliminary protein expression analysis using SDS-PAGE revealed that GenK, although 
abundant, was expressed exclusively as inclusion bodies. Therefore, the resulting 
 49 
supernatant was discarded and the pelleted inclusion bodies were washed three times in 
lysis buffer and dissolved in 20 mL of 50 mM TrisHCl buffer (pH 8.0) containing 20% 
glycerol, 1 mM PMSF and 5 M urea. This material was centrifuged at 4,000  g for 10 
min to remove insoluble material. 
 
2.2.3. Refolding of GenK from Inclusion Bodies and Reconstitution with Iron and 
Sulfide 
The solublized GenK inclusion bodies, processed as described above, were added 
dropwise to 200 mL of refolding buffer composed of 50 mM TrisHCl (pH 8.0), 1 mM 
MgSO4, 5 mM reduced glutathione, 0.5 mM glutathione disulfide, 5 mM DTT, and 10% 
glycerol. This mixture was kept refrigerated for 24 h with gentle stirring and was then 
concentrated to 7 mL in an Amicon YM-10 centrifugal concentrator. The protein was 
dialyzed overnight against 800 mL of 50 mM TrisHCl (pH 8.0) containing 0.1 M NaCl, 
1 mM DTT, and 20% glycerol. Afterward, the protein was centrifuged to remove 
precipitated material and the supernatant was reconstituted with iron and sulfide in an 
anaerobic glovebox according to an established procedure.
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 Iron content in the 
reconstituted GenK was assessed using the ferrozine assay
153
 and the sulfide content was 
determined by the method devised by Helmut Bienert.
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 The iron and sulfide content 
reported in the chapter is an average of three measurements.  
 
2.2.4. Enzymatic Synthesis and Purification of S-Adenosyl-L-Methionine (SAM) 
The gene encoding E. coli SAM synthetase (metK) was cloned into pET28b(+) 
and the resulting construct was used to transform BL21(DE3) for expression of 
recombinant His6-tagged protein. An incubation of 6 L of E. coli containing 
pET28b(+):metK in LB media was induced with 0.1 mM IPTG when the culture had 
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reached an optical density of 0.5 at 600 nm, overexpressed overnight at 25 C, harvested 
by centrifugation (5000  g, 15 min), and resuspended in 100 mL of 50 mM TrisHCl (pH 
8.0), 1 M NaCl, 1 mM -mercaptoethanol, 10 mM imidazole, and 10% glycerol (lysis 
buffer). Resuspended cells were lysed by sonication and the lysate was centrifuged at 
27,200  g for 20 min. Cleared lysate was mixed with 10 mL of Ni
2+
-nitrilotriacetic acid 
(NTA) resin (Qiagen) pre-equilibrated with wash buffer (lysis buffer containing 20 mM 
imidazole) for 90 min. The Ni
2+
-NTA was poured into a column casing and rinsed with 
100 mL of the wash buffer. MetK was eluted by the addition of elution buffer (lysis 
buffer containing 0.25 M imidazole). The pooled MetK was dialyzed against a 1 L 
solution of 50 mM TrisHCl (pH 8.0), 0.15 M NaCl, 1 mM -mercaptoethanol, and 10% 
glycerol. The final yield of MetK was 60 mL of 9.5 mg/mL. MetK was used to prepare 
SAM enzymatically from L-methionine and ATP and purified as described previously.
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13
CD3-methyl-SAM was prepared from 
13
CD3-methyl-L-methionine (purchased from 
SigmaAldrich) using the same procedure. The purity of the enzymatically prepared SAM 
was assessed by high performance liquid chromatography (HPLC) using a Dionex 
CarboPac PA1 (4  250 mm) column with an isocratic 0.5 M ammonium acetate elution 
at 1 mL/min. The purified SAM was lyophilized, resuspended in 2 mL H2O, divided into 
50 µL aliquots, and stored at –80 °C until use. 
 
2.2.5. GenK Activity Assays 
All GenK activity assays were conducted at ambient temperature under anaerobic 
conditions in a Coy anaerobic chamber. The reaction mixture contained the following: 50 
mM TrisHCl (pH 8.0), 10 mM dithiothreitol (DTT), 1 mM methyl viologen (MV), 4 
mM nicotinamide adenine dinucleotide phosphate (NADPH), 4 mM enzymatically 
prepared SAM, 1 mM gentamicin X2 (GenX2) (7), 1 mM cobalamin (Cbl), and 5 µM 
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GenK (unless otherwise noted). Assay reactions were initiated by the addition of GenX2, 
and ran for 8 h unless otherwise specified. Reaction aliquots designated for HPLC 
analysis of adenosylated products, S-adenosylhomocysteine (SAH) and 5'-
deoxyadenosine (5-dAdo), were quenched by adding a volume of 30% trichloroacetic 
acid (TCA) equal to one tenth of the analyte volume. Reaction aliquots designated for 
analysis of aminoglycosides (30 µL) were quenched with a mixture containing 112 µL of 
methanol, 6 µL of 0.5 M NaOH, and 1.8 µL of 8.4 M 1-fluoro-2,4-dinitrobenzene 
(FDNB) to give final concentrations of 20 mM NaOH, 75% methanol, and 0.1 M FDNB. 
These were heated at 80 C for 5 min to promote derivatization of primary amines with 
FDNB so they could be detected by UV absorbance at 340 nm.
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 Reaction aliquots 
analyzed by mass spectroscopy were quenched by passage through YM-10 Microcon 
centrifugal filters to remove GenK. 
 
2.2.6. HPLC Detection of SAH and 5'-dAdo 
A 25 µL aliquot of a TCA-quenched GenK reaction described above was 
analyzed by HPLC equipped with a Varian Microsorb-MV 100-5 C18 (4.6  250 mm) 
column pre-equilibrated in H2O containing 0.1% trifluoroacetic acid (solvent A). After 
sample loading, the column was eluted with a linear gradient from 0–20% acetonitrile 
containing 0.1% trifluoroacetic acid (solvent B) over 30 min to resolve 5-dAdo and 
SAH. The UV detector was set at 260 nm. A blend of authentic, commercially obtained 
5-dAdo and SAH was injected as a retention time standard for each. Quantitation of 5-
dAdo and SAH produced during assays was achieved by comparison of analyte peak 
areas with those of 5-dAdo and SAH standards of known concentration. 
 
2.2.7. HPLC Detection of Aminoglycoside 
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A 10 µL aliquot of a FDNB-derivatized GenK assay mixtures was prepared as 
described in Section 2.2.5, loaded onto a Varian Microsorb-MV 100-5 C18 (4.6  250 
mm) column and eluted with a gradient from 60:40  50:50 water:acetonitrile over 20 
min. The UV detector was set at 340 nm. A blend of authentic, commercially obtained 
GenX2 and G418 was injected as a retention time standard for each. Quantitation of the 
conversion of GenX2 to G418 was achieved by comparing the peak areas for each. 
 
2.2.8. Mass Spectroscopic Analysis of GenK Activity 
Assay mixtures were diluted in methanol and infused directly into an Agilent 
6530 Accurate Mass QTOF-MS at 0.15 mL/min. The analyte was ionized by electrospray 
ionization and detected in positive ion mode. 
 
2.2.9. Synthesis of 2-Steptamine Derivative (4). 
The overall synthetic scheme is shown in Scheme 2-7. Compound 4 was prepared 
as previously described.
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Scheme 2-7. Synthetic scheme for the preparation of 5,6-di-O-acetyl-1,3-diazido-1,2,3-
trideoxy-myo-inositol (4). 
 
2.2.10. Synthesis of Xylose Derivative (8) 
 53 
The overall synthetic scheme is shown in Scheme 2-8. Compound 8 was prepared 
as previously described.
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Scheme 2-8. Synthetic scheme for the preparation of (3R, 3S, 5R)-3,4,5-tris(benzyloxy)-
2-(phenylthio)tetrahydro-2H-pyran (8).  
 
2.2.11. Synthesis of Gentamicin A2 
The overall synthetic scheme is shown in Scheme 2-9. 
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Scheme 2-9. Synthetic scheme for the preparation of gentamicin A2. 
(2R,3S,4R,5R,6S)-5-azido-2-(((tert-butyldiphenylsilyl)oxy)methyl)-6-(phenylthio)tet-
rahydro-2H-pyran-3,4-diol (13): Compound 12 was prepared as previously 
described.
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 To a solution of compound 12 (2.0 g, 6.73 mmol) in anhydrous DMF (60 
mL), imidazole (0.916 g, 13.45 mmol) was added. The mixture was stirred for 30 min at 
room temperature. The mixture was cooled to 0 °C and tert-butyldiphenylchlorosilane 
(2.1 mL, 8.07 mmol) was added. The reaction was then allowed to stand for 10 h at room 
temperature. The mixture was treated with methanol (10 mL) at 0 °C and all the solvent 
was evaporated under reduced pressure. The residue was diluted with dichloromethane 
(80 mL) and washed with saturated aqueous solution of ammonium chloride (70 mL). 
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The aqueous layer was extracted with dichloromethane (70 mL × 2). The combined 
organic extracts were washed with brine, dried over magnesium sulfate, filtered and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 1:1) to afford compound 13 (3.4 g, 94 %) as 
a colorless oil. All NMR spectra were consistent with previously reported data.
160
 HRMS 
(ESI, positive) calculated for C28H33N3O4SSi
+
 [M + Na]
+
 558.1853, found 558.1870. 
(((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyran-
2-yl)methoxy)(tert-butyl)diphenylsilane (14): Sodium hydride (60% dispersion in 
mineral oil, 0.558 g, 13.96 mmol) and benzyl bromide (1.96 mL, 16.5 mmol) was added 
to a solution of compound 13 (3.4 g, 6.35 mmol) in DMF (60 mL) at 0 °C. After stirring 
the mixture for 8 h at room temperature, methanol (20 mL) was added at 0 °C. The 
mixture was stirred for an additional 20 min before concentration under reduced pressure. 
The residue was diluted with dichloromethane (80 mL) and washed with water (60 mL) 
and brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The crude 
compound was purified by flash column chromatography (Hex/EtOAc = 10:1) to give 
compound 14 (4.311 g, 95%) as a clear oil. All NMR spectra were consistent with 
previously reported data.
160
 HRMS (ESI, positive) calculated for C42H45N3O4SSi
+
 [M + 
Na]
+
 739.2792, found 738.2793. 
((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyran-2-
yl)methanol (15): Tetrabutylammonium fluoride (1 M solution in THF, 12.04 mL, 12. 04 
mmol) was added to a solution of compound 14 (4.311 g, 6.02 mmol) in THF (60 mL). 
The reaction mixture was stirred at room temperature for 2 h, and quenched by adding a 
saturated solution of aqueous ammonium chloride (40 mL). The aqueous layer was 
extracted with ethyl acetate (60 mL × 2). The combined organic extracts were washed 
with brine, dried over magnesium sulfate, filtered and concentrated under reduced 
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pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 3:1) to give compound 15 (2.847 g, 99%) as a white solid. All NMR 
spectra were consistent with previously reported data.
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 HRMS (ESI, positive) calculated 
for C42H45N3O4SSi
+
 [M + Na]
+
 739.2792, found 738.2793. 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-methoxybenzyl)oxy)methyl)-2-
(phenylthio)tetrahydro-2H-pyran (16): sodium hydride (60% in mineral oil, 0.289 g, 
7.23 mmol) and p-methoxybenzyl chloride (0.98 mL, 7.23 mmol) were added to a 
solution of compound 15 (2.847 g, 5.96 mmol) in anhydrous DMF (60 mL) at 0 °C. The 
reaction mixture was stirred at room temperature for 8 h. The mixture was treated with 
methanol (10 mL) at 0 °C and all the solvent was evaporated under reduced pressure. The 
residue was diluted with dichloromethane (60 mL) and washed with water (40 mL). The 
aqueous layer was extracted with dichloromethane (60 mL × 2), and the combined 
organic extracts were washed with brine, dried over sodium sulfate, filtered, and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 9:1) to afford compound 16 (2.951 g, 82%) 
as a white solid. 
1
H NMR (400 MHz, CDCl3) δ7.68–7.64 (m, 2H, Ph), 7.40–7.29 (m, 
13H, Ph), 7.26–7.23 (m, 2H, Ph), 6.95–6.90 (m, 2H, Ph), 4.90 (dd, J = 14.0, 10.6 Hz, 2H, 
PMB), 4.83 (d, J = 10.9 Hz, 1H, Bn), 4.62 (d, J = 10.9 Hz, 1H, Bn), 4.61 (d, J = 11.6 Hz, 
1H, Bn), 4.52 (d, J = 11.6 Hz, 1H, Bn), 4.47 (d, J = 10.1 Hz, 1H, H-1), 3.84 (s, 3H, -
OMe), 3.82–3.74 (m, 2H, H-6, H-6'), 3.66 (dd, J = 9.8, 8.9 Hz, 1H, H-4), 3.56 (t, J = 9.1 
Hz, 1H, H-3), 3.53–3.49 (m, 1H, H-5), 3.41 (dd, J = 10.1, 9.2 Hz, 1H, H-2). 13C NMR 
(100 MHz, CDCl3) δ159.3, 134.9, 137.7, 133.6, 131.4, 130.3, 129.34, 129.03, 128.55, 
128.48, 128.35, 128.30, 128.22, 128.03, 127.90, 127.86, 113.8, 86.0, 85.1, 79.4, 77.61, 
75.88, 75.04, 73.1, 68.4, 55.3. HRMS (ESI, positive) calculated for C42H45N3O4SSi
+
 [M + 
Na]
+
 739.2792, found 738.2793. 
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(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-
methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl 
diacetate (17) : Compound 4 (2.023 g, 6.78 mmol) and compound 16 (4.865g, 8.139 
mmol) were co-evaporated from dry toluene three times and further dried under high 
vacuum overnight. A solution of compound 4 and 16 in anhydrous diethyl ether (60 mL) 
and anhydrous dichloromethane (20 mL) was then added to preactivated 4 Å  molecular 
sieves. After stirring for 30 min at room temperature, the mixture was cooled to –40 °C. 
N-Iodosuccinimide (3.968 g, 17.64 mmol) was added, and the reaction mixture was 
stirred for 20 min. Trifluoromethanesulfonic acid (0.30 mL, 3.39 mmol) was slowly 
added, and the reaction was warmed to –20 °C and kept stirring for 30 min. Sodium 
bisulfite (1 g), sodium bicarbonate (1 g), and water (10 mL) were added at 0 °C, and the 
mixture was stirred for 10 min at room temperature. The reaction mixture was diluted 
with dichloromethane (50 mL), filtered through a Celite pad, and washed with a saturated 
solution of aqueous sodium bicarbonate (100 mL). The aqueous layers were extracted 
with dichloromethane (100 mL × 3), and the combined organic phase was washed with 
brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) to 
give compound 17 (3.465 g, 65%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.33–7.23 
(m, 12H, Ph), 7.13–7.11 (m, 2H, Ph), 6.85–6.83 (m, 2H, Ph), 5.15 (t, J = 9.8 Hz, 1H, H-
5), 5.14 (d, J = 3.9 Hz, 1H, H-1'), 4.93 (t, J = 10.0 Hz, 1H, H-6), 4.85 (dd, J = 30.6, 10.6 
Hz, 2H, PMB), 4.77 (d, J = 10.8 Hz, 1H, Bn), 4.61 (d, J = 11.8 Hz, 1H, Bn), 4.48 (d, J = 
10.85 Hz, 1H, Bn), 4.41 (d, J = 11.8 Hz, 1H, Bn), 4.15 (td, J = 8.1, 2.4 Hz, 1H, H-5'), 
3.95 (dd, J = 10.5, 9.0 Hz, 1H, H-3'), 3.81 (dd, J = 10.8, 2.8 Hz, 1H, H-6'), 3.77 (dd, J = 
9.9, 9.3 Hz, 1H, H-4'), 3.76 (s, 3H, -OCH3), 3.67–3.59 (m, 3H, H-1, H-6', H-4), 3.43–
3.38 (m, 1H, H-3), 3.36 (dd, J = 10.5, 3.8 Hz, 1H, H-2'), 2.40 (dt, J = 13.4, 4.6 Hz, 1H, 
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H-2), 2.094 (s, 3H, -OAc), 2.085 (s, 3H, -OAc), 1.60 (q, J = 12.5 Hz, 1H, H-2). 
13
C NMR 
(125 MHz, CDCl3) δ 169.8, 169.5, 159.3, 137.9, 137.8, 129.8, 129.7, 128.45, 128.38, 
127.97, 127.86, 127.75, 127.67, 113.8, 99.3, 79.7, 78.29, 78.11, 75.3, 74.9, 74.1, 73.6, 
73.2, 71.7, 67.4, 63.1, 58.7, 57.7, 55.2, 31.8, 20.64, 20.57. HRMS (ESI, positive) 
calculated for C42H45N3O4SSi
+
 [M + Na]
+
 739.2792, found 738.2793. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-
(((4-methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol 
(18) : Sodium methoxide (4.37 M in methanol, 0.19 mL, 8.14 mmol) was added dropwise 
to a solution of compound 17 (3.2 g, 4.072 mmol) in methanol (40 mL). The reaction 
mixture was stirred at room temperature for 8 h and then neutralized with Amberlite IR-
120 (H
+
 form) resin, filtered and concentrated. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 3:2) to give compound 18 (2.347 g, 82%) as 
a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.35–7.24 (m, 10H, Ph), 7.13–7.11 (m, 
2H, Ph), 6.84–6.82 (m, 2H, Ph), 5.14 (d, J = 3.7 Hz, 1H, H-1'), 4.88 (dd, J = 37.2, 10.6 
Hz, 2H, PMB), 4.75 (d, J = 10.8 Hz, 1H, Bn), 4.60 (d, J = 11.8 Hz, 1H, Bn), 4.48 (d, J = 
10.8 Hz, 1H, Bn), 4.40 (d, J = 11.8 Hz, 1H, Bn), 4.21 (s, 1H, OH), 4.08 (td, J = 8.0, 2.6 
Hz, 1H, H-5'), 3.96 (dd, J = 10.2, 9.1 Hz, 1H, H-3'), 3.78 (dd, J = 10.7, 3.2 Hz, 1H, H-6'), 
3.75 (s, 3H, OCH3), 3.75 (m, 1H, H-4'), 3.66–3.63 (m, 2H, H-2', H-6'), 3.50–3.38 (m, 3H, 
H-4, H-5, H-1), 3.28–3.22 (m, 2H, H-3, H-6), 2.33–2.27 (m, 1H, H-2), 1.53–1.46 (m, 1H, 
H-2). 
13
C NMR (125 MHz, CDCl3) δ 159.3, 137.8, 137.5, 129.74, 129.70, 128.49, 
128.43, 128.05, 127.98, 127.85, 127.72, 113.8, 99.6, 84.0, 80.9, 78.1, 75.82, 75.63, 75.32, 
74.97, 73.2, 71.6, 67.5, 64.3, 59.6, 58.7, 55.2, 32.1. HRMS (ESI, positive) calculated for 
C42H45N3O4SSi
+
 [M + Na]
+
 739.2792, found 738.2793. 
(1S,2R,3S,5R,6S)-3,5-diazido-2-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-
methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-
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tris(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (19): Compound 8 
(2.352 g, 4.59 mmol) and compound 18 (2.925 g, 4.171 mmol) were co-evaporated from 
dry toluene three times and further dried under high vacuum overnight. A solution of 
compound 8 and 18 in anhydrous dichloromethane (50 mL) was added to a preactivated 4 
Å  molecular sieves and N-iodosuccinimide (1.502 g, 6.67 mmol). After stirring for 30 
min at room temperature, the mixture was cooled to –78 °C. Trifluoromethanesulfonic 
acid (0.11 mL, 1.25 mmol) was slowly added, and the reaction was warmed to 0 °C 
slowly. The reaction was quenched by adding solid sodium sulfite (0.5 g), sodium 
bicarbonate (0.5 g) and water (100 mL) at 0 °C. The reaction mixture was diluted with 
dichloromethane, filtered, and washed with a saturated solution of sodium bicarbonate 
and brine. The residue was dried over sodium sulfate, filtered, concentrated in reduced 
pressure, and purified by flash column chromatography on silica gel (Hex:EtOAc = 3:2) 
to give compound 19 (3.746 g, 81%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.44–
7.24 (m, 25H, Ph), 7.14 (m, 2H, Ph), 6.89–6.80 (m, 2H, Ph), 5.47 (d, J = 3.7 Hz, 1H, H-
1'), 5.08 (d, J = 3.6 Hz, 1H, H-1''), 4.95–4.84 (m, 4H, Bn), 4.81–4.72 (m, 4H, Bn), 4.63 
(dd, J = 13.7, 11.7 Hz, 2H, Bn), 4.49 (d, J = 10.9 Hz, 1H, Bn), 4.42 (d, J = 11.8 Hz, 1H, 
Bn), 4.37 (d, J = 2.1 Hz, 1H, OH), 4.16–4.10 (m, 1H, H-5'), 3.97 (dtd, J = 18.4, 9.6, 9.2, 
6.9 Hz, 3H, H-5, H-3', H-3''), 3.84–3.69 (m, 6H, H-5'', H-4', H-6', OMe), 3.65 (ddd, J = 
9.1, 5.3, 2.2 Hz, 2H, H-5, H-6'), 3.62–3.54 (m, 1H, H-4''), 3.54–3.48 (m, 3H, H-1, H-2', 
H-2''), 3.43–3.36 (m, 1H, H-4), 3.36–3.27 (m, 2, H-3, H-6), 2.40–2.31 (m, 1H, H-2), 1.54 
(q, J = 12.7 Hz, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 159.40, 138.89, 138.21, 
138.17, 138.14, 137.97, 129.99, 129.82, 128.61, 128.59, 128.56, 128.52, 128.49, 128.40, 
128.20, 128.17, 128.15, 128.11, 128.05, 128.01, 127.98, 127.92, 127.85, 127.79, 127.73, 
113.89, 99.11, 98.21, 83.41, 81.60, 80.90, 80.52, 79.28, 78.18, 77.75, 75.76, 75.64, 75.25, 
75.02, 73.77, 73.72, 73.28, 71.54, 67.68, 63.88, 61.23, 59.81, 58.83, 55.34, 32.39, 29.84. 
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HRMS (ESI, positive) calculated for C60H65N9O12
+
 [M + Na]
+
 1126.4645, found 
1126.4643. 
(1S,2R,3S,5R,6S)-3,5-diazido-2-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(hy-
droxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-tris(benzyloxy-
)tetrahydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (20): 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (1.183 g, 5.21 mmol) was added to a solution of compound 19 (3.746g, 
2.47 mmol) in dichloromethane (50 mL) and water (5 mL). The reaction mixture was 
stirred for 4 h at room temperature, and then quenched by adding a saturated solution of 
aqueous sodium bicarbonate (30 mL). The aqueous layer was extracted with 
dichloromethane (40 mL × 3), and the combined organic phase was washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) and 
recrystallization with Hex/EtOAc (10:1) to give compound 20 (2.330 g, 70%) as a white 
solid. 
1
H NMR (500 MHz, CDCl3) δ 7.58–7.27 (m, 25H, Bn), 5.50 (d, J = 3.7 Hz, 1H, H-
1'), 5.07 (d, J = 3.6 Hz, 1H, H-1''), 5.00–4.85 (m, 5H, Bn), 4.84–4.70 (m, 4H, Bn), 4.66 
(d, J = 11.5 Hz, 1H, Bn), 4.44 (d, J = 2.1 Hz, 1H, OH), 4.10–4.02 (m, 2H, H-3', H-5'), 
4.01–3.91 (m, 2H, H-3'', H-5''), 3.87 (dd, J = 12.2, 2.5 Hz, 1H, H-6'), 3.80 (dd, J = 12.3, 
3.4 Hz, 1H, H-6'), 3.75 (dd, J = 11.1, 5.8 Hz, 1H, H-5''), 3.69 (m, 2H, H-4', H-5'), 3.61 
(ddd, J = 10.5, 8.6, 5.6 Hz, 1H, H-4''), 3.53 (m, 2H, H-2'', H-1), 3.44 (dd, J = 10.3, 3.7 
Hz, 1H, H-2'), 3.36 (m, 3H, H-4, H-3, H-6), 2.36 (dt, J = 13.0, 4.3 Hz, 1H, H-2), 1.53 (q, 
J = 12.5 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 138.82, 138.15, 138.11, 138.00, 
137.89, 128.58, 128.54, 128.50, 128.41, 128.16, 128.07, 128.03, 127.98, 127.95, 127.92, 
127.67, 98.76, 98.20, 83.90, 81.05, 80.74, 79.21, 77.83, 77.60, 75.63, 75.58, 75.08, 73.67, 
73.65, 72.18, 63.79, 61.36, 61.27, 59.60, 58.94, 32.36. HRMS (ESI, positive) calculated 
for C52H57N9O11
+
 [M + Na]
+
 1006.4070, found 1006.4076. 
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Gentamicin A2 (21): Trimethylphosphine (1 M solution in THF, 1.96 mL, 1.96 mmol) 
was added to a solution of compound 20 (0.476 g, 0.50 mmol) in THF (12 mL) and 0.1 M 
NaOH (3 mL), and the reaction mixture was stirred at 50 °C for 2 h. After cooling to 
room temperature, the solution was evaporated under reduced pressure. After added in a 
mixture of acetic acid (3 mL), water (9 mL) and methanol (9 mL), the solution was 
deaerated by evacuating the air in the flask and refilling it with argon five times. 
Palladium hydroxide on carbon (20%, Degussa type, 0.2 g) was added and the solution 
was charged with hydrogen gas. The reaction mixture was then stirred at room 
temperature under hydrogen gas for 24 h. The solution was then filtered through a Celite 
pad, washed with water and methanol, and concentrated under reduced pressure. The 
residue was purified by chromatography on Amberlite CG-50 resin (0-5% concentrated 
ammonium hydroxide in water), acidified with hydrochloric acid (pH ca. 4), and 
lyophilized to provide compound 21 (0.204 g, 90%) as an oily solid. 
1
H NMR (500 MHz, 
D2O) δ 5.61 (d, J = 4.0 Hz, 1H, H-1'), 4.96 (d, J = 2.5 Hz, 1H, H-1''), 3.89–3.82 (m, 3H, 
H-3', H-5', H-6'), 3.81–3.75 (m, 2H, H-4', H-5), 3.72–3.63 (m, 4H, H-5'', H-6', H-5'', H-
3''), 3.63–3.48 (m, 5H, H-6, H-2'', H-4'', H-1, H-3'), 3.46–3.42 (m, 1H, H-4), 3.42–3.38 
(m, 1H, H-2'), 2.47 (dt, J = 12.6, 4.3 Hz, 1H, H-2), 1.85 (q, J = 12.7 Hz, 1H, H-2). 13C 
NMR (125 MHz, D2O) δ 101.8, 97.1, 83.4, 80.4, 73.72, 73.61, 72.91, 69.36, 68.99, 68.88, 
62.4, 60. 4, 53.9, 49.6, 48.7, 27.9 HRMS (ESI, positive) calculated for C17H33N3O11
+
 [M 
+ Na]
+
 478.2007, found 478.2012. 
 
2.2.12. Synthesis of 6'-Amino-6'-dehydroxy-gentamicin A2 
The overall synthetic scheme is shown in Scheme 2-10. 
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Scheme 2-10. Synthetic scheme for the preparation of 6'-amino-6'-deoxy-gentamicin A2.  
((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(((1R,2S,3S,4R,6S)-4,6-diazido-2-
hydroxy-3-(((2R,3R,4S,5R)-3,4,5-tris(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)cycl-
o-hexyl)oxy)tetrahydro-2H-pyran-2-yl)methyl 4-methylbenzenesulfonate (22): p-
Toluenesulfonyl chloride (0.417 g, 2.19 mmol) was added to a solution of compound 21 
(0.420 g, 0.44 mmol) in pyridine (20 mL) at 0 °C. The reaction mixture was stirred at 
room temperature for 8 h. Methanol (5 mL) was then added to the solution at 0 °C, and 
the mixture was stirred at room temperature for 30 min. The solution was concentrated 
under reduced pressure, and co-evaporated with toluene twice. The residue was diluted 
with dichloromethane (30 mL), and washed with a saturated solution of aqueous sodium 
bicarbonate (20 mL). The aqueous layer was extracted with dichloromethane (30 mL × 
2), and the combined organic phase was washed with brine, dried over magnesium 
sulfate, filtered and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (Hex/EtOAc = 4:1) to give the tosylate 22 
(0.481 g, 97%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.84–7.78 (m, 2H, Bn), 
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7.44–7.27 (m, 25H, Bn), 7.22 (dd, J = 7.5, 2.0 Hz, 2H, Bn), 5.46 (d, J = 3.7 Hz, 1H, H-
1'), 5.04 (d, J = 3.5 Hz, 1H, H-1''), 4.95–4.87 (m, 3H, Bn), 4.86 (d, J = 5.3 Hz, 1H, Bn), 
4.82 (d, J = 6.2 Hz, 1H, Bn), 4.81–4.73 (m, 3H, Bn), 4.65 (d, J = 11.5 Hz, 1H, Bn), 4.54 
(d, J = 10.8 Hz, 1H, Bn), 4.41–4.32 (m, 2H, H-6', H-6'), 4.31–4.17 (m, 2H, H-5'', H-5'), 
4.04–3.87 (m, 3H, H-3'', H-3', H-5''), 3.75 (dd, J = 11.2, 5.7 Hz, 1H, H-5''), 3.70–3.56 (m, 
3H, H-4', H-4'', H-5), 3.56–3.46 (m, 2H, H-2'', H-1), 3.40–3.26 (m, 4H, H-2', H-4, H-3, 
H-6), 2.42 (s, 3H, Ts), 2.34 (dt, J = 13.4, 4.3 Hz, 1H, H-2), 1.50 (q, J = 12.5 Hz, 1H, H-
2). 
13
C NMR (125 MHz, CDCl3) δ 144.90, 138.77, 138.11, 138.09, 138.07, 137.70, 
137.60, 132.93, 129.85, 128.52, 128.51, 128.48, 128.38, 128.37, 128.04, 128.02, 128.00, 
127.97, 127.94, 127.92, 127.89, 127.82, 127.80, 127.64, 98.43, 98.26, 84.28, 80.67, 
80.51, 80.11, 79.14, 77.51, 77.36, 77.31, 77.10, 77.06, 76.85, 76.81, 75.60, 75.50, 75.28, 
75.05, 73.68, 73.64, 69.68, 68.21, 63.47, 61.29, 59.51, 58.68, 32.20, 21.66. HRMS (ESI, 
positive) calculated for C59H63N9O13S
+
 [M + Na]
+
 1160.4158, found 1160.4164. 
(1S,2R,3S,5R,6S)-3,5-diazido-2-(((2R,3R,4R,5R,6R)-3-azido-6-(azidomethyl)-4,5-bis-
(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-tris(benzyloxy)-
tetrahydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (23): Sodium azide (0.137 g, 2.11 
mmol) and tetrabutylammonium iodide (1.5 mg, 4.3 mmol) was added to a solution of the 
previously synthesized tosylate 22 (0.481 g, 0.42 mmol) in DMF (20 mL). The reaction 
mixture was stirred at 60 °C for 7 h. After cooling to room temperature, the reaction 
solution was evaporated under reduced pressure, and the residue was purified by flash 
column chromatography on silica gel (Hex/EtOAc = 5:1) to give compound 23 (0.327 g, 
77%) as a colorless oil. 
1
H NMR (500 MHz, CDCl3)  7.38–7.28 (m, 25H, Bn), 5.53 (d, J 
= 3.7 Hz, 1H, H-1'), 5.02 (d, J = 3.5 Hz, 1H, H-1''), 4.93–4.71 (m, 8H, Bn), 4.66 (m, 2H, 
Bn), 4.37 (d, J = 2.1 Hz, 1H, OH), 4.19 (ddd, J = 10.0, 4.4, 2.5 Hz, 1H, H-5'), 3.99 (dd, J 
= 10.4, 8.8 Hz, 1H, H-3'), 3.97–3.92 (m, 1H, H-3''), 3.92-3.86 (m, 1H, H-5''), 3.72 (dd, J 
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= 11.1, 5.6 Hz, 1H, H-5''), 3.66 (td, J = 9.0, 2.0 Hz, 1H, H-5), 3.61-3.47 (m, 5H, H-4, H-
4', H-4'', H-2'', H-1), 3.44 (dd, J = 6.9, 3.5 Hz, 1H, H-2'), 3.42-3.33 (m, 3H, H-6', H-6', H-
3), 3.30 (t, J = 9.5 Hz, 1H, H-6), 2.35 (dt, J = 13.2, 4.4, 1H, H-2), 1.54–1.48 (m, 1H, H-
2). 
13
C NMR (125 MHz, CDCl3)  138.74, 138.07, 138.03, 137.70, 128.52, 128.50, 
128.48, 128.34, 128.06, 128.01, 127.99, 127.98, 127.95, 127.89, 127.87, 127.80, 127.60, 
98.44, 98.27, 84.26, 80.65, 80.64, 80.10, 79.11, 78.65, 77.47, 75.58, 75.54, 75.33, 75.17, 
73.64, 73.63, 71.07, 63.66, 61.28, 59.54, 58.81, 51.04, 32.30. HRMS (ESI, positive) 
calculated for C52H56N12O10
+
 [M + Na]
+
 1031.4135, found 1031.4142. 
6'-amino-6'-dehydroxy-GenA2 (24): Trimethylphosphine (1 M solution in THF, 1.29 
mL, 1.29 mmol) was added to a solution of compound 23 (0.327 g, 0.324 mmol) in THF 
(12 mL) and 0.1 M NaOH (4 mL). The reaction mixture was stirred at 50 °C for 2 h, 
cooled to room temperature, and concentrated in vacuo. The material was dissolved in a 
mixture of acetic acid (3 mL), water (9 mL) and methanol (9 mL). The solution was 
deaerated by evacuating the air inside of the flask and refilling it with nitrogen five times. 
Palladium hydroxide on carbon (20%, Degussa type, 0.1 g) was added and the solution 
was charged with hydrogen gas. The reaction mixture was stirred at room temperature 
under hydrogen gas for 24 hr. The solution was filtered through Celite pad, washed with 
water and methanol, and concentrated under reduced pressure. The residue was purified 
by chromatography on Amberlite CG-50 resin (NH4
+
 form) (5-10% concentrated 
ammonium hydroxide in water), acidified with hydrochloric acid (pH ca. 4), and 
lyophilized to provide compound 24 (0.13 g, 88%) as an oily solid. 
1
H NMR (500 MHz, 
D2O)  6.02 (d, J = 3.9 Hz, 1H, H-1'), 5.07 (d, J = 2.5 Hz, 1H, H-1''), 4.12–4.01 (m, 3H, 
H-5', H-3', H-5), 3.93 (t, J = 9.1 Hz, 1H, H-4'), 3.85–3.50 (m, 8H, H-5'', H-3'', H-5'', H-6, 
H-2'', H-4'', H1, H3), 3.60–3.50 (m, 3H, H-6', H-4, H-2'), 3.36 (dd, J = 13.6, 6.7 Hz, 1H, 
H-6'), 2.65–2.56 (m, 1H, H-2), 2.01 (q, J = 12.7 Hz, 1H, H-2). 13C NMR (125 MHz, 
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D2O)  101.9, 96.2, 83.6, 77.51, 74.11, 72.88, 71.63, 70.58, 69.2, 68.83, 68.19, 62.5, 
53.4, 49.7, 48.2, 40.2, 27.9. HRMS (ESI, positive) calculated for C17H34N4O10
+
 [M + 
Na]
+
 477.2167, found 477.2167. 
 
2.2.13. Synthesis of 2'-Deamino-2'-hydroxy-gentamicin A2 
The overall synthetic scheme is shown in Scheme 2-11. 
 
 
Scheme 2-11. Synthetic scheme for the preparation of 2'-deamino-2'-hydroxy-GenA2.  
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triyl 
triacetate (27): Compound 26 was prepared as previously described.
162
 Imidazole (4.167 
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g, 36.72 mmol) and tert-butyldiphenylsilyl chloride (5.73 mL, 22.03 mmol) was added to 
a solution of compound 26 (5.00 g,18.36 mmol) in dry DMF (150 mL) at 0 °C, and the 
reaction mixture was stirred at room temperature for 12 h. The solution was cooled to 0 
°C, and methanol (30 mL) was added to quench the reaction. The mixture was 
concentrated and diluted with dichloromethane (100 mL). The solution was then washed 
with a saturated solution of aqueous ammonium chloride (80 mL). The aqueous wash was 
then extracted with dichloromethane (100 mL × 2). The combined organic layers were 
washed with brine, dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 1:2) to give compound 27 (8.533 g, 91 %) as a white solid. 
1
H NMR (500 
MHz, CDCl3) δ 7.75–7.70 (m, 4H, Ph), 7.56–7.52 (m, 2H, Ph), 7.46–7.35 (m, 6H, Ph), 
7.27–7.21 (m, 3H, Ph), 4.53 (d, J = 9.7 Hz, 1H, C-1), 4.00–3.88 (m, 2H, C-6, C-6), 3.69–
3.56 (m, 2H, C-3, C-4), 3.50–3.42 (m, 1H, C-5), 3.36 (t, J = 8.8 Hz, 1H, C-2), 1.07 (s, 
9H, TBDPS). 
13
C NMR (125 MHz, CDCl3) δ 135.65, 135.60, 132.91, 132.80, 132.53, 
131.91, 129.87, 129.86, 129.00, 128.00, 127.82, 127.81, 87.86, 79.01, 77.78, 71.62, 
71.14, 64.32, 26.81, 19.23. HRMS (ESI, positive) calculated for C28H34O5SSi
+
 [M + Na]
+
 
533.1788, found 533.1796. 
(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3,4,5-triol 
(28): Sodium hydride (60% dispersion in mineral oil, 1.039 g, 25.96 mmol) and benzyl 
bromide (3.11 mL, 25.96 mmol) was added to a solution of compound 27 (3.4 g, 6.35 
mmol) in DMF (40 mL) at 0 °C. After stirring the mixture for 8 h at room temperature, 
methanol (40 mL) was added at 0 °C. The mixture was stirred for an additional 20 min 
before concentration under reduced pressure. The residue was diluted with 
dichloromethane (100 mL) and washed with water (80 mL). The remaining aqueous layer 
was extracted with dichloromethane (80 mL × 2). The combined organic layers were 
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washed with brine, dried over magnesium sulfate, filtered and concentrated in vacuo. The 
residue was purified by flash column chromatography (Hex/EtOAc = 10:1) to give 
compound 28 (4.311 g, 95%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.91–7.85 (m, 
2H, Ph), 7.84–7.79 (m, 2H, Ph), 7.74–7.67 (m, 2H, Ph), 7.54–7.21 (m, 24H, Ph), 5.04–
4.94 (m, 4H, Bn), 4.84 (d, J = 10.3 Hz, 1H, Bn), 4.80 (d, J = 10.3 Hz, 2H, H-1, Bn), 4.10 
(dd, J = 11.4, 1.8 Hz, 1H, H-6), 4.04 (dd, J = 11.4, 3.7 Hz, 1H, H-6), 3.91 (t, J = 9.4 Hz, 
1H, H-4), 3.83 (t, J = 9.0 Hz, 1H, H-3), 3.66 (dd, J = 9.8, 8.7 Hz, 1H , H-2), 3.51 (ddd, J 
= 9.6, 3.7, 1.8 Hz, 1H, H-5), 1.20 (s, 9H, TBDPS). 
13
C NMR (125 MHz, CDCl3) δ 
138.43, 138.25, 138.16, 135.96, 135.71, 134.25, 133.54, 132.97, 131.74, 129.76, 129.72, 
129.00, 128.59, 128.52, 128.51, 128.24, 128.06, 128.05, 127.95, 127.94, 127.92, 127.88, 
127.85, 127.77, 127.34, 87.58, 86.96, 80.87, 80.05, 77.51, 77.40, 77.14, 76.89, 76.10, 
75.49, 75.23, 62.76, 26.97, 19.40. HRMS (ESI, positive) calculated for C49H52O5SSi
+
 [M 
+ Na]
+
 803.3197, found 803.3204. 
(2R,3S,4S,5R,6S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-6-(phenylthio)tetrahydro-
2H-pyran-3,4,5-triol (29): Tetrabutylammonium fluoride (1.0 M solution in THF, 25.6 
mL) was added to a solution of compound 28 (10 g, 12.8 mmol) in THF (120 mL) was 
added and the reaction mixture was stirred at room temperature for 2 hr. The reaction was 
quenched by adding a saturated solution of aqueous ammonium chloride (80 mL) at 0 °C. 
The aqueous layer was extracted with ethyl acetate (80 mL × 2). The combined organic 
layers were dried over magnesium sulfate, filtered, and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 2:1) to give compound 29 (6.253 g, 90 %) as a white solid. 
1
H NMR (500 
MHz, CDCl3) δ 7.57–7.50 (m, 2h, Ph), 7.43–7.38 (m, 2H, Ph), 7.38–7.27 (m, 16H, Ph), 
4.97–4.84 (m, 4H, Bn), 4.78 (d, J = 10.2 Hz, 1H, Bn), 4.74 (d, J = 9.9 Hz, 1H, H-1), 4.67 
(d, J = 11.0 Hz, 1H Bn), 3.89 (dd, J = 12.0, 2.7 Hz, 1H, H-6), 3.80–3.66 (m, 2H, H-3, H-
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6), 3.60 (t, J = 9.4 Hz, 1H, H-4), 3.51 (dd, J = 9.8, 8.7 Hz, 1H, H-2), 3.41 (ddd, J = 9.8, 
4.9, 2.7 Hz ,1H, H-5). 
13
C NMR (125 MHz, CDCl3) δ 138.31, 137.90, 137.84, 133.48, 
131.85, 129.06, 128.54, 128.49, 128.46, 128.23, 128.05, 128.05, 127.99, 127.93, 127.81, 
127.77, 127.70, 87.55, 86.57, 81.12, 79.33, 77.60, 75.85, 75.57, 75.14, 62.15. HRMS 
(ESI, positive) calculated for C33H34O5S
+
 [M + Na]
+
 565.2019, found 565.2040. 
tert-butyldiphenyl(((2R,3R,4S,5R,6S)-3,4,5-tris(benzyloxy)-6-(phenylthio)tetrahydr-
o-2H-pyran-2-yl)methoxy)silane (30): Sodium hydride (60% dispersion in mineral oil, 
0.552 g, 13.8 mmol) was added to a solution of compound 29 (6.24 g, 11.5 mmol) in dry 
DMF (100 mL) at 0 °C, and the reaction mixture was stirred at room temperature for 30 
min. The solution was cooled to 0 °C, and p-methoxybenzyl chloride (1.87 mL, 13.8 
mmol) was added. The reaction mixture was stirred at room temperature for 8 h, 
quenched by adding methanol (30 mL) at 0 °C, and concentrated under reduced pressure. 
The residue was diluted with dichloromethane (80 mL) and washed with a saturated 
solution of aqueous ammonium chloride (60 mL). The remaining aqueous solution was 
extracted with dichloromethane (60 mL × 2). The combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered, and concentrated. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 4:1) to provide 
compound 30 (6.326 g, 83%) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.73–7.62 
(m, 2H, Ph), 7.52–7.22 (m, 20H, Ph), 7.01–6.88 (m, 2H, Ph), 5.02–4.97 (m, 2H, Bn), 4.94 
(d, J = 11.0 Hz, 1H, Bn), 4.91 (d, J = 10.9 Hz, 1H, Bn), 4.83 (d, J = 10.3 Hz, 1H, Bn, 
4.77 (d, J = 9.8 Hz, 1H, H-1), 4.70–4.62 (m, 2H, Bn), 4.56 (d, J = 11.6 Hz, 1H,  Bn), 
3.86 (s, 4H, -OMe, H-6), 3.83–3.77 (m, 2H, H-3, H-6), 3.74 (t, J = 9.3 Hz, 1H, H-4), 
3.65–3.56 (m, 2H, H-2, H-5). 13C NMR (125 MHz, CDCl3) δ 159.25, 138.50, 138.15, 
138.13, 134.00, 131.95, 130.41, 129.45, 128.98, 128.53, 128.50, 128.48, 128.30, 127.99, 
127.94, 127.86, 127.78, 127.48, 113.83, 87.56, 86.82, 80.94, 79.19, 77.90, 75.89, 75.50, 
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75.10, 73.14, 68.69, 55.33. HRMS (ESI, positive) calculated for C41H42O6S
+
 [M + Na]
+
 
685.2594, found 685.2607. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(((4-meth-
oxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate 
(31): Compound 4 (2.283 g, 7.65 mmol) and compound 30 (6.088 g, 9.18 mmol) were 
co-evaporated from dry toluene three times under reduced pressure and further dried 
under high vacuum 12 h. A solution of compound 4 and 29 in anhydrous diethyl ether (90 
mL) and anhydrous dichloromethane (30 mL) was added to preactivated 4 Å  molecular 
sieves. After stirring for 30 min at room temperature, the mixture was cooled to –40 °C. 
N-Iodosuccinimide (4.478 g, 19.9 mmol) was added, and the reaction mixture was stirred 
for 20 min. Trifluoromethanesulfonic acid (0.34 mL, 3.83 mmol) was slowly added, and 
the reaction was warmed to –20 °C and kept stirring for 30 min. The reaction solution 
was diluted with dichloromethane, and filtered through a Celite pad. The filtered solution 
was washed with 10% aqueous sodium bisulfite solution (80 mL), and a saturated 
aqueous solution of sodium bicarbonate solution (80 mL). The combined aqueous 
solution was extracted with dichloromethane (100 mL x 2). The combined organic layers 
were washed with brine, dried over sodium sulfate, filtered, and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 3:2) to give compound 31 (4.3 g, 66%) as a clear oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.37–7.22 (m, 15H, Ph), 7.14–7.09 (m, 2H, Ph), 6.88–6.81 (m, 2H, Ph), 5.23–
5.15 (m, 2H, H-5), 4.95 (t, J = 10.0 Hz, 1H, H-6, H-1'), 4.85 (d, J = 10.8 Hz, 1H, Bn), 
4.82–4.77 (m, 2H, Bn), 4.71 (d, J = 11.8 Hz, 1H, Bn), 4.65 (d, J = 11.8 Hz, 1H, Bn), 4.59 
(d, J = 11.8 Hz, 1H, Bn), 4.43 (d, J = 11.0 Hz, 1H, Bn), 4.39 (d, J = 11.8 Hz, 1H, Bn), 
4.06 (dt, J = 10.1, 2.5 Hz, 1H, H-5'), 3.99–3.92 (m, 1H, H-3'), 3.79–3.71 (m, 4H, H-6'), 
3.68 (dd, J = 10.1, 9.1 Hz, 1H, H-4'), 3.66–3.60 (m, 2H, H-6', H-4), 3.60–3.47 (m, 3H, H-
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3, H-2', H-1), 2.35 (dt, J = 13.4, 4.5 Hz, 1H, H-2), 2.09 (s, 3H, OAc), 1.87 (s, 3H), OAc), 
1.53 (dt, J = 13.5, 12.5 Hz, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 169.97, 169.74, 
159.40, 138.75, 138.53, 137.98, 130.05, 129.84, 128.61, 128.50, 128.39, 128.24, 128.05, 
127.73, 127.72, 127.66, 113.89, 98.10, 81.79, 79.71, 77.72, 77.62, 77.36, 75.77, 74.97, 
74.21, 73.76, 73.50, 73.24, 71.55, 67.73, 60.13, 57.92, 55.34, 32.55, 20.90, 20.75. HRMS 
(ESI, positive) calculated for C45H50N6O11
+
 [M + Na]
+
 873.3430, found 873.3441. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(((4-meth-
oxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (32): 
Sodium methoxide (5.4 M solution in methanol, 0.19 mL, 1.01 mmol) was added to a 
solution of compound 31 (4.3 g, 5.05 mmol) in methanol (50 mL), stirred at room 
temperature for 8 h, and neutralized with Amberlite IR-120 (H
+
 form). The mixture was 
filtered through a Celite pad, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc =1:1) to give 
compound 32 (3.139 g, 81 %) as a clear liquid. 
1
H NMR (500 MHz, CDCl3) δ 7.40–7.23 
(m, 15H, Ph), 7.12–7.07 (m, 2H, Ph), 6.86–6.79 (m, 2H, Ph), 4.94 (d, J = 3.8 Hz, 1H, H-
1'), 4.91 (d, J = 2.8 Hz, 2H, Bn), 4.88 (d, J = 11.7 Hz, 1H, Bn), 4.79–4.70 (m, 3H, Bn), 
4.60 (d, J = 11.9 Hz, 1H, Bn), 4.44 (d, J = 10.6 Hz, 1H, Bn), 4.38 (d, J = 11.8 Hz, 1H), 
4.05–3.98 (m, 2H, H-5', H-3'), 3.80–3.68 (m, 5H, OMe, H-6', H-4'), 3.66–3.59 (m, 2H, H-
6', H-2'), 3.48–3.36 (m, 3H, H-1, H-5, H-6 ), 3.28–3.13 (m, 2H, H-3, H-4), 2.27 (dt, J = 
13.3, 4.4 Hz, 1H, H-2), 1.46 (dt, J = 13.4, 12.1 Hz, 1H, H-2). 
13
C NMR (125 MHz, 
CDCl3) δ 159.29, 138.43, 138.03, 136.84, 129.81, 129.79, 128.70, 128.53, 128.48, 
128.43, 128.36, 127.79, 127.73, 127.71, 127.66, 113.76, 101.39, 85.45, 82.38, 79.13, 
77.71, 75.57, 75.55, 75.39, 75.05, 74.58, 73.17, 71.46, 67.52, 59.67, 59.43, 55.20, 32.34. 
HRMS (ESI, positive) calculated for C41H46N6O9
+
 [M + Na]
+
 789.3218, found 789.3232. 
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(1R,2R,3S,5R,6S)-3,5-diazido-2-(((2S,3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(((4-meth-
oxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-tris-
(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (33): Compound 8 (2.668 
g, 5.210 mmol) and compound 32 (3.629 g, 4.73 mmol) were co-evaporated from dry 
toluene under reduced pressure three times and further dried under high vacuum for 8 hr. 
A solution of compound 8 and 32 in anhydrous dichloromethane (150 mL) was added to 
preactivated 4 Å  molecular sieves and N-iodosuccinimide (1.704 g, 7.57 mmol). After 
stirring for 30 min at room temperature, the reaction mixture was cooled to –78 °C. 
Trifluoromethanesulfonic acid (0.13 mL, 1.42 mmol) was added dropwise, and the 
reaction was warmed to 0 °C slowly. The reaction was quenched by adding solid sodium 
sulfite (0.5 g), sodium bicarbonate (0.5 g), and a few drops of water. The reaction mixture 
was diluted with dichloromethane (150 mL), filtered, and washed with a saturated 
aqueous solution of sodium bicarbonate (100 mL × 2) and brine. The residue was dried 
over sodium sulfate, filtered, concentrated under reduced pressure, and purified by flash 
column chromatography on silica gel (Hex:EtOAc = 3:2) to give compound 32 (3.621 g, 
81%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.44–7.27 (m, 29H, Ph), 7.22–7.18 (m, 
1H, Ph), 7.14 (m, 2H, Ph), 6.90–6.81 (m, 2H, Ph), 5.32 (d, J = 3.7 Hz, 1H, H-1'), 5.18 (d, 
J = 3.6 Hz, 1H, H-1''), 4.96 (dd, J = 11.0, 7.6 Hz, 2H, Bn), 4.90 (d, J = 11.0 Hz, 2H, Bn), 
4.80 (td, J = 12.3, 9.1 Hz, 6H, Bn), 4.65 (dd, J = 13.4, 11.7 Hz, 2H, Bn), 4.59–4.53 (m, 
1H, OH), 4.48 (d, J = 10.7 Hz, 1H, Bn), 4.43 (d, J = 11.8 Hz, 1H, Bn), 4.13 (dt, J = 10.1, 
2.5 Hz, 1H, H-5'), 4.07–3.98 (m, 2H, H-3', H-5''), 3.95 (dd, J = 9.6, 8.2 Hz, 1H, H-3''), 
3.86–3.78 (m, 1H, H-6'), 3.78–3.71 (m, 4H, H-4', OMe), 3.71–3.63 (m, 3H, H-5, H-2', H-
6'), 3.63–3.51 (m, 4H, H-5'', H-4'', H-2'', H-1), 3.42–3.35 (m, 1H, H-6), 3.35–3.25 (m, 
2H, H-4, H-3), 2.36 (dt, J = 12.9, 4.3 Hz, 1H, H-2), 1.57 (q, J = 12.5 Hz, 1H, H-2). 
13
C 
NMR (125 MHz, CDCl3) δ 159.27, 138.87, 138.70, 138.32, 138.24, 138.15, 137.34, 
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129.96, 129.76, 128.55, 128.42, 128.41, 128.38, 128.35, 128.33, 128.30, 128.08, 128.00, 
127.95, 127.81, 127.78, 127.74, 127.65, 127.60, 127.57, 113.77, 99.95, 98.03, 83.58, 
82.07, 81.67, 80.99, 79.87, 79.37, 77.88, 77.66, 75.63, 75.57, 75.02, 74.76, 74.14, 73.60, 
73.42, 73.14, 71.22, 67.70, 60.86, 60.13, 58.83, 55.18, 32.29. HRMS (ESI, positive) 
calculated for C67H72N6O13
+
 [M + Na]
+
 1191.5050, found 1191.5050. 
2'-deamino-2'-hydroxy-gentamicin A2 (34): Trimethylphosphine (1 M solution in THF, 
0.08 mL, 0.80 mmol) was added to a solution of compound 33 (0.466 g, 0.39 mmol) in 
THF (9 mL) and 0.1 M NaOH (3 mL). The reaction mixture was stirred at 50 °C for 2 h, 
cooled to room temperature, and concentrated under reduced pressure. The residue was 
dissolved in a mixture of acetic acid (3 mL), water (9 mL) and methanol (9 mL). The 
solution was deaerated by evacuating the air inside of the flask and refilling it with 
nitrogen five times. Palladium hydroxide on carbon (20%, Degussa type, 0.1 g) was 
added and the solution was charged with hydrogen gas. The reaction mixture was stirred 
at room temperature under hydrogen gas for 24 hr. The solution was then filtered through 
a Celite pad, washed with water and methanol, and concentrated under reduced pressure. 
The residue was purified by chromatography on Amberlite CG-50 resin (NH4
+
 form) (1-
5% concentrated ammonium hydroxide in water), concentrated under reduced pressure, 
acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide compound 34 
(0.167 g, 92%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.59 (d, J = 3.9 Hz, 1H, H-
1'), 5.04 (d, J = 3.0 Hz, 1H, H-1''), 4.05 (ddd, J = 10.1, 8.3, 3.2 Hz, 1H, H-5'), 4.00–3.90 
(m, 2H, H-5, H-3''), 3.80 (t, J = 9.5 Hz, 1H, H-3'), 3.76–3.55 (m, 9H, H-4'', H-2', H-4, H-
1, H-5'', H-6, H-5'', H-2'', H-3), 3.47 (dd, J = 13.4, 3.2 Hz, 1H, H-6'), 3.40 (t, J = 9.5 Hz, 
1H, H-4'), 3.20 (dd, J = 13.3, 8.3 Hz, 1H, H-6'), 2.57 (dt, J = 12.6, 4.2 Hz, 1H, H-2), 1.96 
(q, J = 12.4 Hz, 1H, H-2). 
13
C NMR (125 MHz, D2O) δ 101.84, 95.44, 83.82, 78.05, 
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72.95, 72.11, 71.98, 71.73, 70.80, 70.68, 68.90, 68.63, 62.20, 49.95, 47.54, 40.30, 27.52. 
HRMS (ESI, positive) calculated for C17H32N2O12
+
 [M + Na]
+
 479.1847, found 479.1854. 
 
2.2.14. Synthesis of 2'-Deamino-2'-hydroxy-6'-amino-6'-dehydroxy-gentamicin A2 
The overall synthetic scheme is shown in Scheme 2-12. 
 
 
Scheme 2-12. Synthetic scheme for the preparation of 2'-deamino-2'-hydroxy-6'-amino-
6'-dehydroxy-gentamicin A2. 
(1R,2R,3S,5R,6S)-3,5-diazido-2-(((2S,3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(hydroxy-
lmethyl)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-tris(benzyloxy)tetr-
ahydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (35): 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone (0.636 g, 2.802 mmol) was added to a solution of compound 33 (2.184 g, 
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1.87 mmol) in dichloromethane (40 mL) and water (4 mL). The reaction mixture was 
stirred for 4 h at room temperature and quenched by adding a saturated aqueous solution 
of sodium bicarbonate (40 mL). The aqueous layer was extracted with dichloromethane 
(60 mL × 3), and the combined organic phase was washed with brine, dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) to give 
compound 35 (1.251 g, 64%) as a clear liquid. 
1
H NMR (500 MHz, CDCl3) δ 7.36–7.27 
(m, 29H, Ph), 7.21–7.16 (m, 1H, Ph), 5.27 (d, J = 3.7 Hz, 1H, H-1'), 5.12 (d, J = 3.6 Hz, 
1H, H-1''), 5.00–4.82 (m, 6H, Bn), 4.82 – 4.72 (m, 6H, Bn), 4.66 (dd, J = 23.4, 11.3 Hz, 
2H, Bn), 4.07–3.95 (m, 3H, H-5', H-3', H-5''), 3.91 (dd, J = 9.6, 8.2 Hz, 1H, H-3''), 3.84 
(dd, J = 11.9, 2.6 Hz, 1H, H-6'), 3.76 (dd, J = 12.0, 3.6 Hz, 1H, H-6'), 3.64–3.49 (m, 7H, 
H-5, H-4, H-4'', H-2', H-5'', H-1, H-2''), 3.39–3.23 (m, 3H, H-6, H-3, H-4), 2.37 (dt, J = 
13.3, 4.4 Hz, 1H, H-2), 1.54 (q, J = 12.5 Hz, 2H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 
138.79, 138.58, 138.25, 138.09, 138.06, 137.29, 128.56, 128.49, 128.43, 128.39, 128.34, 
128.11, 128.01, 128.00, 127.94, 127.89, 127.81, 127.79, 127.75, 127.64, 127.58, 99.57, 
98.17, 83.23, 82.06, 81.87, 80.88, 79.95, 79.27, 77.75, 77.22, 75.61, 75.11, 74.84, 74.12, 
73.61, 73.46, 71.78, 61.64, 60.95, 60.02, 58.88, 32.34. HRMS (ESI, positive) calculated 
for C59H64N6O12
+
 [M + Na]
+
 1071.4474, found 1071.4477. 
(1R,2R,3S,5R,6S)-3,5-diazido-2-(((2R,3R,4S,5R,6R)-6-(azidomethyl)-3,4,5-tris(ben-
zyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-tris(benzyloxy)tetra-
hydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (36): p-Toluenesulfonyl chloride (1.137 g, 
5.96 mmol) was added to a solution of compound 35 (1.251 g, 1.19 mmol) in pyridine 
(30 mL) at 0 °C. The reaction mixture was stirred at room temperature for 9 hr. After the 
addition of methanol (10 mL) at 0 °C, the mixture was stirred at room temperature for 30 
min. The solution was concentrated under reduced pressure, and co-evaporated with 
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toluene twice. The residue was diluted with dichloromethane (50 mL), and washed with a 
saturated aqueous solution of sodium bicarbonate (40 mL). The aqueous layer was 
extracted with dichloromethane (50 mL × 2), and the combined organic phase was 
washed with brine, dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 3:1) to give tosylate 36 (0.766 g, 56%) as a clear oil. 
1
H NMR (500 MHz, 
CDCl3) δ 7.79 (d, J = 8.2 Hz, 2H, Ph), 7.41–7.27 (m, 29H, Ph), 7.23–7.13 (m, 3H, Ph), 
5.27 (d, J = 3.6 Hz, 1H, H-1'), 5.08 (d, J = 3.6 Hz, 1H, H-1''), 4.93 (dd, J = 20.2, 11.0 Hz, 
2H, Bn), 4.88–4.79 (m, 3H, Bn), 4.79–4.70 (m, 5H, Bn), 4.63 (d, J = 11.5 Hz, 1H, Bn), 
4.48 (d, J = 10.6 Hz, 1H, Bn), 4.43 (s, 1H, OH), 4.35 (dd, J = 10.6, 3.2 Hz, 1H, H-6'), 
4.21 (dd, J = 10.6, 2.1 Hz, 1H, H-6'), 4.15 (dt, J = 10.1, 2.6 Hz, 1H, H-5'), 4.03–3.83 (m, 
3H, H-5'', H-3', H-3''), 3.63–3.46 (m, 7H, H-5, H-4'', H-4', H-5'', H-2', H-1, H-2''), 3.36–
3.23 (m, 3H, H-6, H-3, H-4), 2.40 (s, 3H, Me), 2.37–2.26 (m, 1H, H-2), 1.54–1.42 (m, 
1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 144.81, 138.77, 138.47, 138.21, 138.08, 
137.78, 137,26, 132.84, 129.80, 128.55, 128.43, 128.40, 128.34, 128.29, 128.09, 128.04, 
127.99, 127.93, 127.90, 127.82, 127.81, 127.64, 127.59, 99.02, 98.29, 82.72, 82.43, 
81.68, 80.80, 79.64, 79.23, 77.64, 77.22, 76.83, 75.60, 75.55, 75.07, 74.95, 73.89, 73.62, 
73.49, 69.43, 68.38, 61.02, 59.91, 58.66, 32.18, 21.64. HRMS (ESI, positive) calculated 
for C66H70N6O14S
+
 [M + Na]
+
 1225.4563, found 1225.4569. 
(1R,2R,3S,5R,6S)-3,5-diazido-2-(((2R,3R,4S,5R,6R)-6-(azidomethyl)-3,4,5-tris(ben-
zyloxy)tetrahydro-2H-pyran-2-yl)oxy)-6-(((2R,3R,4S,5R)-3,4,5-tris(benzyloxy)tetra-
hydro-2H-pyran-2-yl)oxy)cyclohexan-1-ol (37): Sodium azide (0.215 g, 3.30 mmol) 
and tetrabutylammonium iodide (0.005 g, 0.013 mmol) was added to a solution of the 
previously synthesized tosylate 36 (0.795 g, 0.66 mmol) in DMF (20 mL). The reaction 
mixture was stirred at 60 °C for 8 h. After cooling to room temperature, the reaction 
 76 
solution was evaporated under reduced pressure. The residue was purified by flash 
column chromatography on silica gel (Hex/EtOAc = 3:1) to give compound 37 (0.511 g, 
72%) as a colorless oil. 
1
H NMR (500 MHz, CDCl3) δ 7.42–7.27 (m, 29H, Ph), 7.23–7.17 
(m, 1H, Ph), 5.39 (d, J = 3.7 Hz, 1H, H-1'), 5.10 (d, J = 3.6 Hz, 1H, H-1''), 4.98 (d, J = 
10.9 Hz, 1H, Bn), 4.92 (d, J = 11.1 Hz, 2H, Bn), 4.86 (d, J = 10.9 Hz, 2H, Bn), 4.82–4.73 
(m, 5H, Bn), 4.64 (dd, J = 11.3, 6.1 Hz, 2H, Bn), 4.47 (d, J = 1.8 Hz, 1H, OH), 4.18 (ddd, 
J = 10.0, 4.3, 2.5 Hz, 1H, H-5'), 4.02 (t, J = 9.4 Hz, 1H, H-3'), 3.98–3.86 (m, 2H, H-5'', 
H-3''), 3.66–3.50 (m, 8H, H-5, H-2', H-5'', H-4'', H-6', H-4', H-1, H-2''), 3.44 (dd, J = 
13.2, 4.3 Hz, 1H, H-6'), 3.40–3.31 (m, 3H, H-6, H-3, H-4), 2.38 (dt, J = 13.5, 4.0 Hz, 1H, 
H-2), 1.63–1.46 (m, 1H, H-2). 13C NMR (125 MHz, CDCl3) δ 138.79, 138.52, 138.23, 
138.10, 137.95, 137.36, 128.55, 128.49, 128.44, 128.42, 128.36, 128.29, 128.08, 128.01, 
127.94, 127.93, 127.82, 127.75, 127.67, 127.60, 98.96, 98.33, 82.91, 82.44, 81.69, 80.79, 
79.96, 79.25, 78.18, 77.63, 77.24, 75.61, 75.21, 75.04, 73.91, 73.62, 73.49, 70.76, 61.05, 
59.94, 58.82, 51.26, 32.31. HRMS (ESI, positive) calculated for C59H63N9O11
+
 [M + Na]
+
 
1096.4539, found 1096.4550. 
2'-deamino-2'-hydroxy-6'-amino-6'-deoxy-gentamicin A2 (38): Trimethylphosphine (1 
M solution in THF, 1.40 mL, 1.40 mmol) was added to a solution of compound 37 (0.5 g, 
0.465 mmol) in THF (9 mL) and 0.1 M NaOH (3 mL). The reaction mixture was stirred 
at 50 °C for 2 h, cooled to room temperature, and concentrated under reduced pressure. 
The residue was dissolved in a mixture of acetic acid (3 mL), water (9 mL) and methanol 
(9 mL). The solution was deaerated by evacuating the air inside of the flask and refilling 
it with nitrogen five times. Palladium hydroxide on carbon (20%, Degussa type, 0.2 g) 
was added and the solution was charged with hydrogen gas. The reaction mixture was 
stirred at room temperature under hydrogen gas for 24 hr. The solution was filtered 
through a Celite pad, washed with water and methanol, and concentrated under reduced 
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pressure. The residue was purified by chromatography on Amberlite CG-50 resin (NH4
+
 
form) (5-10% concentrated ammonium hydroxide in water), concentrated under reduced 
pressure, acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide 
compound 38 (0.188 g, 89%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.62 (d, J = 
3.8 Hz, 1H, H-1'), 5.07 (d, J = 3.2 Hz, 1H, H-1''), 4.08 (ddd, J = 10.0, 8.3, 3.2 Hz, 1H, H-
5'), 4.02–3.95 (m, 2H, H-5, H-3''), 3.86–3.81 (m, 1H, H-3'), 3.81–3.55 (m, 9H, H-4'', H-
5'', H-4, H-5'', H-1, H-6, H-2', H-2'', H-3), 3.50 (dd, J = 13.3, 3.2 Hz, 1H, H-6'), 3.47 – 
3.38 (m, 1H, H-4'), 3.23 (dd, J = 13.4, 8.3 Hz, 1H, H-6'), 2.64 – 2.55 (m, 1H, H-2), 1.99 
(q, J = 12.6 Hz, 1H, H-2). 
13
C NMR (125 MHz, D2O) δ 101.84, 95.47, 83.82, 78.07, 
72.97, 72.13, 72.02, 71.76, 70.84, 70.71, 68.93, 68.65, 62.23, 49.98, 47.59, 40.34, 27.54. 
HRMS (ESI, positive) calculated for C17H33N3O11
+
 [M + Na]
+
 478.2007, found 478.2009. 
 
2.2.15. Synthesis of Garosamine Derivative (44) 
The overall synthetic scheme is shown in Scheme 2-13. 
 
 
Scheme 2-13. Synthetic scheme for the preparation of garosamine derivative (44). 
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(3aR,6S,7R,7aR)-7-(benzyloxy)-1,3a-dimethyl-6-(p-tolylthio)hexahydro-2H-pyrano-
[4,3-d]oxazol-2-one (44): Compound 43 was prepared as previously described.
163
 
Sodium hydride (60% in mineral oil, 1.022 g, 25.56 mmol) was added to a solution of 
compound 43 (7.19 g, 23.24 mmol) in DMF (200 mL) at 0 °C under a nitrogen 
atmosphere. The reaction mixture was stirred for 30 min at room temperature. After the 
reaction solution was cooled to 0 °C, benzyl bromide (3.32 mL, 27.88 mmol) was added, 
and the mixture was stirred at room temperature for 3 h. Methanol (30 mL) was added at 
0 °C to quench the reaction. After all solvents were evaporated under reduced pressure, 
the residue was diluted with dichloromethane (200 mL) and water (150 mL). The 
aqueous layer was extracted with dichloromethane (150 mL × 3). The combined organic 
layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 2:1) to give compound 44 (8.81 g, 95%) as a clear solid. 
1
H 
NMR (500 MHz, CDCl3) δ 7.46–7.28 (m, 7H, Ph), 7.13 (d, J = 7.7 Hz, 2H, Ph), 5.26 (d, 
J = 3.3 Hz, 1H, H-1), 4.84 (d, J = 11.7 Hz, 1H, Bn), 4.54 (d, J = 11.2 Hz, 1H, Bn), 4.16 
(d, J = 12.3 Hz, 1H, H-5), 3.81 (t, J = 3.6 Hz, 1H, H-2), 3.61 (d, J = 12.3 Hz, 1H, H-5), 
3.44 (d, J = 4.1 Hz, 1H, H-3), 2.86 (s, 3H, NMe), 2.34 (s, 3H, PhMe), 1.52 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 157.59, 138.10, 137.00, 132.25, 130.34, 129.97, 128.69, 
128.29, 127.84, 85.96, 75.97, 75.59, 72.93, 66.46, 64.25, 30.36, 24.09, 21.20. HRMS 
(ESI, positive) calculated for C22H25NO4S
+
 [M + Na]
+
 422.1397, found 422.1411. 
     
2.2.16. Synthesis of Gentamicin B 
The overall synthetic scheme is shown in Scheme 2-14. 
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Scheme 2.14. Synthetic scheme for the preparation of gentamicin B. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2R,3R,4S,6R)-4,6-diazido-3-(((2R,3R,4S,5R, 
6R)-6-(azidomethyl)-3,4,5-tris(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)-2-hydro-
xycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-2-one (46): 
Compound 45 was prepared as previously described.
157
 Compound 44 (0.263 g, 0.659 
mmol) and compound 45 (0.402 g, 0.599 mmol) were co-evaporated from dry toluene 
under reduced pressure three times and further dried under high vacuum for overnight. A 
solution of compound 44 and 45 in anhydrous dichloromethane (15 mL) was added to  
preactivated 4 Å  molecular sieves and N-iodosuccinimide (0.216 g, 0.959 mmol) were 
added. After stirring for 30 min at room temperature, the reaction mixture was cooled to 
–78 °C. Trifluoromethanesulfonic acid (0.016 mL, 0.179 mmol) was added dropwise 
over 10 min, and the reaction was warmed to 0 °C slowly. The reaction was quenched by 
adding solid sodium sulfite (0.2 g), sodium bicarbonate (0.2 g), and a few drops of water. 
The reaction mixture was diluted with dichloromethane (20 mL), filtered, and washed 
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with a saturated aqueous solution of sodium bicarbonate (60 mL × 2) and brine. The 
residue was dried over sodium sulfate, filtered, concentrated in reduced pressure, and 
purified by flash column chromatography on silica gel (Hex:EtOAc = 3:2) to give 
compound 46 (0.329 g, 58%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.39–7.28 (m, 
20H, Ph), 5.43 (d, J = 3.7 Hz, 1H, H-1'), 5.18 (d, J = 3.3 Hz, 1H, H-1''), 4.99 (d, J = 10.9 
Hz, 1H, Bn), 4.94–4.85 (m, 3H, Bn), 4.85–4.76 (m, 2H, Bn), 4.64 (d, J = 11.0 Hz, 1H, 
Bn), 4.59 (d, J = 11.5 Hz, 1H, Bn), 4.38 (d, J = 1.6 Hz, 1H, OH), 4.22–4.09 (m, 2H, H-5', 
H-5''), 4.03 (t, J = 9.3 Hz, 1H, H-3'), 3.86 (dd, J = 5.4, 3.3 Hz, 1H, H-2''), 3.71–3.59 (m, 
3H, H-2', H-5, H-5''), 3.58–3.36 (m, 8H, H-6', H-4', H-1, H-6, H-3'', H-6, H-4, H-3), 2.86 
(s, 3H, NMe), 2.36 (dt, J = 13.2, 4.1 Hz, 1H, H-2), 1.56 (q, J = 12.2 Hz, 1H, H-2), 1.30 
(s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 157.36, 138.55, 138.00, 137.53, 137.38, 
128.68, 128.58, 128.57, 128.53, 128.28, 128.23, 128.15, 128.00, 127.93, 127.82, 127.77, 
98.89, 96.15, 82.72, 82.47, 81.77, 80.07, 78.30, 77.57, 75.69, 75.29, 74.83, 74.68, 73.90, 
70.87, 65.59, 62.77, 60.01, 58.81, 51.32, 32.12, 30.47, 23.33. HRMS (ESI, positive) 
calculated for C48H54N10O11
+
 [M + Na]
+
 969.3866, found 969.3864. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2R,3R,4S,6R)-4,6-diazido-3-(((2R,3R,4S,5R,6R)-
6-(azidomethyl)-3,4,5-tris(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyc-
lohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol (47): To a solution 
of compound 46 (0.292 g, 0.309 mmol) in absolute ethanol (5 mL) was added 2N NaOH 
(2 mL). The reaction mixture was stirred at 90 °C for 10 h, and cooled to room 
temperature. The solution was diluted with ethyl acetate (20 mL) and washed with H2O 
(20 mL). The aqueous layer was extracted with ethyl acetate (20 mL × 3). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (4% MeOH in DCM) to give compound 47 (0.231 g, 81%) 
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as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.40–7.30 (m, 20H, Ph), 5.42 (d, J = 3.7 Hz, 
1H, H-1'), 5.31 (d, J = 3.4 Hz, 1H, H-1''), 5.00 (d, J = 11.0 Hz, 1H, Bn), 4.94 (d, J = 11.0 
Hz, 1H, Bn), 4.89 (d, J = 11.0 Hz, 1H, Bn), 4.86–4.76 (m, 3H, Bn), 4.66 (d, J = 11.0 Hz, 
1H, Bn), 4.56 (s, 1H, OH), 4.50 (d, J = 11.8 Hz, 1H, Bn), 4.21 (ddd, J = 10.0, 4.3, 2.5 Hz, 
1H, H-5'), 4.05 (t, J = 9.3 Hz, 1H, H-3'), 3.91 (d, J = 12.3 Hz, 1H, H-5''), 3.70–3.49 (m, 
6H, H-5, H-2', H-6', H-4', H-2'', H-1), 3.48–3.32 (m, 6H, H-6', H-3'', H-4, H-6, H-3, H-
5''), 2.64 (d, J = 10.3 Hz, 1H, NH), 2.53 (s, 3H, NMe), 2.40–2.35 (m, 1H, H-2), 1.66–
1.52 (m, 1H, H-2), 1.11 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 138.50, 137.95, 
137.77, 137.44, 128.65, 128.52, 128.47, 128.18, 128.13, 128.11, 128.09, 127.95, 127.76, 
127.71, 99.06, 96.92, 82.63, 82.45, 81.75, 80.13, 78.27, 76.04, 75.63, 75.24, 75.19, 73.98, 
72.19, 70.98, 70.82, 66.25, 63.01, 60.03, 58.83, 51.27, 38.67, 32.21, 24.57. HRMS (ESI, 
positive) calculated for C47H56N10O10
+
 [M + Na]
+
 943.4073, found 943.4062. 
Gentamicin B (48): Trimethylphosphine (1 M solution in THF, 1.22 mL, 1.22 mmol) 
was added to a solution of compound 47 (0.188 g, 0.204 mmol) in THF (6 mL) and 0.1 M 
NaOH (2 mL) was added. The reaction mixture was stirred at 50 °C for 2 h, cooled to 
room temperature, and concentrated under reduced pressure. The residue was dissolved 
in a mixture of acetic acid (1.5 mL), water (4.5 mL) and methanol (4.5 mL). The solution 
was deaerated by evacuating the air inside of the flask and refilling it with nitrogen five 
times. Palladium hydroxide on carbon (20%, Degussa type, 0.1 g) was added and the 
solution was charged with hydrogen gas. The reaction mixture was stirred at room 
temperature under hydrogen gas for 24 hr. The solution was filtered through a Celite pad, 
washed with water and methanol, and concentrated under reduced pressure. The residue 
was purified by chromatography on Amberlite CG-50 resin (NH4
+
 form) (5-10% 
concentrated ammonium hydroxide in water), concentrated under reduced pressure, 
acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide compound 48 
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(0.086 g, 88%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.58 (d, J = 3.9 Hz, 1H, H-
1'), 5.12 (d, J = 3.7 Hz, 1H, H-1''), 4.23 (dd, J = 10.9, 3.7 Hz, 1H, H-2''), 4.09–3.99 (m, 
2H, H-5', H-5''), 3.98–3.90 (m, 2H, H-5, H-4), 3.82–3.73 (m, 2H, H-3', H-6), 3.69 (dd, J 
= 9.9, 3.9 Hz, 1H, H-2'), 3.67–3.58 (m, 2H, H-1, H-3), 3.52 (dd, J = 25.2, 11.8 Hz, 2H, 
H-3'' H-5''), 3.46 (dd, J = 13.4, 3.3 Hz, 1H, H-6'), 3.40 (dd, J = 10.0, 9.0 Hz, 1H, H-4'), 
3.20 (dd, J = 13.4, 8.0 Hz, 1H, H-6'), 2.94 (s, 3H, NMe), 2.57 (dt, J = 12.5, 4.2 Hz, 1H, 
H-2), 1.95 (q, J = 12.5 Hz, 1H, H-2), 1.36 (s, 3H, Me). 
13
C NMR (125 MHz, D2O) δ 
101.14, 95.76, 83.79, 78.19, 72.28, 72.07, 70.69, 70.65, 69.85, 68.64, 67.68, 66.27, 63.24, 
49.72, 47.52, 40.22, 34.42, 27.50, 20.85. HRMS (ESI, positive) calculated for 
C19H38N4O10
+
 [M + Na]
+
 505.2480, found 505.2480. 
 
2.2.17. Synthesis of JI-20A 
The overall synthetic scheme is shown in Scheme 2-15. 
 
 83 
 
Scheme 2.15. Synthetic scheme for the preparation of JI-20A. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(hy-
droxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (49): 2,3-
Dichloro-5,6-dicyano-1,4-benzoquinone (0.251 g, 1.109 mmol) was added to a stirring 
solution of compound 17 (0.726 g, 0.925 mmol) in dichloromethane (20 mL) and water 
(2 mL). The reaction mixture was stirred at room temperature for 3 h and quenched by 
adding a saturated aqueous solution of sodium bicarbonate (40 mL). The aqueous 
solution was extracted with dichloromethane (50 mL × 3), and the combined organic 
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layers were washed with brine. The organic layers were dried over magnesium sulfate, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography on silica gel (Hex/EtOAc = 3:2) to provide compound 49 
(0.442 g, 72%) as a clear oil. 
1
H NMR (400 MHz, CDCl3) δ 7.42–7.26 (m, 10H, Ph), 5.14 
(t, J = 9.8 Hz, 1H, H-5), 5.08 (d, J = 3.8 Hz, 1H, H-1'), 4.97–4.81 (m, 4H, H-6, Bn), 4.72 
(d, J = 11.0 Hz, 1H, Bn), 4.08 (dt, J = 10.1, 2.9 Hz, 1H, H-5'), 3.98 (dd, J = 10.4, 8.9 Hz, 
1H, H-3'), 3.88–3.76 (m, 2H, H-6', H-6'), 3.68 (dd, J = 10.1, 8.9 Hz, 1H, H-4'), 3.64–3.54 
(m, 2H, H-1, H-4), 3.40 (ddd, J = 12.4, 9.9, 4.6 Hz, 1H, H-3), 3.32 (dd, J = 10.4, 3.8 Hz, 
1H, H-2'), 2.36 (dt, J = 13.3, 4.6 Hz, 1H, H-2), 2.09 (s, 6H, OAc), 1.58 (dt, J = 13.3, 12.5 
Hz, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 169.93, 169.58, 137.77, 137.71, 128.59, 
128.53, 128.06, 128.05, 127.98, 127.94, 99.48, 79.53, 78.67, 77.74, 75.41, 75.08, 74.07, 
73.43, 72.33, 63.23, 61.10, 58.70, 57.63, 31.78, 20.67, 20.60. HRMS (ESI, positive) 
calculated for C30H35N9O9
+
 [M + Na]
+
 688.2450, found 688.2466. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((to-
syloxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (50): p-
Toluenesulfonyl chloride (0.304 g, 1.595 mmol) was added to a solution of compound 49 
(0.213 g, 0.319 mmol) in pyridine  (20 mL) at 0 °C, and the reaction mixture was stirred 
at room temperature for 15 h, and methanol (5 mL) was added at 0 °C to quench the 
reaction. The reaction solution was concentrated under reduced pressure, and 
coevaporated with toluene twice. The residue was diluted with dichloromethane (50 mL) 
and washed with a saturated aqueous solution of ammonium chloride (40 mL × 3). The 
organic layer was washed with brine, dried over magnesium sulfate, filtered, and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 3:1) to provide compound 50 (0.238 g, 91%) 
as a clear liquid. 
1
H NMR (500 MHz, CDCl3) δ 7.80–7.78 (m, 2H, Ph), 7.35–7.30 (m, 
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10H, Ph), 7.21–7.15 (m, 2H, Ph), 5.11 (t, J = 9.7 Hz, 1H, H-5), 5.03 (d, J = 3.6 Hz, 1H, 
H-1'), 4.90 (t, J = 9.8 Hz, 1H, H-6), 4.87–4.81 (m, 2H, 2×Bn), 4.80 (d, J = 10.6 Hz, 1H, 
Bn), 4.51 (d, J = 10.7 Hz, 1H, Bn), 4.35 (dd, J = 10.8, 3.0 Hz, 1H, H-6'), 4.23–4.19 (m, 
2H, H-5', H-6), 3.93 (dd, J = 10.4, 8.8 Hz, 1H, H-3'), 3.65–3.58 (m, 2H, H-4', H-1), 3.55 
(t, J = 9.6 Hz, 1H, H-4), 3.44–3.34 (m, 1H, H-3), 3.28 (dd, J = 10.4, 3.6 Hz, 1H, H-2'), 
2.41 (s, 3H, Me), 2.39–2.32 (m, 1H, H-2), 2.08 (s, 3H, OAc), 2.08 (s, 3H, OAc), 1.61–
1.52 (m, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 169.95(OC(=O)), 169.57 (O(C=O)), 
145.11 (Ph), 137.61 (Ph), 137.47 (Ph), 132.88 (Ph), 129.99 (Ph), 128.63 (Ph), 128.62 
(Ph), 128.13 (Ph), 128.10 (Ph), 128.01 (Ph), 127.95 (Ph), 99.18 (C-1'), 79.58 (C-3'), 
78.36 (C-4), 77.50 (C-4'), 75.46 (Bn), 75.26 (Bn), 74.17 (C-6), 73.52 (C-5), 69.98 (C-5'), 
68.02 (C-6'), 63.06 (C-2'), 58.61 (C-3), 57.77 (C-1), 31.81 (C-2), 21.77 (Me), 20.76 (Ac), 
20.70 (Ac). HRMS (ESI, positive) calculated for C37H41N9O11S
+
 [M + Na]
+
 842.2538, 
found 842.2529. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2R,3R,4R,5R,6R)-3-azido-6-(azidomethyl)-4,5-bis-
(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (51): 
Sodium azide (0.155 g, 2.385 mmol) and tetrabutylammonium iodide (0.02 g, 0.059 
mmol) were added to a stirring solution of compound 50 (0.925 g, 1.192 mmol) in DMF 
(30 mL). The reaction mixture was stirred at 60 °C for 12 h, and cooled to room 
temperature before concentration under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (Hex/EtOAc = 3:1) to provide compound 51 
(0.734 g, 89%) as a clear liquid. 
1
H NMR (400 MHz, CDCl3) δ 7.39–7.26 (m, 10H, Ph), 
5.15 (t, J = 9.8 Hz, 1H, H-5), 5.11 (d, J = 3.8 Hz, 1H, H-1'), 4.93 (t, J = 10.0 Hz, 1H, H-
6), 4.90–4.81 (m, 3H, Bn), 4.62 (d, J = 11.1 Hz, 1H, Bn), 4.23 (dt, J = 10.0, 3.3 Hz, 1H, 
H-5'), 3.95 (dd, J = 10.4, 8.8 Hz, 1H, H-3'), 3.67–3.55 (m, 3H, H-4', H-1, H-4), 3.55–3.49 
(m, 1H, H-6'), 3.48–3.37 (m, 2H, H-6', H-3), 3.34 (dd, J = 10.4, 3.8 Hz, 1H, H-2'), 2.42 
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(dt, J = 13.4, 4.6 Hz, 1H, H-2), 2.09 (d, J = 2.7 Hz, 6H, OAc), 1.69–1.57 (m, 1H, H-2). 
13
C NMR (100 MHz, CDCl3) δ 170.00, 169.67, 137.67, 128.72, 128.67, 128.24, 128.15, 
127.97, 99.27, 79.62, 99.25, 79.62, 78.80, 78.60, 75.57, 75.42, 74.24, 73.60, 71.53, 63.29, 
58.79, 57.83, 50.94, 31.97, 20.81, 20.73. HRMS (ESI, positive) calculated for 
C30H34N12O8
+
 [M + Na]
+ 
713.2515., found 713.2510. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2R,3R,4R,5R,6R)-3-azido-6-(azidomethyl)-4,5-
bis(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (52): Sodium 
methoxide (5 M solution in methanol, 0.05mL, 0.241 mmol) was added to a solution of 
51 (0.834 g, 1.205 mmol) in methanol. The reaction mixture was stirred at room 
temperature for 12 h. The basic solution was neutralized with Amberlite IR-120 resin (H
+
 
form), filtered, and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (Hex/EtOAc = 2:1) to give compound 52 
(0.665 g, 91%) as a clear liquid. 
1
H NMR (400 MHz, CDCl3) δ 7.39–7.26 (m, 10H, Bn), 
5.17 (d, J = 3.7 Hz, 1H, H-1'), 4.95–4.85 (m, 3H, Bn), 4.64 (d, J = 11.0 Hz, 1H, Bn), 
4.16–4.08 (m, 1H, H-5'), 4.06 (d, J = 2.1 Hz, 1H, OH), 3.99 (dd, J = 10.2, 8.9 Hz, 1H, H-
3'), 3.67–3.59 (m, 2H, OH, H-6'), 3.56 (dd, J = 13.3, 2.5 Hz, 1H, H-5), 3.53–3.38 (m, 4H, 
H-5, H-6', H-1, H-4), 3.32 – 3.25 (m, 2H, H-6, H-3), 2.37–2.28 (m, 1H, H-2), 1.55–1.44 
(m, 1H, H-2). 
13
C NMR (100 MHz, CDCl3) δ 137.60, 137.46, 128.74, 128.69, 128.27, 
128.24, 128.21, 127.94, 99.56, 84.04, 80.94, 78.80, 76.08, 75.87, 75.46, 75.43, 71.50, 
64.37, 59.81, 58.93, 51.04, 32.17. HRMS (ESI, positive) calculated for C26H30N12O6
+
 [M 
+ Na]
+ 
629.2303, found 629.2311. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2R,3R,4R,5R,6-
R)-3-azido-6-(azidomethyl)-4,5-bis(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)-2-hyd-
roxycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-2-one (53): 
Compound 44 (0.550 g, 1.378 mmol) and compound 52 (0.698 g, 1.148 mmol) were co-
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evaporated with dry toluene under reduced pressure three times and further dried under 
high vacuum for overnight. A solution of compound 44 and 52 in anhydrous ether (16 
mL) and anhydrous dichloromethane (4 mL) was added to a preactivated 4 Å  molecular 
sieves and N-iodosuccinimide (0.5167 g, 2.297 mmol). After stirring for 30 min at room 
temperature, the reaction mixture was cooled to –48 °C. Silver trifluoromethanesulfonate 
(0.590 g, 2.297 mmol) was added, and the reaction was warmed to –10 °C to stand for 3 
h. The reaction mixture was diluted with ethyl acetate (20 mL) and filtered through a 
Celite pad. The solution was washed with 10% aqueous solution of sodium bisulfite (50 
mL) and a saturated aqueous solution of sodium bicarbonate (50 mL). The combined 
aqueous layers were extracted with ethyl acetate (50 mL × 3). The combined organic 
layers were washed with brine, dried over sodium sulfate, filtered, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 1.2 : 1) to provide compound 53 (0.567g, 56%) as a clear liquid. 
1
H NMR (600 MHz, CDCl3) δ 7.41–7.26 (m, 15H, Ph), 5.62 (d, J = 3.8 Hz, 1H, H-1'), 
5.02 (d, J = 3.2 Hz, 1H, H-1''), 4.94–4.84 (m, 4H, Bn), 4.62 (dd, J = 13.2, 11.4 Hz, 2H, 
Bn), 4.23–4.15 (m, 2H, H-5', H-5''), 4.00 (dd, J = 10.3, 8.9 Hz, 1H, H-3'), 3.95 (dd, J = 
4.3, 3.1 Hz, 1H, H-2''), 3.80 (d, J = 12.4 Hz, 1H, H-5''), 3.68 (td, J = 8.9, 1.5 Hz, 1H, H-
5), 3.57 (dd, J = 10.0, 8.8 Hz, 1H, H-4'), 3.53 (dd, J = 13.2, 2.5 Hz, 1H, H-6'), 3.51–3.44 
(m, 3H, H-1, H-4, H-3''), 3.46–3.35 (m, 4H, H-2', H-6, H-6', H-3), 2.83 (s, 3H, NMe), 
2.33 (dt, J = 13.3, 4.4 Hz, 1H, H-2), 1.57–1.45 (m, 1H, H-2), 1.41 (s, 3H,Me). 13C NMR 
(150 MHz, CDCl3) δ 157.27, 137.85, 137.83, 137.42, 128.75, 128.66, 128.63, 128.42, 
128.16, 128.13, 128.07, 128.04, 127.95, 98.29, 97.12, 84.86, 80.32, 80.14, 78.79, 75.62, 
75.31, 75.20, 74.69, 73.35, 71.21, 67.00, 63.67, 63.10, 59.80, 58.85, 51.15, 32.16, 30.32, 
23.67. HRMS (ESI, positive) calculated for C41H47N13O10
+
 [M + Na]
+ 
904.3461, found 
904.2459. 
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(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2R,3R,4R,5R,6R)-
3-azido-6-(azidomethyl)-4,5-bis(benzyloxy)tetrahydro-2H-pyran-2-yl)oxy)-2-hydro-
xycyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol (54): A 2 N 
aqueous sodium hydroxide solution (4 mL) was added to a solution of compound 53 
(0.4385 g, 0.497 mmol) in ethanol (12 mL). The reaction mixture was stirred at 90 °C for 
12 h, and cooled to room temperature. The solution was diluted with ethyl acetate (20 
mL) and washed with water (20 mL). The residue was washed with brine, dried over 
sodium sulfate, filtered, and concentrated. The crude product was purified by flash 
column chromatography on silica gel (4% methanol in dichloromethane) to give 
compound 54 (0.344 g, 81%) as a clear oil. 
1
H NMR (400 MHz, CDCl3) δ 7.41–7.27 (m, 
15H), 5.57 (d, J = 3.8 Hz, 1H, H-1'), 5.20 (d, J = 3.4 Hz, 1H, H-1''), 4.91–4.84 (m, 3H, 
Bn), 4.78 (d, J = 11.7 Hz, 1H, Bn), 4.63 (d, J = 11.2 Hz, 1H, Bn), 4.52 (d, J = 11.7 Hz, 
1H, Bn), 4.45 (d, J = 1.9 Hz, 1H, OH), 4.20 (ddd, J = 10.0, 4.4, 2.5 Hz, 1H, H-5'), 3.98 
(dd, J = 10.3, 8.8 Hz, 1H, H-3'), 3.89 (d, J = 12.2 Hz, 1H, H-5''), 3.73–3.64 (m, 1H, H-5), 
3.62 (m, 1H, H-2''), 3.59–3.46 (m, 3H, H-4', H-5'', H-6'), 3.46–3.32 (m, 4H, H-2', H-6', H-
4, H-3), 3.30 (t, J = 9.4 Hz, 1H, H-6), 2.69 (d, J = 10.3 Hz, 1H, H-3''), 2.54 (s, 3H, NMe), 
2.38–2.29 (m, 1H, H-2), 1.52 (q, J = 12.7 Hz, 1H, H-2), 1.19 (s, 3H, Me). 13C NMR (125 
MHz, CDCl3) δ 137.85, 137.84, 137.78, 128.82, 128.69, 128.65, 128.38, 128.28, 128.18, 
128.16, 128.11, 127.97, 98.54, 97.40, 84.79, 80.65, 80.24, 78.81, 76.13, 75.85, 75.67, 
75.35, 72.65, 71.23, 71.04, 66.92, 63.76, 63.47, 59.71, 59.01, 51.20, 38.63, 32.37, 25.25. 
HRMS (ESI, positive) calculated for C40H49N13O9
+
 [M + Na]
+ 
878.3668, found 878.3649. 
JI-20A (55): Trimethylphosphine (1 M solution in THF, 1.08 mL, 1.08 mmol) was added 
to a solution of compound 54 (0.231 g, 0.270 mmol) in THF (9 mL) and 0.1 M NaOH (3 
mL). The reaction mixture was stirred at 50 °C for 2 h, cooled to room temperature, and 
concentrated under reduced pressure. The residue was dissolved in a mixture of acetic 
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acid (2 mL), water (6 mL) and methanol (6 mL). The solution was degassed by 
evacuating the air inside of the flask and refilling it with nitrogen five times. Palladium 
hydroxide on carbon (20%, Degussa type, 0.1 g) was added and the solution was charged 
with hydrogen gas. The reaction mixture was stirred at room temperature under hydrogen 
gas for 24 h. The solution was filtered through a Celite pad, washed with water and 
methanol, and concentrated under reduced pressure. The residue was purified by 
chromatography on Amberlite CG-50 resin (NH4
+
 form) (5-10% concentrated ammonium 
hydroxide in water), concentrated under reduced pressure, acidified with hydrochloric 
acid (pH ca. 4), and lyophilized to provide compound 55 (0.110 g, 85%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.99 (d, J = 3.9 Hz, 1H, H-1'), 5.14 (d, J = 3.7 Hz, 1H, H-
1''), 4.25 (dd, J = 10.9, 3.7 Hz, 1H, H-2''), 4.10–4.02 (m, 4H, H-4, H-5', H-3', H-5''), 3.93 
(t, J = 9.1 Hz, 1H, H-5), 3.88–3.81 (m, 1H, H-6), 3.72–3.59 (m, 2H, H-1, H-3), 3.59–3.47 
(m, 5H, H-3'', H-4', H-5'', H-2', H-6'), 3.32 (dd, J = 13.6, 6.9 Hz, 1H, H-6'), 2.95 (s, 3H, 
NMe), 2.57 (dt, J = 12.6, 4.3 Hz, 1H, H-2), 2.07–1.90 (m, 1H, H-2), 1.38 (s, 3H, Me). 13C 
NMR (125 MHz, D2O) δ 101.12, 95.90, 83.63, 77.54, 74.22, 70.60, 69.85, 69.13, 68.19, 
67.85, 66.17, 63.17, 53.43, 49.57, 48.20, 40.07, 34.47, 28.00, 20.90. HRMS (ESI, 
positive) calculated for C19H39N5O9
+
 [M + Na]
+ 
504.2640, found 504.2639. 
 
2.2.18. Synthesis of 2'-Deamino-2'-hydroxy-gentamicin X2 
The overall synthetic scheme is shown in Scheme 2-16. 
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Scheme 2.16. Synthetic scheme for the preparation of 2'-deamino-2'-hydroxy-GenX2.  
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2R,3R,4S,6R)-4,6-diazido-2-hydroxy-3-(((2S,-
3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl-
)oxy)cyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-2-one (57): 
Compound 56 was prepared as previously described.
157
 Compound 44 (0.4478 g, 1.121 
mmol) and compound 56 (0.688 g, 0.934 mmol) were co-evaporated with dry toluene 
under reduced pressure three times and further dried under high vacuum overnight. A 
solution of compound 44 and 56 in anhydrous ether (12 mL) and anhydrous 
dichloromethane (3 mL) was added to preactivated 4 Å  molecular sieves and N-
iodosuccinimide (0.4204 g, 1.868 mmol). After stirring for 30 min at room temperature, 
the reaction mixture was cooled to –40 °C, silver trifluoromethanesulfonate (0.480 g, 
1.868 mmol) was added, and the reaction was warmed to –10 °C to stand for 3 h. The 
reaction mixture was diluted with ethyl acetate (20 mL) and filtered through a Celite pad. 
The solution was washed with a 10% aqueous solution of sodium bisulfite (50 mL) and a 
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saturated aqueous solution of sodium bicarbonate solution (50 mL). The combined 
aqueous layers were extracted with ethyl acetate (50 mL × 3), and the combined organic 
layers were washed with brine, dried over sodium sulfate, filtered, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 1.5 : 1) to provide compound 57 (0.576g,  61%) as a clear 
liquid. 
1
H NMR (500 MHz, CDCl3) δ 7.38–7.26 (m, 23H, Ph), 7.14–7.12 (m, 2H, Ph), 
5.31 (d, J = 3.6 Hz, 1H, H-1'), 5.24 (d, J = 3.7 Hz, 1H, H-1''), 4.95 (d, J = 10.9 Hz, 1H, 
Bn), 4.91–4.85 (m, 2H, 2×Bn), 4.82 (d, J = 11.1 Hz, 2H, 2×Bn), 4.76 (d, J = 11.4 Hz, 1H, 
Bn), 4.65 (d, J = 12.1 Hz, 1H, Bn), 4.57 (d, J = 11.3 Hz, 1H, Bn), 4.49 (dd, J = 22.7, 10.9 
Hz, 3H, 2×Bn, OH), 4.17 (d, J = 12.8 Hz, 1H, H-5''), 4.11–4.07 (m, 1H, H-5'), 4.02 (t, J = 
9.4 Hz, 1H, H-3'), 3.83–3.80 (m, 2H, H-6', H-2''), 3.74 (dd, J = 10.1, 9.0 Hz, 1H, H-4'), 
3.69 (dd, J = 10.6, 1.9 Hz, 1H, H-6'), 3.67–3.56 (m, 3H, H-2', H-5, H-5''), 3.52–3.40 (m, 
3H, H-1, H-6, H-3''), 3.35–3.29 (m, 2H, H-4, H-3), 2.87 (s, 3H, NMe), 2.34 (d, J = 14.5 
Hz, 1H, H-2), 1.58–1.51 (m, 1H, H-2), 1.26 (s, 3H, Me). 13C NMR (125 MHz, CDCl3) δ 
157.50 (N(C=O)O), 138.69 (Ph), 138.28 (Ph), 138.04 (Ph), 137.50 (Ph), 137.41 (Ph), 
128.71 (Ph), 128.63 (Ph), 128.55 (Ph), 128.49 (Ph), 128.32 (Ph), 128.29 (Ph), 128.23 
(Ph), 128.11 (Ph), 127.99 (Ph), 127.97 (Ph), 127.84 (Ph), 127.82 (Ph), 127.81 (Ph), 
127.77 (Ph), 100.00 (C-1'), 95.75 (C-1''), 83.63 (C-4), 82.20 (C-3'), 81.61 (C-6), 80.04 
(C-2'), 77.88 (C-4'), 77.83 (C-4''), 75.72 (Bn), 75.43 (C-2''), 75.20 (Bn), 74.69 (C-5), 
74.24 (Bn), 73.69 (Bn), 73.63 (Bn), 71.39 (C-5'), 68.36 (C-6'), 65.07 (C-5''), 62.76 (C-3''), 
60.22 (C-1), 58.91 (C-3), 32.19 (C-2), 30.70 (NMe),  23.31 (Me). HRMS (ESI, positive) 
calculated for C55H61N7O12
+
 [M + Na]
+ 
1034.4270, found 1034.4252. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2R,3R,4S,6R)-4,6-diazido-2-hydroxy-3-(((2S,3-
R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl)-
oxy)cyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol (58): A 
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solution of 2 N aqueous sodium hydroxide (5 mL) was added to a solution of compound 
57 (0.446 g, 0.441 mmol) in ethanol (15 mL). The reaction mixture was stirred at 90 °C 
for 10 h, and cooled to room temperature. The solution was diluted with ethyl acetate (25 
mL) and washed with water (25 mL). The residue was washed with brine, dried over 
sodium sulfate, filtered, and concentrated. The crude product was purified by flash 
column chromatography on silica gel (4% methanol in dichloromethane) to give 
compound 58 (0.369 g, 85%) as a clear oil. 
1
H NMR (600 MHz, CDCl3) δ 7.38–7.24 (m, 
23H, Ph), 7.13–7.12(m, 2H, Ph), 5.33 (d, J = 3.5 Hz, 1H, H-1''), 5.27 (d, J = 3.7 Hz, 1H, 
H-1'), 4.94 (d, J = 11.0 Hz, 1H, Bn), 4.88 (d, J = 11.0 Hz, 1H, Bn), 4.85–4.79 (m, 3H, 
Bn), 4.75 (d, J = 11.3 Hz, 1H, Bn), 4.65 (d, J = 12.2 Hz, 1H, Bn), 4.53 (d, J = 1.7 Hz, 1H, 
OH), 4.50 (dd, J = 13.3, 11.4 Hz, 2H, Bn), 4.45 (d, J = 11.9 Hz, 1H, Bn), 4.10 (dt, J = 
10.3, 2.5 Hz, 1H, H-5'), 4.02 (dd, J = 9.8, 9.1 Hz, 1H, H-3'), 3.94 (d, J = 12.4 Hz, 1H, H-
5''), 3.81 (dd, J = 10.7, 3.1 Hz, 1H, H-6'), 3.74 (dd, J = 10.2, 9.0 Hz, 1H, H-4'), 3.69 (dd, 
J = 10.7, 2.1 Hz, 1H, H-6'), 3.64 (dd, J = 9.8, 3.7 Hz, 1H, H-2'), 3.62–3.57 (m, 1H, H-5), 
3.56–3.47 (m, 2H, H-1, H-2''), 3.39 (t, J = 9.5 Hz, 1H, H-4), 3.31–3.27 (m, 3H, H-6, H-3, 
H-5''), 2.59 (d, J = 10.4 Hz, 1H, H-3''), 2.49 (s, 3H, NMe), 2.36 (dt, J = 12.9, 4.3 Hz, 1H, 
H-2), 1.56 (q, J = 12.6 Hz, 1H, H-2), 1.05 (s, 3H, Me). 
13
C NMR (150 MHz, CDCl3) δ 
137.89, 128.79, 128.65, 128.58, 128.57, 128.52, 128.33, 128.30, 128.17, 128.14, 128.00, 
127.86, 127.79, 100.26, 96.70, 83.98, 82.29, 81.14, 80.23, 77.90, 77.32, 76.13, 75.75, 
75.24, 75.01, 74.43, 73.73, 72.23, 71.42, 71.15, 68.41, 66.15, 63.10, 60.42, 58.99, 32.37, 
24.77. HRMS (ESI, positive) calculated for C54H63N7O11
+
 [M + H]
+ 
986.4658, found 
986.4660. 
2'-deamino-2'-hydroxy-gentamicin X2 (59): Trimethylphosphine (1 M solution in THF, 
0.66 mL, 0.66 mmol) was added to a solution of compound 58 (0.164 g, 0.166 mmol) in 
THF (6 mL) and 0.1 M NaOH (2 mL). The reaction mixture was stirred at 50 °C for 2 h, 
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cooled to room temperature, and concentrated under reduced pressure. The residue was 
dissolved in a mixture of acetic acid (1 mL), water (3 mL) and methanol (3 mL). The 
solution was deaerated by evacuating the air inside of the flask and refilling it with 
nitrogen five times. Palladium hydroxide on carbon (20%, Degussa type, 0.05 g) was 
added and the solution was charged with hydrogen gas. The reaction mixture was stirred 
at room temperature under hydrogen gas for 24 h. The solution was filtered through a 
Celite pad, washed with water and methanol, and concentrated under reduced pressure. 
The residue was purified by chromatography on Amberlite CG-50 resin (NH4
+
 form) (1-
5% concentrated ammonium hydroxide in water), concentrated under reduced pressure, 
acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide compound 59 
(0.067 g, 84%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.41 (d, J = 4.0 Hz, 1H, H-
1'), 5.10 (d, J = 3.8 Hz, 1H, H-1''), 4.22 (dd, J = 10.9, 3.7 Hz, 1H, H-2''), 4.02 (d, J = 12.9 
Hz, 1H, H-5''), 3.96–3.88 (m, 2H, H-6', H-5), 3.88–3.80 (m, 2H, H-5', H-6), 3.80–3.73 
(m, 2H, H-3', H-4), 3.73–3.66 (m, 2H, H-2', H-6'), 3.66–3.57 (m, 2H, H-1, H-3), 3.54 (d, 
J = 10.8 Hz, 1H, H-3''), 3.49 (d, J = 12.9 Hz, 1H, H-5''), 3.39 (dd, J = 10.1, 9.0 Hz, 1H, 
H-4'), 2.93 (s, 3H, NMe), 2.55 (dt, J = 12.6, 4.3 Hz, 1H, H-2), 1.93 (q, J = 12.6 Hz, 1H, 
H-2), 1.35 (s, 3H, Me). 
13
C NMR (125 MHz, D2O) δ 100.99, 98.48, 83.06, 80.71, 73.06, 
72.90, 72.50, 71.09, 69.88, 69.47, 67.60, 66.30, 63.30, 60.64, 49.71, 48.30, 34.46, 27.62, 
20.87. HRMS (ESI, positive) calculated for C19H37N3O11
+
 [M + Na]
+ 
506.2320, found 
506.2328. 
 
2.3. RESULTS AND DISCUSSION 
2.3.1. Gene Analysis 
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 GenK is assigned to be a Cbl-dependent radical SAM enzyme based on gene 
analysis of Micromonospora echinospora.
77
 A sequence analysis and comparison with 
other putative Cbl-dependent radical SAM sp
3
-carbon methyltransferases is shown in 
Figure 2-1. The absence of a conserved histidine residue within the Cbl-binding domain 
indicates that the corrin cobalt is probably coordinated to dimethylbenzimidazole. This is 
in contrast to methionine synthase, methyl malonyl-CoA mutase, glutamate mutase and 
others in which histidine in a conserved DXHX2G motif serves as the lower axial ligand 
for the corrinoid cobalt.
121
 The sequence alignment also suggests that Cbl-dependent 
radical SAM sp
3
 C-methyltransferases harbor a single [4Fe-4S] cluster per monomer as 
only the cysteine residues comprising the CX3CX2C motif (highlighted in grey) are 
universally conserved in this class of enzymes.  
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Figure 2-1. Partial amino acid sequence alignment of demonstrated and putative Cbl-
dependent radical SAM sp
3
-carbon methyltransferases. GenK (gi|85814024) from 
Micromonospora echinospora, Fms7 (gi|1125024) from Micromonospora 
olivasterospora, Fom3 (gi|196166519) from Streptomyces fradiae, ThnK (gi|30577688), 
ThnL (gi|30577689), and ThnP (gi|30577693) from Streptomyces cattleya, PtmL 
(gi|212379254), PtmM (gi|212379255), and PtmN (gi|212379256) from Streptomyces 
pactum, CndI (gi|223940938) from Chondromyces crocatus, Swb9 (gi|283131230) from 
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Streptomyces sp. SNA15896, and BchQ (gi|21674591) from Chlorobium tepidum TLS 
are involved in the biosynthesis of gentamicin, fortimicin, fosfomycin, thienamycin, 
pactamycin, chondrochlorens, quinomycin, 2-methylhopanoid, and bacteriochlorophyll 
biosynthesis, respectively. 
 
2.3.2. Purification of GenK 
 The genK gene was amplified from the genomic DNA of M. echinospora using 
polymerase chain reaction (PCR) and was cloned into a pET24 vector. The recombinant 
genK was heterologously overexpressed in Escherichia coli. Although the expression of 
GenK was quite good, the protein was obtained only as insoluble inclusion bodies. It was 
therefore subjected to denaturation with 5 M urea and the refolding protocol described in 
Section 2.2.3. The refolded GenK was then incubated with FeCl3 and Na2S under 
anaerobic conditions in order to reconstituted [4Fe-4S] cluster unless otherwise stated. In 
some cases, MeCbl was added during reconstitution. Unbound iron and sulfide was 
removed by gel filtration. The purity of refolded, reconstituted GenK was assessed by 
SDS-PAGE (Figure 2-2).  
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Figure 2-2. UV-visible absorbance spectra and SDS PAGE of isolated GenK. The green, 
blue, and red spectra correspond to as-isolated GenK (8 mM), reconstituted GenK (15 
mM), and reconstituted GenK (15 mM) treated with 1 mM sodium dithionite. The 
bleaching of the absorbance shoulder at 420 nm is characteristic of a bound iron-sulfur 
cluster. The calculated molecular weight of GenK is 69.3 kDa. 
The UV-visible spectrum of reconstituted GenK and the bleaching of the 
characteristic absorbance shoulder at 420 nm in the presence of sodium dithionite are 
consistent with the presence of a bound [4Fe-4S] cluster. Further analysis revealed that 
3.5 ± 0.9 equivalents of iron and 3.8 ± 1.1 equivalents of sulfide are bound to each GenK 
monomer, implying that GenK contains a single [4Fe-4S] cluster as predicted by the 
amino acid sequence alignment.  
 
2.3.3. In vitro Activity Assays of GenK 
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The activity of GenK was assayed using 1 mM commercially available 
Gentamicin X2 as the substrate in 50 mM Tris•HCl buffer (pH 8.0) containing 10 mM 
DTT, 4 mM SAM, and 1 mM cobalamin (Cbl). NADPH (4 mM) and methyl viologen 
(MV, 1mM) were employed as the electron source and mediator, respectively, to reduce 
the GenK [4Fe-4S] cluster to the active +1 redox state. Methylcobalamin (MeCbl) or 
hydroxocobalamin (HOCbl) were usually present in the GenK assay, but other 
cobalamins also supported GenK activity. The incubation time was usually 8 h, however, 
assays to check for the presence of active enzyme or assess cobalamin dependency had 
different times as discussed below. The assay concentration of GenK was typically 0.01 
mM unless otherwise states.  
 
2.3.4. Products of GenK Catalysis 
The GenK-catalyzed reaction was monitored using reversed-phased HPLC and 
two different elution programs: one to detect the formation of 5'-dAdo and SAH and 
another to detect the conversion of GenX2 to G418. As aminoglycosides do not have any 
UV-active chromophore, the amino moieties of GenX2 and G418 were derivatized with 
1-fluoro-2,4-dinitorobenzene (FDNB) allowing detection at 340 nm. HPLC traces 
monitoring the formation of the conversion of GenX2 to G418 catalyzed by GenK are 
shown in Figure 2-3. HPLC traces monitoring the formation of 5'-dAdo and SAH 
formation as co-product during turnover are shown in Figure 2-4. Control assays without 
cobalamin, without substrate, without enzyme, or with non-reconstituted enzyme were 
also conducted. In the presence of either MeCbl or HOCbl (but not without Cbl), GenK 
catalyzes methylation of GenX2 to produce G418 (traces b and c in Figure 2-3) as well as 
the formation of 5'-Ado and SAH from SAM (traces b and c in Figure 2-4). 
Reconstitution of GenK with iron and sulfide is required to obtain activity (trace h in 
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Figure 2-3 and Figure 2-4). The presence of SAH in assays without GenK indicates that a 
notable extent of Cbl methylation takes place non-enzymatically under the conditions 
employed even when MeCbl is used as substrate (traces d, e, and f in Figure 2-4).
164
 This 
suggests that the C-Co bond of MeCbl is prone to non-enzymatic cleavage during the 
assay (see Section 3.3.4). 
 
 
Figure 2-3. HPLC traces showing conversion of GenX2 to G418 in the presence of 
GenK. The small peaks at ~16.6 min in traces d-g and ~15.4 min in trace f are unrelated 
to product and substrate. Trace (a) is a standard composed of derivatized, authentic 
GenX2 and G418, reaction mixtures. The other HPLC traces correspond to reaction 
mixtures containing (b) MeCbl, (c) HOCbl, (d) MeCbl but no GenK, (e) HOCbl but no 
GenK, (f) MeCbl but no GenX2, (g) no Cbl, (h) MeCbl and non-reconstituted GenK. 
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Figure 2-4. HPLC traces showing the production of both 5-dAdo and SAH during the 
GenK reaction. Trace (a) is a standard composed of authentic 5-dAdo and SAH. The 
other HPLC traces correspond to reaction mixtures containing (b) MeCbl, (c) HOCbl, (d) 
MeCbl but no GenK, (e) HOCbl but no GenK, (f) MeCbl but no GenX2, (g) no Cbl, (h) 
MeCbl and non-reconstituted GenK. Detector was set at 260 nm. 
 
2.3.5. Reducing Systems for GenK  
In order to check which reducing systems can reduce the [4Fe-4S]
2+
 cluster of 
GenK to active [4Fe-4S]
1+
 state, various reducing systems including E. coli flavodoxin 
(fld)/flavodoxin reductase (fpr)/NADPH, methyl viologen (MV)/NADPH, benzyl 
viologen (BV)/ NADPH, dithionite, dithionite/MV, and dithionite/BV were investigated 
(Figure 2-5). The reaction was monitored by the formation of SAH and 5'-dAdo 
(Although SAH is present in all traces, separate experiments demonstrated that it is 
formed non-enzymatically due to the methylation of reduced cobalamin under the 
reaction conditions employed). Among the experimental conditions, only MV and 
NADPH or the flavodoxin/flavodoxin reductase/NADPH (fpr/fld/NADPH) system were 
 101 
capable of activating GenK. Although dithionite is commonly used to activate radical 
SAM enzymes for in vitro studies, it is no effective for GenK. Neither NADPH and 
benzyl viologen (BV), dithionite and MV, nor dithionite and BV are capable of activating 
GenK. The coordination of SO2
–
 to the corrinoid cobalt may compromise the ability of 
dithionite to support multiple turnovers with Cbl-dependent radical SAM enzymes.  
 
 
Figure 2-5. Effectiveness of various reducing systems for the activation of GenK. HPLC 
traces with UV detection at 260 nm for observation of SAH and 5-dAdo are shown.  
2.3.6. Stoichiometry of Products Catalyzed by GenK 
In order to measure the quantity of 5'-dAdo and SAH produced by GenK, assays 
with different concentrations of the enzyme (2, 4, 6, 8, and 10 M) over a time course (8, 
12, 16, and 20 h) were conducted. Control reactions without GenK were used to assess 
the quantity of non-enzymatically produced SAH and this amount was subtracted out of 
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the enzyme assay results. The results indicate that that 5'-dAdo and SAH are produced in 
equal proportions (Figure 2-6). Also they show a linear relationship between the enzyme 
concentration and extent of product formation. Based on 8 h incubation, the average rate 
of both 5-dAdo and SAH production was estimated to be approximately 0.02 min-1. 
 
 
Figure 2-6. 5'-dAdo and SAH production vs GenK concentration at different times. 
Figure 2-7 indicates the stoichiometry of product formation at 0.01 mM GenK 
over a time course. This figure also demonstrates that 5'-dAdo and SAH are produced in 
equal proportion. The relative amounts of 5'-dAdo and G-418 produced by GenK reaction 
were also measured. Quantification of 5'-dAdo from trace b and c in figure 2-4, and G418 
in traces b and c in Figure 2-3, gives 0.49, 0.32, 0.49, and 0.40 mM, respectively, 
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demonstrating that 5'-dAdo and G418 are produced at a ratio close to 1:1. Combined with 
the previous data, 5'-dAdo, SAH and G418 are each produced in equivalent amounts.   
 
 
Figure 2-7. Stoichiometry of 5'-dAdo and SAH production during the GenK reaction 
 
2.3.7. Methyl Transfer Manner of GenK Using Labeled SAM 
In order to further investigate the role of cobalamin and the origin of the methyl 
group during the methyl transfer reaction, assays were conducted in the presence of either 
HOCbl or MeCbl and unlabeled SAM or 
13
CD3-methyl-SAM followed by mass 
spectroscopic analysis of G418 and Cbl. The results are shown in Figures 2-8, 2-9, and 2-
10. Figure 2-8 shows the mass spectra limited to the regions for substrate and product. 
And Figure 2-9 and Figure 2-10 display mass regions for the [M + 2H]
2+
 and [M + H]
+
 
ions, respectively, of the cobalamin complexes. Mass spectra of cobalamin complexes 
appeared clearly [M + 2H]
2+
 region rather than [M + H]
+
 region. When unlabeled SAM 
was used as a substrate in the GenK reaction with HOCbl (trace a in Figure 2-8, 2-9 and 
2-10) or MeCbl (trace e in Figure 2-8, 2-9 and 2-10), unlabeled G418 ([M + H]
+
 m/z 
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497.28), MeCbl
2+
 ([M + H]
2+
 m/z 672.80), and MeCbl
+
 ([M + H]
+
 m/z 1344.58) were 
detected in the mass spectra. When 
13
CD
3
-methyl-SAM was used with HOCbl, 
13
CD3-
labeled products were detected in both G418 ([M + H]
+
 m/z 501.30) (trace b in Figure 
2.8) and Cbl ([M + H]
2+
 m/z 674.81, [M + H]
+
 m/z 1348.57) (trace b in Figure 2-9 and 2-
10). When 
13
CD3-methyl-SAM was used with MeCbl (f), both 
13
CD3-labeled and 
unlabeled G418 (trace f in Figure 2-8) and 
13
CD3-labeled Cbl and unlabeled Cbl (trace f 
in Figure 2-9 and 2-10) were detected. As control reactions, assays without GenK were 
conducted (c, d, g, and h in Figure 2-8, 2-9 and 2-10). As expected, G418 was not 
obtained at all (trace c, d, g, and h in Figure 2-8), and 
13
CD3-labelled or unlabeled MeCbl 
or HOCbl appeared (trace c, d, g, and h in Figure 2-9 and 2-10). These observations 
indicate that methylcobalamin can be generated from SAM and cobalamin and with or 
without the presence of the enzyme. Second, SAM is the methyl source for 
methylcobalamin is SAM, that is, the S-methyl substituent in SAM is transferred to Cbl. 
Third, combined with the previous results that methylation at GenX2 does not occur 
without cobalamin (trace g in Figure 2-3 and Figure 2-4), the methyl group cannot be 
directly transferred from SAM to substrate to generate product. Fourth, the methyl group 
of product is from methylcobalamin because methylcobalamin was generated and the 
methyl group was transferred to GenX2 to generate G418 when hydroxocobalamin 
instead of methylcobalamin was used in the GenK assay (trace a in Figure 2-8, 2-9, and 
2-10). Altogether, methyl group is transferred from SAM to Cbl, and subsequently to 
GenX2 to give G418.  
 
 
 
 105 
 
Figure 2-8. Mass spectra of GenX2 and G418. The spectra correspond to assays with (a) 
HOCbl and unlabeled SAM, (b) HOCbl and 
13
CD3-methyl-SAM, (c) HOCbl and 
unlabeled SAM without GenK, (d) HOCbl and 
13
CD3-methyl-SAM without GenK, (e) 
MeCbl and unlabeled SAM, (f) MeCbl and 
13
CD3-methyl-SAM, (g) MeCbl and unlabeled 
SAM without GenK, (h) MeCbl and 
13
CD3-methyl-SAM without GenK. 
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Figure 2-9. Mass spectra of the Cbl [M + H]
2+
 region. Traces are described in the legend 
of Figure 2-10. 
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Figure 2-10. Mass spectra of the Cbl [M + H]
+
 region. Traces are described in the legend 
of Figure 2-10. 
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2.3.8. Cobalamin Dependence of GenK Activity 
In order to test whether any form of cobalamin will support GenK activity or only 
methylcobalamin is required for methylation reaction, methyl-, hydroxo-, cyano-, and 
adenosyl-cobalamin were considered in the assay. The formation of 5'-dAdo and SAH 
were monitored by HPLC (Figure 2-11). Assays with different types of cobalamin 
showed the formation of 5'-dAdo and SAH (traces c, d, e, and f in Figure 2-8). Combined 
with the previous results in Section 2.3.4 which the formation of 5'-dAdo is related to 
methylation on GenX2 (Figure 2-3 and 2-4), these results indicates that any of these 
complexes can support GenK activity. However, there was no observable formation of 5'-
dAdo and SAH in absence of any cobalamin (trace b in Figure 2-11).  
 
Figure 2-11. HPLC traces of GenK reaction in the presence of cobalamin. Trace (a) is a 
standard composed of authentic 5'-dAdo and SAH. The other HPLC traces correspond to 
reaction mixtures containing (b) no Cbl, (c) MeCbl, (d) HOCbl, (e) CNCbl, and (f) 
AdoCbl. Detector was set at 260 nm. 
In order to check whether cobalamin is a cofactor and MeCbl is regenerated via 
methylation by SAM, assays with different concentrations of MeCbl were conducted at 
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various time points, 4, 8, 12 and 16 h (Figure 2-12). Considered that the formations of a 
product, G418, and 5'-dAdo are related (Section 2.3.6), G418 production is nearly 
maximized in the presence of any cobalamin (as same amount as the substrate GenX2). 
This observation shows that cobalamin is used as a co-substrate for the GenK reaction.  
 
 
Figure 2-12. GenK activity vs concentrations of [MeCbl]. 
 
2.3.9. Syntheses of Putative GenK Substrates 
As shown in Scheme 2-9 in section 2.2.11 and Scheme 2-10 in section 2.2.12, 
syntheses of gentamicin A2 and 6'-amino-6'-dehydroxy-gentamicin A2 began from D-
glucosamine. Acetylation of free alcohols and amino groups with acetic anhydride on 
pyridine, thiophenyl group introduction using boron trifluoride diethyletherate and basic 
hydrolysis with 2 N aqueous sodium hydroxide solution gave the triol 11. Azide 
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interconversion from the amine used the diazotransfer reaction with triflic azide and 
copper sulfate in methanol and dichloromethane.
165
 The primary alcohol was selectively 
protected with tert-butyl diphenylsilyl (TBDPS) group and secondary alcohols were 
protected with benzyl group. TBDPS group removal using tetrabutyl ammonium fluoride 
and p-methoxybenzyl (PMB) group protection on the primary alcohol gave compound 
16. Coupling with 2-streptamine derivative 4 with N-iodosuccinimide and 
trifluoromethanesulfonic acid in ether and dichloromethane at –20 °C gave 
pseudodisaccharide 17. After basic hydrolysis of the acetyl group using sodium 
methoxide, another coupling reaction with the xylose derivative 8 provided the 
pseudotrisaccharide 19. PMB group deprotection using 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone gave the alcohol 20. The azide groups were converted to amines using the 
Staudinger reaction.
157
 Final deprotection of benzyl group by hydrolysis provided 
gentamicin A2 in 2.5% yield over 14 steps. 
From the alcohol 20, an azide group was introduced via SN2 type reaction using 
sodium azide and tetrabutylammonium iodide after tosylate group was introduced. 
Staudinger reaction and hydrogenation gave 6'-amino-6'-dehydroxy-gentamicin A2 in 
66% yield over 4 steps from the previous synthesized compound 20. 
As shown in Scheme 2-11 in Section 2.2.13 and Scheme 2-12 in Section 2.2.14, 
the syntheses of 2'-deamino-2'-hydroxy-gentamicin A2 and 2'-deamino-2'-hydroxy-6'-
amino-6'-dehydroxy-gentamicin A2 started from β-D-glucose pentaacetate. The following 
steps in the syntheses were similar to the syntheses of gentamicin A2 and 6'-amino-6'-
dehydroxy-gentamicin A2. The synthesis of 2'-deamino-2'-hydroxy-gentamicin A2 was 
finished in 7.8% yield over 11 steps. The synthesis of 2'-deamino-2'-hydroxy-6'-amino-6'-
dehydroxy-gentamicin A2 was accomplished with 23% yield over 5 steps from the 
previously synthesized compound 33.  
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As shown in Scheme 2-13 in Section 2.2.15, the synthesis of garosamine 
derivative 44 began from acidic hydrolysis using anhydrous hydrochloric acid (acetyl 
chloride in methanol) of gentamicin sulfate (a mixture of gentamicin C1A, gentamicin C1 
and gentamicin C2). The secondary amine was selectively protected with 
trichloroethyloxycarbonyl (Troc) group. Selective benzoylation of the secondary alcohol 
and replacement of the anomeric methoxy group with thioglycoside followed. 
Oxazolidinone ring formation via treatment with methylamine (33% MeNH2 in EtOH) 
resulted in simultaneous removal of the benzoate to provide the compound 43. Benzyl 
protection with benzyl bromide and sodium hydroxide in DMF gave the oxazolidinone 
donor 44 in 17.7% yield over 6 steps. 
As shown in Scheme 2-14 in Section 2.2.16, the synthesis of gentamicin B started 
from the previously synthesized compound 45. After coupling reaction with garosamine 
derivative 44 and N-iodosuccinimide and trifluoromethanesulfonic acid in 
dichloromethane under –78 °C, basic hydrolysis using 2 N aqueous sodium hydroxide to 
remove oxazolidinone ring followed. Staudinger reaction and hydrogenation gave 
gentamicin B in 41.3% yield over 4 steps. 
As shown in Scheme 2-15 in Section 2.2.17, the synthesis of JI-20A started from 
pseudodisaccharide 17. After PMB deprotection using DDQ, azide introduction, basic 
hydrolysis, coupling with garosamine derivative 44 with N-iodosuccinimide and silver 
trifluoromethanesulfonate in ether and dichloromethane at –10 °C gave 
pseudotrisaccharide 53. Basic hydrolysis and final deprotections of azide and benzyl 
groups using the Staudinger reaction and hydrogenation furnished JI-20A in 21.2% yield 
over 8 steps. 
As shown in Scheme 2-16 in Section 2.2.18, the synthesis of 2'-deamino-2'-
hydroxy-gentamicin X2 began from previously synthesized pseudodisaccharide 56. The 
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following steps followed the same reactions as the synthesis of gentamicin B. The 
synthesis of 2'-deamino-2'-hydroxy-gentamicin X2 was finished in 43.6% over 4 steps. 
  
 
Figure 2-13. Early biosynthetic pathway for gentamicins. 
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2.3.10. Substrates Catalyzed by GenK  
Members of class B RSMTs such as TsrM
128
 and ThnK
132
 can accept other 
compounds besides the intermediates in their biosynthetic pathway. Also previous 
experiments using mutation and reconstitution for target genes showed that GenK may 
catalyze methylation with gentamicin A2 and gentamicin A.
81
  
In order to probe the substrate specificity of GenK catalysis, nine intermediates 
from earlier steps in the biosynthetic pathway for gentamicin, paromamine, gentamicin 
A2, 6'-amino-6'-dehydroxy-gentamicin A2, 2'-deamino-2'-hydroxy-6'-amino-6'-
dehydroxy-gentamicin A2, 2'-deamino-2'-hydroxy-gentamicin A2, gentamicin A, JI-20A, 
gentamicin B, 2'-deamino-2'-hydroxy-gentamicin X2 (boxed compounds in Figure 2-13), 
and neamine were selected. Paromamine
166
 and neamine
167
 were obtained by acidic 
hydrolysis of paromomycin and neomycin.   
GenK assays with various substrate homologues were conducted with 0.02 mM of 
GenK and 1 mM of substrate for 18 h (other conditions were the same as before). 
Formation of 5'-dAdo was followed by HPLC to check whether 5'-dAdo• can abstract a 
hydrogen atom from the putative substrates (Figure 2-14). HPLC traces of the incubation 
using pseudodisaccharides, paromamine and neamine, in the GenK assay did not show 
the appearance of the 5'-dAdo peak, indicating that GenK does not accept disaccharide as 
a substrate (trace b and c in Figure 2-14). GenK assays with eight pseudotrisaccharides 
showed the formation of 5'-dAdo, even though the majority of these compounds gave 
only small amounts of 5'-dAdo detected by HPLC (traces d–m in Figure 2-15). The 
relative proportions of 5'-dAdo formation compared to consumption of GenX2 were 3.0% 
(gentamicin A2), 6.5% (6'-amino-6'-dehydroxy-gentamicin A2), 2.1% (2'-deamino-2'-
hydroxy-6'-amino-6'-dehydroxy-gentamicin A2), 7.6% (2'-deamino-2'-hydroxy-
gentamicin A2), 80.8% (gentamicin A), 29.0% (JI-20A), 3.1% (gentamicin B), and 6.5% 
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(2'-deamino-2'-hydroxy-gentamicin X2). Except gentamicin A and JI-20A, other 
compounds showed very slow formation of 5'-dAdo.  
 Mass spectroscopic data shown in Figure 2-15 indicated that all eight compounds 
were converted to their methylated products by GenK. Even though the observed 
molecular ion peaks of these methylated products were weak, their masses were 
confirmed by HRMS (gentamicin A2: calc. [M + H]
+
 470.2344, observed 470.2340, 6'-
amino-6'-dehydroxy-gentamicin A2: calc. [M + H]
+
 469.2504, observed 469.2502, 2'-
deamino-2'-hydroxy-6'-amino-6'-dehydroxy-gentamicin A2: calc. [M + H]
+
 471.2185, 
observed 471.2163, 2'-deamino-2'-hydroxy-gentamicin A2: calc. [M + H]
+
 470.2344, 
observed 470.2343, Gentamicin A: calc. [M + Na]
+
 505.2480, observed 505.2491, JI-
20A: calc. [M + Na]
+
 518.2796, observed 518.2794, gentamicin B: calc. [M + H]
+
 
497.2817, observed 497.2816, 2-deamino-2'-hydroxy-gentamicin X2: calc. [M + H]
+
 498. 
2657, observed 497.2654). These data indicate that GenK can accept a variety of 
alternative substrates but substitutions at C2' or C6', or garosamine moiety have 
significant influence on GenK activity. GenX2 remains the substrate-choice for GenK.  
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Figure 2-14. HPLC traces of GenK reaction with the following putative substrates; a) is 
corresponding to SAH and 5'-dAdo standard b) paromamine, c) neamine, d) GenA2, e) 6'-
amino-6'-dehydroxy-GenA2, f) 2'-deamino-2'-hydroxy-6'-amino-6'-dehydroxy-GenA2, g) 
2'-deamino-2'-hydroxy-GenA2, h) GenA, i) JI-20A, j) GenB, k) 2'-deamino-2'-hydroxy-
GenX2, l) without any substrate, and m) GenX2.. 
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Figure 2-15. Mass spectroscopic data of GenK reaction with A) GenA2, B) 6'-amino-6'-
dehydroxy-GenA2, C) 2'-deamino-2'-hydroxy-6'-amino-6'-dehydroxy-GenA2, D) 2'-
deamino-2'-hydroxy-GenA2, E) GenA, F) JI-20A, G) GenB, H) 2'-deamino-2'-hydroxy-
GenX2. 
 
2.4. CONCLUSION 
The existence of cobalamin (Cbl)-dependent enzymes that are members of the 
radical S-adenosyl-L-methionine (SAM) superfamily was previous predicted on the basis 
of bioinformatics analysis. A number of these are Cbl-dependent methyltransferases. In 
this Chapter, in vitro activity of GenK, a Cbl-dependent radical SAM enzyme that 
methylates an unactivated sp
3
 carbon during the biosynthesis of gentamicin, an 
aminoglycoside antibiotic, was demonstrated. Experiments to investigate the 
stoichiometry of the GenK reaction revealed that 1 equiv each of 5'-deoxyadenosine and 
S-adenosyl-homocysteine are produced for each methylation reaction catalyzed by GenK. 
Furthermore, isotope-labeling experiments demonstrated that the S-methyl group from 
SAM is transferred to Cbl and the aminoglycoside product during the course of the 
reaction. The catalytic cycle of GenK, and likely other Cbl-dependent radical SAM 
methyltransferases, involves the consumptions of two SAM molecules and two reducing 
equivalents. The first molecule of SAM acts as the source of 5'-dAdo•, which abstracts a 
hydrogen atom from C6' of GenX2 to give 5'-dAdo and the GenX2 radical. The second 
SAM is used to methylate Cbl(I) during turnover to regenerate Me-Cbl for a subsequent 
round of catalysis. GenK does not only catalyze methylation of GenX2, but also catalyzes 
the methylation of many aminoglycoside intermediates in the biosynthetic pathway of 
gentamicin even though the methylation rate is slower compared to the original substrate, 
GenX2. These results demonstrate the promiscuity of GenK catalysis. Efforts to further 
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elucidate the chemical mechanism of this intriguing enzyme will be discussed in Chapter 
3. Although it is a technical challenge to study Cbl-dependent radical SAM enzymes, this 
emerging class of biocatalysts offers considerable potential for the discovery of new and 
unprecedented enzyme chemistry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
Chapter 3: Mechanistic Studies of GenK 
3.1. INTRODUCTION 
Most methylation reactions in nature involve the transfer of the S-adenosyl-L-
methionine (SAM) (1) methyl group to the target molecule through an SN2 type reaction 
with a carbon, nitrogen, oxygen or sulfur anion serving as the nucleophile.
168
 However, 
cases of enzyme-catalyzed methylation reaction involving a single electron transfer 
mechanism, referred to as radical SAM methyltransferases, are increasing.
115
 In the 
introduction to Chapter 2, several examples of these enzymes were examined. The methyl 
transfer reaction for most radical SAM methyltransferases is initiated by single electron 
transfer from the reduced ion-sulfur cluster to the positively charged sulfonium moiety of 
SAM accompanied by homolysis of the C5'-S bond to generate methionine (2) and a 5'-
deoxyadenosyl radical (5'-dAdo•) (3) (Figure 3-1).101 This 5'-dAdo radical can then 
induce the subsequent methylation reaction by abstracting a hydrogen atom from a 
substrate to generate substrate radical, which then reacts with the methyl donor.
101
 
The class B radical SAM methyltransferases contain a cobalamin (Cbl)-binding 
domain at the N-terminus and a characteristic Cx3Cx2C or similar sequence at the C-
terminus, which are important for their activities.
115
 Members of this class whose activity 
has been demonstrated in vitro include PhpK,
133-135
 TsrM,
127-129
 Fom3,
130-131
 GenD1,
81
 
and ThnK.
132
 Recent research has provided some insights into their mechanisms.  
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Figure 3-1. Initial reaction of radical SAM enzymes. 
The mechanism of PhpK, the P-methyltransferase responsible for the formation of 
the second C-P bond in L-phosphinotricin, was explored by Wang et al.
133-135
 They used a 
two-dimensional 
1
H-
31
P gradient heteronuclear single quantum correlation (gHSQC) 
nuclear magnetic resonance (NMR) experiment to determine that methylcobalamin 
(MeCbl) is a direct methyl donor.
133
 They also performed a 
13
C-
31
P multiple quantum 
1
H-
13
C-
31
P(HCP) experiment in 
1
H-
31
P two-dimensional mode directly on a PhpK-catalyzed 
reaction mixture using 
13
CH3-labeled methylcobalamin as the methyl group donor. The 
observation of a 3:1:1:3 mutiplet in the spectrum suggested direct bond formation 
between 
13
CH3 and 
31
P.
135
 These results indicated that the primary methyl donor is MeCbl 
in the reaction. However, they did not report the isolation of 5'-deoxyadenosine (5'-dAdo) 
(4) and/or other SAM cleavage products. Figure 3-2 shows two proposed mechanisms for 
PhpK catalysis.
135
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In Figure 3-2A, after hydrogen abstraction by 5'-dAdo•, the substrate radical 
obtains a methyl radical from MeCbl to yield the methylated product. The oxidation state 
of cobalamin is changed from Cbl(III) to Cbl(II). In Figure 3-2B, after reductive cleavage 
of SAM followed by reduction of phosphinate radical with one electron and one proton, a 
nucleophilic attack by the phosphorus anion on MeCbl(III) provides the methylated 
intermediate and Cbl(I). A final deprotonation reaction furnishes the product.    
 
Figure 3-2. Proposed mechanisms for PhpK catalysis.  
The mechanistic studies of tryptophan methyltransferase TsrM, involved in the 
biosynthesis of the thiopeptide antibiotic thiostrepton, have been done by Berteau et 
al.
127-128
 Isotope-labeling experiments using [methyl-
2
H3]-SAM as the substrate showed 
the generation of [methyl-
2
H3]-2-methyltryptophan as a product, even when unlabeled 
MeCbl was used. These results suggest that the enzyme initially transfers a methyl group 
from SAM to cobalamin in the reaction. UV-visible spectroscopic monitoring of the 
reaction showed a slight increase in absorption between 400 and 476 nm and a decrease 
at 520 nm, which are indicative of the formation of Cbl(II). Unlike a number of radical 
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SAM enzymes, the TsrM reaction did not produce 5'-dAdo and did not require an 
external electron donor like dithionite. A mutant TsrM which lacks the canonical 
CxxxCxxC motif did not catalyze methylation of tryptophan, but it produced large 
amounts of S-adenosylhomocysteine (SAH) (5) and MeCbl. These results indicate that 
radical SAM chemistry was not required to initiate the methyl transfer reaction. The 
proposed mechanism for TsrM is shown in Figure 3-3.
127
 Following transfer of the 
methyl radical to C2 of tryptophan, deprotonation occurs to give the observed methylated 
product. A one-electron transfer from the radical intermediate to the [4Fe-4S]
2+
 cluster is 
proposed, and the electron is then transferred from the reduced [4Fe-4S]
1+
 cluster to 
Cbl(II) to generate Cbl(I). The generated Cbl(I) attacks the electrophilic methyl group of 
SAM to regenerate MeCbl and form SAH (5).    
 
 
Figure 3-3. Proposed mechanism for TsrM catalysis. 
Mechanistic studies concerning Fom3, a putative Cbl-dependent radical SAM 
enzyme which catalyzes the methylation of 2-hydroxyethylphosphonate (2-HEP) to 
produce 2-hydroxypropylphosphonate (2-HPP), have not yielded much insight. Wang et 
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al demonstrated through spectroscopic evidence using electron paramagnetic resonance 
(EPR) that Fom3 catalyzes methyl group transfer to 2-HEP.
130
 The proposed mechanism 
of Fom3 is shown in Figure 3-4. Fom3 uses radical SAM chemistry to generate 5'-dAdo• 
(3) which abstracts a hydrogen atom from the C-2 position of 2-HEP to produce 5'-dAdo 
(4) and a substrate radical. The C-2 substrate radical reacts with MeCbl(III) to yield 2-
HPP and Cbl(II).  
 
 
Figure 3-4. Hypothesized mechanism for Fom3. 
The catalytic mechanism of GenD1, a Cbl-dependent methyltransferase which 
uses gentamicin A (GenA) to generate gentamicin X2 (GenX2) in the biosynthetic 
pathway of gentamicin C1, has not yet been proposed. Leadlay and Sun et al detected the 
formation of the product and 5'-dAdo using reconstituted GenD1.
81
 One result they found 
was that assays using hydroxocobalamin (HOCbl) instead of MeCbl also showed GenD1 
activity, presumably demonstrating that MeCbl is regenerated by a methyltransfer 
process during catalysis. However, the formation of SAH was not observed. The 
mechanism of GenD1 proposed in Figure 3-5 is based on these results. 
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Figure 3.5. Proposed mechanism of GenD1. 
ThnK, a Cbl-dependent methyltransferase which catalyzes the methylation 
required to form the C6-ethyl side chain in a stereocontrolled manner in thienamycin 
biosynthesis, was studied by Townsend et al.
132
 They found near-equimolar amounts of 
SAH (5) and 5'-dAdo (4) during ThnK catalysis. Early labeling studies showed that the 
C-6 ethyl side chain of thienamycin originates from methionine.
169
 An experiment using 
a chiral [
1
H, 
2
H, 
3
H-methyl]-L-methionine showed that the absolute configuration of the 
terminal methyl in the C6 side chain is retained.
169
 This result is consistent with an 
overall methyl transfer processes involving two inversions and a MeCbl intermediate. 
The proposed mechanism of ThnK is shown in Figure 3.6. 
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Figure 3-6. Proposed mechanism of ThnK. 
Class B radical SAM methyltransferases potentially utilizes two molecules of 
SAM. The 5'-dAdo• (3) from one SAM initiates the methylation reaction, and the other 
SAM acts as the methyl source. Cobalamin is an intermediate methyl group carrier 
between SAM and the substrate. The general mechanism of class B radical SAM 
methyltransferases is shown in Figure 3-7.    
       
 
Figure 3-7. Proposed mechanism of Class B radical SAM methyltransferases. 
Several mechanisms can be envisioned for the GenK-catalyzed conversion of 
GenX2 (6) to G418 (7). In this chapter, possible GenK reaction mechanisms are proposed, 
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and several attempts to elucidate the chemical mechanism of this enzyme are reported. 
These experiments involve analysis by UV-visible spectroscopy, assays using isotope-
labeled compounds, and mechanistic investigation using various substrate analogs. 
 
3.2. EXPERIMENTAL PROCEDURES 
3.2.1. Materials and Equipment 
All chemicals were purchased from Fisher Science (Pittsburgh, PA) or Sigma-
Aldrich (St. Louise, MO) and used without further purification unless otherwise 
specified. DNA gel extraction and spin minipreps were obtained from Qiagen (Valencia, 
CA). All reagents for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Amicon and Microcon YM-10 filtration products were purchased from Bio-
Rad (Hercules, CA) and Millipore (Billerica, MA), respectively. Escherichia coli DH5a 
cells were bought from Bethesda Research Laboratories (Muskegon, MI). The vector 
pET24b (+) and enzyme KOD DNA polymerase were purchased from Novagen 
(Madison, WI). DNA modifying enzymes (for restriction digestion and ligation), PCR 
primers, and the overexpression host E. coli BL21 star (DE3) were acquired from 
Invitrogen (Carlsbad, CA) and New England Biolabs (NEB, Beverly, MA). Luria Bertani 
(LB) media are products of Difco (Detroit, MI) or Fisher Scienctific (Pittsburgh, PA). 
Pre-stained protein markers were purchased from NEB. Protein concentrations were 
determined by Bradford Assay
149
 using bovine serum albumin as the standard. The 
relative molecular mass and purity of enzyme samples were determined using SDS-
PAGE. The general methods and protocols for recombinant DNA manipulations are as 
described by Sambrook et al.
150
 DNA sequencing was performed at the Core Facilities of 
the Institute of Cellular and Molecular Biology, University of Texas at Austin. All 
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reactions involving GenK were performed in a Coy Anaerobic Chamber (glovebox) 
under an atmosphere of approximately 97.5% N2 and 2.5% H2 with less than 1 ppm O2. 
All solvents used for GenK assays were deaerated by bubbling with nitrogen gas before 
they were transferred into the glovebox. The solvents in the glove box were stirred open 
to the anaerobic atmosphere overnight to allow equilibration before use. Gentamicin X2, 
G-418, and GenA were purchased from TOKU-E (Bellingham, WA). Tetrahydrofuran 
(THF) was distilled from sodium benzophenone and dichloromethane (CH2Cl2) was 
distilled from calcium hydride under a nitrogen atmosphere. Other anhydrous solvents 
were purchased from Acros Organics (Pittsburgh, PA). Analytic thin layer 
chromatography (TLC) was performed on pre-coated TLC glass plates (Silica gel, grade 
60, F254, 0.25 mm layer thickness) purchased from EMD chemicals (Madison, WI). 
Flash column chromatography was carried out on silica gel (230-400 mesh, grade 60) 
from Sorbent Technologies (Atlanta, GA) by eluting with the specific solvents. 
1
H and 
13
C NMR spectra were recorded at 400, 500, 600 MHz and 100, 125, 150 MHz with a 
Varian Gemini spectrometer. Chemical shifts are reported as parts per million (ppm) 
relative to the deuteriochloroform (CDCl3), 7.26 ppm for 
1
H NMR and 77.16 ppm for 
13
C 
NMR, respectively. Visualization was effected with p-phosphoryl molybdic acid solution.  
The MS analyses were carried out at the Mass Spectrometry and Proteomics Facility of 
the Department of Chemistry, University of Texas at Austin. 
 
3.2.2. Cloning, Expression, Refolding and Reconstitution of GenK 
Cloning, expression, refolding and reconstitution of GenK were identical to the 
previous methods in Sections 2.2.2 and 2.2.3. 
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3.2.3. GenK Activity Assays, HPLC detection of SAH, 5'-dAdo, Aminoglycosides, 
and Mass Spectroscopic Analysis of GenK Activity 
GenK activity assays, HPLC detection of SAH, 5'-dAdo and aminoglycosides, 
and mass spectroscopic analysis of GenK activity were conducted by following the 
previous methods outlined in Sections 2.2.5, 2.2.6, 2.2.7, and 2.2.8.  
 
3.2.4. Synthesis of [6'S-
2
H]-Gentamicin X2 (20) 
The overall synthetic scheme is shown in Scheme 3-1.  
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Scheme 3-1. Synthetic scheme for the preparation of [6'S-
2
H]-GenX2 (20). 
Methyl(2S,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-p-
yran-2-carboxylate (9): (2,2,6,6,-Tetramethylpiperidin-1-yl)oxyl (TEMPO) (0.025 g, 
0.16 mmol) and (diacetoxyiodo)benzene (0.646 g, 2.01 mmol) were added to a solution 
of compound 8 (0.384 g, 0.80 mol) in dichloromethane (10 mL) and water (10 mL). The 
reaction mixture was stirred at room temperature for 2 h, and 10% aqueous solution of 
sodium sulfite (30 mL) was added to quench the reaction. The two layers were separated, 
and the aqueous layer was extracted with ethyl acetate (30 mL × 3). The combined 
organic layers were washed with brine, dried over magnesium sulfate, filtered, and 
concentrated under reduced pressure. The crude acid was dissolved in 
dimethylformamide (20 mL). Potassium carbonate (0.333 g, 2.41 mmol) and 
iodomethane (0.10 mL, 1.61 mmol) were added to the solution. The reaction mixture was 
stirred at room temperature for 12 h, and concentrated under reduced pressure. The 
residue was diluted with dichloromethane (30 mL) and washed with saturated aqueous 
solution of ammonium chloride (30 mL × 3). The combined aqueous solution was 
extracted with dichloromethane (40 mL × 3). The combined organic layers were washed 
with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The crude product was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 4:1 ~ 2:1) to provide compound 9 (0.357 g, 88%) as a white solid. 
1
H 
NMR (400 MHz, CDCl3) δ 7.71–7.63 (m, 2H, Ph), 7.45–7.33 (m, 11H, Ph), 7.32–7.29 
(m, 2H, Ph), 4.91 (d, J = 1.3 Hz, 2H, 2×Bn), 4.82 (d, J = 10.9 Hz, 1H, Bn), 4.66 (d, J = 
10.9 Hz, 1H, Bn), 4.50 (d, J = 10.1 Hz, 1H, C-1), 3.97 (d, J = 9.8 Hz, 1H, H-5), 3.82 (dd, 
J = 9.8, 9.0 Hz, 1H, H-4), 3.79 (s, 3H, OMe), 3.59 (t, J = 9.2 Hz, 1H, H-3), 3.43 (dd, J = 
10.1, 9.3 Hz, 1H, H-2). 
13
C NMR (100 MHz, CDCl3) δ 168.29, 137.54, 137.40, 133.84, 
130.57, 129.15, 128.70, 128.53, 128.46, 128.22, 128.10, 127.98, 127.87, 86.64, 84.17, 
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79.08, 78.06, 75.92, 75.09, 64.59, 52.57. HRMS (ESI, positive) calculated for 
C27H27N3O5S
+
 [M + Na]
+ 
528.1564, found 528.1564. 
((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyran-2-
yl)methan-d2-ol (10): Lithium aluminum deuteride (0.315 g, 7.52 mmol) was added to a 
solution of compound 9 (2.923 g, 5.78 mmol) in tetrahydrofuran (50 mL) at – 78 °C. The 
reaction mixture was stirred for 1 h and ethyl acetate (20 mL) was added. The solution 
was warmed to room temperature and water (10 mL) was added to quench the reaction. 
Diethyl ether (20 mL) and 10% aqueous solution of sodium hydroxide (5 mL) were 
added. The mixtures were filtered through a Celite pad and washed with diethyl ether (50 
mL). The filtered solution was dried over sodium sulfate, filtered again, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 2:1) to provide compound 10 (1.385 g, 50%) as a white solid. 
1
H 
NMR (400 MHz, CDCl3) δ 7.58–7.49 (m, 2H, Ph), 7.38–7.27 (m, 13H, Ph), 4.91–4.79 
(m, 3H, 3×Bn), 4.64 (d, J = 11.0 Hz, 1H, Bn), 4.46 (dd, J = 10.2, 1H, H-1'), 3.58–3.46 
(m, 2H, H-4, H-5), 3.40–3.29 (m, 2H, H-2, H-3). 13C NMR (100 MHz, CDCl3) δ 137.75, 
137.63, 133.64, 131.17, 129.29, 128.72, 128.69, 128.36, 128.22, 128.07, 86.23, 85.06, 
79.61, 76.06, 75.27, 65.41. HRMS (ESI, positive) calculated for C26H25D2N3O4S
+
 [M + 
Na]
+ 
502.1740, found 502.1741.  
(2S,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyran-2-
carbaldehyde-d (11): Dimethyl sulfoxide (8.04 mL, 57.72 mmol) was added dropwise to 
a solution of oxalyl chloride (1.48 mL, 17.31 mmol) in dichloromethane (80 mL) at –78 
°C. After stirring for 15 min, compound 10 (5.534 g, 11.54 mmol) in dichloromethane 
(30 mL) was added dropwise. After stirring for 45 min, trimethylamine (8.04 mL, 57.72 
mmol) was added slowly. After stirring for 20 min, the solution was warmed to room 
temperature, and the reaction mixture was stirred for additional 1 h. The reaction was 
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quenched by adding H2O (100 mL). The aqueous layer was extracted with 
dichloromethane (80 mL × 3). The combined organic layers were washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude 
product was not purified and used for the next reaction.  
(S)-((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyr-
an-2-yl)methan-d-ol (12): Compound 11 was dissolved in dichloromethane (120 mL). 
(R)-Alpine-Borane
®
 (0.5 M solution in THF, 25.39 mL, 12.70 mmol) was added to the 
stirring solution and the reaction mixture was stirred for 24 h. Acetaldehyde (20 mL) was 
added to the solution and the mixture was stirred for 1 h. The solution was concentrated 
under reduced pressure. The residue was diluted with THF (110 mL) and 3 N aqueous 
solution of sodium hydroxide (80 mL) and 30% hydrogen peroxide (80 mL) was added at 
0 °C. The solution was stirred for 1 h, and concentrated under reduced pressure until all 
organic solvents disappeared. The remaining aqueous residue was extracted with ethyl 
acetate (100 mL × 3). The combined organic layers were washed with brine, dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 2:1) to provide 
compound 12 (3.809 g, 69%) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.57–7.52 
(m, 2H,, Ph), 7.39–7.27 (m, 13H, Ph), 4.91–4.81 (m, 3H, 3×Bn), 4.64 (d, J = 11.0 Hz, 
1H, Bn), 4.46 (d, J = 10.1 Hz, 1H, H-1), 3.67 (d, J = 4.7 Hz, 1H, H-6'), 3.57–3.47 (m, 2H, 
H-4, H-5), 3.41–3.29 (m, 2H, H-2, H-3). 13C NMR (125 MHz, CDCl3) δ 137.78, 137.67, 
133.64, 131.23, 129.29, 128.71, 128.69, 128.36, 128.21, 128.08, 86.28, 85.09, 79.71, 
75.27, 65.47. HRMS (ESI, positive) calculated for C26H26DN3O4S
+
 [M + Na]
+ 
501.1677, 
found 501.1679. 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((S)-(benzyloxy)methyl-d)-2-(phenyl-
thio)tetrahydro-2H-pyran (13): Sodium hydride (60% dispersion in mineral oil, 0.177 
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g, 4.20 mmol) was added to a solution of compound 12 (1.321 g, 2.80 mmol) in 
dimethylformamide (30 mL) at 0 °C. The solution was warmed to room temperature, and 
the reaction mixture was stirred for 30 min. The temperature was cooled to 0 °C, and 
benzyl bromide (0.49 mL, 4.20 mmol) was added. The reaction mixture was stirred at 
room temperature for 13 h. At 0 °C, methanol (10 mL) was added slowly and the reaction 
solution was concentrated under reduced pressure. The residue was diluted with 
dichloromethane (70 mL), and washed with water (70 mL × 2). The combined aqueous 
layers were extracted with dichloromethane (70 mL × 2). The combined organic layers 
were washed with brine, dried over magnesium sulfate, filtered, and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 15:1) to provide compound 13 (1.194 g, 75%) as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.64–7.60 (m, 2H, Ph), 7.40–7.16 (m, 18H, Ph), 4.89–4.82 
(m, 2H, 2×Bn), 4.80 (d, J = 10.9 Hz, 1H, Bn), 4.65–4.57 (m, 2H, 2×Bn), 4.55 (d, J = 12.0 
Hz, 1H, Bn), 4.43 (d, J = 10.1 Hz, 1H, H-1), 3.73 (d, J = 4.3 Hz, 1H, H-6), 3.62 (dd, J = 
9.7, 9.0 Hz, 1H, H-4), 3.52 (t, J = 9.1 Hz, 1H, H-3), 3.48 (dd, J = 9.7, 4.4 Hz, 1H, H-5), 
3.36 (dd, J = 10.1, 9.2 Hz, 1H, H-2). 
13
C NMR (100 MHz, CDCl3) δ 138.33, 137.98, 
137.74, 133.75, 131.30, 129.10, 128.63, 128.58, 128.48, 128.31, 128.12, 128.00, 127.95, 
127.72, 127.68, 86.07, 85.19, 79.40, 77.65, 75.99, 75.15, 73.51, 65.19. HRMS (ESI, 
positive) calculated for C33H32DN3O4S
+
 [M + Na]
+ 
591.2147, found 591.2148. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((S)-
(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate 
(15): Compound 13 (0.812 g, 1.43 mmol) and compound 14 (0.327 g, 1.10 mmol) were 
co-evaporated from dry toluene three times and further dried under high vacuum 
overnight. A solution of compound 13 and 14 in anhydrous diethyl ether (15 mL) and 
anhydrous dichloromethane (3 mL) was then added to preactivated 4 Å  molecular sieves. 
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After stirring for 30 min at room temperature, the mixture was cooled to –40 °C. N-
Iodosuccinimide (0.641 g, 2.85 mmol) was added, and the reaction mixture was stirred 
for 20 min. Trifluoromethanesulfonic acid (0.07 mL, 0.77 mmol) was slowly added, and 
the reaction was warmed to –20 °C and kept stirring for 30 min. The reaction solution 
was diluted with ether and filtered. The residue was washed with 10% aqueous solution 
of sodium bisulfite (20 mL) and saturated aqueous solution of sodium bicarbonate (20 
mL). The combined aqueous solutions were extracted with dichloromethane (30 mL × 3). 
The combined organic layers were washed with brine, dried over sodium sulfate, filtered, 
and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 2:1) to provide compound 15 (0.506 g, 61%) 
as a clear oil. 
1
H NMR (400 MHz, CDCl3) δ 7.46–7.26 (m, 13H, Ph), 7.18–7.15 (m, 2H, 
Ph), 5.19–5.10 (m, 2H, H-1', H-5), 4.92–4.88 (dd, J = 19.7, 10.1 Hz, 2H, Bn, H-6), 4.86–
4.77 (m, 2H, 2×Bn), 4.65 (d, J = 12.1 Hz, 1H, Bn), 4.55 (d, J = 10.9 Hz, 1H, Bn), 4.50 (d, 
J = 12.1 Hz, 1H, Bn), 4.16 (dd, J = 10.1, 2.9 Hz, 1H, H-5'), 3.96 (dd, J = 10.4, 8.9 Hz, 
1H, H-3'), 3.85–3.73 (m, 2H, H-6', H-4'), 3.69–3.54 (m, 2H, H-4, H-1), 3.45–3.31 (m, 
2H, H-3, H-2'), 2.39 (dt, J = 13.3, 4.6 Hz, 1H, H-2), 2.09 (s, 3H, OAc), 2.09 (s, 3H, 
OAc), 1.59 (q, J = 12.7 Hz, 1H, H-2'). 
13
C NMR (100 MHz, CDCl3) δ 169.99, 169.65, 
137.97, 137.89, 137.85, 128.58, 128.54, 128.52, 128.11, 128.02, 127.92, 127.87, 127.84, 
99.48, 79.68, 78.39, 78.20, 75.47, 75.10, 74.20, 73.66, 71.71, 63.22, 58.75, 57.80, 31.90, 
20.77, 20.70. HRMS (ESI, positive) calculated for C37H40DN9O9
+
 [M + Na]
+ 
779.2982, 
found 779.2980. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((S)-
(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (16): 
Sodium methoxide (4.37 M in methanol, 0.06 mL, 0.24 mmol) was added dropwise to a 
solution of compound 15 (0.610 g, 0.81 mmol) in methanol (9 mL) and tetrahydrofuran 
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(1 mL). The reaction mixture was stirred at room temperature for 6 h and then neutralized 
with Amberlite IR-120 (H
+
 form) resin, filtered, and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 2:1) to give compound 16 (0.493 g, 91%) as a pale yellow oil. 
1
H NMR 
(600 MHz, CDCl3) δ 7.38–7.27 (m, 13H, Ph), 7.21–7.12 (m, 2H, Ph), 5.17 (d, J = 3.6 Hz, 
1H, H-1'), 4.93 (d, J = 10.6 Hz, 1H, Bn), 4.86 (d, J = 10.7 Hz, 1H, Bn), 4.79 (d, J = 10.8 
Hz, 1H, Bn), 4.64 (d, J = 12.0 Hz, 1H, Bn), 4.55 (d, J = 10.9 Hz, 1H, Bn), 4.50 (d, J = 
12.0 Hz, 1H, Bn), 4.10 (dd, J = 10.1, 3.3 Hz, 1H, H-5'), 3.99 (dd, J = 10.2, 9.0 Hz, 1H, H-
3'), 3.81–3.76 (m, 2H, H-6', H-4'), 3.64 (dd, J = 10.2, 3.6 Hz, 1H, H-2'), 3.52–3.46 (m, 
1H, H-5), 3.44 (t, J = 9.1 Hz, 1H, H-6), 3.42–3.37 (m, 1H, H-1), 3.30–3.22 (m, 2H, H-4, 
H-3), 2.29 (dt, J = 12.9, 4.0 Hz, 1H, H-2), 1.54–1.44 (m, 1H, H-2). 13C NMR (150 MHz, 
CDCl3) δ 137.91 (Ph), 137.87 (Ph), 137.68 (Ph), 128.62 (Ph), 128.59 (Ph), 128.54 (Ph), 
128.19 (Ph), 128.11 (Ph), 128.08 (Ph), 128.00 (Ph), 127.91 (Ph), 127.89 (Ph), 99.66 (C-
1'), 83.98 (C-4), 81.08 (C-3'), 78.29 (C-4'), 76.01 (C-5), 75.77 (Bn), 75.47 (C-6), 75.15 
(Bn), 73.71 (Bn), 71.77 (C-5'), 64.40 (C-2'), 59.78 (C-1), 58.90 (C-3), 32.22 (C-2). 
HRMS (ESI, positive) calculated for C33H36DN9O7
+
 [M + Na]
+ 
695.2771, found 
695.2768. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6-
R)-3-azido-4,5-bis(benzyloxy)-6-((S)-(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-
yl)oxy)-2-hydroxycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-
2-one (18): Compound 16 (0.369 g, 0.549 mmol) and compound 17 (0.263 g, 0.659 
mmol) were co-evaporated from dry toluene three times and further dried under high 
vacuum overnight. A solution of compound 16 and 17 in anhydrous diethyl ether (5 mL) 
and anhydrous dichloromethane (1 mL) was added to a preactivated 4 Å  molecular sieves 
and N-iodosuccinimide (0.247 g, 1.098 mmol). After stirring 30 min at room temperature, 
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the mixture was cooled to –40 °C. Silver trifluoromethanesulfonate (0.282 g, 1.098 
mmol) was added, and the reaction was warmed to –10 °C to stand for 12 h. The reaction 
mixture was diluted with ethyl acetate (20 mL) and filtered through a Celite pad. The 
solution was washed with 10% aqueous solution of sodium bisulfite (20 mL) and 
saturated aqueous solution of sodium bicarbonate (20 mL). The combined aqueous layers 
were extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed 
with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (Hex/EtOAc = 
1.5 : 1) to provide compound 18 (0.390 g, 75%) as a clear liquid. 
1
H NMR 
1
H NMR (500 
MHz, CDCl3) δ 7.38–7.25 (m, 18 H, Bn), 7.21–7.13 (m, 2H, Bn), 5.57 (d, J = 3.8 Hz, 1H, 
H-1'), 5.05 (d, J = 3.2 Hz, 1H, H-1''), 4.90–4.88 (m, 3H, Bn), 4.80 (d, J = 10.9 Hz, 1H, 
Bn), 4.63 (d, J = 12.1 Hz, 1H, Bn), 4.59 (d, J = 11.6 Hz, 1H, Bn), 4.55 (d, J = 11.0 Hz, 
1H, Bn), 4.49 (d, J = 12.1 Hz, 1H, Bn), 4.24–4.09 (m, 3H, H-5'', H-5', OH), 4.00 (t, J = 
9.6 Hz, 1H, H-3'), 3.93 (t, J = 3.9 Hz, 1H, H-2''), 3.84–3.71 (m, 4H, H-6', H-6, H-5'', H-
4'), 3.66 (t, J = 9.0 Hz, 1H, H-5), 3.50–3.43 (m, 4H, H-4, H-1, H-3'', H-2'), 3.41–3.26 (m, 
2H, H-6, H-3), 2.83 (s, 3H, NMe), 2.30 (dt, J = 13.4, 4.6 Hz, 1H, H-2), 1.48 (d, J = 12.7 
Hz, 1H, H-2), 1.38 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 157.22, 138.07, 137.98, 
137.93, 137.37, 128.62, 128.47, 128.41, 128.25, 128.04, 127.92, 127.89, 127.86, 127.73, 
127.70, 98.60, 96.71, 84.06, 80.62, 80.26, 78.14, 77.24, 75.44, 75.02, 74.95, 74.38, 73.55, 
73.50, 71.39, 66.54, 63.64, 62.87, 59.75, 58.72, 32.01, 30.24, 23.47. HRMS (ESI, 
positive) calculated for C48H53DN10O11
+
 [M + Na]
+ 
970.3929, found 970.3925. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-
3-azido-4,5-bis(benzyloxy)-6-((S)-(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-yl)o-
xy)-2-hydroxycyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol 
(19): A 2 N aqueous solution of sodium hydroxide (4 mL) was added to a solution of 
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compound 11 (0.302 g, 0.329 mmol) in ethanol (12 mL). The reaction mixture was stirred 
at 90 °C for 12 h, and cooled to room temperature. The solution was diluted with ethyl 
acetate (15 mL) and washed with water (15 mL). The residue was washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel (5% methanol in 
dichloromethane) to provide compound 19 (0.261 g, 89%) as a clear oil. 
1
H NMR (500 
MHz, CDCl3) δ 7.44–7.23 (m, 18H, Bn), 7.18–7.16 (m, 2H, Bn), 5.52 (d, J = 3.7 Hz, 1H, 
H-1'), 5.25 (d, J = 3.3 Hz, 1H, H-1''), 4.93–4.84 (m, 2H, Bn), 4.81 (dd, J = 11.3, 2.8 Hz, 
2H, Bn), 4.65 (d, J = 12.1 Hz, 1H, Bn), 4.55 (d, J = 10.9 Hz, 1H, Bn), 4.52 (d, J = 6.3 Hz, 
1H, Bn), 4.50 (d, J = 6.6 Hz, 1H, Bn), 4.15 (dd, J = 10.1, 3.2 Hz, 1H, H-5'), 4.00 (dd, J = 
10.3, 8.9 Hz, 1H, H-3'), 3.95 (d, J = 12.3 Hz, 1H, H-5''), 3.84–3.72 (m, 2H, H-6', H-4'), 
3.68 (t, J = 9.0 Hz, 1H, H-5), 3.61 (dd, J = 10.2, 3.4 Hz, 1H, H-2''), 3.56–3.46 (m, 3H, H-
5'', H-1, H-2'), 3.42 (dd, J = 10.0, 8.9 Hz, 1H, H-4), 3.38–3.25 (m, 2H, H-3, H-6), 2.68 (d, 
J = 10.3 Hz, 1H, H-3''), 2.54 (s, 3H, NMe), 2.34 (dt, J = 13.2, 4.5 Hz, 1H, H-2), 1.52 (q, J 
= 12.7 Hz, 1H, H-2), 1.18 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 138.11, 138.02, 
137.96, 137.81, 128.74, 128.56, 128.51, 128.48, 128.28, 128.22, 128.13, 128.00, 127.97, 
127.85, 127.83, 127.81, 98.97, 97.11, 83.77, 81.23, 80.47, 78.20, 76.14, 75.61, 75.59, 
75.06, 73.61, 72.46, 71.49, 71.05, 66.68, 63.81, 63.27, 59.79, 58.90, 38.67, 32.29, 24.55. 
HRMS (ESI, positive) calculated for C47H55DN10O10
+
 [M + Na]
+ 
944.4136, found 
944.4142. 
[6'S-
2
H]-Gentamicin X2 (20): Trimethylphosphine (1 M solution in THF, 0.34 mL, 0.34 
mmol) was added to a solution of compound 19 (0.63 mg, 0.068 mmol) in THF (3 mL) 
and 0.1 M aqueous solution of sodium hydroxide (1 mL). The reaction mixture was 
stirred at 50 °C for 2 h, cooled to room temperature, and concentrated under reduced 
pressure. The residue was dissolved in a mixture of acetic acid (0.5 mL), water (1.5 mL), 
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and methanol (1.5 mL). The solution was deaerated by evacuating the air inside of the 
flask and refilling it with nitrogen five times. Palladium hydroxide on carbon (20%, 
Degussa type, 0.05 g) was added and the solution was charged with hydrogen gas. The 
reaction mixture was stirred at room temperature under hydrogen gas for 24 h. The 
solution was filtered through a Celite pad, washed with water and methanol, and 
concentrated under reduced pressure. The residue was purified by chromatography on 
Amberlite CG-50 resin (NH4
+
 form) (5-10% concentrated ammonium hydroxide in 
water), concentrated under reduced pressure, acidified with hydrochloric acid (pH ca. 4), 
and lyophilized to provide compound 20 (0.03 g, 92%) as an oily solid. 
1
H NMR (500 
MHz, D2O) δ 5.75 (d, J = 4.0 Hz, 1H, H-1'), 5.17 (d, J = 3.7 Hz, 1H, H-1''), 4.26 (dd, J = 
11.0, 3.7 Hz, 1H, H-2''), 4.07 (d, J = 12.8 Hz, 1H, H-5''), 4.02–3.95 (m, 2H, H-3', H-4), 
3.89–3.76 (m, 4H, H-4', H-5, H-6', H-6), 3.70–3.60 (m, 2H, H-1, H-3), 3.59–3.46 (m, 4H, 
H-2', H-3', H-5', H-5'''), 2.96 (s, 3H, NMe), 2.60 (dt, J = 12.7, 4.3 Hz, 1H, H-2), 2.00 (q, J 
= 12.6 Hz, 1H, H-2), 1.39 (s, 3H. Me). 
13
C NMR (125 MHz, D2O) δ 101.03, 96.88, 
83.33, 80.11, 73.75, 73.57, 69.88, 69.35, 68.93, 67.77, 66.20, 63.26, 53.93, 49.50, 48.65, 
34.50, 27.79, 20.90. HRMS (ESI, positive) calculated for C19H37DN4O10
+
 [M + H]
+ 
484.2723, found 484.2723.  
 
3.2.5. Synthesis of [6'R-
2
H]-Gentamicin X2 (29) 
The overall synthetic scheme is shown in Scheme 3-2.  
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Scheme 3-2. Synthetic scheme for the preparation of [6'R-
2
H]-GenX2 (29).  
(S)-((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyra-
n-2-yl)methyl-d 4-methylbenzenesulfonate (21): p-Toluenesulfonyl chloride (0.457 g, 
2.40 mmol) was added to a solution of 12 (0.574 g, 1.20 mmol) in pyridine (12 mL). The 
reaction mixture was stirred at room temperature for 24 h, and concentrated under 
reduced pressure. The residue was diluted with dichloromethane (40 mL) and washed 
with saturated aqueous solution of ammonium chloride (30 mL). The remaining aqueous 
layer was washed with dichloromethane (30 mL × 3). The combined organic layers were 
washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced 
pressure. The crude product was purified by flash column chromatography on silica gel 
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(Hex/EtOAc = 4:1) to provide compound 21 (0.689 g, 91%) as an oil. 
1
H NMR (400 
MHz, CDCl3) δ 7.81–7.79 (m, 2H, Ph), 7.58–7.45 (m, 2H, Ph), 7.41–7.24 (m, 13H, Ph), 
7.20–7.18 (m, 2H, Ph), 4.86 (d, J = 10.6 Hz, 1H, Bn), 4.83–4.73 (m, 2H, 2×Bn), 4.50 (d, 
J = 10.7 Hz, 1H, Bn), 4.33 (d, J = 10.1 Hz, 1H, H-1), 4.15 (d, J = 4.0 Hz, 1H, H-6), 3.50–
3.38 (m, 3H, H-3, H-4, H-5), 3.25 (t, J = 9.5 Hz, 1H, H-2'), 2.40 (s, 3H, OMe). 
13
C NMR 
(100 MHz, CDCl3) δ 145.15, 137.50, 137.39, 134.03, 132.93, 130.69, 130.05, 129.17, 
128.70, 128.27, 128.16, 128.12, 85.97, 84.98, 76.04, 75.28, 64.98, 21.79. HRMS (ESI, 
positive) calculated for C33H32DN3O6S2
+
 [M + Na]
+ 
655.1766, found 655.1764. 
(R)-((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyr-
an-2-yl)methyl-d benzoate (22): Sodium benzoate (0.388 g, 3.40 mmol) was added to a 
solution of compound 21 (0.717 g, 1.13 mmol) in dimethylformamide (11mL). The 
reaction mixture was stirred at 100 °C for 12 h, cooled to room temperature, and 
concentrated under reduced pressure. The residue was diluted with dichloromethane (40 
mL) and washed with water (30 mL × 3). The combined aqueous layers were extracted 
with dichloromethane (40 mL × 3). The combined organic layers were washed with 
brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. 
The crude product was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 4:1) to provide compound 22 (0.582 g, 89%) as a clear oil. 
1
H NMR (400 
MHz, CDCl3) δ 8.05–7.99 (m, 2H, Ph), 7.67–7.59 (m, 1H, Ph), 7.59–7.53 (m, 2H, Ph), 
7.50–7.45 (m, 2H, Ph), 7.40–7.22 (m, 10H, Ph), 7.17–7.10 (m, 2H, Ph), 4.92 (d, J = 10.3 
Hz, 1H, Bn), 4.86 (d, J = 10.2 Hz, 2H, Bn), 4.69 (d, J = 2.0 Hz, 1H, H-6), 4.61 (d, J = 
10.9 Hz, 1H, Bn), 4.45 (d, J = 10.1 Hz, 1H, H-1), 3.70–3.53 (m, 3H, H-3, H-4, H-5), 
3.40–3.29 (m, 1H, H-2). 13C NMR (100 MHz, CDCl3) δ 166.10, 137.41, 137.38, 134.30, 
133.37, 130.47, 129.91, 129.86, 129.04, 128.77, 128.71, 128.69, 128.58, 128.50, 128.35, 
 140 
128.28, 128.16, 85.72, 85.21, 77.27, 77.22, 76.26, 75.35, 64.99. HRMS (ESI, positive) 
calculated for C33H30DN3O5S
+
 [M + Na]
+ 
605.1939, found 605.1947. 
(R)-((2R,3S,4R,5R,6S)-5-azido-3,4-bis(benzyloxy)-6-(phenylthio)tetrahydro-2H-pyr-
an-2-yl)methan-d-ol (23): 2 N aqueous solution of sodium hydroxide (2.52 mL, 5.03 
mmol) was added to a solution of 22 (0.733 g, 1.26 mmol) in methanol (12 mL). The 
reaction mixture was stirred at room temperature for 5 h, neutralized with Amberlite IR-
120 (H
+
 form) resin, filtered, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 2:1) to give 
compound 23 (0.560 g, 93%) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.57–7.52 
(m, 2H, Ph), 7.37–7.27 (m, 13H), 4.91–4.81 (m, 3H, 3×Bn), 4.64 (d, J = 11.0 Hz, 1H, 
Bn), 4.46 (d, J = 10.2 Hz, 1H, H-1), 3.86 (d, J = 2.6 Hz, 1H, H-6), 3.57–3.49 (m, 2H, H-
4, H-5), 3.39 – 3.29 (m, 2H, H-2, H-3). 13C NMR (125 MHz, CDCl3) δ 137.79, 137.68, 
133.64, 131.24, 129.29, 128.71, 128.69, 128.36, 128.21, 128.07, 86.29, 85.09, 75.27, 
65.47. HRMS (ESI, positive) calculated for C26H26DN3O4S
+
 [M + Na]
+ 
501.1677, found 
501.1679. 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((R)-(benzyloxy)methyl-d)-2-(phenyl-
thio)tetrahydro-2H-pyran (24): Sodium hydride (60% dispersion in mineral oil, 0.072 
g, 1.71 mmol) was added to a solution of compound 23 in dimethylformamide (9 mL) at 
0 °C. The reaction mixture was stirred at room temperature for 30 min. Benzyl bromide 
(0.20 mL, 1.71 mmol) was added at 0 °C, and the reaction mixture was stirred at room 
temperature for 12 h. At 0 °C, methanol (5 mL) was added slowly, and the solution was 
concentrated under reduced pressure. The residue was diluted with dichloromethane (50 
mL) and washed with water (30 mL × 2). The combined aqueous layers were extracted 
with dichloromethane (40 mL × 3). The combined organic layers were washed with 
brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The 
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crude product was purified by flash column chromatography on silica gel (Hex/EtOAc = 
15:1) to provide compound 24 (0.364 g, 75%) as a white solid. 
1
H NMR (400 MHz, 
CDCl3) δ 7.67–7.59 (m, 2H, Ph), 7.39–7.19 (m, 18H, Ph), 4.90–4.82 (m, 2H, 2×Bn), 4.80 
(d, J = 10.9 Hz, 1H, Bn), 4.66–4.58 (m, 2H, Bn), 4.55 (d, J = 12.0 Hz, 1H, Bn, 4.43 (d, J 
= 10.1 Hz, 1H, H-1), 3.77 (d, J = 1.9 Hz, 1H, H-6), 3.63 (dd, J = 9.7, 9.0 Hz, 1H, H-4), 
3.52 (t, J = 9.1 Hz, 1H, H-3), 3.48 (dd, J = 9.7, 1.9 Hz, 1H, H-5), 3.36 (dd, J = 10.1, 9.3 
Hz, 1H, H-2). 
13
C NMR (100 MHz, CDCl3) δ 138.32, 137.98, 137.72, 133.74, 131.28, 
129.08, 128.62, 128.57, 128.47, 128.30, 128.11, 127.98, 127.93, 127.71, 127.67, 86.06, 
85.18, 79.39, 77.64, 75.98, 75.14, 73.51, 65.17. HRMS (ESI, positive) calculated for 
C33H32DN3O4S
+
 [M + Na]
+ 
591.2147, found 591.2146. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((R)-
(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate 
(25): Compound 24 (0.956 g, 1.68 mmol) and compound 14 (0.385 g, 1.29 mmol) were 
co-evaporated from dry toluene three times and further dried under high vacuum 
overnight. A solution of compound 24 and 14 in anhydrous diethyl ether (15 mL) and 
anhydrous dichloromethane (3 mL) was then added to preactivated 4 Å  molecular sieves. 
After stirring for 30 min at room temperature, the mixture was cooled to –40 °C. N-
Iodosuccinimide (0.756 g, 3.36 mmol) was added, and the reaction mixture was stirred 
for 30 min. Trifluoromethanesulfonic acid (0.08 mL, 0.90 mmol) was slowly added, and 
the reaction was warmed to –20 °C and kept stirring for 30 min. The reaction solution 
was diluted with ether (15 mL) and filtered. The residue was washed with 10% aqueous 
solution of sodium bisulfite (15 mL) and saturated aqueous solution of sodium 
bicarbonate (15 mL). The combined aqueous solutions were extracted with 
dichloromethane (40 mL × 3). The combined organic layers were washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
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was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:1) to provide 
compound 25 (0.595 g, 61%) as a clear oil. 
1
H NMR (400 MHz, CDCl3) δ 7.43–7.27 (m, 
13H, Ph), 7.18–7.15 (m, 2H, Ph), 5.21–5.09 (m, 2H, H-1', H-5), 4.95–4.88 (dd, J = 20.3, 
10.3 Hz, 2H, Bn, H-6), 4.85–4.77 (m, 2H, 2×Bn), 4.65 (d, J = 12.1 Hz, 1H, Bn), 4.54 (d, 
J = 10.9 Hz, 1H, Bn), 4.52–4.46 (m, 1H, Bn), 4.16 (dd, J = 10.1, 2.0 Hz, 1H, H-5'), 3.96 
(dd, J = 10.4, 8.9 Hz, 1H, H-3'), 3.79 (dd, J = 10.1, 9.0 Hz, 1H, H-4'), 3.70–3.56 (m, 3H, 
H-4, H-1, H-6'), 3.46–3.40 (m, 1H, H-3), 3.36 (dd, J = 10.4, 3.9 Hz, 1H, H-2'), 2.39 (dt, J 
= 13.4, 4.6 Hz, 1H, H-2), 2.09 (s, 3H, OAc), 2.08 (s, 3H, OAc), 1.59 (q, J = 12.7 Hz, 1H, 
H-2). 
13
C NMR (100 MHz, CDCl3) δ 169.99, 169.66, 138.00, 137.91, 137.86, 128.59, 
128.55, 128.53, 128.12, 128.03, 127.93, 127.89, 127.84, 99.49, 79.70, 75.47, 75.11, 
74.21, 73.68, 73.64, 71.73, 63.24, 58.77, 57.81, 31.92, 20.78, 20.71. HRMS (ESI, 
positive) calculated for C37H40DN9O9
+
 [M + Na]
+ 
779.2982, found 779.2996. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((R-
)-(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (26): 
Sodium methoxide (4.37 M in methanol, 0.08 mL, 0.35 mmol) was added dropwise to a 
solution of compound 25 (0.874 g, 1.15 mmol) in methanol (10 mL). The reaction 
mixture was stirred at room temperature for 1 h and then neutralized with Amberlite IR-
120 (H
+
 form) resin, filtered, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 2:1) to give 
compound 26 (0.738 g, 95%) as a pale yellow oil. 
1
H NMR (500 MHz, CDCl3) δ 7.38–
7.28 (m, 13H, Ph), 7.21–7.15 (m, 2H, Ph), 5.22 (d, J = 3.7 Hz, 1H, H-1'), 4.94 (d, J = 
10.7 Hz, 1H, Bn), 4.87 (d, J = 10.7 Hz, 1H, Bn), 4.81 (d, J = 10.9 Hz, 1H, Bn), 4.66 (d, J 
= 12.1 Hz, 1H, Bn), 4.57 (d, J = 10.9 Hz, 1H, Bn), 4.51 (d, J = 12.0 Hz, 1H, Bn), 4.12 
(dd, J = 10.0, 2.1 Hz, 1H, H-5'), 4.01 (dd, J = 10.2, 9.0 Hz, 1H, H-3'), 3.80 (dd, J = 10.1, 
9.0 Hz, 1H, H-4'), 3.69 (d, J = 2.0 Hz, 1H, H-6'), 3.63 (dd, J = 10.2, 3.6 Hz, 1H, H-2'), 
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3.50 (t, J = 8.7 Hz, 1H, H-5), 3.47–3.35 (m, 2H, H-6, H-1), 3.34–3.22 (m, 2H, H-4, H-3), 
2.28 (dt, J = 12.9, 4.2 Hz, 1H, H-2), 1.48 (dt, J = 13.0, 11.7 Hz, 1H, H-2). 
13
C NMR (125 
MHz, CDCl3) δ 137.92 (Ph), 137.86 (Ph), 137.69 (Ph), 128.57 (Ph), 128.54 (Ph), 128.50 
(Ph), 128.15 (Ph), 128.04 (Ph), 127.93 (Ph), 127.87 (Ph), 127.83 (Ph), 99.51 (C-1'), 83.56 
(C-4), 80.96 (C-3'), 78.27 (C-4'), 75.69 (C-5), 75.46 (C-6), 75.09 (Bn), 73.65 (Bn), 71.70 
(C-5'), 67.90 (C-6'), 64.30 (C-2'), 59.77 (C-1), 58.89 (C-3), 32.15 (C-2). HRMS (ESI, 
positive) calculated for C33H36DN9O7
+
 [M + Na]
+ 
695.2771, found 695.2770. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6-
R)-3-azido-4,5-bis(benzyloxy)-6-((R)-(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-
yl)oxy)-2-hydroxycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-
2-one (27): Compound 26 (0.721 g, 1.07 mmol) and compound 17 (0.471 g, 1.18 mmol) 
were co-evaporated from dry toluene three times and further dried under high vacuum 
overnight. A solution of compound 26 and 17 in anhydrous diethyl ether (10 mL) and 
anhydrous dichloromethane (2 mL) was added to a preactivated 4 Å  molecular sieves and 
N-iodosuccinimide (0.482 g, 2.14 mmol). After stirring 30 min at room temperature, the 
mixture was cooled to –40 °C. Silver trifluoromethanesulfonate (0.551 g, 2.14 mmol) 
was added, and the reaction was warmed to –10 °C to stand for 3 h. The reaction mixture 
was diluted with ethyl acetate (10 mL) and filtered through a Celite pad. The solution was 
washed with 10% aqueous solution of sodium bisulfite (15 mL) and saturated aqueous 
solution of sodium bicarbonate (15 mL). The combined aqueous layers were extracted 
with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) to provide 
compound 27 (0.589 g, 58%) as a clear liquid. 
1
H NMR (500 MHz, CDCl3) δ 7.42–7.26 
(m, 18H, Bn), 7.19–7.14 (m, 2H, Bn), 5.57 (d, J = 3.7 Hz, 1H, H-1'), 5.06 (d, J = 3.2 Hz, 
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1H, H-1''), 4.92–4.87 (m, 3H, Bn), 4.81 (d, J = 10.9 Hz, 1H, Bn), 4.65 (d, J = 12.1 Hz, 
1H, Bn), 4.61 (d, J = 11.6 Hz, 1H, Bn), 4.55 (d, J = 11.0 Hz, 1H, Bn), 4.50 (d, J = 12.2 
Hz, 1H, Bn), 4.24–4.12 (m, 3H, H-5'', H-5', OH), 4.00 (dd, J = 10.3, 8.9 Hz, 1H, H-3'), 
3.94 (dd, J = 4.5, 3.2 Hz, 1H, H-2''), 3.85–3.73 (m, 3H, H-6, H-5'', H-4'), 3.70–3.63 (m, 
2H, H-5, H-6'), 3.48 (ddd, J = 8.7, 5.7, 4.1 Hz, 4H, H-4, H-1, H-3'', H-2'), 3.45–3.37 (m, 
H, H-6), 3.37–3.29 (m, 1H, H-3), 2.84 (s, 3H, NMe), 2.32 (dt, J = 13.2, 4.5 Hz, 1H, H-2), 
1.56–1.44 (m, 1H, H-2), 1.40 (s, 3H, Me). 13C NMR (100 MHz, CDCl3) δ 157.35, 
138.13, 138.03, 137.98, 137.41, 128.74, 128.59, 128.53, 128.39, 128.16, 128.03, 128.00, 
127.86, 98.77, 96.81, 84.15, 80.85, 80.41, 78.21, 77.35, 75.60, 75.09, 74.50, 73.69, 73.63, 
71.50, 66.64, 63.75, 63.01, 59.88, 58.79, 32.14, 30.37, 23.60. HRMS (ESI, positive) 
calculated for C48H53DN10O11
+
 [M + Na]
+ 
970.3929, found 970.3925. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-
3-azido-4,5-bis(benzyloxy)-6-((R)-(benzyloxy)methyl-d)tetrahydro-2H-pyran-2-yl)o-
xy)-2-hydroxycyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol 
(28): A 2 N aqueous solution of sodium hydroxide (10 mL) was added to a solution of 
compound 27 (0.592 g, 0.625 mmol) in ethanol (30 mL). The reaction mixture was stirred 
at 90 °C for 14 h, and cooled to room temperature. The solution was diluted with ethyl 
acetate (30 mL) and washed with water (30 mL). The residue was washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel (5% methanol in 
dichloromethane) to provide compound 28 (0.437 g, 76%) as a clear oil. 
1
H NMR (500 
MHz, CDCl3) δ 7.41–7.24 (m,18, Bn), 7.17–7.15 (m, 2H, Bn), 5.51 (d, J = 3.7 Hz, 1H, 
H-1'), 5.25 (d, J = 3.3 Hz, 1H, H-1''), 4.88 (d, J = 3.3 Hz, 2H, Bn), 4.83–4.76 (m, 2H, 
Bn), 4.65 (d, J = 12.1 Hz, 1H, Bn), 4.56–4.47 (m, 3H, Bn), 4.42 (s, 1H, OH), 4.13 (dd, J 
= 10.1, 2.1 Hz, 1H, H-5'), 3.99 (dd, J = 10.3, 9.0 Hz, 1H, H-3'), 3.94 (d, J = 12.3 Hz, 1H, 
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H-5''), 3.77 (dd, J = 10.1, 8.9 Hz, 1H, H-4'), 3.70–3.64 (m, 3H, H-5, H-6', H-4'), 3.64–
3.58 (m, 1H, H-2''), 3.56–3.45 (m, 3H, H-1, H-5'', H-2'), 3.41 (dd, J = 10.1, 8.9 Hz, 1H, 
H-4), 3.37–3.28 (m, 2H, H-6, H-3), 2.68 (d, J = 10.3 Hz, 1H, H-3''), 2.54 (s, 3H, NMe), 
2.34 (dt, J = 13.2, 4.4 Hz, 1H, H-2), 1.51 (q, J = 12.7 Hz, 1H, H-2), 1.18 (s, 3H, Me). 
13
C 
NMR (125 MHz, CDCl3) δ 138.14, 138.04, 137.98, 137.81, 128.77, 128.60, 128.54, 
128.52, 128.32, 128.27, 128.16, 128.03, 128.00, 127.89, 127.85, 99.02, 97.11, 83.75, 
81.30, 80.51, 78.23, 77.36, 76.13, 75.64, 75.62, 75.09, 73.66, 72.50, 71.53, 71.07, 63.85, 
63.35, 59.83, 58.92, 38.66, 32.32, 24.54. HRMS (ESI, positive) calculated for 
C47H55DN10O11
+
 [M +Na]
+ 
944.4136, found 944.4106. 
[6'R-
2
H]-Gentamicin X2 (29): Trimethylphosphine (1 M solution in THF, 0.84 mL, 0.84 
mmol) was added to a solution of compound 28 (0.129 mg, 0.14 mmol) in THF (4.8 mL) 
and 0.1 M aqueous solution of sodium hydroxide (1.6 mL). The reaction mixture was 
stirred at 50 °C for 2 h, cooled to room temperature, and concentrated under reduced 
pressure. The residue was dissolved in a mixture of acetic acid (1.2 mL), water (3.6 mL) 
and methanol (3.6 mL). The solution was degassed by evacuating the air inside of the 
flask and refilling it with nitrogen five times. Palladium hydroxide on carbon (20%, 
Degussa type, 0.1 g) was added and the solution was charged with hydrogen gas. The 
reaction mixture was stirred at room temperature under hydrogen gas for 24 h. The 
solution was filtered through a Celite pad, washed with water and methanol, and 
concentrated under reduced pressure. The residue was purified by chromatography on 
Amberlite CG-50 resin (NH4
+
 form) (5% concentrated ammonium hydroxide in water), 
concentrated under reduced pressure, acidified with hydrochloric acid (pH ca. 4), and 
lyophilized to provide compound 29 (0.057 g, 84%) as an oily solid. 
1
H NMR (500 MHz, 
D2O) δ 5.70 (d, J = 4.0 Hz, 1H, H-1'), 5.13 (d, J = 3.7 Hz, 1H, H-1''), 4.24 (dd, J = 10.9, 
3.7 Hz, 1H, H-2''), 4.04 (d, J = 12.8 Hz, 1H, H-5''), 3.99–3.90 (m, 3H, H-6', H-3', H-4), 
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3.90–3.79 (m, 3H, H-4', H-5, H-6), 3.68–3.58 (m, 2H, H-1, H-3), 3.57–3.44 (m, 4H, H-
5'', H-3'', H-5', H-2'), 2.94 (s, 3H, NMe), 2.57 (dt, J = 12.6, 4.3 Hz, 1H, H-2), 1.95 (q, J = 
12.7 Hz, 1H, H-2), 1.37 (s, 3H, Me). 
13
C NMR (125 MHz, D2O) δ 101.05, 97.01, 83.36, 
80.22, 73.69, 73.59, 69.83, 69.27, 68.92, 67.78, 66.17, 63.20, 53.86, 49.43, 48.57, 34.45, 
27.81, 20.87. HRMS (ESI, positive) calculated for C19H37DN4O10
+
 [M + H]
+ 
484.2723, 
found 484.2725.  
 
3.2.6. Synthesis of [6'-F]-gentamicin X2 (35) 
The overall synthetic scheme is shown in Scheme 3-3.  
 
 
Scheme 3-3. Synthetic scheme for the preparation of [6'-F]-GenX2 (35) 
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(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6S)-3-azido-4,5-bis(benzyloxy)-6-(flu-
oromethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (31): 
Diethylaminosulfur trifluoride (DAST) (0.20 mL, 1.53 mmol) was added to a solution of 
compound 30 (0.511 g, 0.767 mmol) in dichloromethane (10 mL) at 0 °C. The reaction 
mixture was stirred at 0 °C for 30 min and at room temperature for 12 h. The reaction 
was quenched by adding saturated aqueous solution of sodium bicarbonate (20 mL). The 
aqueous layer was extracted with dichloromethane (30 mL × 3). The combined organic 
layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. 
The crude product was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 4:1) to provide compound 31 (0.307 g, 60%) as a clear liquid. 
1
H NMR 
(500 MHz, CDCl3) δ 7.40–7.34 (m, 10H, Ph), 5.19–5.15 (m, 2H, H-1', H-5), 4.99–4.87 
(m, 4H, H-6, 3×Bn), 4.82–4.55 (m, 3H, Bn, H-6', H-6'), 4.22 (dd, J = 31.2, 10.2 Hz, 1H, 
H-5'), 4.02 (t, J = 9.6 Hz, 1H, H-3'), 3.72 (t, J = 9.6 Hz, 1H, H-4'), 3.66 (t, J = 9.8 Hz, 1H, 
H-4), 3.64–3.54 (m, 1H, H-1), 3.41–3.36 (m, 2H, H-2', H-3), 2.35 (dt, J = 13.4, 4.7 Hz, 
1H, H-2), 2.12 (s, 1H, Ac), 2.09 (s, 1H, Ac), 1.62 (q, J = 12.7 Hz, 1H, H-2). 
13
C NMR 
(125 MHz, CDCl3) δ 169.75 (Ac), 169.46 (Ac), 137.59 (Ph), 137.52 (Ph), 128.50 (Ph), 
128.45 (PH), 127.98 (Ph), 127.96 (Ph), 127.92 (Ph), 127.78 (Ph), 99.29 (C-1'), 81.43 (d, J 
= 173.4, C-6'), 79.44 (C-3'), 78.40 (C-4), 77.30 (d, J = 5.1 Hz, C-4'), 75.29 (Bn), 75.17 
(Bn), 73.94 (C-6), 73.31 (C-5), 71.08 (d, J = 18.2 Hz, C-5'), 62.93 (C-2'), 58.42 (C-3), 
57.53(C-1), 31.44 (C-2), 20.52 (OAc), 20.48 (OAc). 
19
F NMR (375 MHz, CDCl3) δ -
234.52 (td, J = 47.7, 31.3 Hz). HRMS (ESI, positive) calculated for C30H34FN9O8
+
 [M + 
Na]
+ 
690.2407, found 690.2414. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6S)-3-azido-4,5-bis(benzyloxy)-6-(flu-
oromethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (32): Sodium metho-
xide (4.37 M in methanol, 0.7 mL, 0.33 mmol) was added to a solution of compound 31 
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(0.735 g, 1.10 mmol) in tetrahydrofuran (2 mL) and methanol (18 mL). The reaction 
mixture was stirred at room temperature for 12 h, neutralized with Amberlite IR-120 (H
+
 
form) resin, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 2:1) to give 
compound 32 (0.426 g, 73%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.37–7.30 (m, 
10H, Bn), 5.17 (d, J = 3.7 Hz, 1H, H-1'), 4.95 (d, J = 10.6 Hz, 1H, Bn), 4.91–4.86 (m, 
2H, Bn), 4.76–4.52 (m, 3H, Bn, H-6', H-6'), 4.18–3.97 (m, 2H, H-5', H-3'), 3.71 (dd, J = 
10.2, 9.0 Hz, 1H, H-4'), 3.63 (dd, J = 10.2, 3.6 Hz, 1H, H-2'), 3.55–3.36 (m, 3H, H-4, H-
5, H-1), 3.32–3.19 (m, 2H, H-6, H-3), 3.03 (s, 1H, OH), 2.31 (dt, J = 12.9, 3.9 Hz, 1H, H-
2), 1.58–1.43 (m, 1H, H-2). 13C NMR (125 MHz, CDCl3) δ 137.59 (Ph), 137.49 (Ph), 
128.73 (Ph), 128.67 (Ph), 128.23 (Ph), 128.21 (Ph), 127.93 (Ph), 99.77 (C-1'), 84.09 (C-
6), 81.63 (d, J = 172.1, C-6'), 80.94 (C-3'), 77.46 (d, J = 5.4, C-4'), 76.07 (Bn), 75.87 (C-
4), 75.43 (Bn, C-5), 71.35 (d, J = 18.2, C-5'), 64.28 (C-2'), 59.78 (C-1), 58.91 (C-3), 
32.12 (C-2). 
19
F NMR (470 MHz, CDCl3) δ -235.11 (td, J = 47.8, 30.9 Hz). HRMS (ESI, 
positive) calculated for C26H30FN9O6
+
 [M + Na]
+ 
606.2195, found 606.2202. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6-
S)-3-azido-4,5-bis(benzyloxy)-6-(fluoromethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hy-
droxycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-2-one (33): 
Compound 32 (0.543 g, 0.808 mmol) and compound 17 (0.355 g, 0.888 mmol) were co-
evaporated from dry toluene three times and further dried under high vacuum overnight. 
A solution of compound 32 and 17 in anhydrous diethyl ether (10 mL) and anhydrous 
dichloromethane (2 mL) was added to a preactivated 4 Å  molecular sieves and N-
iodosuccinimide (0.364 g, 1.616 mmol). After stirring 30 min at room temperature, the 
mixture was cooled to –40 °C. Silver trifluoromethanesulfonate (0.415 g, 1.616 mmol) 
was added, and the reaction was warmed to –10 °C to stand for 3 h. The reaction mixture 
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was diluted with ethyl acetate (10 mL) and filtered through a Celite pad. The solution was 
washed with 10% aqueous solution of sodium bisulfite (20 mL) and saturated aqueous 
solution of sodium bicarbonate (25 mL). The combined aqueous layers were extracted 
with ethyl acetate (40 mL × 3). The combined organic layers were washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) to provide 
compound 33 (0.365 g, 53%) as a clear liquid. 
1
H NMR (500 MHz, CDCl3) δ 7.42–7.28 
(m, 15H, Ph), 5.60 (d, J = 3.8 Hz, 1H, H-1'), 5.03 (d, J = 3.2 Hz, 1H, H-1''), 4.92–4.87 
(m, 4H, 4×Bn), 4.74–4.52 (m, 4H, 2×Bn, H-6', H-6' ), 4.22–4.08 (m, 3H, H-5'', OH, H-
5'), 4.03 (dd, J = 10.3, 8.9 Hz, 1H, H-3'), 3.95 (dd, J = 4.4, 3.1 Hz, 1H, H-2''), 3.80 (d, J = 
12.4 Hz, 1H, H-5''), 3.70–3.65 (m, 2H, H-4', H-5), 3.51–3.38 (m, 5H, H-1, H-3'', H-4, H-
2', H-6), 3.35 (ddd, J = 12.4, 10.0, 4.4 Hz, 1H, H-3), 2.83 (s, 3H, NMe), 2.33 (dt, J = 
13.2, 4.4 Hz, 1H, H-2), 1.51 (q, J = 12.6 Hz, 1H, H-2), 1.41 (s, 3H, Me). 
13
C NMR (125 
MHz, CDCl3) δ 157.28 (N(C(=O)O), 137.85 (Ph), 137.82 (Ph), 137.41 (Ph), 128.73 (Ph), 
128.64 (Ph), 128.61 (Ph), 128.39 (Ph), 128.15 (Ph), 128.08 (Ph), 128.05 (Ph), 128.02 
(Ph), 127.91 (Ph), 98.54 (C-1'), 97.00 (C-2''), 84.60 (C-6), 81.76 (d, J = 173.3 Hz, C-6'), 
80.50 (C-4), 80.15 (C-3'), 77.36 (C-4'), 77.21 (C-4''), 75.63 (Bn), 75.33 (Bn), 75.12 (C-5), 
74.63 (Bn), 73.42 (C-2''), 71.06 (d, J = 18.2 Hz, C-5'), 66.87 (C-5''), 63.58 (C-2'), 63.04 
(C-3''), 59.78 (C-1), 58.77 (C-3), 32.08 (C-2), 30.32 (NMe), 23.63 (Me). 
19
F NMR (375 
MHz, CDCl3) δ -234.59 (td, J = 47.8, 30.7 Hz). HRMS (ESI, positive) calculated for 
C41H47FN10O10
+
 [M + Na]
+ 
881.3353, found 881.3368. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6S)-
3-azido-4,5-bis(benzyloxy)-6-(fluoromethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydro-
xycyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol (34): A 2 N 
aqueous solution of sodium hydroxide (5 mL) was added to a solution of compound 33 
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(0.365 g, 0.425 mmol) in ethanol (15 mL). The reaction mixture was stirred at 90 °C for 
10 h, and cooled to room temperature. The solution was diluted with ethyl acetate (20 
mL) and washed with water (20 mL). The residue was washed with brine, dried over 
sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel (5–8% methanol in 
dichloromethane) to provide compound 34 (0.251 g, 71%) as a clear oil. 
1
H NMR (500 
MHz, CDCl3) δ 7.39–7.30 (m, 15H, Ph), 5.56 (d, J = 3.7 Hz, 1H, H-1'), 5.23 (d, J = 3.3 
Hz, 1H, H-1''), 4.89 (d, J = 8.7 Hz, 3H, 3×Bn), 4.78 (d, J = 11.6 Hz, 1H, Bn), 4.75–4.64 
(m, 2H, Bn H-6'), 4.63–4.50 (m, 2H, Bn H-6'), 4.20–4.09 (m, 1H, H-5'), 4.03 (dd, J = 
10.3, 9.0 Hz, 1H, H-3'), 3.92 (d, J = 12.2 Hz, 1H, H-5''), 3.74–3.64 (m, 3H, H-2'', H-5, H-
4'), 3.57–3.47 (m, 2H, H-5'', H-1), 3.47–3.39 (m, 2H, H-2', H-4), 3.39–3.27 (m, 2H, H-3, 
H-6), 2.72 (d, J = 10.3 Hz, 1H, H-3''), 2.56 (s, 3H, NMe), 2.34 (dt, J = 13.2, 4.5 Hz, 1H, 
H-2), 1.52 (q, J = 12.7 Hz, 1H, H-2), 1.21 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 
137.80 (Ph), 137.78 (Ph), 137.74 (Ph), 128.72 (Ph), 128.63 (Ph), 128.59 (Ph), 128.28 
(Ph), 128.23 (Ph), 128.14 (Ph), 128.08 (Ph), 128.04 (Ph), 127.90 (Ph), 98.76 (C-1'), 97.27 
(C-1''), 84.42 (C-6), 81.74 (d, J = 173.3 Hz, C-6'), 80.81 (C-4), 80.21 (C-3'), 77.37 (C-4'), 
77.33 (C-4''), 76.12 (C-2''), 75.71 (C-5), 75.63 (Bn), 75.32 (Bn), 72.54 (Bn), 71.04 (d, J = 
18.1 Hz, C-5'), 67.07 (C-5''), 63.59 (C-2'), 63.44 (C-3''), 59.65 (C-1), 58.86 (C-3), 38.41 
(C-2), 32.21 (NMe), 24.26 (Me). 
19
F NMR (376 MHz, Chloroform-d) δ -234.58 (td, J = 
47.7, 30.8 Hz). HRMS (ESI, positive) calculated for C40H49FN10O9
+
 [M + Na]
+ 
855.3560, 
found 855.3570. 
[6'-F]-gentamicin X2 (35): Trimethylphosphine (1 M solution in THF, 1.89 mL, 1.89 
mmol) was added to a solution of compound 34 (0.165 mg, 0.198 mmol) in THF (3 mL) 
and 0.1 M aqueous solution of NaOH (1 mL). The reaction mixture was stirred at 50 °C 
for 2 h, cooled to room temperature, and concentrated under reduced pressure. The 
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residue was dissolved in a mixture of acetic acid (2 mL), water (6 mL) and methanol (6 
mL). The solution was degassed by evacuating the air inside of the flask and refilling it 
with nitrogen five times. Palladium hydroxide on carbon (20%, Degussa type, 0.1 g) was 
added and the solution was charged with hydrogen gas. The reaction mixture was stirred 
at room temperature under hydrogen gas for 24 h. The solution was filtered through a 
Celite pad, washed with water and methanol, and concentrated under reduced pressure. 
The residue was purified by chromatography on Amberlite CG-50 resin (NH4
+
 form) (5% 
concentrated ammonium hydroxide in water), concentrated under reduced pressure, 
acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide compound 35 
(0.080 g, 84%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.79 (d, J = 4.0 Hz, 1H, H-
1'), 5.14 (d, J = 3.7 Hz, 1H, H-1''), 4.85–4.82 (m, 1H, H-6'), 4.74–4.67 (m, 1H, H-6'), 
4.25 (dd, J = 10.9, 3.7 Hz, 1H, H-2''), 4.11–4.01 (m, 2H, H-5', H-5''), 4.00–3.95 (m, 2H, 
H-3', H-4), 3.90 (t, J = 9.0 Hz, 1H, H-5), 3.83 (dd, J = 10.2, 8.9 Hz, 1H, H-6), 3.69–3.59 
(m, 3H, H-1, H-3, H-4'), 3.56 (d, J = 10.9 Hz, 1H, H-3''), 3.54 (d, J = 12.8 Hz, 1H, H-5''), 
3.51 (dd, J = 10.9, 4.0 Hz, 1H, H-2'), 2.94 (s, 3H, NMe), 2.58 (dt, J = 12.6, 4.2 Hz, 1H, 
H-2), 1.96 (q, J = 12.6 Hz, 1H, H-2), 1.38 (s, 3H, Me). 
13
C NMR (125 MHz, D2O) δ 
101.07 (C-1''), 96.85 (C-1'), 83.43 (C-6), 82.21 (d, J = 167.3 Hz, C-6'), 79.52 (C-4), 73.84 
(C-5), 72.22 (d, J = 17.6 Hz, C-5'), 69.85 (C-4''), 68.77 (C-3'), 68.19 (d, J = 7.2 Hz, C-4'), 
67.83 (C-5''), 66.17 (C-2''), 63.19 (C-3''), 53.70 (C-2'), 49.46 (C-1), 48.37 (C-3), 34.48 
(NMe), 27.80 (C-2), 20.90 (Me). 
19
F NMR (565 MHz, D2O) δ -233.97 (td, J = 47.1, 25.3 
Hz). HRMS (ESI, positive) calculated for C19H37FN4O9
+
 [M + H]
+ 
485.2617, found 
485.2628. 
 
3.2.7. Synthesis of [6',6' 6'-
2
H,
 2
H,F]-Gentamicin X2 (43) 
The overall synthetic scheme is shown in Scheme 3-4. 
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Scheme 3-4. Synthetic scheme for the preparation of [6', 6', 6'-
2
H,
 2
H,F]-GenX2 (43). 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-methoxybenzyl)oxy)methyl-d2)-
2-(phenylthio)tetrahydro-2H-pyran (36): Sodium hydride (60% dispersion in mineral 
oil, 0.125 g, 2.97 mmol) and 4-methoxybenzyl chloride (0.47 mL, 3.43 mmol) were 
added to a solution of compound 10 (1.096 g, 2.29 mmol) in dimethylformamide (20 mL) 
at 0 °C. The reaction mixture was stirred at room temperature for 12 h, and concentrated. 
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The residue was diluted with dichloromethane (80 mL) and washed with water (60 mL). 
The aqueous layer was extracted with dichloromethane (50 mL × 3). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 10:1) to give compound 36 (1.109 g, 81%) 
as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.68–7.63 (m, 2H, Ph), 7.40–7.28 (m, 
13H, Ph), 7.25–7.21 (m, 2H, Ph), 6.94–6.88 (m, 2H, Ph), 4.93–4.85 (m, 2H, PMB), 4.82 
(d, J = 10.9 Hz, 1H, Bn), 4.61 (d, J = 11.3 Hz, 2H, Bn), 4.51 (d, J = 11.6 Hz, 1H), Bn, 
4.46 (d, J = 10.1 Hz, 1H, H-1), 3.83 (s, 3H, -OMe), 3.64 (dd, J = 9.7, 8.9 Hz, 1H, H-4), 
3.56 (d, J = 9.2 Hz, 1H), H-3, 3.49 (d, J = 9.6 Hz, 1H, H-5), 3.40 (dd, J = 10.1, 9.2 Hz, 
1H, H-2). 
13
C NMR (100 MHz, CDCl3) δ 159.29, 137.97, 137.73, 133.64, 131.39, 
130.36, 129.37, 129.07, 128.58, 128.52, 128.40, 128.26, 128.07, 127.94, 127.90, 113.86, 
86.09, 85.14, 79.35, 77.63, 75.92, 75.07, 73.12, 65.19, 55.34. HRMS (ESI, positive) 
calculated for C34H33D2N3O5S
+
 [M + Na]
+ 
622.2315, found 622.2317. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-
methoxybenzyl)oxy)methyl-d2)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl 
diacetate (37): Compound 36 (1.040 g, 1.73 mmol) and compound 14 (0.431 g, 1.44 
mmol) were co-evaporated from dry toluene three times and further dried under high 
vacuum overnight. A solution of compound 36 and 14 in anhydrous diethyl ether (18 mL) 
and anhydrous dichloromethane (6 mL) was then added to preactivated 4 Å  molecular 
sieves. After stirring for 30 min at room temperature, the mixture was cooled to –40 °C. 
N-Iodosuccinimide (0.845 g, 3.75 mmol) was added, and the reaction mixture was stirred 
for 30 min. Trifluoromethanesulfonic acid (0.08 mL, 0.87 mmol) was slowly added, and 
the reaction was warmed to –20 °C and kept stirring for 30 min. The reaction solution 
was diluted with ether and filtered. The residue was washed with 10% aqueous solution 
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of sodium bisulfite (20 mL) and saturated aqueous solution of sodium bicarbonate (20 
mL). The combined aqueous solutions were extracted with dichloromethane (40 mL × 3). 
The combined organic layers were washed with brine, dried over sodium sulfate, filtered, 
and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 3:1) to provide compound 37 (0.682 g, 60%) 
as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.41–7.23 (m, 12H, Ph), 7.15–7.13 (m, 2H, 
Ph), 6.86–6.84 (m, 2H, Ph), 5.18–5.11 (m, 2H, H-5, H-1'), 4.94 (t, J = 10.0 Hz, 1H, H-6), 
4.89 (d, J = 10.5 Hz, 1H, PMB), 4.83 (d, J = 10.7 Hz, 1H, PMB), 4.77 (d, J = 10.9 Hz, 
1H, Bn), 4.61 (d, J = 11.8 Hz, 1H, Bn), 4.49 (d, J = 10.9 Hz, 1H, Bn), 4.42 (d, J = 11.8 
Hz, 1H, Bn), 4.15 (d, J = 10.1 Hz, 1H, H-5'), 3.96 (dd, J = 10.5, 8.9 Hz, 1H, H-3'), 3.84–
3.72 (m, 4H, -OCH', H-4' ), 3.68–3.56 (m, 2H, H-1, H-4), 3.46–3.33 (m, 2H, H-3, H-2'), 
2.40 (dt, J = 13.3, 4.5 Hz, 1H, H-2), 2.09 (d, J = 3.6 Hz, 6H, OAc), 1.60 (q, J = 12.6 Hz, 
1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 169.86, 169.52, 159.31, 137.92, 137.80, 
129.82, 129.67, 128.48, 128.47, 128.45, 128.39, 128.38, 127.99, 127.88, 127.77, 127.68, 
127.63, 113.80, 99.40, 79.56, 78.28, 78.08, 75.33, 74.93, 74.11, 73.54, 73.15, 71.55, 
63.12, 58.68, 57.71, 55.21, 31.82, 20.66, 20.60. HRMS (ESI, positive) calculated for 
C38H41D2N9O10
+
 [M + Na]
+ 
810.3151, found 810.3144. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(hy-
droxymethyl-d2)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (38): 
2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (0.250 g, 1.10 mmol) was added to a 
solution of compound 37 (0.5784 g, 0.734 mmol) in dichloromethane (20 mL) and water 
(2 mL). The reaction mixture was stirred for 4 h at room temperature and quenched by 
adding saturated aqueous solution of sodium bicarbonate (20 mL). The aqueous layer was 
extracted with dichloromethane (30 mL × 3), and the combined organic phase was 
washed with brine, dried over magnesium sulfate, filtered, and concentrated under 
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reduced pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 3:2) to give compound 38 (0.367 g, 75%) as a clear liquid. 
1
H NMR (500 
MHz, CDCl3) δ 7.37–7.28 (m, 10H, Ph), 5.14 (t, J = 9.8 Hz, 1H, H-5), 5.08 (d, J = 3.9 
Hz, 1H, H-1'), 4.92 (dd, J = 14.0, 10.3 Hz, 2H, H-6, Bn), 4.89–4.82 (m, 2H, Bn), 4.70 (d, 
J = 11.1 Hz, 1H, Bn), 4.06 (dd, J = 10.1, 0.5 Hz, 1H, H-5'), 3.98 (dd, J = 10.4, 8.9 Hz, 
1H, H-3'), 3.68–3.57 (m, 3H, H-4', H-1, H-4), 3.42 (ddd, J = 12.4, 9.9, 4.6 Hz, 1H, H-3), 
3.32 (dd, J = 10.4, 3.8 Hz, 1H, H-2'), 2.40 (dt, J = 13.4, 4.6 Hz, 1H, H-2), 2.09 (s, 6H, 
OAc), 1.59 (dt, J = 13.5, 12.5 Hz, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 170.02, 
169.65, 137.85, 137.80, 128.70, 128.63, 128.17, 128.16, 128.08, 128.06, 99.58, 79.67, 
78.81, 77.83, 75.55, 75.21, 74.23, 73.58, 72.30, 63.41, 58.90, 57.80, 32.02, 20.80, 20.72. 
HRMS (ESI, positive) calculated for C30H33D2N9O9
+
 [M + Na]
+ 
690.2575, found 
690.2578. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6S)-3-azido-4,5-bis(benzyloxy)-6-(flu-
oromethyl-d2)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (39): 
Diethylaminosulfur trifluoride (DAST) (0.104 mL, 0.786 mmol) was added to a solution 
of compound 38 (0.262 g, 0.393 mmol) in dichloromethane (5 mL) at 0 °C. The reaction 
mixture was stirred at 0 °C for 30 min and at room temperature for 12 h. The reaction 
was quenched by adding saturated aqueous solution of sodium bicarbonate (10 mL). The 
aqueous layer was extracted with dichloromethane (20 mL × 3). The combined organic 
layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated. 
The crude product was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 4:1) to provide compound 39 (0.171 g, 65%) as a clear liquid. 
1
H NMR 
(500 MHz, CDCl3) δ 7.39–7.28 (m, 10H, Bn), 5.19–5.09 (m, 2H, H-1', H-5), 4.98–4.82 
(m, 4H, H-6, 3×Bn), 4.67 (d, J = 11.0 Hz, 1H, Bn), 4.16 (dd, J = 31.2, 10.2 Hz, 1H, H-5'), 
4.02–3.94 (m, 1H, H-3'), 3.72–3.58 (m, 3H, H-4', H-4, H-1), 3.41 (ddd, J = 12.4, 10.0, 
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4.5 Hz, 1H, H-2'), 3.35 (dd, J = 10.4, 3.8 Hz, 1H, H-3), 2.40 (dt, J = 13.4, 4.6 Hz, 1H, H-
2), 2.09 (d, J = 0.8 Hz, 6H, OAc), 1.61 (q, J = 12.7 Hz, 1H, H-2). 
13
C NMR (125 MHz, 
CDCl3) δ 169.96 (Ac), 169.63 (Ac), 137.70 (Ph), 137.65 (Ph), 128.69 (Ph), 128.63 (Ph), 
128.17 (Ph), 128.12 (Ph), 128.11 (Ph), 127.93 (Ph), 99.47 (C-1'), 79.61 (C-3'), 78.60 (C-
4), 77.48 (C-4') , 75.56 (Bn), 75.40 (Bn), 74.19 (C-6), 73.55 (C-5), 71.20 (d, J = 18.2 Hz, 
C-5'), 63.19 (C-2'), 58.72 (C-3), 57.79 (C-1), 31.86 (C-2), 20.77 (Ac), 20.70 (Ac). 
19
F 
NMR (375 MHz, CDCl3) δ -236.30 (d, J = 31.3 Hz). HRMS (ESI, positive) calculated for 
C30H32D2FN9O8
+
 [M + Na]
+ 
692.2532, found 692.2525. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6S)-3-azido-4,5-bis(benzyloxy)-6-(flu-
oromethyl-d2)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (40): Sodium 
methoxide (4.37 M in methanol, 0.004 mL, 0.019 mmol) was added to a solution of 
compound 39 (0.043 g, 0.065 mmol) in tetrahydrofuran (0.5 mL) and methanol (4.5 mL). 
The reaction mixture was stirred at room temperature for 5 h, neutralized with Amberlite 
IR-120 (H
+
 form) resin, filtered, and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography on silica gel (Hex/EtOAc = 2:1) to 
give compound 40 (0.033 g, 85%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.41–7.29 
(m, 10H, Bn), 5.19 (d, J = 3.7 Hz, 1H, H-1'), 4.95 (d, J = 10.6 Hz, 1H, Bn), 4.92–4.85 (m, 
2H, Bn), 4.69 (d, J = 10.9 Hz, 1H, Bn), 4.17 (s, 1H, OH), 4.13–3.98 (m, 2H, H-5', H-3'), 
3.71 (dd, J = 10.2, 9.0 Hz, 1H, H-4'), 3.63 (dd, J = 10.2, 3.6 Hz, 1H, H-2'), 3.55–3.36 (m, 
3H, H-4, H-5, H-1), 3.35–3.22 (m, 2H), H-6, H-3, 3.17 (s, 1H, OH), 2.31 (dt, J = 12.9, 
4.0 Hz, 1H, H-2), 1.57–1.42 (m, 1H, H-2). 13C NMR (125 MHz, CDCl3) δ 137.58 (Ph), 
137.48 (Ph), 128.71 (Ph), 128.65 (Ph), 128.20 (PH), 128.19 (Ph), 127.92 (Ph), 99.73 (C-
1'), 83.97 (C-6), 80.90 (C-3'), 77.45 (C-4'), 76.09 (Bn), 75.84 (C-4), 75.42 (Bn), 75.40 
(C-5), 71.21 (d, J = 18.1 Hz, C-5'), 64.24 (C-2'), 59.78 (C-1), 58.90 (C-3), 32.10 (C-2). 
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19
F NMR (375 MHz, CDCl3) δ -235.84 (d, J = 31.1 Hz). HRMS (ESI, positive) 
calculated for C26H28D2FN9O6
+
 [M + Na]
+ 
608.2321, found 608.2313. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6-
S)-3-azido-4,5-bis(benzyloxy)-6-(fluoromethyl-d2)tetrahydro-2H-pyran-2-yl)oxy)-2-
hydroxycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-2-one 
(41): Compound 40 (0.418 g, 0.714 mmol) and compound 17 (0.342 g, 0.856 mmol) were 
co-evaporated from dry toluene three times and further dried under high vacuum 
overnight. A solution of compound 40 and 17 in anhydrous diethyl ether (10 mL) and 
anhydrous dichloromethane (2 mL) was added to a preactivated 4 Å  molecular sieves and 
N-iodosuccinimide (0.321 g, 1.427 mmol). After stirring 30 min at room temperature, the 
mixture was cooled to –40 °C. Silver trifluoromethanesulfonate (0.367 g, 1.427 mmol) 
was added, and the reaction was warmed to –10 °C to stand for 12 h. The reaction 
mixture was diluted with ethyl acetate (20 mL) and filtered through a Celite pad. The 
solution was washed with 10% aqueous solution of sodium bisulfite (20 mL) and 
saturated aqueous solution of sodium bicarbonate (20 mL). The combined aqueous layers 
were extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed 
with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (Hex/EtOAc = 
3:2) to provide compound 41 (0.387 g, 63%) as a clear liquid. 
1
H NMR (500 MHz, 
CDCl3) δ 7.40–7.29 (m, 15H, Ph), 5.60 (d, J = 3.7 Hz, 1H, H-1'), 5.03 (d, J = 3.2 Hz, 1H, 
H-1''), 4.92–4.86 (m, 4H, 4×Bn), 4.68 (d, J = 11.1 Hz, 1H, Bn), 4.61 (d, J = 11.6 Hz, 1H, 
Bn), 4.22–4.17 (m, 2H, H-5'',OH), 4.13 (dd, J = 30.6, 10.2 Hz, 1H, H-5'), 4.07–4.00 (m, 
1H, H-3'), 3.95 (dd, J = 4.4, 3.2 Hz, 1H, H-2''), 3.80 (d, J = 12.4 Hz, 1H, H-5''), 3.73–3.63 
(m, 2H, H-4', H-5), 3.53–3.38 (m, 5H, H-1, H-3'', H-4, H-2', H-6), 3.35 (ddd, J = 12.4, 
10.0, 4.4 Hz, 1H, H-3), 2.83 (s, 3H, NMe), 2.33 (dt, J = 13.2, 4.5 Hz, 1H. H-2), 1.51 (q, J 
 158 
= 12.6 Hz, 1H, H-2), 1.41 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 157.28 
(N(C(=O)O), 137.85 (Ph), 137.82 (Ph), 137.41 (Ph), 128.73 (Ph), 128.64 (Ph), 128.61 
(Ph), 128.39 (Ph), 128.15 (Ph), 128.08 (Ph), 128.05 (Ph), 128.02 (Ph), 128.01 (Ph), 
127.91 (Ph), 98.54 (C-1'), 97.00 (C-1''), 84.60 (C-6), 80.50 (C-4), 80.15 (C-3'), 77.34 (C-
4'), 77.22 (C-4''), 75.63 (Bn), 75.32 (Bn), 75.12 (C-5), 74.62 (Bn), 73.41 (C-2''), 70.93 (d, 
J = 18.2 Hz, C-5'), 66.87 (C-5''), 63.57 (C-2''), 63.03 (C-3''), 59.78 (C-1), 58.76 (C-3), 
32.08 (C-2), 30.32 (NMe), 23.63 (Me). HRMS (ESI, positive) calculated for 
C41H45D2FN10O10
+
 [M + H]
+ 
883.3478, found 883.3499. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6S)-
3-azido-4,5-bis(benzyloxy)-6-(fluoromethyl-d2)tetrahydro-2H-pyran-2-yl)oxy)-2-hy-
droxycyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol (42): A 2 
N aqueous solution of sodium hydroxide (5 mL) was added to a solution of compound 41 
(0.303 g, 0.352 mmol) in ethanol (15 mL). The reaction mixture was stirred at 90 °C for 
10 h, and cooled to room temperature. The solution was diluted with ethyl acetate (15 
mL) and washed with water (15 mL). The residue was washed with brine, dried over 
sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel (5–6% methanol in 
dichloromethane) to provide compound 42 (0.221 g, 75%) as a clear oil. 
1
H NMR (500 
MHz, CDCl3) δ 7.40–7.30 (m, 15H, Ph), 5.55 (d, J = 3.7 Hz, 1H, H-1'), 5.22 (d, J = 3.3 
Hz, 1H, H-1''), 4.89 (d, J = 8.5 Hz, 3H, 3×Bn), 4.79 (d, J = 11.7 Hz, 1H, Bn), 4.67 (d, J = 
11.0 Hz, 1H, Bn), 4.51 (d, J = 11.7 Hz, 1H, Bn), 4.13 (dd, J = 30.7, 10.2 Hz, 1H, H-5'), 
4.02 (dd, J = 10.2, 9.0 Hz, 1H, H-3'), 3.91 (d, J = 12.3 Hz, 1H, H-5''), 3.72–3.58 (m, 3H, 
H-5, H-2'', H-4), 3.56–3.48 (m, 2H, H-5'', H-1), 3.47–3.39 (m, 2H, H-2', H-4), 3.37–3.26 
(m, 2H, H-3, H-6), 2.68 (d, J = 10.3 Hz, 1H, H-3''), 2.53 (s, 3H, NMe), 2.34 (dt, J = 13.2, 
4.5 Hz, 1H, H-2), 1.52 (q, J = 12.7 Hz, 1H, H-2), 1.18 (s, 3H, Me). 
13
C NMR (125 MHz, 
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CDCl3) δ 137.82 (Ph), 137.80 (Ph), 137.79 (Ph), 128.76 (Ph), 128.66 (Ph), 128.62 (Ph), 
128.31 (Ph), 128.22 (Ph), 128.16 (Ph), 128.11 (Ph), 128.07 (Ph), 127.92 (Ph), 98.78 (C-
1'), 97.30 (C-1''), 84.38 (C-6), 80.87 (C-4), 80.24 (C-3'), 77.34 (C-4'), 76.14 (C-2''), 75.71 
(C-5), 75.67 (Bn), 75.34 (Bn), 72.54 (Bn), 70.87 (d, J = 18.3, C-5'), 66.80 (C-5''), 63.63 
(C-2'), 63.30 (C-3''), 59.69 (C-1), 58.88 (C-3), 38.66 (C-2), 32.26 (NMe), 24.53 (Me). 
19
F 
NMR (375 MHz, CDCl3) δ -235.80 (d, J = 30.7 Hz). HRMS (ESI, positive) calculated for 
C40H47D2FN10O9
+
 [M + H]
+ 
837.3686, found 857.3686. 
[6',6',6'-
2
H,
 2
H,F]-gentamicin X2 (43): Trimethylphosphine (1 M solution in THF, 0.8 
mL, 0.789 mmol) was added to a solution of compound 42 (0.109 mg, 0.132 mmol) in 
THF (4 mL) and 0.1 M aqueous solution of NaOH (1.3 mL). The reaction mixture was 
stirred at 50 °C for 2 h, cooled to room temperature, and concentrated under reduced 
pressure. The residue was dissolved in a mixture of acetic acid (2 mL), water (6 mL) and 
methanol (6 mL). The solution was degassed by evacuating the air inside of the flask and 
refilling it with nitrogen five times. Palladium hydroxide on carbon (20%, Degussa type, 
0.05 g) was added and the solution was charged with hydrogen gas. The reaction mixture 
was stirred at room temperature under hydrogen gas for 24 h. The solution was filtered 
through a Celite pad, washed with water and methanol, and concentrated under reduced 
pressure. The residue was purified by chromatography on Amberlite CG-50 resin (NH4
+
 
form) (5% concentrated ammonium hydroxide in water), concentrated under reduced 
pressure, acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide 
compound 43 (0.049 g, 76%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.79 (d, J = 
4.0 Hz, 1H, H-1'), 5.14 (d, J = 3.6 Hz, 1H, H-1''), 4.25 (dd, J = 10.9, 3.7 Hz, 1H, H-2''), 
4.09–4.02 (m, 2H, H-5', H-5''), 4.01–3.96 (m, 2H, H-3', H-4), 3.90 (t, J = 9.1 Hz, 1H, H-
5), 3.84 (dd, J = 10.2, 8.9 Hz, 1H, H-6), 3.69–3.59 (m, 3H, H-1, H-3, H-4'), 3.56 (d, J = 
11.0 ppm, 1H, H-3''), 3.55 (d, J = 12.9 Hz, 1H, H-5''), 3.51 (dd, J = 10.9, 4.1 Hz, 1H, H-
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2'), 2.95 (s, 3H, NMe), 2.59 (dt, J = 12.5, 4.2 Hz, 1H, H-2), 1.97 (q, J = 12.6 Hz, 1H, H-
2), 1.38 (d, J = 1.5 Hz, 3H, Me). 
13
C NMR (125 MHz, D2O) δ 101.08 (C-1''), 96.85 (C-
1'), 83.44 (C-6), 79.52 (C-4), 73.84 (C-5), 72.10 (d, J = 17.8 Hz, C-5'), 69.85 (C-4''), 
68.77 (C-3'), 68.17 (d, J = 7.4 Hz, C-4'), 66.17 (C-2''), 63.19 (C-3''), 53.69 (C-2'), 49.46 
(C-1), 48.36 (C-3), 34.47 (NMe), 27.81 (C-2), 20.89 (Me). 
19
F NMR (565 MHz, D2O) δ -
234.65 (d, J = 25.0 Hz). HRMS (ESI, positive) calculated for C19H35D2FN4O9
+
 [M + H]
+ 
487.2743, found 487.2742. 
 
3.2.8. Synthesis of [6'-OMe]-Gentamicin X2 (49) 
The overall synthetic scheme is shown in Scheme 3-5. 
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Scheme 3-5. Synthetic scheme for the preparation of [6'-OMe]-GenX2 (49). 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(methoxymethyl)-2-(phenylthio)-tetr-
ahydro-2H-pyran (44): Sodium hydride (60% dispersion in mineral oil, 0.267 g, 6.34 
mmol) was added to a solution of compound 8 (1.515 g, 3.17 mmol) in 
dimethylformamide (30 mL) at 0 °C. The reaction mixture was stirred at room 
temperature for 1 h. Iodomethane (0..40 mL, 6.34 mmol) was added at 0 °C and the 
reaction mixture was stirred at room temperature for 12 h. At 0 °C, methanol (10 mL) 
was added slowly and the reaction mixture was stirred at room temperature for additional 
30 min. After being concentrated under reduced pressure, the mixture was diluted with 
dichloromethane (70 mL) and water (70 mL). The aqueous layer was extracted with 
dichloromethane (60 mL × 3). The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The 
crude product was purified by flash column chromatography on silica gel (Hex/EtOAc = 
4:1) to give compound 44 (1.17 g, 75%) as a clear liquid. 
1
H NMR (500 MHz, CDCl3) δ 
7.75–7.70 (m, 2H, Ph), 7.48–7.36 (m, 13H, Ph), 5.00–4.89 (m, 3H, 3×Bn), 4.75 (d, J = 
11.0 Hz, 1H, Bn), 4.53 (d, J = 10.2 Hz, 1H, H-1), 3.75 (d, J = 3.1 Hz, 2H, H-6), 3.71 (t, J 
= 9.4 Hz, 1H, H-4), 3.62 (t, J = 9.1 Hz, 1H, H-3), 3.54–3.45 (m, 5H, H-5, OMe, H-2). 13C 
NMR (125 MHz, CDCl3) δ 137.89 (Ph), 137.60 (Ph), 133.25 (Ph), 131.51 (Ph), 128.90 
(Ph), 128.40 (Ph), 128.39 (Ph), 128.16 (Ph), 128.06 (Ph), 127.87 (Ph), 127.80 (Ph), 
127.72 (Ph), 86.17 (C-1), 84.93(C-3), 79.16 (C-5), 77.37 (C-4), 75.68 (Bn), 74.87 (Bn), 
70.96 (C-6), 65.11 (C-2), 59.30 (OMe). HRMS (ESI, positive) calculated for 
C27H29N3O4S
+
 [M + Na]
+ 
514.1771, found 514.1784. 
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(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(me-
thoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (45): 
Compound 44 (1.413 g, 2.83 mmol) and compound 14 (0.714 g, 2.39 mmol) were co-
evaporated from dry toluene three times and further dried under high vacuum overnight. 
A solution of compound 44 and 14 in anhydrous diethyl ether (30 mL) and anhydrous 
dichloromethane (10 mL) was then added to preactivated 4 Å  molecular sieves. After 
stirring for 30 min at room temperature, the mixture was cooled to –40 °C. N-
Iodosuccinimide (1.401 g, 6.23 mmol) was added, and the reaction mixture was stirred 
for 30 min. Trifluoromethanesulfonic acid (0.11 mL, 0.120 mmol) was slowly added, and 
the reaction was warmed to –20 °C and kept stirring for 30 min. The reaction solution 
was diluted with diethyl ether (40 mL) and filtered. The residue was washed with 10% 
aqueous solution of sodium bisulfite (50 mL) and saturated aqueous solution of sodium 
bicarbonate (50 mL). The combined aqueous solutions were extracted with 
dichloromethane (60 mL × 3). The combined organic layers were washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:1) to provide 
compound 45 (1.009 g, 62%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.38–7.27 (m, 
10, Ph), 5.18–5.10 (m, 2H, H-5, H-1'), 4.98–4.88 (m, 2H, Bn, H-6), 4.88–4.80 (m, 2H, 
2×Bn), 4.66 (d, J = 11.0 Hz, 1H, Bn), 4.13 (dt, J = 10.2, 2.3 Hz, 1H, H-5'), 3.96 (dd, J = 
10.4, 8.9 Hz, 1H, H-3'), 3.79–3.69 (m, 2H, H-4', H-6'), 3.67–3.55 (m, 3H, H-4, H-1, H-
6'), 3.46–3.32 (m, 5H, H-3, OMe, H-2'), 2.39 (dt, J = 13.4, 4.6 Hz, 1H, H-2), 2.09 (s, 3H, 
OAc), 2.08 (s, 3H, OAc), 1.60 (q, J = 12.8 Hz, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 
169.88 (OAc), 169.56 (OAc), 138.02 (Ph), 137.84 (Ph), 128.55 (Ph), 128.50 (Ph), 128.03 
(Ph), 127.93 (Ph), 127.92 (Ph), 127.84 (Ph), 99.51 (C-1'), 79.56 (C-3'), 78.45 (C-4), 78.08 
(C-4'), 75.35 (Bn), 75.09 (Bn), 74.13 (C-6), 73.55 (C-5), 71.57 (C-5'), 70.36 (C-6'), 63.15 
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(C-2'), 59.26 (OMe), 58.70 (C-3), 57.73 (C-1), 31.82 (C-2), 20.67(OAc), 20.62 (OAc). 
HRMS (ESI, positive) calculated for C31H37N9O9
+
 [M + Na]
+ 
702.2606, found 702.2604. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(m-
ethoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (46): Sodium 
methoxide (4.37 M in methanol, 0.04 mL, 0.086 mmol) was added to a solution of 
compound 45 (0.585 g, 0.861 mmol) in methanol (20 mL). The reaction mixture was 
stirred at room temperature for 5 h, neutralized with Amberlite IR-120 (H
+
 form) resin, 
filtered, and concentrated under reduced pressure. The crude product was purified by 
flash column chromatography on silica gel (Hex/EtOAc = 1:1) to give compound 46 
(0.468 g, 91%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.37–7.29 (m, 10H, Ph), 5.16 
(d, J = 3.7 Hz, 1H, H-1'), 4.94 (d, J = 10.6 Hz, 1H, Bn), 4.86 (d, J = 10.6 Hz, 1H, Bn), 
4.85 (d, J = 11.0 Hz, 1H, Bn), 4.66 (d, J = 11.0 Hz, 1H, Bn), 4.25 (d, J = 2.3 Hz, 1H, 
OH), 4.07 (ddd, J = 10.1, 2.9, 1.9 Hz, 1H, H-5'), 3.99 (dd, J = 10.2, 9.0 Hz, 1H, H-3', H-
3'), 3.75 (dd, J = 10.1, 9.0 Hz, 1H, H-4'), 3.71 (dd, J = 10.7, 3.2 Hz, 1H, H-6'), 3.63 (dd, J 
= 10.2, 3.7 Hz, 1H, H-2', H-2'), 3.59 (dd, J = 10.7, 2.0 Hz, 1H, H-6'), 3.52–3.38 (m, 3H, 
H-5, H-6, H-1), 3.37 (s, 3H, OMe), 3.28–3.25 (m, 3H, H-3, H-4, OH), 2.33–2.25 (m, 1H, 
H-2), 1.56 – 1.43 (m, 1H, H-2). 13C NMR (125 MHz, CDCl3) δ 137.98 (Ph), 137.67 (Ph), 
128.63 (Ph), 128.57 (Ph), 128.16 (Ph), 128.05 (Ph), 128.02 (Ph), 127.89 (Ph), 99.74 (C-
1'), 83.96 (C-4), 80.98 (C-3'), 78.15 (C-4'), 76.05 (C-5), 75.70 (Bn), 75.42 (C-6), 75.17 
(Bn), 71.60 (C-5'), 70.56 (C-6'), 64.31 (C-2'), 59.75 (C-1), 59.32 (OMe), 58.92 (C-3), 
32.18 (C-2). HRMS (ESI, positive) calculated for C27H33N9O7
+
 [M + Na]
+ 
618.2395, 
found 618.2396. 
(3aR,6R,7R,7aR)-7-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6-
R)-3-azido-4,5-bis(benzyloxy)-6-(methoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-
hydroxycyclohexyl)oxy)-1,3a-dimethylhexahydro-2H-pyrano[4,3-d]oxazol-2-one 
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(47): Compound 46 (0.432 g, 0.726 mmol) and compound 17 (0.319 g, 0.798 mmol) were 
co-evaporated from dry toluene three times and further dried under high vacuum 
overnight. A solution of compound 46 and 17 in anhydrous dichloromethane (10 mL) 
was added to a preactivated 4 Å  molecular sieves and N-iodosuccinimide (0.261 g, 1.161 
mmol). After stirring 30 min at room temperature, the mixture was cooled to –78 °C. 
Trifluoromethanesulfonic acid (0.02 mL, 0.217 mmol) was added slowly, and the 
reaction was warmed to 0 °C during 1 h. Sodium sulfite (0.1 g), sodium bicarbonate (0.1 
g), and few drops of water were added to the reaction solution. The reaction mixture was 
diluted with dichloromethane (20 mL) and filtered through a Celite pad. The solution was 
washed with saturated aqueous solution of sodium bicarbonate (30 mL). The combined 
aqueous layers were extracted with dichloromethane (30 mL × 3). The combined organic 
layers were washed with brine, dried over sodium sulfate, filtered, and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 1:1) to provide compound 47 (0.480 g, 76%) as a clear solid. 
1
H 
NMR (500 MHz, CDCl3) δ 7.39–7.29 (m, 15H, Ph), 5.53 (d, J = 3.7 Hz, 1H, H-1'), 5.07 
(d, J = 3.2 Hz, 1H, H-1''), 4.93–4.83 (m, 4H, 4×Bn), 4.66 (d, J = 11.1 Hz, 1H, Bn), 4.60 
(d, J = 11.6 Hz, 1H, Bn), 4.21 (d, J = 12.4 Hz, 1H, H-5''), 4.17 (d, J = 1.6 Hz, 1H, OH), 
4.13–4.07 (m, 1H, H-5'), 4.00 (dd, J = 10.3, 9.0 Hz, 1H, H-3'), 3.93 (dd, J = 4.6, 3.2 Hz, 
1H, H-2''), 3.79 (d, J = 12.6 Hz, 1H, H-5''), 3.76–3.63 (m, 3H, H-4', H-6', H-5), 3.58 (dd, 
J = 10.6, 2.0 Hz, 1H, H-6'), 3.53–3.39 (m, 5H, H-1, H-3'', H-6, H-2', H-4), 3.40–3.30 (m, 
4H, OMe, H-3), 2.84 (s, 3H, NMe), 2.33 (dt, J = 13.2, 4.5 Hz, 1H, H-2), 1.60–1.44 (m, 
1H, H-2), 1.40 (s, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 157.30 (N(C=O)O), 138.20 
(Ph), 138.00(Ph), 137.41 (Ph), 128.70 (Ph), 128.57 (Ph), 128.53 (Ph), 128.34 (Ph), 
128.11 (Ph), 128.00 (Ph), 127.93 (Ph), 127.91 (Ph), 127.88 (Ph), 98.83 (C-1'), 96.77 (C-
1''), 84.07 (C-6), 80.97 (C-4), 80.29 (C-3'), 78.12 (C-4'), 77.30 (C-4''), 75.51 (Bn), 75.11 
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(Bn), 75.05 (C-5), 74.45 (Bn), 73.70 (C-2''), 71.37 (C-5'), 70.66 (C-6'), 66.59 (C-5''), 
63.71 (C-3''), 62.98 (C-2'), 59.86 (C-1), 59.32 (OMe), 58.77 (C-3), 32.11 (C-2), 30.33 
(NMe), 23.56 (Me). HRMS (ESI, positive) calculated for C42H50N10O11
+
 [M + Na]
+ 
893.3553, found 893.3556. 
(3R,4R,5R,6R)-5-(benzyloxy)-6-(((1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-
3-azido-4,5-bis(benzyloxy)-6-(methoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hyd-
roxycyclohexyl)oxy)-3-methyl-4-(methylamino)tetrahydro-2H-pyran-3-ol (48): A 2 
N aqueous solution of sodium hydroxide (8 mL) was added to a solution of compound 47 
(0.431 g, 0.495 mmol) in ethanol (20 mL). The reaction mixture was stirred at 90 °C for 
10 h, and cooled to room temperature. The solution was diluted with ethyl acetate (20 
mL) and washed with water (20 mL). The residue was washed with brine, dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. The crude product 
was purified by flash column chromatography on silica gel (5% methanol in 
dichloromethane) to provide compound 48 (0.355 g, 85%) as a white solid. 
1
H NMR (500 
MHz, CDCl3) δ 7.39–7.29 (m, 15H, Ph), 5.48 (d, J = 3.8 Hz, 1H, H-1'), 5.25 (d, J = 3.4 
Hz, 1H, H-1''), 4.90 (d, J = 10.7 Hz, 1H, Bn), 4.86 (d, J = 10.8 Hz, 1H, Bn), 4.85 (d, J = 
11.1 Hz, 1H, Bn) 4.80 (d, J = 11.7 Hz, 1H, Bn), 4.65 (d, J = 11.1 Hz, 1H), 4.49 (d, J = 
11.8 Hz, 1H, Bn), 4.45–4.39 (m, 1H, OH), 4.10 (dt, J = 10.1, 2.5 Hz, 1H, H-5'), 3.99 (dd, 
J = 10.3, 9.0 Hz, 1H, H-3'), 3.94 (d, J = 12.3 Hz, 1H, H-5''), 3.77–3.71 (m, 1H, H-4'), 
3.71–3.63 (m, 2H, H-6', H-5), 3.60–3.49 (m, 4H, H-2'', H-6', H-5'', H-1), 3.46 (dd, J = 
10.3, 3.8 Hz, 1H, H-2'), 3.40 (dd, J = 10.1, 8.8 Hz, 1H, H-4), 3.37–3.30 (m, 5H, OMe, H-
6, H-3), 2.66 (d, J = 10.3 Hz, 1H, H-3''), 2.52 (s, 3H, NMe), 2.35 (dt, J = 13.1, 4.4 Hz, 
1H, H-2), 1.53 (dt, J = 13.2, 12.4 Hz, 1H, H-2), 1.16 (s, 3H, Me). 
13
C NMR (125 MHz, 
CDCl3) δ 138.21 (Ph), 137.99 (Ph), 137.82 (Ph), 128.76 (Ph), 128.61 (Ph), 128.57 (Ph), 
128.31 (Ph), 128.23 (Ph), 128.15 (Ph), 127.98 (Ph), 127.96 (Ph), 127.91 (Ph), 99.10 (C-
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1'), 97.11 (C-1''), 83.66 (C-6), 81.46 (C-4), 80.43 (C-3'), 78.14 (C-4'), 76.17 (C-2''), 75.58 
(C-5, Bn), 75.15 (Bn), 72.47 (Bn), 71.39 (C-5'), 71.08 (C-4''), 70.69 (C-6'), 66.64 (C-5''), 
63.81 (C-2'), 63.24 (C-3''), 59.84 (C-1), 59.35 (OMe), 58.90 (C-3), 38.73 (NMe), 32.32 
(C-2), 24.63 (Me). HRMS (ESI, positive) calculated for C41H52N10O10
+
 [M + Na]
+ 
867.3760, found 867.3764. 
[6'-OMe]-Gentamicin X2 (49): Trimethylphosphine (1 M solution in THF, 1.01 mL, 
1.01 mmol) was added to a solution of compound 48 (0.143 mg, 0.169 mmol) in THF (6 
mL) and 0.1 M aqueous solution of sodium hydroxide (2 mL). The reaction mixture was 
stirred at 50 °C for 2 h, cooled to room temperature, and concentrated under reduced 
pressure. The residue was dissolved in a mixture of acetic acid (2 mL), water (6 mL) and 
methanol (6 mL). The solution was deaerated by evacuating the air inside of the flask and 
refilling it with nitrogen five times. Palladium hydroxide on carbon (20%, Degussa type, 
0.1 g) was added and the solution was charged with hydrogen gas. The reaction mixture 
was stirred at room temperature under hydrogen gas for 24 h. The solution was filtered 
through a Celite pad, washed with water and methanol, and concentrated under reduced 
pressure. The residue was purified by chromatography on Amberlite CG-50 resin (NH4
+
 
form) (5% concentrated ammonium hydroxide in water), concentrated under reduced 
pressure, acidified with hydrochloric acid (pH ca. 4), and lyophilized to provide 
compound 49 (0.068 g, 81%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.63 (d, J = 
4.0 Hz, 1H, H-1'), 5.12 (d, J = 3.7 Hz, 1H, C-1''), 4.22 (dd, J = 10.9, 3.7 Hz, 1H, H-2''), 
4.04 (d, J = 12.8 Hz, 1H, H-5''), 3.98–3.94 (m, 1H, H-5'), 3.94–3.88 (m, 1H, H-3'), 3.86–
3.82 (m, 2H, H-4, H-5), 3.82–3.75 (m, 2H, H-6', H-6), 3.66 (dd, J = 10.9, 6.6 Hz, 1H, H-
6'), 3.62–3.47 (m, 5H, H-1, H-3'', H-5'', H-4', H-3), 3.44 (dd, J = 10.8, 4.0 Hz, 1H, H-2'), 
3.41 (s, 3H, OMe), 2.93 (s, 3H, NMe), 2.50 (dt, J = 12.9, 4.3 Hz, 1H, H-2), 1.86 (q, J = 
12.6 Hz, 1H, H-2), 1.36 (s, 3H, Me). 
13
C NMR (125 MHz, D2O) δ 100.90 (C-1''), 97.13 
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(C-1'), 83.66 (C-6), 81.34 (C-4), 73.73 (C-5), 72.22 (C-5'), 70.75 (C-6'), 69.84 (C-4''), 
69.34 (C-4'), 69.13 (C-3'), 67.71 (C-5''), 66.19 (C-2''), 63.26 (C-3''), 58.72 (OMe), 53.94 
(C-2'), 49.58 (C-1), 48.60 (C-3), 34.51 (NMe), 28.68 (C-2), 20.89 (Me). HRMS (ESI, 
positive) calculated for C20H40N4O10
+
 [M + Na]
+ 
519.2637, found 519.2642. 
 
3.3. RESULTS AND DISCUSSION 
3.3.1. Proposed Mechanism 
As discussed in Chapter 2, three mechanisms have been proposed for the GenK 
catalyzed methylation of GenX2 (6) to form G418 (7) (Scheme 3-6). In the first 
mechanism (Scheme 3-6A), the 5'-dAdo• (3) is generated via reductive cleavage of SAM 
(1) and abstracts a hydrogen atom from C-6' of the substrate (6). The resulting radical 
(50) then accepts a methyl radical from Me-Cbl to generate Cbl(II) and the G418 product 
(7). A similar mechanism has been proposed for most class B radical SAM 
methyltransferases, such as Fom3,
130
 GenD1,
81
 and ThnK
132
 as mentioned in Section 3.1. 
In this mechanism, MeCbl could be regenerated after each turnover via reduction of 
Cbl(II) to Cbl(I), followed by methylation by SAM (1).  
Given that the transfer of a methyl radical is heretofore unprecedented among the 
Cbl-dependent methyltransferases, mechanisms involving the transfer of a methyl cation 
from Me-Cbl were also considered (Scheme 3-6B, C). The early steps of these alternative 
mechanism are identical to those of Scheme 3-6A. However, after hydrogen atom 
abstraction, the radical intermediate (50) is deprotonated to form a ketyl radical 51/52, 
similar to those in the reactions catalyzed by DesII
152, 170–176
 and (R)-2-hydroxyacyl-CoA 
dehydratase.
177–178
 Nucleophilic attack by the ketyl radical anion (52) on Me-Cbl leads to 
the transfer of an electrophilic methyl cation, yielding a Cbl(I) intermediate (as in 
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traditional Me-Cbl chemistry)
179-180
, and an alkoxy product radical (53). The alkoxy 
radical (53) could then be quenched by an external electron and a proton (Scheme 3-6B), 
or via hydrogen atom transfer from 5'-dAdo (4) (Scheme 3-6C). In this latter mechanism, 
SAM is regenerated while restoring the [4Fe-4S] cluster to the +1 redox state. The 
resultant SAM (1) could then methylate Cbl(I), releasing SAH (5) as the sole 
adenosylated product. Thus, in this mechanism, the input of exogenous electrons is not 
required and only a single equivalent of SAM (1) is consumed during each catalytic 
cycle. This is in contrast to mechanisms A and B, in which two equivalents of SAM (1) 
(in addition to two reducing equivalents) are consumed for each methyl transfer event 
catalyzed by GenK.    
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Scheme 3-6. Possible GenK reaction mechanisms. (A) GenX2 radical (50) is quenched by 
the transfer of methyl radical from Me-Cbl(III) to give Cbl(II), which is reduced to Cbl(I) 
in order to accept a new methyl group from SAM (1). (B) Transfer of methyl cation to 
GenX2 ketyl radical (52) followed by reduction and protonation of product radical (53). 
(C) Product radical (53) is quenched by a hydrogen from 5'-dAdo (4) to give 5'-dAdo• 
(3), which can be re-incorporated into SAM (1). In this mechanism, a single equivalent of 
SAM (1) can serve as a source of both 5'-dAdo• (3) and CH3
+
. 
 
3.3.2. Syntheses of [6'S-
2
H]-GenX2 (20) and [6'R-
2
H]-GenX2 (29) 
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To characterize the initial hydrogen abstraction by 5'-dAdo• (3) and determine the 
stereochemistry of the methyltransfer reaction from GenX2 (6) to produce G418 (7), two 
isotope-labeled compounds, [6'S-
2
H]-GenX2 (20) and [6'R-
2
H]-GenX2 (29), were 
examined. In the mechanism proposed for GenK in Section 3.3.1, hydrogen atom 
abstraction by 5'-dAdo• (3) occurs at the C6' position of GenX2 (6). The syntheses of the 
two stereochemically labeled compounds began from the alcohol (8) which was used in 
the synthesis of gentamicin A2 in Section 2.2.11. Scheme 3-1 in Section 3.2.4 and 
Scheme 3-2 in Section 3.2.5 show the overall schemes to synthesize [6'S-
2
H]-GenX2 (20) 
and [6'R-
2
H]-GenX2 (29) respectively. Oxidation using 2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO) and (diacetoxyiodo)benzene (BAIB) generated 6'-carboxylic 
acid,
181
 and the following methylation reaction with iodomethane and mildly basic 
potassium carbonate converted the carboxylic acid to a methyl ester to provide compound 
9. The C6'-dideuterated alcohol (10) was then generated by the hydride reduction of the 
ester (9) with lithium aluminum tetradeuteride. The resulting dideuterated O-6 primary 
alcohol of compound 10 was oxidized to an aldehyde with one deuterium by Swern 
oxidation. Selective reduction with (R)-(+)-Alpine-Borane
®
 gave [6'-S-
2
H]-substrate 
(12).
176
 The synthesis of [6'-R-
2
H]-substrate (23) was attempted using (S)-(–)-Alpine-
Borane
®
, however the diastereomer, [6'-S-
2
H]-substrate (12), was also produced. In order 
to produce one stereospecific compound with (R) stereochemistry, an SN2 type 
conversion was used instead to invert the (S)-isomer. From compound 12, the formation 
of tosylate, followed by nucleophilic benzoate substitution, and basic hydrolysis with 
sodium methoxide was performed to get [6'-R-
2
H]-substrate (23). The benzyl protection 
reaction on the primary alcohol gave tribenzylated compounds, 13 and 24. NMR spectra 
in Figure 3-8 shows tribenzylated compounds, 13 and 24, with varying stereochemisty. 
The compound 12 in Figure 3-8A was obtained from using (R)-(+)-Alpine-Borane
®
. 
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NMR spectrum displays only one stereoisomer (doublet at 3.72 ppm (J = 4.4 Hz) for the 
pro-(S) proton). The compounds in Figure 3-8B was acquired using (S)-(–)-Alphine-
Borane
®
, and two diastereomers were found (doublet in 3.76 ppm (J = 1.9 Hz) for the 
pro-(R) proton and 3.72 ppm (J = 4.4 Hz) for the pro-(S) proton) with a ratio of S 
isomer/R isomer = 0.65/ 0.23 based on NMR integration. The compound in Figure 3-8C 
was obtained by the stereochemical inversion through SN2 reaction, and its NMR 
spectrum indicates the presence of only a single diastereomer (doublet at 3.75 ppm (J = 
1.9 Hz) having the pro-(R) proton at C6'.  
After coupling to the 2-strepatamine derivative 14 and basic hydrolysis with 
sodium methoxide, another coupling reaction of compounds 16 and 26 with the 
garosamine derivative 17 gave pseudotrisaccharides 19 and 27 respectively. Basic 
hydrolysis, and a final deprotection reaction using a Staudinger reaction and 
hydrogenation using palladium hydroxide on carbon gave [6'S-
2
H]-GenX2 (20) and [6'R-
2
H]-GenX2 (29). The synthesis of [6'S-
2
H]-GenX2 (20) was completed with a 7.1% yield 
over 10 steps from the known compound 8. The synthesis of [6'-R-
2
H]-GenX2 (29) was 
completed with a 3.4% yield over 13 steps from the intermediate 12 in the synthesis of 
[6'S-
2
H]-GenX2 (20).   
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Figure 3-8. NMR spectra of two labeled compounds, 20 and 29 obtained from A) (R)-
(+)-Alpine-Borane
®
, B) (S)-(–)-Alphine-Borane® , and C) (R)-(+)-Alpine-Borane®  and 
stereochemical inversion through SN2 reaction.     
 
3.3.3. Stereospecific Hydrogen Abstraction 
 GenK assays with 6'-deuterated compounds, 20 and 29, were conducted to 
determine the stereochemical course of the hydrogen abstraction step. Assay conditions 
are the same as the previously described GenK assays. Three substrates, GenX2 (6), [6'S-
2
H]-GenX2 (20) and [6'R-
2
H]-GenX2 (29) were used in the assays. Detection of 5'-dAdo 
(4) by mass spectroscopy was conducted after collecting the corresponding fractions by 
HPLC (Figure 3-9).  
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Figure 3-9. HPLC traces showing the production of 5'-dAdo (4) and SAH (5) during 
GenK assays with 6'-labeled compounds. Trace (a) a standard composed of authentic 5'-
dAdo (4) and SAH (5). The remaining traces result from reaction mixtures containing (b) 
GenX2 (6), (c) [6'S-
2
H]-GenX2 (20), and (c) [6'R-
2
H]-GenX2 (29) 
Figure 3-10 shows the mass spectroscopic data used to identify 5'-dAdo (4; m/z 
calc. 252.2 [M + H]
+
) when the three previously mentioned substrates were used (GenX2 
(6) in 3-10A, [6'S-
2
H]-GenX2 (20) in 3-10B, and [6'R-
2
H]-GenX2 (21) in 3-10C). When 
GenX2 (6) and [6'S-
2
H]-GenX2 (20) were used for the GenK reaction, an m/z 252 peak 
was observed. However, when [6'R-
2
H]-GenX2 (29) was used, a m/z 253 peak was 
identified, indicating that deuterium from the substrate is incorporated into 5'-dAdo• (3) 
to form the deuterated 5'-dAdo (54; calc. [M + H]
+
 253.2 m/z). The small peak around 
252 in Figure 3-10C might be due to uncoupled quenching of one electron reduction 
followed by protonation. These results demonstrate that the pro-R hydrogen at the C6' 
position of the substrate is abstracted by 5'-dAdo• (4) in the beginning of the GenK 
reaction. 
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Figure 3-10. Electrospray ionization (ESI) mass data of resulting 5'-dAdo (4) generated 
in the assays of GenK with A) GenX2 (6), B) [6'S-
2
H]-GenX2 (20), and C) [6'R-
2
H]-
GenX2 (29). 
 In order to examine mechanism C outlined in Section 3.3.1 where SAM is 
regenerated and SAH is released at the end of each catalytic cycle, the reaction mixture 
was analyzed by ESIMS to check for SAH (5; calc. [M + H]
+
 = 385.1 m/z)and SAM (1; 
calc. [M + H]
+
 = 399.1 m/z) in the assays using GenX2 (6), [6'S-
2
H]-GenX2 (20), and 
[6'R-
2
H]-GenX2 (29) as substrates (Figures 3-11 and 3-12). All three mass spectra appear 
to be the same in Figures 3-11 and 3-12, and there is no deuterium incorporation in SAH 
(5) and SAM (1). These results combined with the observation that 5'-dAdo (4), SAH (5), 
and G418 (7) are each produced in equivalent amounts (See Section 2.3.6) indicate that 
mechanism C can be ruled out. Two SAM molecules are consumed per reaction. The first 
molecule of SAM (1) acts as the source of the 5'-dAdo• (3), which abstracts a hydrogen 
atom from C-6' of GenX2 (6) to give 5'-dAdo (4) and the GenX2 radical (3). The second 
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SAM (1) is used to re-methylate Cbl(I) during turnover to regenerate Me-Cbl for the 
subsequent round of catalysis.     
 
 
Figure 3-11. ESI Mass data of resulting SAH (5; calc. [M + H]
+
 = 385.1 m/z) in the 
assays using A) GenX2 (6), B) [6'S-
2
H]-GenX2 (20), and C) [6'R-
2
H]-GenX2 (29). 
 
 
Figure 3-12. ESI mass data of resulting SAM (1; calc. [M + H]
+
 = 399.1 m/z) in the 
assays using A) GenX2 (6), B) [6'S-
2
H]-GenX2 (20), and C) [6'R-
2
H]-GenX2 (29). 
 Figure 3-13 shows mass spectra of the product in the assays using GenX2 (6), 
[6'S-
2
H]-GenX2 (20), and [6'R-
2
H]-GenX2 (29). When unlabeled substrate (6; [M + H]
+
 = 
483.27 m/z) and [6'R-
2
H]-GenX2 (29; [M + H]
+
 = 484.28 m/z) were used, unlabeled G418 
(7; [M + H]
+
 = 497.27 m/z) was produced as a result of GenK catalysis. However, when 
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[6'S-
2
H]-GenX2 (20) was utilized as a substrate, labeled G418 (55; [M + H]
+
 = 498.28 
m/z) was detected.  
 
 
Figure 3-13. ESI mass data of resulting G418 in the assays using A) GenX2 (6), B) [6'S-
2
H]-GenX2 (20), and C) [6'R-
2
H]-GenX2 (29). 
In addition, products in the assays using GenX2 (6), [6'S-
2
H]-GenX2 (20), and 
[6'R-
2
H]-GenX2 (29) were collected by HPLC after derivatizations with 1-fluoro-2,4-
dinitrobenzene (FDNB) to add a UV-active chromophore which would otherwise be 
absent in the aminoglycosides. FDNB-derivatized G418 (56; [M + H]
+
 = 995.3 m/z) was 
detected at [M+H]
+
 995.3 m/z when unlabeled GenX2 (6) and [6'R-
2
H]-GenX2 (29) were 
used (Figure 3-14A). However, FDNB-derivatized G418 with deuterium (57; [M+H]
+
 
996.4 m/z) was produced when [6'S-
2
H]-GenX2 (20) was treated in the assay. These 
results also show that deuterium in [6'R-
2
H]-GenX2 (29) was incorporated into 5'-dAdo 
 177 
(4) and the methyl group from Me-Cbl was transferred at C6' position with retention of 
configuration. As expected, in the GenK reaction with [6'S-
2
H]-GenX2 (20), deuterium 
was retained in the product, producing deuterated G418 (55).  
 
 
Figure 3-14. Chemical ionization (CI) mass data of 1-fluoro-2,4-dinitrobenzene (FDNB)-
derivatized G418 in the assays using A) GenX2(6), B) [6'S-
2
H]-GenX2 (20), and C) [6'R-
2
H]-GenX2 (29). 
Combined with the results concerning 5'-dAdo (4) formation in the assays using 
[6'S-
2
H]-GenX2 (20), and [6'R-
2
H]-GenX2 (29) and the absolute stereochemistry of G418 
(7) obtained by X-ray crystallography,
14
 it can be concluded that the pro-R hydrogen at 
the C6' position of GenX2 (6) is abstracted by 5'-dAdo• (3) and without any rotation, the 
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methyl group is transferred from Me-Cbl to the exact same position of pro-R hydrogen. 
The overall stereochemistry in GenK catalysis is maintained from the substrate to the 
product. 
 
3.3.4. UV-Vis Spectroscopic Experiments 
In order to investigate the redox states of cobalamin during GenK catalysis, the 
reaction was monitored by UV-visible spectroscopy under anaerobic conditions for 1 h 
and the spectrum of the reaction mixture was recorded every 5 min. (Figure 3-15). This 
experiment was conducted using this assay conditions containing GenK (0.005 mM), 
DTT (1 mM), MeCbl (0.1 mM), NADPH (0.4 mM), MV (0.1 mM), SAM (0.4 mM), 
GenX2 (6) (0.1 mM) in Tris∙HCl buffer (5 mM; pH 8.0) under anaerobic condition. The 
spectra in Figure 3-15 correspond to assays resulting from (A) the reaction mixture, (B) 
no GenX2 (6), (C) no GenK, and (D) no GenK and no SAM. In Figure 3-15A, the peak 
around 520 nm corresponding to Cbl(III)
183
 was found to decrease, while the peak around 
400 nm (Cbl(I))
184
 increased. In Figures 3-15B and 3-15C, a clear shift from ~520 nm to 
~476 nm and an increase in the absorbance between 400 nm and 450 nm were observed. 
Both are characteristics of MeCbl(III) conversion into Cbl(II).
184
 It was also noted that 
without SAM or GenK (Figure 3-15D), the decrease of the peak at ~520 nm was not as 
significant as those observed in other spectra, but increases of the peak around 476 and 
400 nm were detected, indicating that Cbl(II) and Cbl(I) were generated from MeCbl in 
the presence of the reducing system (methyl viologen and NADPH). Thus, based on the 
combined spectroscopic data, it can be concluded that the Me-Cbl(III) bond of 
methylcobalamin is easily cleaved in the presence of SAM and MV/NADPH to give 
Cbl(I) regardless whether GenK is present or absent. However, in the absence of SAM, 
the cleavage rate of Me-Cbl bond was much slower when compared to other conditions. 
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The formation of Cbl(II) is not obvious in the presence of GenK and GenX2 (6). The peak 
around 476 nm was not obvious in the assay of all reaction mixtures (Figure 3-15A). In 
the absence of substrate, SAM, or GenK, the peak about 476 nm corresponding to Cbl(II) 
was discerned clearly (Figures 3-15B, 3-15C, and 3-15D). In the presence of GenK and 
GenX2 (Figure 3-15A), Cbl(II) might exist too transiently to be detected by UV-vis 
spectrometry, or Cbl(II) might not exist during the GenK reaction. From UV-vis 
spectroscopy, it was not possible to differentiate between mechanism A and mechanism 
B described in Section of 3.3.1.  
 
 
Figure 3-15. UV-visible analysis of GenK assay. The traces (A-D) are from the reaction 
mixtures containing GenK (0.05 mM), DTT (10 mM), MeCbl (1 mM), NADPH (4 mM), 
MV (1 mM), SAM (4 mM), GenX2 (1 mM) in Tris∙HCl buffer (50 mM; pH 8.0) under 
anaerobic condition with the following modifications: A) no changes, B) no GenX2, C) 
no GenK, and D) no GenK and no SAM. Measurements were performed every 5 min 
from 0 min to 30 min and every 10 min from 30 min to 60 min (from blue to red).  
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3.3.5. Syntheses of [6'-F]-GenX2 (35), [6',6',6'-
2
H,
2
H,F]-GenX2 (43), and [6'-OMe]-
GenX2 (49) 
 To distinguish between mechanisms A and B in Section 3.3.1, [6'-F]-GenX2 (35) 
and [6',6',6'-
2
H,
2
H,F]-GenX2 (43) were designed as a probe because an alkoxy radical 
could not be generated from [6'-F]-GenX2 (35) and the GenK reaction could only proceed 
via mechanism A if GenK can accept it as a substrate. Using [6',6',6'-
2
H,
2
H,F]-GenX2 
(43) as a probe may give clues to distinguish the mechanism of the reaction. The 
synthesis of [6'-F]-GenX2 (35) began with the alcohol 30 which was used for the 
synthesis of JI-20A in Section 2.2.17. The fluoro group was introduced through an SN2 
type reaction using diethylaminosulfur trifluoride (DAST) in dichloromethane to provide 
compound 31. After basic hydrolysis using sodium methoxide, coupling of compound 32 
with garosamine derivative 17 gave the pseudotrisaccharide 33. After basic hydrolysis of 
the carbamate, final deprotection using the Staudinger reaction, and hydrogenation with 
palladium hydroxide on carbon, [6'-F]-GenX2 (35) was obtained with a 14% yield over 6 
steps from the previous synthesized compound 30. The synthesis of [6',6',6'-
2
H,
2
H,F]-
GenX2 (43) was conducted using the similar methods as the synthesis of [6'-F]-GenX2 
(35) with 7% yield over 9 steps from the previously synthesized dideuterated alcohol 10. 
 Another possible substrate to distinguish between mechanisms A and B in the 
Section 3.3.1 is [6'-OMe]-GenX2 (49), because deprotection of the initially formed C6' 
radical (50) by a base cannot occur and thus the alkoxy radical species (51) cannot be 
produced. If the reaction proceeds via mechanism B, no reaction is expected. The 
synthesis of [6'-OMe]-GenX2 (49) began from the alcohol 8 which was prepared in the 
synthesis of gentamicin A2 in Section 2.2.11. A methoxy group was introduced with 
sodium hydride and methyl iodide in dimethylformamide (DMF) to provide compound 
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44. The following steps were similar to the other substrate syntheses. The overall yield of 
the synthesis was 22% over 7 steps from the previously synthesized compound 8.    
 
3.3.6. Assays with GenX2 Derivatives 
 Assays with GenX2 derivatives, [6'-F]-GenX2 (35), [6',6',6'-
2
H,
2
H,F]-GenX2 (43), 
and [6'-OMe]-GenX2 (49) were conducted under the same conditions as before, and 5'-
dAdo (4) formation was monitored by HPLC as the evidence of radical reaction initiation 
(Figure 3-16). For comparison, the assay with the original substrate GenX2 (6) was also 
performed. Neither [6'-F]-GenX2 (35), [6',6',6'-
2
H,
2
H,F]-GenX2 (43), nor [6'-OMe]-
GenX2 (49) showed any reaction with GenK. Different reducing systems like 
MV/NADPH, BV/NADPH, dithionite, fld/fdr/NADPH, dithionite/MV and dithionite/BV 
were all tested with [6'-F]-GenX2 (35), but none of them resulted in the formation of 5'-
dAdo (4). These three GenX2 derivatives which were designed as mechanistic probes to 
determine the mechanism of GenK are not recognized by GenK.  
 
 
Figure 3-16. HPLC traces with GenK reaction with the following GenX2 derivatives; a) 
SAH and 5'-dAdo standard, b) [6'-F]-GenX2 (35), c) [6',6',6'-
2
H,
2
H,F]-GenX2 (43), and d) 
[6'-OMe]-GenX2 (49)  
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 Whether [6'-F]-GenX2 (35) is an inhibitor for GenK was also tested because it has 
a similar structure to the natural substrate. If [6'-F]-GenX2 (35) could compete with 
GenX2 (6), it may be considered as an inhibitor competing for the active site of the 
enzyme even though GenK does not catalyze the radical formation reaction. Inhibition 
assays were conducted under the same conditions as before, but the incubation time was 
20 h. When the concentration of GenX2 (6) was fixed at 1 mM and lower concentrations 
of [6'-F]-GenX2 (35) were used (0.05, 0.1, 0.2, 0.5, and 1 mM) in the GenK assay, the 
amounts of 5'-dAdo (4) and SAH (5) formations were the same as when GenX2 (6) was 
used alone (Figure 3-17). Even in the GenK assays where the enzyme was pre-incubated 
with [6'-F]-GenX2 (35) for 4 h and GenX2 (6) was added later, the results were similar as 
in the absence of pre-incubation time. Experiments with higher concentrations of GenX2 
(6) compared to [6'-F]-GenX2 (35) did not provide any evidences that the fluoride-
substrate binds to the active site of GenK and inhibits methylation of the enzyme.   
 
 
 
Figure 3-17. Formations of A) 5'-dAdo and B) SAH from the co-incubation of [6'-F]-
GenX2 (35) and GenX2 (6) in the GenK reaction for 20 h. Concentration of GenX2 (6) 
was fixed as 1 mM, and concentration of [6'-F]-GenX2 (35) was changed from 0 to 1 
mM.   
 183 
  
 
Assays with excess [6'-F]-GenX2 (35) compared to GenX2 (6) (1 mM) showed 
that although the fluoro-substrate inhibits the activity of GenK, it is a very weak inhibitor 
(Figure 3-18). Assuming that it competes with GenX2 (6) for the active site, it does not 
display a strong affinity. Combined with the results of the [6'-OMe]-GenX2 (49) assay, it 
may be concluded that the 6'-hydroxy group plays a role in binding GenX2 to GenK. 
 
 
Figure 3-18. Formations of A) 5'-dAdo and B) SAH from the co-incubation of [6'-F]-
GenX2 (35) and GenX2 (6) in the GenK reaction for 20 h. Concentration of GenX2 (6) 
was fixed as 1 mM, and concentration of [6'-F]-GenX2 (35) was changed from 1 to 20 
mM.   
 
3.4. CONCLUSION 
The mechanism of methyl transfer by Class B radical SAM methyltransferase has 
not yet been elucidated. In this chapter, three mechanisms were considered for the GenK-
catalyzed conversion of GenX2 to G418. In the first mechanism, the 5'-dAdo• generated 
via the reductive cleavage of SAM abstracts a hydrogen atom from C-6' of the substrate. 
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The resulting substrate radical accepts a methyl radical from Me-Cbl to generate Cbl(II) 
and the G418 product. Other mechanisms, which involve the transfer of a methyl cation 
from Me-Cbl, were also considered. After hydrogen atom abstraction, the radical 
intermediate is deprotonated to form a ketyl radical. Nucleophilic attack by an anion at 
the Me-Cbl leads to methyl transfer, yielding a Cbl(I) intermediate and an alkoxide 
product radical. The radical could then be quenched by an external electron and proton or 
via hydrogen atom transfer from 5'-dAdo.  In this latter mechanism, SAM is regenerated 
while restoring the [4Fe-4S] cluster to the +1 redox state. 
The observation that 5'-dAdo, SAH and G418 are each produced in equivalent 
amounts is consist with mechanisms A and B, but not C, because in mechanisms A and B 
two equivalents of SAM are consumed for each methyl transfer event (one to initiate the 
radical reaction and the other as a methyl donor), but in mechanism C the input of 
exogenous electrons is not required and only a single equivalent of SAM is necessary for 
each catalytic cycle.  
Incorporation of deuterium into 5'-dAdo and loss of deuterium from GenX2 were 
observed by mass spectra, which showed that the reaction with (R)-deuterated GenX2 
gave deuterated 5'-dAdo and non-deuterated product, and that the reaction with (S)-
deuterated GenX2 gave the opposite results. These results indicate that the 6'-pro-R 
hydrogen is abstracted by the 5'-dAdo radical. Combined with the reported structure of 
G418, it was ascertained that methylation occurs with retention of configuration at C6'. 
To distinguish the manner of methyl transfer, three GenX2 derivatives were 
tested. However, none of them showed turnover upon incubation with GenK. The 
fluoride substrate did inhibit the activity of GenK very weakly. Assuming that it 
competes with GenX2 for the active site, then it must not have a strong affinity for the 
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active site. The 6'-hydroxyl group apparently plays a key role in binding of GenX2 to 
GenK.  
Efforts are currently underway to further elucidate the chemical mechanism of 
this intriguing enzyme. Another substrate [5'-F]-GenX2 would be a possible substrate to 
distinguish the two mechanisms. If the methyl transfer reaction proceeds via methyl 
radical reaction (mechanism A), this compound would produce [5'-F]-G418. However, if 
an anionic mechanism is operative (mechanism B), and both the leaving group and the 
anion have an anti-orientation, the product would not contain fluoride because an anion at 
the C6' position would result in the elimination of fluoride. The synthesis of [5'-F]-GenX2 
is currently underway in our group. 
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Chapter 4: Characterization of the Radical SAM Enzyme AprD4 and 
Its Reductase Partner AprD3 
4.1. INTRODUCTION 
 The aminoglycosides are an important class of antibiotics for the treatment of 
Gram-negative bacterial infections.
1-2,185
 Their biological activity is a result of their 
ability to bind the bacterial 30S ribosome and subsequently inhibit protein synthesis. 
Several years after aminoglycosides were first used to treat human antibacterial 
chemotherapy, new organisms resistant to these drugs began to appear. The major cause 
of aminoglycoside resistance is decreased affinity of the drug to the bacterial ribosome. 
Numerous genetic and biological studies have focused on the mechanisms of bacterial 
resistance to aminoglycosides.
185-188
 Among these mechanisms, enzymatic inactivation of 
the antibiotic is the most clinically important. Three classes of aminoglycoside-modifying 
enzymes have been described: the aminoglycoside nucleotidyltransferases (ANTs), the 
aminoglycoside phosphotransferases (APHs), and the aminoglycoside acetyltransferases 
(AACs). The regioselective modification site on the targeted aminoglycoside by a 
specific enzyme is specified in parentheses. For example, AAC(2') is an aminoglycoside 
acetyltranferase catalyzing the acetylation of hydroxyl group at C2' position.  
 Aminoglycoside adenyltransferases found in both Gram-negative and Gram-
positive bacteria can be either plasmid-encoded or chromosomally encoded. The reaction 
sites are 2'' and 3'' for enzymes found in Gram-negative bacteria, and 4', 6, and 9 for those 
derived from Gram-positive organisms.
189
 These enzymes catalyze O-adenylation of 
aminoglycosides using Mg-ATP and in the process generate magnesium chelated 
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inorganic pyrophosphate (Figure 4-1). Adenylation at the 2'' and 4' are clinically the most 
significant and have been well-studied. 
 
  
Figure 4-1. 4'-O-adenylation of kanamycin A by ANT(4') 
The aminoglycoside phosphotransferases represent a large group of 
aminoglycoside-modifying enzymes that play important roles in the clinical resistance of 
Staphylococcal and Enterococcal species to aminoglycosides.
185
 They can 
regioselectively transfer the γ-phosphate of ATP to one of the hydroxyl groups of the 
aminoglycoside (Figure 4-2). Among them, the plasmid-encoded APH(3')-IIIa enzymes 
from Enterococcus faecalis  that have been the focus of biochemical investigations.
190-
194
  
 
 
Figure 4-2. 3'-O-phosphorylation of kanamycin A by APH(3') 
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 Acetyl coenzyme A-dependent aminoglycoside acetylases (AACs) catalyze N-
acetylation of the four amino groups of aminoglycosides: the 1- or 3-amino groups of the 
central 2-deoxystreptamine ring or the 2' or 6'-amino groups of the 6-amino-6-deoxy 
glucose ring (Figure 4-3). Two types of AAC have been identified in E. coli and 
Actinomycete bacterial strains; however, they are not clinically important, because these 
enzymes are not virulence factors with respect to infection of humans.
195-196
      
 
 
Figure 4-3. 4'-N-acetylation of kanamycin A by AAC(6') 
A number of aminoglycosides, such as apramycin (2),
6
 tobramycin (3),
197
 
nebramycin 5' (4),
198
 and lividomycin B (5),
199
 possess the 2-deoxystreptamine (2-DOS; 
1) core decorated with a variety of carbohydrates necessary for activity; however, they 
are characterized by a C3'-deoxyhexose linked to the C4 position of 2-DOS via a 
glycosidic bond (Figure 4-4). The absence of a C3' hydroxyl group in these 
aminoglycosides renders them more effective as antimicrobial agents, because they are 
less susceptible to modification by aminoglycoside phosphotransferase (APH(3')), which 
is a known mechanism of resistance.
185
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Figure 4-4. Selected examples of aminoglycosides. 
Although the biosynthesis of paromamine has been investigated (see Section 
1.1.3.2), little is known about the mechanism of C3'-deoxygenation despite its importance 
to the development and improvement of clinically useful aminoglycoside antibiotics.
200
 
C3'-deoxygenation of paromamine is similar to the reactions catalyzed by Cbl-dependent 
dehydratases like diol dehydratases (DD), propanediol hydro-lyase, glycerol dehydratase 
(GD), and glycerol hydro-lyase, which catalyze the conversion of 1,2-propanediol and 
other 1,2-diols to the corresponding aldehydes, or deaminases such as ethanolamine 
ammonia-lyase (EAL) or ethanolamine deaminase which catalyze the conversion of 
ethanolamine to acetaldehyde in the presence of AdoCbl.
201-202
 The mechanism of DDs is 
shown in Figure 4-5. Two water molecules are bound in the active site of the holoenzyme 
and are displaced upon substrate binding. The adenosyl radical generated by homolytic 
cleavage of the carbon-cobalt bond in adenosylcobalamin abstracts a hydrogen atom from 
the C1 position of the substrate. The resulting substrate radical then undergoes hydroxyl 
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group migration from C2 to C1, generating a 1,1-diol-2-yl radical. The resulting radical 
then abstracts a hydrogen atom from the C5' methyl of 5'-deoxyadenosine to form the 
aldehyde product and adenosyl radical, the latter of which recombines with cob(II)alamin 
to regenerate AdoCbl. The mechanism of EAL is similar to that of the DDs. One 
particular thing is that DDs and EAL are not enantioselective: the adenosyl radical can 
abstract either the pro-R or pro-S hydrogen from the substrate.
202
 Another example of a 
radical mediated dehydration is the reaction catalyzed by Cbl-independent glycerol 
dehyratase.
203
 In the case of both, Cbl-dependent DDs and Cbl-independent glycerol 
dehydratase, the radical initiator is typically regenerated.  
 
 
Figure 4-5. Mechanism of the diol dehydratases. 
The gene clusters responsible for the biosynthesis of apramycin (2), tobramycin 
(3), and lividomycin B (5) in Streptomyces and Streptoalloteichius species have been 
described,
8,204-206
 and significant progress has been made in elucidating the reactions 
involved in the tobramycin pathway.
55,68
 Although no gene product in the tobramycin 
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cluster has been implicated in catalyzing C3'-deoxygenation,
8,204
 gene-knockout 
studies
207
 of the aparamycin and lividomycin B pathway have identified the 
AprD4/AprD3 and LivW/LivY enzyme pairs as likely candidates for their activity. For 
example, incorporation of the aprD4 and aprD3 genes into the kanamycin-producing 
strain S. kanamyceticus led to the isolation of 3'-deoxykanamycins (such as 7),
204
 which 
are not normally produced. Likewise previous studies have also shown the conversion of 
neamine (9) to nebramine (10) in cell-free extracts of S. venezuelae expressing protein 
AprD4 and AprD3.
204
 However, no conversion of kanamycin B (8) to tobramycin (3) was 
observed under the same conditions, leading to the suggestion that the substrate for 
AprD4/AprD3 may be a pseudo-disaccharide (such as 9) rather than a pseudo-
trisaccharide (such as 8).
204
 Since apramycin (2) and tobramycin (3) are produced 
together in the same bacterial strains, it is possible that AprD4/AprD3 serves as the C3'-
deoxygenation machinery for both pathways. 
This chapter describes the purification and biochemical characterization of AprD4 
and AprD3 from S. tenebraris and demonstrates their ability to catalyze 3'-deoxygenation 
of paromamine (11) to lividamine (13) in vitro (Scheme 4-1). Using various paromamine 
derivatives, the mechanistic details regarding the AprD4-catalyzed conversion of 
paromamine to 4-oxolividamine (12) are considered. 
 
 
Scheme 4-1. AprD4/AprD3 catalysis. 
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4.2. EXPERIMENTAL PROCEDURES 
4.2.1. Materials and Equipment 
All chemicals were purchased from Fisher Science (Pittsburgh, PA) or Sigma-
Aldrich (St. Louise, MO) and used without further purification unless otherwise 
specified. DNA gel extraction and spin miniprep were obtained from Qiagen (Valencia, 
CA). All reagents for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Amicon and Microcon YM-10 filtration products were purchased from Bio-
Rad (Hercules, CA) and Millipore (Billerica, MA), respectively. Escherichia coli DH5a 
cells were bought from Bethesda Research Laboratories (Muskegon, MI). The vector 
pET24b (+) and enzyme KOD DNA polymerase were purchased from Novagen 
(Madison, WI). DNA modifying enzymes (for restriction digestion and ligation), PCR 
primers, and the overexpression host E. coli BL21 star (DE3) were acquired from 
Invitrogen (Carlsbad, CA) and New England Biolabs (NEB, Beverly, MA). Luria Bertani 
(LB) media are products of Difco (Detroit, MI) or Fisher Scienctific (Pittsburgh, PA). 
Pre-stained protein markers were bought from NEB. Kits for Protein concentrations were 
determined by Bradford Assay
149
 using bovine serum albumin as the standard. The 
relative molecular mass and purity of enzyme samples were determined using SDS-
PAGE. The general methods and protocols for recombinant DNA manipulations were as 
described by Sambrook et al.
150
 DNA sequencing was performed at the Core Facilities of 
the Institute of Cellular and Molecular Biology, University of Texas at Austin. All 
reactions involving AprD4 were performed in a Coy Anaerobic Chamber (glovebox) 
under an atmosphere of approximately 97.5% N2 and 2.5% H2 with less than 1 ppm O2. 
All solvents using AprD4 reaction were deaerated by bubbling with nitrogen gas before 
they were transferred into the glovebox. The solvents in the glove box were stirred open 
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to the anaerobic atmosphere overnight to allow equilibration before use. Paromamine 
(11) was obtained by acidic hydrolysis of paromomycin.
166
 SAM was prepared as 
described in Section 2.2.4. [5-
2
H2]-SAM were prepared as previous described.
173
  
Tetrahydrofuran (THF) was distilled from sodium benzophenone and dichloromethane 
(CH2Cl2) was distilled from calcium hydride under a nitrogen atmosphere. Other 
anhydrous solvents were purchased from Acros Organics (Pittsburgh, PA). Analytic thin 
layer chromatography (TLC) was performed on pre-coated TLC glass plates (Silica gel, 
grade 60, F254, 0.25 mm layer thickness) purchased from EMD chemicals (Madison, 
WI). Flash column chromatography was carried out on silica gel (230-400 mesh, grade 
60) from Sorbent Technologies (Atlanta, GA) by eluting with the specific solvents. 
1
H 
and 
13
C NMR spectra were recorded at 400, 500, 600 MHz and 100, 125, 150 MHz with 
a Varian Gemini spectrometer. Chemical shifts are reported as parts per million (ppm) 
from ppm relative to the deuteriochloroform (CDCl3), 7.26 ppm for 
1
H NMR and 77.16 
ppm for 
13
C NMR, respectively. Visualization was effected with p-phosphoryl molybdic 
acid solution.  The MS analyses were carried out at the Mass Spectrometry and 
Proteomics Facility of the Department of Chemistry, University of Texas at Austin. 
 
4.2.2. Cloning and Expression of Streptomyces tenebrarius AprD3 
The apramycin/tobramycin producer S. tenebrarius was obtained from the 
Agricultural Research Service of the US Department of Agriculture as a lyophilized 
sample. It was inoculated into 10 mL of tryptic soy broth (TSB) starter culture,
151
 and the 
resulting solution was incubated overnight at 30 C with shaking at 250 rpm. The 
following day, 0.1 mL of the starter culture was inoculated into 10 mL of fresh TSB, and 
the resulting culture was incubated at 30 °C for 72 hr. Chromosomal DNA was extracted 
from 1.5 mL of this culture using a Qiagen DNeasy tissue kit. The aprD3 gene was PCR 
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amplified from the isolated S. tenebrarius DNA with the following primers: 5-
CATATGGAGCAACG-GTACGTGCTGGTCACCGGGGCCAGTCGCGGTCTGGG-3' 
(forward), 5-AAGCTTCATCACGACGC-CGACCACCGCGGGACGGGGGGGCGG-3' 
(reverse), and cloned into a pCR:blunt vector (Invitrogen) prior to excision with NdeI and 
HindIII ligation into the pET28b(+) vector (Invitrogen). The resulting expression 
plasmid, pET28b(+):aprD3, was used to transform E. coli BL21 cells for expression of 
the native, recombinant AprD3. An overnight culture of E. coli transformed with the 
pET28b:aprD3 plasmid was grown at 37 °C in LB medium containing 34 g/mL 
kanamycin, and used to inoculate 6 x 1 L of the same medium in a 100-fold dilution. 
Then 1 L cultures were incubated at 37 °C until cell had reached an optical density of 0.6 
at 600 nm. At which point AprD3 expression was induced by 1mM IPTG. The cells were 
harvested by centrifugation at 20000 x g for 30 min, thawed and suspended in 50 mM 
EPPS (pH 8.0) with 20 mM imidazole and 300 mM NaCl. After sonication (8 x 1 min), 
the lysate was spun at 26500 x g for 40 min. 1 mM PMSF was added. The supernatant 
was mixed with 8 mL of Ni-NTA resin at 4 °C. The slurry was transferred to an empty 
column and washed with 100 mL of 50 mM EPPS buffer (pH 8.0) containing 300 mM 
NaCl and 20 mM imidazole. The protein was eluted with 50 mL of 50 mM EPPS buffer 
(pH 8.0) containing 300 mM NaCl and 300 mM imidazole. The purified protein was 
dialyzed twice against 1 L of 50 mM EPPS buffer (pH 8.0) containing 300 mL NaCl. The 
dialyzed protein was frozen with liquid nitrogen and stored at –80 °C until use.     
  
4.2.3. Cloning, Expression and Reconstitution of Streptomyces tenebrarius AprD4 
The aprD4 gene was PCR amplified from the isolated S. tenebrarius DNA with 
the following primers: 5'-CATATGCGACGAATGCGGCTCGGCACGGTAC-3' 
(forward), 5'-AAGCTTCATCAGGCG-TCACCGGTCGACCAGGCGTG-3' (reverse), 
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and cloned into a pCR:blunt vector (Invitrogen) prior to excision with NdeI and HindIII 
and ligation into the pET28 vector (Invitrogen). The resulting expression plasmid, 
pET28:aprD4, was used to transform E. coli Rosetta DE3 (Novagen) for expression of 
native, recombinant AprD4. Transformants were grown in 6 x 1 L of LB medium with 34 
g/mL kanamycin and 68 g/mL chloramphenicol at 37 °C with shaking at 200 rpm. AprD4 
expression was induced with 1 mM IPTG when the cells had reached an optical density 
of 0.6 at 600 nm. Cells were harvested by centrifugation at 4500 x g for 20 min, thawed 
and suspended in 50 mM Tris buffer (pH 8.0, HCl) with 20 mM imidazole. After 
sonication (8 x 1 min), the lysate was spun at 26500 x g for 30 min. Lysate was loaded on 
a Ni-NTA column (8 mL) pre-equilibrated with 50 mM Tris buffer (pH 8.0, HCl) and 20 
mM imidazole. After washing with 10 mL of 50 mM Tris buffer (pH 8.0, HCl) and 20 
mM imidazole, the column was developed with 8 mL of 50 mM Tris buffer (pH 8.0, 
HCl) and 40 mM imidazole, 8 mL of 50 mM Tris buffer (pH 8.0, HCl) and 100 mM 
imidazole, and 8 mL of 50 mM Tris buffer (pH 8.0, HCl) and 300 mM imidazole. The 
fractions were collected and centrifuged with a YM-10 filter at 4500 × g for 1 min. The 
protein was dialyzed twice against 1 L of 50 mM Tris buffer (pH 8.0, HCl). The dialyzed 
protein was frozen with liquid nitrogen and stored at –80 °C until reconstitution with iron 
and sulfur.     
Reconstitution followed the previously published procedure.
152
 Approximately 3–
5 mg of AprD4 was thawed, and transferred into a conical vial. The vial was transferred 
to the glovebox. The enzyme was diluted with 20 mM NH4HCO3 buffer (pH 7.8) 
containing 5 mM DTT to a volume of ca. 2 mL and gently stirred at ca. 10 °C in an open 
vial for ca. 2 h in order to equilibrate with the anaerobic atmosphere. The solution was 
made 1.88 mM in dithiothreitol and allowed to stir for 15 min. To this solution was 
slowly added 42 μL of a 50 mM solution of Fe(NH4)2(SO4)2 in anaerobic water over 10 
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min. After 10 min, 42 μL of a 50 mM solution of Na2S in anaerobic buffer containing 20 
mM NH4HCO3 (pH 7.8) and 5 mM DTT was added over 10 min. The solution was gently 
stirred at ca. 10 °C for 2 hr. The reconstituted enzyme was loaded onto a 50 mL 
Sephadex G-25 column pre-equilibrated with anaerobic buffer containing 20 mM 
NH4HCO3 (pH 7.8) and 5 mM DTT, and the column was eluted with the same buffer. 
Protein fractions were collected, concentrated to approximately 100 μM of enzyme and 
stored in the glovebox at ca. 10 °C until use. Iron content in the reconstituted AprD4 was 
assessed using the ferrozine assay,
153
 and the sulfide content was determined by the 
method devised by Helmut Bienert.
154
 The iron and sulfide content reported in the text is 
an average of three measurements. 
 
4.2.4. AprD4 Activity Assays and AprD3 Activity Assays 
The reaction mixture contained the following: 50 mM NH4HCO3 (pH 7.8), 10 
mM DTT, 1 mM paromamine (11), 2 mM enzymatically prepared SAM, 2 mM sodium 
dithionite, and 0.01 mM AprD4.  Assays were initiated by the addition of AprD4, 
incubated for 8 h at room temperature, and quenched by passage through YM-10 
Microcon centrifugal filters to remove enzymes. The filtrate of each sample was frozen 
and stored at –80 °C until analysis of HPLC and mass spectroscopy. 
To find proper reducing systems for the AprD4 reaction, all reactions were treated 
with 1 mM of the chemical reductants being tested.  When flavodoxin and flavodoxin 
reductase from E. coli (obtained as previously described
170
) were used as the reducing 
system, the protein concentration was 0.1 mM.  
To an assay mixture of AprD4, 0.01 mM AprD3 and 1 mM NAD(P)H were 
added. Assays were incubated for 1 h at room temperature, quenched by passage through 
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YM-10 Microcon centrifugal filters to remove enzymes. The filtrate of each sample was 
frozen and stored at –80 °C until analysis of HPLC and mass spectroscopy. 
 
4.2.5. HPLC Detection of 5'-Deoxyadenosine (5'-dAdo) 
A 20 μL aliquot of the quenched AprD3/AprD4 reaction or AprD4 reaction 
described above was analyzed using HPLC equipped with a Varian Microsorb-MV 100-5 
C18 (4.6 x 250 nm) column pre-equilibrated in H2O containing 0.1% trifluoroacetic acid 
(solvent A). After sample loading, the column was eluted with a linear gradient from 0–
20% acetonitrile containing 0.1% trifluoroacetic acid (Solvent B) over 30 min. The UV 
detector was set at 260 nm. An authentic, commercially obtained 5'-dAdo was injected as 
a retention time standard for each. The stoichiometric ratio reported in the text is an 
average of three measurements.  
 
4.2.6. HPLC Detection of AprD4/AprD3 Reaction Product 
A 10 L aliquot of the quenched AprD4/AprD3 reaction or the AprD4 reaction was 
analyzed using HPLC equipped with a Varian Microsorb-MV 100-5 C18 (4.6 x 250 nm) 
and eluted with H2O containing 0.4% trifluoroacetic acid for 15 min. The elution was 
monitored by Corona
®
 charged aerosol detector. An authentic paromamine was injected 
as a retention time standard. 
 
4.2.7. Mass Spectroscopic Analysis of AprD3/AprD4 Activity and AprD4 Activity 
Assay mixtures were diluted in water and injected directly into an Agilent 6350 
Accurate Mass QTOF-MS at 0.15 mL/min. The analyte was ionized by electrospray 
ionization and detected in positive ion mode. 
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4.2.8. Synthesis of Lividamine 
The overall synthetic scheme is shown in Scheme 4-2. 
 
 
Scheme 4-2. Synthetic scheme for the preparation of lividamine. 
(3R,5S,6R)-6-(acetoxymethyl)-3-azidotetrahydro-2H-pyran-2,5-diyl diacetate (29): 
Compound 27 was prepared as previously described.
209
 Copper sulfate (0.158 g, 1.01 
mmol), triethylamine (14.09 mL, 101.09 mmol), and triflic azide (0.4 M solution in 
dichloromethane, 80 mL) was added to a solution of compound 27 (2.0181 g, 10.11 
mmol) in methanol (60 mL) at 0 °C. The reaction mixtures were stirred at room 
temperature for 24 h, and concentrated in vacuo. The residue was dissolved in acetonitrile 
and washed with water. The remaining aqueous layer was extracted with acetonitrile five 
times, and the combined organic layers were dried over magnesium sulfate, filtered, and 
concentrated under reduced pressure. The residue was filtered by short column filled with 
silica gel by 20% methanol in dichloromethane. Acetic anhydride (50 mL) was added to a 
solution of the crude compound 28 in pyridine (50 mL) at 0 °C. The reaction mixture was 
stirred at room temperature for 12 h, and concentrated. The residue was diluted with 
dichloromethane and washed with saturated aqueous solution of sodium bicarbonate (50 
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mL) two times. The organic layer was dried over magnesium sulfate, filtered, and 
concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 2:1) to give compound 29 (1.75 g, 55% over 
two steps) as a light yellow liquid. 
1
H NMR (500 MHz, CDCl3) α isomer δ 6.18 (d, J = 
3.3 Hz, 1H, H-1), 4.88 (ddd, J = 13.2, 8.3, 4.9 Hz, 1H, H-4), 4.29–4.24 (m, 1H, H-6), 
4.12–4.09 (m, 1H, H-6), 4.0 (ddd, J = 10.3, 4.5, 2.3, 1H, H-5), 3.54–3.50 (m, 1H, H-2), 
2.48 (dt, J = 11.5, 4.8 Hz, H-3), 2.21 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.08 (s, 3H, OAc), 
2.05–1.98 (m, 1H, H-3). β isomer δ 5.53 (d, J = 8.4 Hz, H-1), 4.80 (ddd, J = 12.9, 8.1, 4.9 
Hz, H-4), 4.29–4.24 (m, 1H, H-6), 4.16–4.12 (m, 1H, H-6), 3.79 (ddd, J = 10.0, 5.2, 2.6 
Hz, 1H, H-5), 3.60 (ddd, J = 12.8, 7.9, 5.0 Hz, 1H, H-2), 2.55 (dt, J = 12.6, 4.9 Hz, 1H, 
H-3), 2.19 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.07 (s, 3H, OAc), 1.59–1.51 (m, 1H, H-3). 
13
C NMR (125 MHz, CDCl3) α isomer δ 170.71 (OAc), 169.58 (OAc), 168.77 (OAc), 
89.6 (C-1), 69.9 (C-5), 65.4 (C-4), 61.9 (C-6), 55.3 (C-2), 28.5 (C-3), 21.05 (OAc), 20.89 
(OAc, 20.74 (OAc). β isomer δ 170.71 (OAc), 169.69 (OAc), 168.93 (OAc), 94.7 (C-1), 
75.8 (C-5), 65.2 (C-4), 61.9 (C-6), 57.6 (C-2), 33.2 (C-3), 21.03 (OAc), 20.87 (OAc), 
20.76 (OAc). HRMS (ESI, positive ion mode) calculated for C12H17N3O7
+
 [M + Na]
+
 
338.0959, found 338.0960. 
((2R,3S,5R)-3-acetoxy-5-azido-6-(phenylthio)tetrahydro-2H-pyran-2-yl)methyl acet-
ate (30): Boron trifluoride etherate (ca. 48%, 0.99 mL, 2.99 mmol) was added to a 
solution of compound 29 (0.787 g, 2.50 mmol) and thiophenol (0.51 mL, 4.99 mmol) in 
dichloromethane (40 mL) at 0 °C under nitrogen atmosphere, and the reaction mixture 
was stirred at room temperature for 6 h. The reaction was quenched by the addition of 
saturated aqueous solution of sodium bicarbonate (20 mL) at 0 °C, and the aqueous layer 
was extracted by dichloromethane (40 mL × 3). The combined organic layers were dried 
over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue 
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was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:1) to provide 
compound 30 (α/β = 4:1, 0.759 g, 83%) as a clear liquid. 1H NMR (500 MHz, CDCl3) α 
isomer δ 7.53–7.51 (m, 2H, Ph), 7.33–7.28 (m, 3H, Ph), 5.53 (d, J = 4.6 Hz, 1H, H-1), 
4.82 (ddd, J = 13.1, 8.1, 4.9 Hz, 1H, H-4), 4.49 (ddd, J = 10.0, 5.6, 2.3 Hz, 1H, H-5), 4.27 
(dd, J = 12.2, 5.6 Hz, 1H, H-6), 4.11 (dd, J = 12.2, 2.3 Hz, 1H, H-6), 4.0 (ddd, J = 12.7, 
5.1, 4.3 Hz, 1H, H-2), 2.45–2.41 (m, 1H, H-3), 2.08 (s, 3H, OAc), 2.02 (s, 3H, OAc), 
1.9–1.82 (m, 1H, H- –7.57 (m, 2H, Ph), 7.30–7.27 (m, 3H, Ph), 4.70 
(ddd, J = 12.9, 8.2, 4.8 Hz, 1H, H-4), 4.46 (d, J = 8.9 Hz, 1H, H-1), 4.24–4.16 (m, 2H, H-
6, H-6), 3.62 (ddd, J = 9.9, 5.4, 2.7 Hz, 1H, H-5), 3.42 (ddd, J = 12.3, 8.4, 4.9 Hz,1H, H-
2), 2.60 (dt, J = 12.4, 4.9 Hz, 1H, H-3), 2.07 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.55 (q, J = 
11.8 Hz, 1H, H-3). 
13
C NMR (125 MHz, CDCl3) α isomer δ 170.60 (OAc), 169.72 
(OAc), 132.91 (Ph), 132.32 (Ph), 129.13 (Ph), 127.85 (Ph), 87.94 (C-1), 68.71 (C-5), 
66.11 (C-4), 62.42 (C-6), 57.23 (C-2), 30.64 (C-3), 20.91 (OAc), 20.71 (OAc). β isomer δ 
170.62 (OAc), 169.64 (OAc), 133.43 (Ph), 131.36 (Ph), 128.92 (Ph), 128.38 (Ph), 88.18 
(C-1), 77.87 (C-5), 65.76 (C-4), 62.66 (C-6), 57.88 (C-2), 35.47 (C-3), 20.86 (OAc), 
20.76 (OAc). HRMS (ESI, positive) calculated for C27H27N3O5S
+
 [M + Na]
+
 528.1569, 
found 528.1559. 
(2R,3S,5R)-5-azido-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-pyran-3-ol (31): 
Sodium methoxide (4.35 M in methanol, 95.4 μL, 0.42 mmol) was added to a solution of 
compound 30 (0.759 g, 2.08 mmol) in methanol (40 mL). The reaction mixture was 
stirred at room temperature for 10 h, and neutralized with Amberlite IR-120 (H
+
 form). 
The mixture was filtered through a Celite pad, and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (Hex/EtOAc = 
1:2) to give compound 31 (α/β mixtures, 0.450 g, 85%) as a white solid. As time goes, β 
isomer converted into α isomer. 1H NMR (400 MHz, CDCl3) α isomer δ 7.55–7.50 (m, 
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2H, Ph), 7.35–7.28 (m, 3H, Ph), 5.49 (d, J = 5.0 Hz, 1H, H-1), 4.09 (m, 1H, H-4), 3.91–
3.77 (m, 3H, H-2, H-6, H-5), 2.33–2.28 (m, 1H, H-3), 1.91–1.82 (m, 1H, H-3). β isomer δ 
7.55–7.50 (m, 2H, Ph), 7.35–7.28 (m, 3H, Ph), 4.50 (d, J = 9.9 Hz, 1H, H-1), 3.91–3.77 
(m, 2H, H-4, H-6), 3.74–3.68 (m, 1H, H-4), 3.39–3.33 (m, 1H, H-2), 3.32–3.27 (m, 1H, 
H-5), 2.50 (dt, J = 12.5, 4.7 Hz, 1H, H-3), 1.59 (q, J = 11.6 Hz, 1H, H-3). 
13
C NMR (125 
MHz, CDCl3) α isomer δ 133.21 (Ph), 132.51 (Ph), 129.16 (Ph), 127.84 (Ph), 88.2 (C-1), 
72.9 (C-4), 65.84 (C-5), 62.5 (C-6), 57.8 (C-2), 33.7 (C-3). β isomer δ 133.06 (Ph), 
132.83 (Ph), 129.08 (Ph), 128.26 (Ph), 88.2 (C-1), 81.9 (C-5), 65.4 (C-4), 62.7 (C-6), 
58.6 (C-2), 33.9 (C-3). HRMS (ESI, positive ion mode) calculated for C12H15N3O3S
+
 [M 
+ Na]
+
 304.0726, found 304.0726.   
(3R,5S,6R)-3-azido-5-(benzyloxy)-6-((benzyloxy)methyl)-2-(phenylthio)tetrahydro-2-
H-pyran (32): Sodium hydride (60% dispersion in mineral oil, 0.165 g, 3.91 mmol) was 
added to a solution of compound 31 (0.458 g, 1.63 mmol) in dry dimethylformamide (25 
mL) under nitrogen gas at 0 °C. The reaction mixture was stirred at room temperature for 
30 min. The reaction solution was cooled to 0 °C and benzyl bromide (0.48 mL) was 
added. The reaction mixture was stirred at room temperature for 8 h. After adding 
methanol (5 mL) at 0 °C, the solution was concentrated under reduced pressure. The 
residue was diluted with dichloromethane (30 mL) and washed with water (20 mL). The 
organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography on silica gel (Hex/EtOAc = 5:1) to 
give compound 32 (α/β mixtures, 0.721 g, 96%) as a clear liquid. 1H NMR (400 MHz, 
CDCl3) α isomer δ 7.56–7.53 (m, 2H, Ph), 7.36–7.29 (m, 7H, Ph),7.29–7.25 (m, 6H), 
5.55 (d, J = 5.1 Hz, 1H, H-1), 4.62 (d, J = 12.0 Hz, 1H, Bn), 4.62 (d, J = 11.2 Hz, 1H, 
Bn), 4.48 (d, J = 12 Hz, 1H, Bn), 4.46 (d, J = 11.5 Hz, 1H, Bn), 4.35–4.31 (m, 1H, H-5), 
3.90–3.81 (m, 2H, H-2, H-6), 3.74–3.68 (m, 2H, H-6, H-4), 2.46–4.40 (m, 1H, H-3), 
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1.89–1.80 (m, 1H, H-3). β isomer δ 7.62–7.60 (m, 2H, Bn), 7.36–7.24 (m, 13H, Bn), 4.62 
(d, J = 12.1 Hz, 1H, Bn), 4.58 (d, J = 11.6 Hz, 1H, Bn), 4.56 (d, J = 11.9 Hz, 1H, Bn), 
4.50 (d, J = 9.9 Hz, 1H, H-1), 4.45 (d, J = 11.5 Hz, 1H, Bn), 3.82 (dd, J = 10.9, 1.8 Hz, 
1H, H-6), 3.73 (dd, J = 10.9, 4.5 Hz, 1H, H-6), 3.59–3.48 (m, 2H, H-4, H-5), 3.35 (ddd, J 
= 13.3, 8.4, 4.9 Hz, 1H, H-2), 2.61 (dt, J = 12.4, 4.5 Hz, 1H, H-3), 1.61–1.52 (m, 1H, H-
3). 
13
C NMR (125 MHz, CD3Cl3) α isomer δ 138.03 (Ph), 137.71 (Ph), 133.63 (Ph), 
132.24 (Ph), 128.99 (Ph), 128.33 (Ph), 127.90 (Ph), 127.81 (Ph), 127.77 (Ph), 127.65 
(Ph), 127.51 (Ph), 88.5 (C-1), 73.4 (Bn), 71.62 (C-5), 71.48 (C-4), 71.34 (Bn), 68.49 (C-
6), 57.8 (C-2), 31.0 (C-3). β isomer δ 138.35 (Ph), 137.72 (Ph), 132.89 (Ph), 132.19 (Ph), 
128.87 (Ph), 128.44 (Ph), 128.31 (Ph), 127.88 (Ph), 127.72 (Ph), 127.59 (Ph), 127.53 
(Ph), 88.26 (C-1), 81.36 (C-5), 73.41 (Bn), 71.46 (Bn), 71.21 (C-4), 69.1 (C-6), 58.48 (C-
2), 35.96 (C-3). HRMS (ESI, positive) calculated for C26H27N3O3S
+ 
[M + Na]
+
 484.1665, 
found 484.1669. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,5S,6R)-3-azido-5-(benzyloxy)-6-((benzylox-
y)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diyl diacetate (34): Compo-
und 33 (0.244 g, 0.821 mmol) and compound 32 (0.417 g, 0.903 mmol) were co-
evaporated from dry toluene three times and further dried under high vacuum overnight. 
A solution of compound 33 and compound 32 in anhydrous dichloromethane (10 mL) 
was added to a preactivated 4 Å  molecular sieves and N-iodosuccinimide (0.295 g, 1.31 
mmol). After stirring for 20 min at room temperature, the mixture was cooled to –78 °C. 
Trifluoromethanesulfonic acid (21 μL, 0.246 mmol) was slowly added, and the reaction 
was warmed to 0 °C slowly. The reaction was quenched by adding solid sodium sulfite 
(0.3 g), sodium bicarbonate (0.3 g) and a few drops of water. The color of solution turned 
to clear from dark yellow. The reaction mixture was diluted with dichloromethane, 
filtered, and washed with saturated solution of sodium bicarbonate and brine. The residue 
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was dried over magnesium sulfate, filtered, concentrated under reduced pressure, and 
purified by flash column chromatography on silica gel (Hex:EtOAc =3:1) to give 
compound 34 as a clear oil. 
1
H NMR (600 MHz, CDCl3) δ 7.34–7.26 (m, 8H, Bn), 7.23–
7.21 (m, 2H, Bn), 5.14 (t, J = 9.8 Hz, 1H, H-5), 5.07 (d, J = 3.5 Hz, 1H, H-1'), 4.92 (t, J = 
10.0 Hz, 1H, H-6), 4.64 (d, J = 12.2 Hz, 1H, Bn), 4.59 (d, J =11.4 Hz, 1H, Bn), 4.50 (d, J 
= 12.2 Hz, 1H, Bn), 4.43 (d, J = 11.3 Hz, 1H, Bn), 4.08 (ddd, J = 9.9, 3.0, 2.1 Hz, 1H, H-
5'), 3.83 (dd, J = 10.7, 3.1 Hz, 1H, H-6'), 3.73–3.69 (m, 2H, H-4, H-4'), 3.66 (dd, J = 
10.7, 2.0 Hz, 1H, H-6'), 3.62 (ddd, J = 12.5, 10.0, 4.5 Hz, 1H, H-1), 3.43 (ddd. J = 12.4, 
9.9, 4.6 Hz, 1H, H-3), 3.10 (ddd, J = 13.1, 4.5, 3.6 Hz, 1H, H-2'), 2.38 (dt, J = 13.4, 4.6 
Hz, 1H, C-2), 2.32 (dt, J = 11.5, 4.5 Hz, 1H, C-3'), 2.08 (s, 3H, OAc), 2.07 (s, 3H, OAc), 
1.98 (dt, J = 13.2, 11.3 Hz, 1H, C-3'), 1.58 (dt, J = 13.4, 12.5 Hz, 1H, C-2). 
13
C NMR 
(150 MHz, CDCl3) δ 169.82 (OAc), 169.48 (OAc), 138.04 (Ph), 137.81 (Ph), 128.39 
(Ph), 128.34 (Ph), 127.84 (Ph), 127.73 (Ph), 127.65 (Ph), 98.5 (C-1'), 77.7 (C-4), 74.15 
(C-6), 73.84 (C-5), 73.53 (Bn), 71.63 (C-5'), 71.30 (Bn), 71.13 (C-4'), 68.05 (C-6'), 58.75 
(C-3), 57.72 (C-1), 56.09 (C-2'), 31.82 (C-2), 27.83 (C-3'), 20.67 (OAc), 20.55 (OAc). 
HRMS (ESI, positive) calculated for C30H35N9O8
+
 [M + Na]
+
 672.2501, found 672.2515. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,5S,6R)-3-azido-5-(benzyloxy)-6-((benzyloxy-
)methyl)tetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol (35): Sodium methoxide 
(4.35 M in methanol, 7.8 mL, 0.034 mmol) was added to a solution of compound 34 
(0.221 g, 0.341 mmol) in methanol (10 mL). The reaction mixture was stirred at room 
temperature for 4 h, and neutralized with Amberlite IR-120 (H
+
 form) resin. The mixture 
was filtered through a Celite pad, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) to give 
compound 35 (0.146 g, 76%) as a clear oil. 
1
H NMR (500 MHz, CDCl3) δ 7.37–7.28 (m, 
8H, Bn), 7.24–7.21 (m, 2H, Bn), 5.20 (d, J = 3.5 Hz, 1H, H-1'), 4.64 (d, J = 12.0 Hz, 1H, 
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Bn), 4.60 (d, J = 11.4 Hz, 1H, Bn), 4.50 (d, J = 11.4 Hz, 1H, Bn), 4.43 (d, J = 12.1 Hz, 
1H, Bn), 4.07 (ddd, J = 9.9, 3.8, 2.00 Hz, 1H, H-5'), 3.95 (d, J = 3.0 Hz, 1H, OH), 3.80 
(dd, J = 10.6, 3.8 Hz, 1H, H-6'), 3.75–3.62 (m, 2H, H-4', H-6'), 3.57–3.43 (m, 2H, C-2', 
H-5), 3.43–3.35 (m, 3H, H-1,H-4, H-6), 3.31 (ddd, J = 12.3, 9.9, 4.5 Hz, 1H, H-3), 3.13 
(s, 1H, OH), 2.38 (ddt, J = 11.6, 4.6 Hz, 1H, H-3'), 2.28 (dt, J = 13.3, 4.2 Hz, 1H, H-2), 
2.00 (dt, J = 12.9, 11.3 Hz, 1H, H-3'), 1.53–1.36 (m, 1H, H-2). 13C NMR (125 MHz, 
CDCl3) δ 137.87 (Ph), 137.76 (Ph), 128.45 (Ph), 128.39 (Ph), 127.97 (Ph), 127.88 (Ph), 
127.76 (Ph), 97.59 (C-1'), 82.0 (C-6), 75.98 (C-5), 75.56 (C-4), 73.56 (Bn), 71.40 (C-5), 
71.30 (Bn), 71.18 (C-4'), 68.37 (C-6'), 59.65 (C-1), 58.76 (C-3), 57.58 (C-2'), 32.09 (C-
3'), 28.57 (C-2). HRMS (ESI, positive ion mode) calculated for C26H31N9O6
+
 [M + Na]
+
 
588.2290, found 588.2294.   
Lividamine (13): Trimethylphosphine (1 M solution in THF, 1.12 mL, 1.123 mmol) was 
added to a solution of compound 35 (0.105 g, 0.187 mmol) in THF (6 mL) and 0.1 M 
NaOH (2 mL). The reaction mixture was stirred at 50 °C for 2 h, cooled to room 
temperature, and concentrated in vacuo. The residue was dissolved in a mixture of acetic 
acid (1 mL), water (3 mL) and methanol (3 mL). The solution was deaerated by 
evacuating the air inside of the flask and refilling it with nitrogen five times. Palladium 
hydroxide on carbon (20%, Degussa type, 0.1 g) was added and the solution was charged 
with hydrogen gas. The reaction mixture was stirred at room temperature under hydrogen 
gas for 24 hr. The solution was filtered through a Celite pad, washed with water and 
methanol, and concentrated under reduced pressure. The residue was purified by 
chromatography on Amberlite CG-50 (NH4
+
 form) resin (5-10% concentrated ammonium 
hydroxide in water), acidified with hydrochloric acid (pH ca. 4), and lyophilized to 
provide compound 13 as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.51 (d, J = 3.5 Hz, 
1H, H-1'), 3.95–3.88 (m, 2H, H-5, H-5'), 3.84 (ddd, J = 9.3, 7.1, 2.5 Hz, 1H, H-6'), 3.80–
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3.65 (m, 4H, H-6', H-2', H-6, H-4'), 3.65–3.57 (m, 2H, H-4, H-1), 3.38 (ddd, J = 12.5, 
10.2, 4.3 Hz, 1H, H-2), 2.54 (dt, J = 12.7, 4.3 Hz, 1H, H-2), 2.31 (dt, J = 12.3, 4.4 Hz, 
1H, H-3'), 1.99 (td, J = 12.0, 10.0 Hz, 1H, H-3'), 1.91 (q, J = 12.6 Hz, 1H, H-2). 
13
C 
NMR (125 MHz, D2O) δ 95.3, 80.2, 75.13, 74.54, 72.26, 63.16, 60.04, 49.61, 48.86, 
48.10, 29.76, 28.17. HRMS (ESI, positive) calculated for C12H25N3O6
+
 [M + Na]
+
 
330.1636, found 330.1645. 
 
4.2.9. Synthesis of [4'-
2
H]-Paromamine (47) 
The overall synthetic scheme is shown in Scheme 4-3. 
 
 
Scheme 4-3. Synthetic scheme for the preparation of [4'-
2
H]-paromamine. 
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(4aR,6S,7R,8R,8aS)-7-azido-2-(4-methoxyphenyl)-6-(phenylthio)hexahydropyrano-
[3,2-d][1,3]dioxin-8-ol (37): Compound 36 was prepared as previously described.
159
 
Compound 36 (12.88 g, 43.32 mmol) and anisaldehyde dimethyl acetal (9.14 mL, 53.72 
mmol) were dissolved in dimethylformamide (200 mL). p-Toluenesulfonic acid 
monohydrate (0.745 g, 4.33 mmol) was added and the flask was attached to a rotary 
evaporator, rotated, evacuated, and lowered into a water bath at approximately 60 °C to 
remove the methanol, which was formed during the reaction. After 1 h, triethylamine (10 
mL) was added and all solvent was removed by evaporation. The residue was diluted 
with ethyl acetate (200 mL) and saturated aqueous solution of sodium bicarbonate (100 
mL). The aqueous layer was extracted with dichloromethane (3 × 200 mL). The 
combined organic extracts were washed with brine, dried over magnesium sulfate, 
filtered and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (Hex/EtOAc = 2:1) to afford compound 37 (13.50 g, 72%) 
as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.61–7.54 (m, 2H, Ph), 7.40–7.26 (m, 5H, 
Ph), 6.92–6.87 (m, 2H, Ph), 5.49 (s, 1H, PMPCH), 4.55 (d, J = 10.2 Hz, 1H, H-1), 4.36 
(dd, J = 10.2, 4.1 Hz, 1H, H-4), 3.80 (s, 3H, OMe), 3.79–3.73 (m, 2H, 2×H-6), 3.50–3.43 
(m, 2H, H-5, H-3), 3.36 (dd, J = 10.1, 9.0 Hz, 1H, H-2), 2.68 (d, J = 2.7 Hz, 1H, OH). 
13
C 
NMR (150 MHz, CD3OD) δ 161.7, 134.9, 132.5, 130.8, 130.6, 130.0, 129.2, 115.2, 
103.2, 88.0, 81.6, 75.2, 71.7, 69.7, 66.6, 56.7. HRMS (ESI, positive ion mode) calculated 
for C20H21N3O5S
+
 [M + Na]
+
 438.1100, found 438.1093. 
(4aR,6S,7R,8R,8aS)-7-azido-8-(benzyloxy)-2-(4-methoxyphenyl)-6-(phenylthio)hexa-
hydropyrano[3,2-d][1,3]dioxine (38): Sodium hydride (60% dispersion in mineral oil, 
0.945g, 23.62 mmol) was added to a solution of compound 37 (7.55 g, 18.17 mmol) in 
anhydrous dimethylformamide (120 mL) at 0 °C under nitrogen atmosphere. The mixture 
was warmed to room temperature and was stirred for 30 min. The mixture was cooled to 
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0 °C and benzyl bromide (2.81 mL, 23.62 mmol) was added dropwise. The reaction was 
then allowed to stand for 12 h at room temperature. The mixture was treated with 
methanol at 0 °C and all the solvent was evaporated under reduced pressure. The residue 
was diluted with dichloromethane (200 mL) and washed with saturated aqueous solution 
of sodium bicarbonate (100 mL). The aqueous layer was extracted with dichloromethane 
(3 × 100 mL). The combined organic extracts were washed with brine, dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 3:1) to afford 
compound 38 (6.68 g, 73 %) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.58–7.56 
(m, 2H, Ph), 7.42–7.40 (m, 2H, Ph), 7.39–7.30 (m, 8H, Ph), 6.96–6.91 (m, 2H, Ph), 5.54 
(s, 1H, PMPCH), 4.92 (d, J = 10.9 Hz, 1H, PhCH2), 4.79 (d, J = 11.0 Hz, 1H, PhCH2), 
4.50 (d, J = 10.2, 1H, H-1), 4.38 (dd, J = 10.5, 5.5 Hz, 1H, H-4), 3.83 (s, 3H, OCH3), 
3.78 (t, J = 10.3 Hz, 1H, H-3), 3.65–3.61 (m, 2H, H-6), 3.47–3.43 (m, 1H, H-5), 3.37  
(dd, J = 10.3, 8.8 Hz, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 160.24, 137.70, 134.01, 
130.77, 129.67, 129.23, 128.83, 128.55, 128.54, 128.43, 128.11, 127.40, 127.40, 113.78, 
101.37, 86.73, 81.36, 81.08, 75.29, 70.63, 68.56, 64.81, 55.42. HRMS (ESI, positive) 
calculated for C27H27N3O5S
+
 [M + Na]
+
 528.1569, found 528.1559. 
(2R,3S,4R,5R,6S)-5-azido-4-(benzyloxy)-2-(((4-methoxybenzyl)oxy)methyl)-6-(phen-
ylthio)tetrahydro-2H-pyran-3-ol (39): A mixture of compound 38 (4.544 g, 8.99 
mmol), sodium cyanoborohydride (4.518 g, 71.91 mmol), and freshly activated 4 Å  
molecular sieve (1 g) in dry dimethylformamide (90 mL) was stirred at room temperature 
under nitrogen for 30 min. Trifluoroacetic acid (6.87 mL, 89.88 mmol) was added 
dropwise at 0 °C. After stirring at room temperature for 12 h, the reaction mixture was 
filtered through a Celite pad and poured into ice-cold saturated aqueous solution of 
sodium bicarbonate (100 mL). The mixture was diluted with ethyl acetate (200 mL), 
 208 
washed with saturated aqueous solution of sodium bicarbonate (50 mL), brine, dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 3:1) to give 
compound 39 (4.326 g, 95%) as a clear oil. Compound 39 was unstable, only mass 
spectra were measured. HRMS (ESI, positive) calculated for C27H29N3O5S
+
 [M + Na]
+
 
530.1726, found 530.1718. 
 (2R,3R,4R,5R,6S)-5-azido-4-(benzyloxy)-2-(((4-methoxybenzyl)oxy)methyl)-6-(phe-
nylthio)tetrahydro-2H-pyran-3-d-3-ol (40): Dess-Martin periodinane (7.229 g, 17.04 
mmol) was added to a mixture of compound 39 (4.326 g, 8.52 mmol) in dry 
dichloromethane (100 mL). After stirring for 12 h under nitrogen gas at room 
temperature, mixtures (60 mL) of 10% aqueous solution of sodium thiosulfate and 
saturated aqueous solution of sodium bicarbonate (1:1) were added to the reaction 
mixture. The reaction was allowed to stir for an additional 30 min. The organic layer was 
washed with aqueous solution of sodium thiosulfate/sodium bicarbonate (1:3) (3 × 60 
mL) and then brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. 
The crude ketone compound was dissolved in anhydrous methanol (50 mL) and dry 
dichloromethane (50 mL). Sodium borodeuteride (0.428 g, 10.23 mmol) was added 
portionwise to this solution 0 °C. After stirring for 10 min at 0 °C, the reaction mixture 
was stirred at room temperature for an additional 3 h. The reaction was quenched by the 
addition of saturated aqueous solution of ammonium chloride (50 mL), and the aqueous 
layer was extracted with dichloromethane. The combined organic layers were dried over 
magnesium sulfate, filtered, and concentrated under reduced pressure. Purification by 
flash column chromatography on silica gel (Hex/EtOAc = 3:1) gave compound 40 (3.294 
g, 76%) as a white solid.  
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1
H NMR (600 MHz, CDCl3) δ 7.60– 7.57 (m, 2H, Ph), 7.39– 7.32 (m, 4H, PH, 7.28–7.23 
(m, 6H, PMP, Ph)), 6.89–6.85 (m, 2H, Ph), 4.69 (d, J = 11.5 Hz, 1H, Bn), 4.65 (d, J = 
11.5 Hz, 1H, Bn), 4.52–4.47 (m, 2H, PMP), 4.37 (d, J = 10.2 Hz, 1H, H-1), 3.79 (s, 3H, 
OMe), 3.77–3.70 (m, 2H, 2×H-6), 3.64 (dd, J = 10.2, 9.5 Hz, 1H, H-2), 3.52 (t, J = 5.7 
Hz, 1H, H-5), 3.37 (d, J = 9.5 Hz, 1H, H-3). 
13
C NMR (150 MHz, CDCl3) δ 159.43, 
137.08, 133.20, 131.78, 129.97, 129.55, 129.05, 128.71, 128.34, 128.23, 128.14, 113.95, 
86.39, 81.12, 73.49, 72.01, 69.08, 61.08, 55.38. HRMS (ESI, positive) calculated for 
C27H28DN3O5S
+ 
[M + Na]
+
 531.1788, found 531.1780. 
(2R,3R,4R,5R,6S)-5-azido-4-(benzyloxy)-2-(((4-methoxybenzyl)oxy)methyl)-6-(phen-
ylthio)tetrahydro-2H-pyran-3-yl-3-d methanesulfonate (41): Methanesulfonyl 
chloride (1.77 mL, 22.93 mmol) and dimethylaminopyridine (0.028 g, 0.23 mmol) was 
added to a solution of compound 40 (2.332 g, 4.59 mmol) in anhydrous pyridine (40 mL) 
at 0 °C. The reaction mixture was stirred at room temperature for 10 h. Methanol (10 mL) 
was added to quench the reaction at 0 °C. The mixture was concentrated under reduced 
pressure and co-evaporated with toluene (3 × 30 mL). The residue was diluted with 
dichloromethane (50 mL) and water (50 mL). The aqueous layer was extracted with 
dichloromethane (3 × 50 mL), dried over magnesium sulfate, filtered, and concentrated. 
The residue was purified by flash column chromatography on silica gel (Hex/EtOAc = 
3:1) to afford compound 41 (2.081g, 77%) as a light yellowish oil. 
1
H NMR (400 MHz, 
CDCl3) δ 7.60–7.57 (m, 2H, Ph), 7.42–7.30 (m, 10H, Ph), 6.91–6.89 (m, 2H, Ph), 4.81 (d, 
J = 10.6, 1H, Bn), 4.58 (dd, J = 10.7, 2.0 Hz, 2H, PMP), 4.43 (d, J = 10.8 Hz, 1H, Bn), 
4.41 (d, J = 9.56 Hz, 1H, H-1) 3.81 (s, 3H, OCH3), 3.75–3.69 (m, 3H, 2×H-6, H-3), 3.54–
3.44 (m, 2H, H-2, H-5), 2.92 (s, 3H, SCH3). 
13
C NMR (100 MHz, CDCl3) δ 159.51, 
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136.40, 133.52, 131.26, 130.03, 129.77, 129.06, 128.72, 128.66, 128.54, 128.50, 113.95, 
86.39, 79.36, 75.56, 73.60, 72.81, 67.51, 61.14, 55.37, 39.16. HRMS (ESI, positive) 
calculated for C28H30DN3O7S2
+
 [M + Na]
+
 609.1564, found 609.1559. 
(2R,3S,4R,5R,6S)-5-azido-4-(benzyloxy)-2-(((4-methoxybenzyl)oxy)methyl)-6-(phen-
ylthio)tetrahydro-2H-pyran-3-yl-3-d benzoate (42): Sodium benzoate (1.214 g, 10.64 
mmol) and 15-crown-5 (50 μL) were added to a solution of compound 41 (2.081 g, 3.55 
mmol) in anhydrous dimethylformamide (DMF, 100 mL). The reaction mixture was 
heated to reflux for 15 h. The solvent was evaporated under reduced pressure, and the 
residue was diluted with dichloromethane (50 mL) and water (50 mL). The aqueous layer 
was extracted with dichloromethane (3 × 50 mL), dried over magnesium sulfate, filtered, 
and concentrated. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 3:1) to give compound 42 (1.316 g, 60 %) as a white solid. 
1
H NMR (600 
MHz, CDCl3) δ 7.97–7.95 (m, 2H, Bz), 7.61–7.59 (m, 3H, Ph, Bz), 7.45–7.43 (m, 2H, 
Bz), 7.32–7.29 (m, 3H, Ph), 7.16–7.11 (m, 7H, PMB, Bn), 6.77–6.75 (m, 2H, PMB), 4.72 
(d, J = 10.8 Hz, Bn), 4.58 (d, J = 10.8 Hz, Bn), 4.51 (d, J = 10.8 Hz, 1H, H-1), 4.41 (m, 
2H, PMB), 3.76 (s, 3H, OCH3), 3.72 (m, 1H, H-6), 3.66 (d, J = 9.3 Hz, 1H, H-3), 3.59 
(m, 2H, H-5, H-6), 3.47 (dd, J = 10.1, 9.2 Hz, 1H, H-2). 
13
C NMR (150 MHz, CDCl3) δ 
165.31, 159.24, 137.09, 133.63, 133.51, 131.17, 130.00, 129.88, 129.51, 129.45, 129.20, 
128.61, 128.59, 128.43, 128.37, 128.05, 113.78, 86.25, 82.48, 78.07, 75.51, 73.32, 69.23, 
64.93, 55.35. HRMS (ESI, positive) calculated for C34H32DN3O6S
+
 [M + Na]
+
 632.2051, 
found 635.2013. 
(2R,3S,4R,5R,6S)-5-azido-4-(benzyloxy)-2-(((4-methoxybenzyl)oxy)methyl)-6-(phen-
ylthio)tetrahydro-2H-pyran-3-d-3-ol (43): Sodium methoxide (4.37 M in methanol, 
0.18 mL, 0.78 mmol) was added dropwise to a solution of compound 42 (2.399 g, 3.92 
mmol) in anhydrous methanol (10 mL) and anhydrous dichloromethane (40 mL). The 
 211 
reaction mixture was stirred at 45 °C for 10 h. After cooling down to room temperature, 
the reaction mixture was neutralized with Amberlite IR-120 (H
+
 form) resin, filtered, and 
concentrated. The residue was purified by flash column chromatography (Hex/EtOAc = 
3:1) on silica gel to give compound 43 (1.215 g, 61%) as a clear oil. Compound 34 was 
unstable so it was characterized only by mass spectroscopy. HRMS (ESI, positive) 
calculated for C27H28DN3O5S
+
 [M + Na]
+
 531.1788, found 531.1781. 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-methoxybenzyl)oxy)methyl)-2-
(phenylthio)tetrahydro-2H-pyran-5-d (44): Sodium hydride (60% dispersion in 
mineral oil, 0.215g, 5.39 mmol) was added portionwise to a solution of compound 43 
(2.283 g, 4.49 mmol) in anhydrous DMF (50 mL) at 0 °C under nitrogen atmosphere. The 
mixture was warmed to room temperature and stirred for 30 min. The solution was 
cooled to 0 °C and benzyl bromide (0.64 mL, 5.39 mmol) was added dropwise. The 
reaction was continued with stirring for 9 h at room temperature. The mixture was 
quenched with methanol at 0 °C and the solvent was evaporated in vacuo. The residue 
was diluted with dichloromethane (100 mL) and washed with saturated aqueous solution 
of sodium bicarbonate (50 mL). The aqueous layer was repeatedly extracted with 
dichloromethane (3 × 50 mL). The combined extracts were washed with brine, dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (Hex/EtOAc = 4:1) to provide 
compound 44 (2.208 g, 82 %) as a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.70–7.68 
(m, 2H, Ph), 7.41–7.33 (m, 13H, Ph), 7.28–7.27 (m, 2H, Ph), 6.96–6.94 (m, 2H, Ph), 
4.95–4.90 (m, 2H, Bn), 4.86 (d, J = 10.9 Hz, 1H, Bn), 4.66–4.63 (m, 2H, PMB), 4.55 (d, 
J = 11.6 Hz, 1H, Bn), 4.50 (d, J = 10.1 Hz, 1H, H-1), 3.86 (s, 3H, OCH3), 3.84-3.78 (m, 
2H, H-6), 3.58 (d, J = 9.5 Hz, 1H, H-3), 3.53 (dd, J = 4.12, 2.1 Hz, 1H, H-5), 3.44 (t, J = 
9.7, 1H, H-2). 
13
C NMR (125 MHz, CDCl3) δ 159.3, 138.0, 137.7, 131.4, 130.3, 129.4, 
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129.0, 128.6, 128.5, 128,4, 128.2, 128.1, 127.92, 127.88, 113.9, 86.1, 85.1, 79.4, 75.9, 
75.0, 73.2, 68.4, 65.2, 55.3. HRMS (ESI, positive) calculated for C34H34DN3O5S
+
 [M + 
Na]
+
 621.2258, found 621.2250. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-
methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl-5-d)oxy)cyclohexane-1,2-diyl 
diacetate (45): Compound 44 (2.208 g, 3.69 mmol) and compound 33 (0.916 g, 3.07 
mmol) were co-evaporated from dry toluene (500 mL) three times and further dried under 
high vacuum overnight. A solution of compound 44 and 33 in anhydrous diethyl ether 
(30 mL) and anhydrous dichloromethane (10 mL) was added to a preactivated 4 Å  MS (3 
g). The mixture was stirred for 30 min at room temperature, and cooled to –40 °C. N-
Iodosuccinimide (1.797 g, 7.99 mmol) was added, and the reaction mixture was stirred 
for 20 min. Trifluoromethanesulfonic acid (136 μL, 1.53 mmol) was slowly added, and 
the reaction was warmed to –20 °C and kept stirring for 30 min. The reaction mixture 
was diluted with dichloromethane (100 mL), filtered through a Celite pad, and washed 
with 10% aqueous solution of sodium bisulfite (100 mL) and saturated aqueous solution 
of sodium bicarbonate (100 mL). The aqueous layers were extracted with 
dichloromethane (3 × 50 mL). The combined organic phase was washed with brine, dried 
over magnesium sulfate, filtered and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 3:2) to give 
compound 45 (2.212g, 92%) as a sticky liquid. 
1
H NMR (400 MHz, CDCl3) δ 7.33–7.23 
(m, 12H, Ph), 7.13–7.11 (m, 2H, Ph), 6.83 (d, J = 8.4 Hz, 2H, Ph), 5.14 (t, J = 9.2 Hz, 
1H, H-5), 5.13 (d, J = 4 Hz, 1H, H-1'), 4.92 (t, J = 10.0 Hz, 1H, H-6), 4.84 (dd, J = 25.0, 
10.5 Hz, 2H, PMB), 4.75 (d, J = 10.8 Hz, 1H, Bn), 4.60 (d, J = 11.6 Hz, 1H, Bn), 4.47 (d, 
J = 11.2 Hz, 1H, Bn), 4.40 (d, J = 11.6 Hz, 1H, Bn), 4.13 (s, 1H, H-5'), 3.93 (d, J = 10.4 
Hz, 1H, H-3'), 3.80 (dd, J = 10.6, 2.0 Hz, 1H, H-6'), 3.75 (s, 3H, -OCH3), 3.66–3.58 (m, 
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3H, H-1, H-6', H-4), 3.43–3.37 (m, 1H, H-3), 3.35 (dd, J = 10.2, 3.6 Hz, 1H, H-2'), 2.40 
(dt, J = 13.6, 4.4 Hz, 1H, H-2), 1.585 (q, J = 12.8 Hz, 1H, H-2). 
13
C NMR (100 MHz, 
CDCl3) δ 169.95, 169.61, 159.43, 138.05, 137.92, 129.92, 129.77, 128.56, 128.49, 
128.08, 127.97, 127.86, 127.77, 113.92, 99.50, 79.60, 78.40, 75.42, 74.97, 74.23, 73.67, 
73.32, 71.72, 67.52, 63.25, 58.81, 57.83, 55.32, 31.94, 20.75, 20.68. HRMS (ESI, 
positive) calculated for C38H42DN9O10
+
 [M + Na]
+
 809.3093, found 809.3079. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-(((4-
methoxybenzyl)oxy)methyl)tetrahydro-2H-pyran-2-yl-5-d)oxy)cyclohexane-1,2-diol 
(46): Sodium methoxide (4.37 M in methanol, 64 μL, 0.28 mmol) was added dropwise to 
a solution of compound 45 (2.196 g, 2.79 mmol) in methanol (30 mL) and 
dichloromethane (10 mL). The reaction mixture was stirred at room temperature for 10 h. 
The reaction mixture was neutralized with Amberlite IR-120 (H
+
 form) resin, filtered, 
and concentrated. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 3:2) to give compound 46 (1.215 g, 92%) as a clear oil. 
1
H NMR (500 
MHz, CDCl3) δ 7.35–7.23 (m, 10H, Ph), 7.14–7.10 (m, 2H, Ph), 6.85–6.81 (m, 2H, Ph), 
5.13 (d, J = 3.2 Hz, 1H, H-1), 4.88 (dd, J = 31.2, 10.8 Hz, 2H, PMB), 4.75 (d, J = 10.4 
Hz, 1H, Bn), 4.60 (d, J = 12.0 Hz, 1H, Bn), 4.48 (d, J = 10.8 Hz, 1H, Bn), 4.40 (d, J = 
11.6 Hz, 1H, Bn), 4.19 (s, 1H, OH), 4.07 (t, J = 2.0, 1H, H-5'), 3.96 (d, J = 10.4 Hz, 1H, 
H-3'), 3.78 (dd, J = 10.6, 2.8 Hz, 1H, H-6'), 3.75 (s, 3H, OCH3), 3.66–3.62 (m, 2H, H-2', 
H-6'), 3.49–3.38 (m, 3H, H-4, H-5, H-1), 3.25 (dd, J = 5.6, 2.8 Hz, 2H, H-3, H-6), 2.33–
2.28 (m, 1H, H-2), 1.49–1.45 (m, 1H, H-2). 13C NMR (125 MHz, CDCl3) δ 159.45, 
137.90, 137.67, 129.87, 129.83, 128.62, 128.56, 128.18, 128.11, 127.98, 127.85, 113.92, 
99.71, 84.12, 81.03, 75.98, 75.76, 75.46, 75.04, 73.35, 71.73, 67.61, 64.38, 59.76, 58.88, 
55.34, 32.23. HRMS (ESI, positive) calculated for C34H38DN9O8
+
 [M + Na]
+
 725.2882, 
found 725.2876. 
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[4'-
2
H]-Paromamine (47): Trimethylphosphine (1 M solution in THF, 2.21 mL) was 
added to a solution of compound 46 (0.259 g, 0.37 mmol) in THF (9 mL) and 0.1 M 
NaOH (3 mL). The reaction mixture was stirred at 50 °C for 2 h. After cooling down to 
room temperature, the solution was evaporated under reduced pressure. The material was 
dissolved in a mixture of acetic acid (2 mL), water (6 mL) and methanol (6 mL). The 
solution was deaerated by evacuating the air in the flask and refilling it with nitrogen five 
times. Palladium hydroxide on carbon (20%, Degussa type, 0.095 g) was added and the 
solution was charged with hydrogen. The reaction mixture was stirred at room 
temperature under hydrogen gas for 24 h. The solution was filtered through a Celite pad 
and concentrated. The residue was purified by chromatography on Amberlite CG-50 resin 
(NH4
+
 form) (2.5% concentrated ammonium hydroxide in water), concentrated, acidified 
with hydrochloric acid (pH ca. 4), and lyophilized to provide compound 47 (0.086 g, 
73%) as an oily solid. 
1
H NMR (400 MHz, D2O) δ 5.65 (d, J = 4.0 Hz, 1H, H-1'). 3.96–
3.79 (m, 4H, H-3', H-5, H-6', H-5'), 3.75–3.72 (m, 1H, H-6'), 3.67 (dd, J = 12.0, 6.5 Hz, 
1H, H-6), 3.61–3.55 (m, 2H, H-1, H-4), 3.45 (dd, J = 12.2, 6.6, 1H, H-2'), 3.37–3.31 (m, 
1H, H-3), 2.50 (dt, J = 12.6, 4.3 Hz, 1H, H-2), 1.86 (q, J = 12.6 Hz, 1H, H-2) . 
13
C NMR 
(150 MHz, D2O) δ 97.1 (C-1'), 80.4 (C-5), 74.7 (C-6), 73.6 (C-5'), 72.3 (C-4), 69.0 (C-
4'), 60.3 (C-6'), 54.0 (C-2'), 49.6 (C-3), 48.8 (C-1), 28.3 (C-2). HRMS (ESI, positive) 
calculated for C12H24DN3O7
+
 [M + H]
+
 325.1829, found 325.1834. 
 
4.2.10. Synthesis of [3'-
2
H]-Paromamine (65) 
The overall synthetic scheme is shown in Scheme 4-4. Yu-Cheng Yeh synthesized 
this compound. 
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Scheme 4-4. Synthetic scheme for the preparation of [3'-
2
H]-paromamine. 
(3aR,5S,6S)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetrahydrofuro[2,3-
d][1,3]dioxol-6-d-6-ol (52): Compound 51 was prepared as previously described.
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Compound 51 (1.059 g, 2.90 mmol) was dissolved in 5% solution of sodium hydroxide in 
methanol (0.1 M, 29 mL), and the reaction mixture was stirred for 2 h. The solvent was 
removed under reduced pressure, and the residue was dissolved in dichloromethane (40 
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mL). The organic layer was washed with water (40 mL × 2), brined, dried over sodium 
sulfate, filtered, and concentrated. The crude product was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 1:1) to give compound 52 (0.652 g, 86%) as 
a white solid. 
1
H NMR (500 MHz, CDCl3) δ 5.95 (d, J = 3.6 Hz, 1H, H-1), 4.53 (d, J = 
3.7 Hz, 1H, H-2), 4.34 (ddd, J = 7.6, 6.2, 5.4 Hz, 1H, H-5), 4.17 (dd, J = 8.6, 6.2 Hz, 1H, 
H-6), 4.07 (d, J = 7.6 Hz, 1H, H-4), 3.98 (dd, J = 8.6, 5.4 Hz, 1H, H-6), 2.48 (s, 1H, OH), 
1.50 (d, J = 0.7 Hz, 3H, Me), 1.44 (d, J = 0.7 Hz, 3H, Me), 1.36 (d, J = 0.7 Hz, 3H, Me), 
1.32 (d, J = 0.7 Hz, 3H, Me). 
13
C NMR (125 MHz, CDCl3) δ 111.99(acetal), 109.82 
(acetal), 105.47 (C-1), 85.18 (C-2), 81.21 (C-4), 73.71 (C-5), 67.83 (C-6), 27.01 (Me), 
26.92 (Me), 26.34 (Me), 25.29 (Me). HRMS (ESI, positive) calculated for C12H19DO6
+
 
[M + Na]
+
 284.1215, found 284.1215. 
(3aR,5R,6S)-6-(benzyloxy)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2,2-dimethyltetra-
hydrofuro[2,3-d][1,3]dioxole-6-d (53): Sodium hydride (60% dispersion in mineral oil, 
1.15 g, 28.70 mmol) was added to a solution of compound 52 (6.25 g, 23.92 mmol) in 
dimethylformamide (205 mL) at 0 °C. The reaction mixture was stirred at room 
temperature for 30 min. Benzyl bromide (3.5 mL, 28.70 mmol) was added at 0 °C, and 
the reaction mixture was stirred for 15 h. Methanol (10 mL) was added slowly at 0 °C. 
The reaction solution was concentrated under reduced pressure. The residue was diluted 
with dichloromethane (200 mL), and washed with water (150 mL × 2). The combined 
aqueous layers were extracted with dichloromethane (200 mL × 2). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and 
concentrated under reduced pressure. The crude compound was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 4:1) to provide compound 53 (8.047 g, 96%) 
as a white solid. 
1
H NMR (400 MHz, CDCl3) δ 7.38–7.28 (m, 5H, Ph), 5.90 (d, J = 3.7 
Hz, 1H), 4.72–4.61 (m, 2H, 2×Bn), 4.58 (d, J = 3.7 Hz, 1H, H-2), 4.37 (dt, J = 7.7, 6.0 
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Hz, 1H, H-5), 4.17–4.08 (m, 2H, H-6, H-4), 4.05–3.94 (m, 1H, H-6), 1.49 (d, J = 0.6 Hz, 
3H, OAc), 1.43 (d, J = 0.7 Hz, 3H, OAc), 1.37 (d, J = 0.7 Hz, 3H, OAc), 1.31 (s, 3H, 
OAc). HRMS (ESI, positive) calculated for C19H25DO6
+
 [M + Na]
+
 374.1684, found 
374.1690. 
(3R,4S,5R,6R)-6-(acetoxymethyl)-4-(benzyloxy)tetrahydro-2H-pyran-2,3,5-triyl-4-d 
triacetate (54): Compound 53 (8.047 g, 22.90 mmol) was dissolved in acetic acid (69 
mL) and H2O (46 mL), and the reaction mixture was stirred at 90 °C for 12 h. The 
reaction solution was evaporated under reduced pressure and co-evaporated with toluene 
three times. The residue was dissolved in pyridine (0.4 M, 57 mL) and acetic anhydride 
(0.4 M, 57 mL) was added at 0 °C. The reaction mixture was stirred at room temperature 
for 6 h. The reaction solution was evaporated under reduced pressure and co-evaporated 
with toluene three times. The residue was dissolved in ethyl acetate (100 mL) and washed 
with saturated aqueous solution of sodium bicarbonate (60 mL × 2) and brine. The 
organic layer was dried over magnesium sulfate, filtered, and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 1:1) to provide compound 54 (9.47 g, 94%) as a clear oil. 
1
H NMR (500 
MHz, CDCl3) α isomer δ 7.36–7.21 (m, 5H, Ph), 6.32 (d, J = 3.6 Hz, 1H), 5.19 – 5.12 (m, 
1H, H-4), 5.06 (d, J = 3.7 Hz, 1H, H-2), 4.71 (d, J = 11.8 Hz, 1H, Bn), 4.65–4.56 (m, 
1H), Bn, 4.21–4.18 (m, 1H, H-6), 4.10–4.05 (m, 1H, H-6), 4.02 (ddd, J = 10.3, 4.5, 2.4 
Hz, 1H, H-5), 2.17 (s, 3H, OAc), 2.08 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.97 (s, 3H). β 
isomer δ 7.36–7.21 (m, 5H, Ph), 5.66 (d, J = 8.2 Hz, 1H, H-1), 5.19–5.12 (m, 2H, H-2, H-
4), 4.65–4.56 (m, 2H, 2×Bn), 4.21 (ddd, J = 12.5, 9.9, 4.7 Hz, 1H, H-6), 4.08 (td, J = 
12.4, 2.4 Hz, 1H, H-6), 3.74 (ddt, J = 10.1, 4.9, 2.5 Hz, 1H, H-5), 2.10 (s, 3H, OAc), 2.07 
(s, 3H, OAc), 1.98 (s, 6H, 2×OAc). 
13
C (125 MHz, CDCl3) α isomer 170.75 (O(C=O)), 
169.61 (O(C=O)), 169.29 (O(C=O)), 168.79 (O(C=O)), 137.99 (Ph), 128.49 (Ph), 127.87 
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(Ph), 127.55 (Ph), 89.54 (C-1), 74.77 (Bn), 71.50 (C-2), 70.32 (C-5), 69.07 (C-4), 61.87 
(C-6), 20.93 (OAc), 20.76 (OAc), 20.74 (OAc), 20.62 (OAc). β isomer 170.72 (O(C=O)), 
169.32 (O(C=O)), 169.24 (O(C=O)), 169.11 (O(C=O)), 137.63 (Ph), 128.53 (Ph), 127.99 
(Ph), 127.83 (Ph), 92.04(C-1), 74.18 (Bn), 73.04 (C-5), 71.55 (C-2), 69.07 (C-4), 61.87 
(C-6), 20.89 (OAc), 20.77 (OAc), 20.76 (OAc), 20.73 (OAc). HRMS (ESI, positive) 
calculated for C21H25DO10
+
 [M + Na]
+
 462.1481, found 462.1487. 
(2R,3R,4S,5R,6S)-2-(acetoxymethyl)-4-(benzyloxy)-6-(phenylthio)tetrahydro-2H-
pyran-3,5-diyl-4-d diacetate (55): Thiophenol (2.43 mL, 23.7 mmol) and boron 
trifluoride diethyl etherate (6.3 mL, 23.7 mmol) were added to a solution of compound 54 
(9.47 g, 21.55 mmol) in dichloromethane (215 mL) at 0 °C. The reaction mixture was 
warmed to room temperature and stirred for 5 h. The reaction mixture was quenched by 
adding saturated aqueous solution of sodium bicarbonate (150 mL) at 0 °C. The aqueous 
layer was extracted with dichloromethane (100 mL × 3). The combined organic layers 
were washed with brine, dried over sodium sulfate, filtered, and concentrated under 
reduced pressure. The crude product was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 2:1) to provide compound 55 (6.35 g, 60%) as a clear solid. 
1
H 
NMR (500 MHz, CDCl3) δ 7.52–7.45 (m, 2H, Ph), 7.34–7.25 (m, 6H, Ph), 7.23–7.19 (m, 
2H, Ph), 5.08–5.04 (m, 2H, H-4, H-2), 4.64 (d, J = 10.0 Hz, 1H, H-1), 4.63–4.57 (m, 2H, 
2×Bn), 4.19–4.15 (m, 2H, 2×H-6), 3.63 (ddd, J = 10.1, 5.1, 3.2 Hz, 1H, H-5), 2.07 (s, 3H, 
OAc), 2.04 (s, 3H, OAc), 1.96 (s, 3H, OAc). 
13
C NMR (125 MHz, CDCl3) δ 170.76 
(O(C=O)), 169.44 (O(C=O)), 169.31 (O(C=O)), 137.80 (Ph), 132.71 (Ph), 132.63 (Ph), 
128.96 (Ph), 128.57 (Ph), 128.16 (Ph), 127.99 (Ph), 127.88 (Ph), 86.34 (C-1), 76.21 (C-
5), 74.27 (Bn), 71.41 (C-2), 69.69 (C-4), 62.67 (C-6), 21.06 (OAc), 20.87 (OAc), 20.84 
(OAc). HRMS (ESI, positive) calculated for C25H27DO8S
+
 [M + Na]
+
 512.1460, found 
512.1465. 
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(2R,3R,4S,5R,6S)-4-(benzyloxy)-2-(hydroxymethyl)-6-(phenylthio)tetrahydro-2H-
pyran-4-d-3,5-diol (56): Sodium methoxide (5.4 M solution in methanol, 0.24 mL, 1.29 
mmol) was added to a solution of compound 55 (6.35 g, 12.97 mmol) in methanol (130 
mL). The reaction mixture was stirred for 10 h, neutralized with Amberlite IR-120 (H
+
 
form) resin, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography on silica gel (EtOAc/DCM = 1:1) to provide 
compound 56 (4.37 g, 93%) as a white solid. No characterization of this compound was 
conducted. 
(4aR,6S,7R,8R,8aR)-8-(benzyloxy)-2-phenyl-6-(phenylthio)hexahydropyrano[3,2-
d][1,3]dioxin-8-d-7-ol (57): p-Toluenesulfonic acid monohydrate (0.247 g, 1.30 mmol) 
and compound 56 (4.72 g, 12.99 mmol) was co-evaporated from dry toluene (30 mL) 
three times and further dried under high vacuum overnight. Compound 56 and p-
toluenesulfonic acid were dissolved in dimethylformamide, and benzaldehyde dimethyl 
acetal (3.90 mL, 26 mmol) was added. The reaction mixture stirred at 70 °C for 10 h 
under house vacuum. The solvent was removed under reduced pressure. The residue was 
diluted with dichloromethane (70 mL), and washed with saturated aqueous solution of 
sodium bicarbonate (60 mL × 2). The combined aqueous layers were extracted with 
dichloromethane (70 mL × 2). The combined organic layers were washed with brine, 
dried over sodium sulfate, filtered, and concentrated. The crude product was purified by 
flash column chromatography on silica gel (Hex:EtOAc = 1:1) to provide compound 57 
(4.44 g, 76%) as a white solid. 
1
H NMR (600 MHz, CDCl3) δ 7.56–7.53 (m, 2H, Ph), 
7.51–7.47 (m, 2H, Ph), 7.40–7.35 (m, 6H, Ph), 7.35–7.31 (m, 5H, Ph), 5.58 (s, 1H, 
PhCHO2), 4.96 (d, J = 11.5 Hz, 1H, Bn), 4.80 (d, J = 11.6 Hz, 1H, Bn), 4.64 (d, J = 9.8 
Hz, 1H, H-1), 4.39 (dd, J = 10.5, 5.0 Hz, 1H, H-6), 3.80 (t, J = 10.3 Hz, 1H, H-6), 3.66 
 220 
(d, J = 9.4 Hz, 1H, H-4), 3.58–3.49 (m, 2H, H-2, H-5). 13C NMR (150 MHz, CDCl3) δ 
138.30 (Ph), 137.31 (Ph), 133.32 (Ph), 131.44 (Ph), 129.17 (Ph), 129.15 (Ph), 128.60 
(Ph), 128.50 (Ph), 128.39 (Ph), 128.25 (Ph), 128.02 (Ph), 126.13 (Ph), 101.40 (PhCHO2), 
88.59 (C-1), 81.17 (C-4), 74.91 (Bn), 72.31 (C-2), 70.87 (C-5), 68.76 (C-6). HRMS (ESI, 
positive) calculated for C26H25DO5S
+
 [M + Na]
+
 474.1456, found 474.1459. 
(4aR,6S,7S,8R,8aR)-8-(benzyloxy)-2-phenyl-6-(phenylthio)hexahydropyrano[3,2-
d][1,3]dioxin-8-d-7-ol (58): Dess-Martin periodinane (8.341 g, 19.66 mmol) was added 
to a solution of compound 57 (4.44 g, 9.83 mmol) in dichloromethane (98 mL). The 
reaction mixture was stirred for 12 h. Saturated aqueous solutions of sodium sulfite (50 
mL) and sodium bicarbonate (50 mL) were added, and the reaction mixture was stirred 
for additional 30 min. The organic layer was washed with saturated aqueous solutions of 
sodium sulfite (30 mL) and sodium bicarbonate (90 mL) three timed. The combined 
organic layers were washed with brine, dried over magnesium sulfate, filtered, and 
concentrated. The resulting ketone was dissolved in methanol (98 mL), and cooled to 0 
°C. Sodium borohydride (0.470 g, 11.80 mmol) was added portionwise during 10 min. 
The reaction mixture was stirred at 0 °C for 10 min and at room temperature for 1 h. The 
reaction was quenched by adding saturated aqueous solution of ammonium chloride (50 
mL). The solvent was evaporated under reduced pressure. The residue was dissolved in 
dichloromethane (100 mL) and washed with water (100 mL). The aqueous layer was 
extracted with dichloromethane (120 mL × 3). The combined organic layers were washed 
with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was 
purified by flash column chromatography on silica gel (EtOAc/DCM = 1:9) to give 
compound 58 (2.51 g, 57%) as a white solid. Compound 58 was unstable, only 
1
H NMR 
and mass spectra were measured. 
1
H NMR (400 MHz, CDCl3) δ 7.55–7.45 (m, 4H, Ph), 
7.43–7.26 (m, 11H, Ph), 5.62 (s, 1H, PhCHO2), 4.93–4.81 (m, 2H, H-1, Bn), 4.76 (d, J = 
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12.1 Hz, 1H, Bn), 4.38–4.28 (m, 2H, H-6, H-2), 4.17 (d, J = 9.4 Hz, 1H, H-4), 3.93 (t, J = 
10.3 Hz, 1H, H-6), 3.49–3.36 (m, 1H, H-5), 2.82 (d, J = 1.8 Hz, 1H, OH). HRMS (ESI, 
positive) calculated for C26H25DO5S
+
 [M + Na]
+
 474.1456, found 474.1458. 
 (4aR,6S,7S,8S,8aR)-8-(benzyloxy)-2-phenyl-6-(phenylthio)hexahydropyrano[3,2-
d][1,3]dioxin-7-yl-8-d trifluoromethanesulfonate (59): Trifluoromethanesulfonic 
anhydride (4.69 mL, 27.9 mmol) was added to a solution of compound 58 (2.52 g, 5.58 
mmol) in dry pyridine (28 mL) and dry dichloromethane (28 mL) at –15 °C. The reaction 
mixture was warmed to room temperature, and diluted with ethyl acetate (50 mL). The 
reaction was quenched by adding few drops of water. The reaction solution was washed 
with saturated aqueous solutions of ammonium chloride (40 mL) and sodium bicarbonate 
(40 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered, 
and concentrated under reduced pressure. The crude product was used in next step 
without further purification. 
(4aR,6S,7R,8R,8aS)-7-azido-8-(benzyloxy)-2-phenyl-6-(phenylthio)hexahydro-
pyrano[3,2-d][1,3]dioxine-8-d (60): Sodium azide (1.814 g, 27.9 mmol) was added to a 
solution of the crude compound 59 in dimethylformamide (56 mL) at 0 °C. The reaction 
mixture was stirred at room temperature for 10 h, and diluted with ethyl acetate (50 mL). 
The organic layer was washed with water (40 mL × 3). The combined aqueous layers 
were extracted with ethyl acetate (60 mL × 2). The combined organic layers were washed 
with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. 
The crude product was purified by flash column chromatography on silica gel 
(Hex/EtOAc = 4:1) to provide compound 60 (2.32 g, 87%) as a clear oil. Compound 60 
was unstable, only 
1
H NMR and mass spectra were measured. 
1
H NMR (400 MHz, 
CDCl3) δ 7.60–7.54 (m, 2H, Ph), 7.50–7.44 (m, 2H, Ph), 7.42–7.28 (m, 11H, Ph), 5.57 (s, 
1H, PhCHO2), 4.91 (d, J = 10.9 Hz, 1H, Bn), 4.78 (d, J = 10.9 Hz, 1H, Bn), 4.49 (d, J = 
 222 
10.2 Hz, 1H, H-1), 4.39 (dd, J = 10.5, 5.0 Hz, 1H, H-6), 3.84–3.75 (m, 1H, H-6), 3.63 (d, 
J = 9.4 Hz, 1H, H-4), 3.46 (ddd, J = 10.0, 9.4, 5.0 Hz, 1H, H-5), 3.36 (d, J = 10.3 Hz, 1H, 
H-2). HRMS (ESI, positive) calculated for C26H24DN3O5S
+
 [M + Na]
+
 499.1521, found 
499.1518. 
(2R,3S,4R,5R,6S)-5-azido-4-(benzyloxy)-2-(hydroxymethyl)-6-(phenylthio)tetra-
hydro-2H-pyran-4-d-3-ol (61): p-toluenesulfonic acid monohydrate (0.046 g, 0.242 
mmol) was added to a solution of compound 60 (1.154 g, 2.42 mmol) in methanol (24 
mL). The reaction mixture was stirred for 14 h. The solvent was removed under reduced 
pressure, and the residue was diluted with ethyl acetate (25 mL). The organic layer was 
washed with saturated aqueous solution of sodium bicarbonate (20 mL × 2). The 
combined aqueous layers were extracted with ethyl acetate (30 mL × 2). The combined 
organic layers were washed with brine, dried over magnesium sulfate, filtered, and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 1:1) to give compound 61 (0.895 g, 95%) as 
a white solid. 
1
H NMR (500 MHz, CDCl3) δ 7.57–7.51 (m, 2H, Ph), 7.39–7.35 (m, 4H, 
Ph), 7.34–7.32 (m, 4H, Ph), 4.95 (d, J = 11.2 Hz, 1H, Bn), 4.76 (d, J = 11.3 Hz, 1H, Bn), 
4.48 (d, J = 10.1 Hz, 1H, H-1), 3.87 (dd, J = 12.0, 3.3 Hz, 1H, H-6), 3.76 (dd, J = 12.0, 
4.9 Hz, 1H, H-6), 3.54 (d, J = 9.7 Hz, 1H, H-4), 3.32 (ddd, J = 10.1, 5.0, 3.6 Hz, 2H, H-5, 
H-2). 
13
C NMR (125 MHz, CDCl3) δ 137.87 (Ph), 133.44 (Ph), 131.34 (Ph), 129.27 (Ph), 
128.89 (Ph), 128.65 (Ph), 128.41 (Ph), 128.29 (Ph), 86.56 (C-1), 79.48 (C-5), 75.58 (Bn), 
70.31 (C-4), 65.00 (C-2), 62.57 (C-6). HRMS (ESI, positive) calculated for 
C19H20DN3O4S
+
 [M + Na]
+
 411.1208, found 411.1212. 
(2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((benzyloxy)methyl)-2-(phenylthio)-
tetrahydro-2H-pyran-4-d (62): Sodium hydride (60% dispersion in mineral oil, 0.216 g, 
5.41 mmol) was added to a solution of compound 61 (0.841 g, 2.16 mmol) in 
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dimethylformamide (22 mL) at 0 °C. The reaction mixture was stirred at room 
temperature for 30 min. Benzyl bromide (0.65 mL, 5.41 mmol) was added at 0 °C, and 
the reaction mixture was stirred for 11 h. Methanol (5 mL) was added slowly at 0 °C. The 
reaction solution was concentrated under reduced pressure. The residue was diluted with 
dichloromethane (30 mL), and washed with water (20 mL × 3). The combined aqueous 
layers were extracted with dichloromethane (30 mL × 3). The combined organic layers 
were washed with brine, dried over sodium sulfate, filtered, and concentrated under 
reduced pressure. The crude compound was purified by flash column chromatography on 
silica gel (Hex/EtOAc = 3:1) to provide compound 62 (1.189 g, 97%) as a white solid. 
1
H 
NMR (600 MHz, CDCl3) δ 7.62–7.58 (m, 2H, Ph), 7.36–7.23 (m, 16H, Ph), 7.22–7.18 
(m, 2H, Ph), 4.86 (d, J = 10.5 Hz, 1H, Bn), 4.82 (d, J = 10.6 Hz, 1H, Bn), 4.78 (d, J = 
10.9 Hz, 1H, Bn), 4.61 (d, J = 12.0 Hz, 1H, Bn), 4.58 (d, J = 10.9 Hz, 1H, Bn), 4.54 (d, J 
= 12.0 Hz, 1H, Bn), 4.41 (d, J = 10.2 Hz, 1H, H-1), 3.77 (dd, J = 10.9, 2.0 Hz, 1H, H-6), 
3.74 (dd, J = 11.0, 4.2 Hz, 1H, H-6), 3.60 (d, J = 9.8 Hz, 1H H-4), 3.47 (ddd, J = 9.8, 4.2, 
2.0 Hz, 1H, H-5), 3.34 (d, J = 10.2 Hz, 1H, H-2). 
13
C NMR (150 MHz, CDCl3) δ 138.33 
(Ph), 137.98 (Ph), 137.74 (Ph), 133.76 (Ph), 131.29 (Ph), 129.11 (Ph), 128.65 (Ph), 
128.60 (Ph), 128.50 (Ph), 128.48 (Ph), 128.33 (Ph), 128.14 (Ph), 128.02 (Ph), 127.97 
(Ph), 127.74 (Ph), 127.70 (Ph), 86.08 (C-1), 79.46 (C-5), 77.60 (C-4), 75.97 (Bn), 75.18 
(Bn), 73.57 (Bn), 68.87 (C-6) 65.11 (C-2). HRMS (ESI, positive) calculated for 
C33H32DN3O4S
+
 [M + Na]
+
 591.2147, found 591.2149. 
(1S,2S,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-((be-
nzyloxy)methyl)tetrahydro-2H-pyran-2-yl-4-d)oxy)cyclohexane-1,2-diyl diacetate 
(63): Compound 33 (0.087 g, 0.293 mmol) and compound 62 (0.200 g, 0.352 mmol) were 
co-evaporated from dry toluene three times and further dried under high vacuum 
overnight. A solution of compound 33 and 62 in anhydrous diethyl ether (3 mL) and 
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anhydrous dichloromethane (1 mL) was then added to preactivated 4 Å  molecular sieves. 
After stirring for 30 min at room temperature, the mixture was cooled to –40 °C. N-
Iodosuccinimide (0.171 g, 0.762 mmol) was added, and the reaction mixture was stirred 
for 20 min. Trifluoromethanesulfonic acid (0.013 mL, 0.147 mmol) was slowly added, 
and the reaction was warmed to –20 °C and kept stirring for 30 min. Sodium bisulfite 
(0.1 g), sodium bicarbonate (0.1 g), and water (1 mL) were added at 0 °C, and the 
mixture was stirred for 10 min at room temperature. The reaction mixture was diluted 
with dichloromethane (10 mL), filtered through a Celite pad, and washed with a saturated 
solution of aqueous sodium bicarbonate (15 mL). The aqueous layers were extracted with 
dichloromethane (15 mL × 3), and the combined organic phase was washed with brine, 
dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (Hex/EtOAc = 2:1) to give 
compound 63 (0.135 g, 61%) as a clear oil. 
1
H NMR (600 MHz, CDCl3) δ 7.36–7.26 (m, 
13H, Ph), 7.18–7.14 (m, 2H, Ph), 5.17–5.11 (m, 2H, H-1', H-5), 4.92 (t, J = 10.0 Hz, 1H, 
H-6), 4.88 (d, J = 10.5 Hz, 1H, Bn), 4.82 (d, J = 10.7 Hz, 1H, Bn), 4.79 (d, J = 10.9 Hz, 
1H, Bn), 4.64 (d, J = 12.1 Hz, 1H, Bn), 4.54 (d, J = 10.9 Hz, 1H, Bn), 4.49 (d, J = 12.1 
Hz, 1H, Bn), 4.18–4.12 (m, 1H, H-5'), 3.83 (dd, J = 10.8, 2.9 Hz, 1H, H-6'), 3.78 (d, J = 
10.1 Hz, 1H, H-4'), 3.68 (dd, J = 10.8, 2.1 Hz, 1H, H-6'), 3.66–3.58 (m, 2H, H-4, H-1), 
3.41 (ddd, J = 12.5, 10.0, 4.6 Hz, 1H, H-3), 3.36 (d, J = 3.8 Hz, 1H, H-2'), 2.39 (dt, J = 
13.4, 4.5 Hz, 1H, H-2), 2.09 (s, 3H, OAc), 2.08 (s, 3H, OAc), 1.65–1.54 (m, 1H, H-2). 
13
C NMR (150 MHz, CDCl3) δ 169.99 (O(C=O)), 169.65 (O(C=O)), 138.04 (Ph), 137.94 
(Ph), 137.91 (Ph), 128.60 (Ph), 128.56 (Ph), 128.54 (Ph), 128.12 (Ph), 128.04 (Ph), 
128.02 (Ph), 127.93 (Ph), 127.90 (Ph), 127.85 (Ph), 99.51 (C-1'), 78.44 (C-4), 78.19 (C-
4'), 75.43 (Bn), 75.14 (Bn), 74.24 (C-6), 73.74 (Bn), 73.68 (C-5), 71.83 (C-5'), 68.08 (C-
6'), 63.23 (C-2'), 58.82 (C-3), 57.85 (C-1), 31.97 (C-2), 20.79 (OAc), 20.72 (OAc). 
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HRMS (ESI, positive) calculated for C37H40DN9O9
+
 [M + Na]
+
 779.2982, found 
779.3050. 
(1S,2R,3R,4S,6R)-4,6-diazido-3-(((2S,3R,4R,5S,6R)-3-azido-4,5-bis(benzyloxy)-6-
((benzyloxy)methyl)tetrahydro-2H-pyran-2-yl-4-d)oxy)cyclohexane-1,2-diol (64): 
Sodium methoxide (5.4 M in methanol, 0.006 mL, 0.032 mmol) was added dropwise to a 
solution of compound 63 (0.245 g, 0.324 mmol) in methanol (3.2 mL). The reaction 
mixture was stirred at room temperature for 8 h and then neutralized with Amberlite IR-
120 (H
+
 form) resin, filtered and concentrated. The residue was purified by flash column 
chromatography on silica gel (Hex/EtOAc = 3:2) to give compound 64 (0.187 g, 86%) as 
a pale yellow oil. 
1
H NMR (400 MHz, CDCl3) δ 7.37–7.27 (m, 13H, Ph), 7.18–7.12 (m, 
2H, Ph), 5.15 (d, J = 3.6 Hz, 1H, H-1'), 4.93 (d, J = 10.6 Hz, 1H, Bn), 4.85 (d, J = 10.6 
Hz, 1H, Bn), 4.79 (d, J = 10.8 Hz, 1H, Bn), 4.65 (d, J = 12.0 Hz, 1H, Bn), 4.54 (d, J = 
10.8 Hz, 1H, Bn), 4.49 (d, J = 12.0 Hz, 1H, Bn), 4.21 (s, 1H, OH), 4.10 (ddd, J = 10.1, 
3.4, 2.1 Hz, 1H, H-5'), 3.85–3.75 (m, 2H, H-6', H-4'), 3.69 (dd, J = 10.8, 2.0 Hz, 1H, H-
6'), 3.65 (d, J = 3.6 Hz, 1H, H-5), 3.56–3.38 (m, 3H, H-6, H-1, H-4), 3.30–3.22 (m, 2H, 
H-3, H-2'), 2.37–2.24 (m, 1H, H-2), 1.56–1.41 (m, 1H, H-2). HRMS (ESI, positive) 
calculated for C33H36DN9O7
+
 [M + Na]
+
 695.2771, found 695.2770. 
[3'-
2
H]-Paromamine (65): Trimethylphosphine (1 M solution in THF, 1.418 mL) was 
added to a solution of compound 64 (0.159 g, 0.236 mmol) in THF (5.9 mL) and 0.1 M 
NaOH (2 mL). The reaction mixture was stirred at 50 °C for 2 h. After cooling down to 
room temperature, the solution was evaporated under reduced pressure. The material was 
dissolved in a mixture of acetic acid (1.3 mL), water (3.9 mL) and methanol (3.9 mL). 
The solution was deaerated by evacuating the air in the flask and refilling it with nitrogen 
five times. Palladium hydroxide on carbon (20%, Degussa type, 0.1 g) was added and the 
solution was charged with hydrogen. The reaction mixture was stirred at room 
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temperature under hydrogen gas for 24 h. The solution was filtered through a Celite pad 
and concentrated. The residue was purified by chromatography on Amberlite CG-50 resin 
(NH4
+
 form) (2.5% concentrated ammonium hydroxide in water), concentrated, acidified 
with hydrochloric acid (pH ca. 4), and lyophilized to provide compound 65 (0.067 g, 
81%) as an oily solid. 
1
H NMR (500 MHz, D2O) δ 5.72 (d, J = 3.9 Hz, 1H, H-1'), 3.98 
(dd, J = 12.0, 2.2 Hz, 1H, H-6'), 3.95 (dd, J = 10.2, 9.1 Hz, 1H, H-5), 3.89 (ddd, J = 9.9, 
6.6, 2.1 Hz, 1H, H-5'), 3.80 (dd, J = 12.1, 6.6 Hz, 1H, H-6'), 3.73 (t, J = 9.2 Hz, 1H, H-6), 
3.69–3.61 (m, 2H, H-1, H-4), 3.55 (d, J = 9.9 Hz, 1H, H-4'), 3.51 (d, J = 4.0 Hz, 1H, H-
2'), 3.40 (ddd, J = 12.4, 10.3, 4.2 Hz, 1H, H-3), 2.57 (dt, J = 12.7, 4.3 Hz, 1H, H-2), 1.93 
(q, J = 12.6 Hz, 1H, H-2). 
13
C NMR (125 MHz, D2O) δ 97.07 (C-1'), 80.33 (C-5), 74.69 
(C-6), 73.65 (C-5'), 72.33 (C-4), 69.30 (C-4'), 60.36 (C-6'), 53.91 (C-2'), 49.62 (C-3), 
48.85 (C-1), 28.27 (C-2). HRMS (ESI, positive) calculated for C12H24DN3O7
+
 [M + H]
+
 
325.1829, found 325.1824. 
 
4.3. RESULTS AND DISCUSSION 
4.3.1. Gene Analysis 
 Sequence analysis led to the assignment of AprD3 as an NAD-dependent 
dehydrogenase and AprD4 as a member of the radical S-adenosyl-L-methionine (SAM) 
family of enzymes. The catalytic [4Fe-4S] cluster characteristic of radical SAM enzyme 
is typically coordinated by a highly conserved CxxxCxxC motif, however, in the case of 
AprD4, a noncanonical CxxxCxxxC motif is found instead. Recently a number of 
examples of radical SAM enzymes with different [4Fe-4S]-binding motifs have been 
reported. PhnJ, which catalyzes cleavage of the C-P bond of phosphonates, has a 
Cx2Cx21Cx5C motif.
209-210
 HmdB, which is involved in the biosynthesis of hydrogenase 
 227 
cofactor, contains a Cx5Cx2C cluster-binding motif.
211
 QueE participates in the synthesis 
of 7-carboxy-7-deazaguanine and contains a Cx14Cx2C cluster-binding motif.
212
 ThiC, the 
thiamine pyrimidine synthase found in plants and bacteria, has a Cx2Cx4C motif.
213
 Also 
GenD1 has a Cx4Cx2C motif.
81
 Although these radical SAM enzymes do indeed exhibit 
atypical [4Fe-4S] binding motifs, the noncanonical motif of AprD4 still raises questions, 
as to whether AprD4 operates as a radical SAM enzyme and the mechanism by which 
C3'-deoxygenation is effected during the biosynthesis of aminoglycosides. 
 
4.3.2. Purification of AprD3 and AprD4 
Both the aprD3 and aprD4 genes were amplified by polymerase chain reaction 
from S. tenebrarius genomic DNA, cloned in to a pET28 vector, and heterologously 
overexpressed in Escherichia coli (Figure 4-6 for AprD3 and Figure 4-7 for AprD4). The 
His6-tagged AprD4 was isolated from cell lysates using a nickel-nitrilotriacetate (Ni-
NTA) affinity column and was then subjected to anaerobic incubation with 
[Fe(NH)4(SO4)2] and Na2S in a Coy anaerobic chamber with an atmosphere of more than 
97% N2 and 3% H2 to reconstituted the [4Fe-4S] cluster. Iron
153 
and Sulfur analysis
154
 of 
the reconstituted AprD4 revealed the presence of 9.2 ± 0.6 equivalents of iron and 8.2 ± 
0.7 equivalents of sulfide per AprD4 monomer. These results indicated the presence of 
two [4Fe-4S] clusters bound to each AprD4 monomer. Likewise, the UV/Vis absorption 
spectrum of the reconstituted AprD4 exhibits a shoulder around λ = 420 nm, which is 
typical of [4Fe-4S]
2+
-containing proteins.
214-215
 Furthermore, addition of sodium 
dithionite (2mM) to the reconstituted enzyme led to a decrease in the absorbance at λ = 
420 nm, implying reduction of the cluster.  
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Figure 4-6. SDS PAGE of AprD3. The calculated molecular weight of AprD3 is 29.4 
kDa. 
 
 
Figure 4-7. UV-visible absorption spectra and SDS PAGE of AprD4. The blue, red, and 
green spectra correspond to no reconstituted AprD4 (8 mM), reconstituted AprD4 (15 
mM), and reconstituted AprD4 (15 mM) treated with 1 mM sodium dithionite. The 
bleaching of the absorbance shoulder at 420 nm is characteristic of a bound iron-sulfur 
cluster. The calculated molecular weight of AprD4 is 52.5 kDa. 
 
4.3.3. Synthesis of Lividamine 
  As shown in Scheme 4-2 in Section 4.2.8, D-lividosamine (27) was obtained after 
four steps from N-acetyl-D-glucosamine.
208
 N-acetyl-D-glucosamine was converted into a 
furanosyl oxazoline intermediate using dry acetone at reflux. The hydroxyl group at C3 
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position was removed using Barton-McCombie deoxygenation.
216
 Deprotection of 
oxazoline ring was conducted in 2 N HCl at reflux to give D-lividosamine. After 
introduction of an azide group at the C2 position and acetylation of the remaining 
alcohols, a thiophenyl group was incorporated at C1. After changing the protecting group 
on the alcohols, a coupling reaction with 2-streptamine derivative 33 was used to give 
pseudo-disaccharide 34. Basic hydrolysis of the acetyl group with sodium methoxide, 
Staudinger reaction, and hydrogenation using palladium hydroxide on carbon gave 
lividamine (13) in 11.4% over 9 steps from compound 27.   
 
4.3.4. In vitro AprD3 and AprD4 Assay 
 Co-incubation of reconstituted AprD4 (0.01 mM) with 1 mM paromamine and 2 
mM SAM in the presence of 10 mM dithiothreitol (DTT) and 2 mM dithionite (50 mM 
NH4HCO3 buffer, pH 7.8) at room temperature led to the formation of 5'-dAdo, as 
detected by monitoring the change in the absorption at λ = 260 nm (Figure 4-8 , trace b). 
Although exclusion of dithionite from the reaction did not lead to detectable levels of 5'-
dAdo formation, the replacement of dithionite with either methyl viologen and NADPH 
or the E. coli flavodoxin/flavodoxin reductase/NADPH system were effective at doing so 
(Figure 4-9). In contrast, benzyl viologen with NADPH was not suitable for observing 
enzyme activity. Likewise, when the incubation was performed without prior 
reconstitution of the enzyme, no 5'-dAdo was detected (trace e in Figure 4-8). Finally, 
although uncoupled formation of 5'-dAdo was discernible in the absence of paromamine, 
the extent of SAM turnover to 5'-dAdo was significantly lower than that of the full 
reaction (traces d and b in Figure 4-8). These results strongly imply that AprD4 is able to 
catalyze radical homolysis of SAM consistent with its assignment as a radical SAM 
enzyme.
101,117
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Figure 4-8. HPLC traces of AprD4 reaction mixtures for production of 5'-dAdo observed 
by UV detection at 260 nm. Trace (a) corresponds to 5'-dAdo. The remaining traces (b-h) 
are from reaction mixtures containing AprD4 (10 μM), paromamine (1 mM), SAM (2 
mM), DTT (10 mM), dithionite (2 mM) in NH4HCO3 (50 mM; pH 7.8) buffer with the 
following modifications: b) no changes, c) no AprD4, d) no paromamine, e) non-
reconstituted AprD4, f) no SAM, g) with AprD3 (10 μM) and NADPH (1 mM), and h) 
with AprD3 (10 μM) and no NADPH.  
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Figure 4-9. Competence of various reducing systems for supporting AprD4 activity. 
HPLC traces with UV detection at 260 nm showed 5'-dAdo formation. 
 The AprD4 reaction was monitored by HPLC using a Corona charged aerosol 
detector (CAD)
217
 as well as FDNB derivatization method with UV absorbance detect at 
340 nm, because the pseudo-disaccharide substrate paromamine and its products lack a 
UV-absorbing chromophore (Figure 4-10). Despite the detected conversion of SAM to 5'-
dAdo, neither significant consumption of paromamine nor new product formation was 
noted, unless AprD3 (10 μM) and NADPH (1mM) were also include in the reaction 
mixture (trace b and g in Figure 4-10). In trace g in Figure 4-10A, a new peak with a 
retention time of 7.2 min was detected, in addition to the consumption of paromamine. 
Electrospray ionization mass spectra (ESIMS) of the new product revealed a signal at m/z 
330.1638, consistent with the sodium adduct of lividamine (13; calc. 330.1636 [M + 
Na]
+
; Figure 4-11, Figure 4-12E). In trace g in Figure 4-10B, a new peak with the same 
retention time with lividamine standard at 12.9 min was detected. This result 
demonstrated that the position where the deoxygenation reaction occurs is the C3' of 
paromamine. These findings led to the hypothesis that AprD4 operates as a radical-
mediated dehydratase with AprD3 serving as its reductase partner to effect the overall 
reduction of paromamine to lividamine (11→12→13).   
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Figure 4-10. HPLC traces of AprD4 reaction mixtures showing the consumption of 
paromamine, monitored using A) a Corona CAD, and B) UV detection at 340 nm after 
the assay mixture was subjected to the reaction with 1-fluoro-2,4-dinitrobenzene 
(FDNB). Traces b–h are as described in the legend of Figure 4-8. The small peaks at ~12 
min in trace c, g, and h are unrelated to product and substrate. 
 
 
Figure 4-11. (A) Low resolution, and (B) high resolution mass spectra of the collected 
peak at 7.2 min shown in Figure 4-9A, trace g. (A) LRMS (ESI, positive) calculated for 
C12H25N3O6
+
 [M + H]
+
 308.18 and [M + Na]
+
 330.16, observed 308.18 and 330.16, 
 233 
respectively. (B) HRMS (ESI, positive) calcd [M + Na]
+
 330.1636, observed 330.1638. 
These results were consistent with the chemical structure of lividamine (13).  
As a first test of this hypothesis, reaction mixtures excluding AprD3 were 
analyzed by ESIMS to check for low concentrations of the putative dehydration product 
of paromamine that may have gone undetected by Corona CAD and FDNB 
derivatization. As shown in Figure 4-12A, a signal was detected at m/z 328.15, consistent 
with the sodium adduct of such an intermediary species (12). To further support 
assignment of this MS signal to the putative ketone intermediate, the AprD4 reaction in 
the absence of AprD3 was run in the presence of phenylhydrazine (10 mM) for 4 h prior 
to analysis by ESIMS. In this case, a new signal at m/z 418.20 was detected whereas the 
signal at m/z 328.15 was significantly decreased, suggesting formation of a 
phenylhydrazone derivative (14; Figure 4-12B; Scheme 4-6). Moreover, treatment of the 
AprD4-only reaction with NaBH4 or NaBD4 resulted in a shift of the signal at m/z 328.15 
to 330.17 and 331.17, respectively (Figure 4-12C, D; Scheme 4-6). These results support 
the hypothesis that AprD4 catalyzes the first of two half-reactions, resulting in the 
dehydration of paromamine to form a keto intermediate such as 12.  
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Figure 4-12. Electrospray ionization (ESI) mass spectra of the AprD4 reaction with 
paromamine (11) (A), together with the addition of (B) phenylhydrazine, (C) NaBH4 and 
(D) NaBD4 as described in the text. (E) ESI mass spectrum of the AprD4/AprD3 co-
incubation with paromamine and NADPH. 
 
 
Scheme 4-6. The reduction of paromamine (11) to lividamine (13) catalyzed by AprD4 
and AprD3. Derivatization reactions carried out in the absence of AprD3 are also shown. 
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4.3.5. Proposed Mechanism of AprD4 Catalysis 
Based on the results in the Section 4.3.4, at least two mechanisms can be 
envisioned for the AprD4-catalyzed dehydration of paromamine (Scheme 4-7). 
Consistent with radical SAM chemistry, both mechanisms begin with initial hydrogen-
atom abstraction from the C4' position of paromamine (11→20) by the 5'-dAdo radical 
(18) generated by the reductive homolysis of SAM. The resulting substrate radical (20) 
may then be deprotonated to form a ketyl radical 21/22 that subsequently undergoes β-
elimination of the 3'-OH group to yield the enol radical 23 (Scheme 4-7, route A). This 
mechanism is similar to the mechanisms proposed for (R)-2-hydroxyacyl-CoA 
dehydratase
178
 and ribonucleotide reductase.
218
 One-electron reduction of the resulting 
enol radical intermediate would then complete the dehydration reaction (23/24→12). 
Alternatively, the initially formed substrate radical 20 may instead undergo a radical-
induced 1,2-hydroxy shift to form the gem-diol radical 25 (Scheme 4-7, route B), in 
direct analogy to the mechanisms of the Cbl-dependent diol-dehydratases and 
ethanolamine ammonia lyase.
201-202
 Following reduction , the gem-diol intermediate 26 
would then be converted into 12 upon elimination of water.    
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Scheme 4-7. Proposed mechanisms for the AprD4-catalyzed dehydration of paromamine. 
 
4.3.6. Synthesis of [4′-2H]-Paromamine 
As shown in Scheme 4-3 in section 4.2.9, [4′-2H]-paromamine (47) was prepared 
from 36 as summarized below. Intermediate 39 was obtained from 36
159
 via 4,6-diol 
protection with anisaldehyde dimethyl acetal (36→37), followed by benzyl protection of 
the 3-OH group (37→38) and selective reduction using sodium cyanoborohydride and 
trifluoroacetic acid.
219
 Equatorial introduction of deuterium at C4 was achieved via Dess-
Martin oxidation and sodium borodeuteride reduction (39→40).174 The stereochemistry at 
C4 of 40 was inverted in a two-step procedure with sodium benzoate serving as a 
nucleophile under reflux conditions (40→41→42).220 Alkaline hydrolysis of the benzoate 
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protecting group in 42 followed by benzyl protection of the exposed hydroxyl at C4 
provided 44. Intermediate 44 was then coupled with an azide derivative of 2-
deoxystreptamine (33)
157
 in the presence of N-iodosuccinimide and 
trifluoromethanesulfonic acid to provide the pseudodisaccharide 45. Next, the acetyl 
protecting groups were removed by alkaline hydrolysis to give 46, and the azide groups 
were converted to amines using Staudinger reduction. Final deprotection of benzyl group 
by hydrogenolysis provided 47 in 7.4% yield over 13 steps.  
 
4.3.7. Synthesis of [3′-2H]-Paromamine 
 As shown in Scheme 4-4 in Section 4.2.10, the synthesis of [3′-2H]-paromamine  
(65) began from commercially available 1,2,5,6-di-O-isopropylidene-α-D-glucofuranose 
(48). Deuterium was incorporated at the C3 position with double inversion of 
stereochemistry to provide compound 52. After benzyl protection of the C3 alcohol of 
compound 52, furanose was converted into pyranose by acid hydrolysis and the 
remaining alcohols were acetylated to form the triacetylate 54. A thiophenyl group was 
introduced at the C1 position using the Lewis acid boron trifluoride diethyletherate to 
provide compound 55. The acetyl group was hydrolyzed by basic hydrolysis using 
catalytic amounts of sodium methoxide. Selective protection of the C4 and C6 alcohols 
with benzylidine acetal was conducted to provide the intermediate 57. An azide group 
was introduced at C2 again with double inversion of stereochemistry using oxidation, 
reduction, and SN2 type reaction to give compound 60. After acid hydrolysis to remove 
benzylidine acetal, the free alcohols of compound 61 were protected as benzyl group. 
Coupling reaction of compound 62 with 2-deoxystreptamine derivative 33, basic 
hydrolysis, Staudinger reaction, and hydrogenation gave [3′-2H]-paromamine (65) in 3.2 
% over 21 steps from compound 48.   
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4.3.8. Mechanistic Studies of AprD4 Catalysis  
When AprD4 (10 μM) was incubated with [4'-2H]-paromamine (1 mM), SAM (2 
mM), and dithionite (2 mM) in NH4HCO3 (50 mM; pH 7.8) for 8 h at room temperature, 
formation of 5'-dAdo was again detected and this time with single-deuterium 
incorporation beyond natural abundance as determined by ESIMS (Figure 4-13). A 
complimentary assay with unlabeled paromamine (11) and AprD4 using the dideuterated 
[5'-
2
H2]-SAM isotopologue
173
 in the incubation revealed hydrogen transfer from 11 to [5'-
2
H2]- 5'-dAdo• to yield [5'-
2
H2]- 5'-dAdo as the product (Figure 4-14). These results 
further substantiated the proposed early steps of AprD4 catalysis shown Scheme 4-7, 
where AprD4 acts as a radical SAM enzyme that initiates a radical-mediated dehydration 
of paromamine through hydrogen-atom abstraction from the C4' position. 
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Figure 4-13. Mass spectra of (A) [5'-
2
H]-5'-dAdo isolated from the incubation of SAM 
and AprD4/D3 with [4'-
2
H]-paromamine (47). (B) assay mixture showing formation of 
product (13) in the incubation of [4'-
2
H]-paromamine (47) with AprD4/AprD3. 
 
 
Figure 4-14. Mass spectra of [5'-
2
H2]-5'-dAdo produced during the AprD4/AprD3 
reaction with [5'-
2
H2]-SAM and unlabeled paromamine (11). 
  Proton transfer manner at C3' position from paromamine to lividamine by AprD4 
catalysis was determined by 
1
H NMR spectroscopic analysis with the labeled substrate, 
[3'-
2
H]-paromamine. Assays were conducted with 0.06 mM AprD4/D3, 20 mM 
dithionite, 20 mM SAM, 10 mM NADPH, 100 mM DTT in NH4HCO3 buffer (500 mM; 
pH 7.8) with 10 mM of paromamine, [3'-
2
H]-paromamine, lividamine, or without 
substrate. After a 16 h incubation, assay mixtures were analyzed by 
1
H NMR 
spectroscopy. Additionally, to confirm AprD4 reaction with [3'-
2
H]-paromamine, ESIMS 
of [3'-
2
H]-lividamine was verified at m/z 331.1701 (calc. [M + Na]
+
 331.1698). 
Paromamine and lividamine NMR standards in pH 7.8 buffer were prepared for 
comparison with the 
1
H NMR spectra. A new peak in the assay with paromamine was 
observed at approximately 1.7 ppm (Figure 4-15a). In the assay with [3'-
2
H]-
paromamine, this peak was not seen (Figure 4-15c). This peak is also observed in the 
assays with lividamine and the lividamine standard spectra (Figure 4-15b and 4-15e), but 
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not without any substrate and paromamine standard (Figure 4-15d and 4-15f). The peak 
around 1.7 ppm corresponds to the axial hydrogen at C3' of lividamine. These results 
demonstrated that the axial hydrogen at C3' of paromamine is retained in lividamine 
during AprD4/D3 catalysis, whereas the equatorial hydroxyl group at C3' of paromamine 
is replaced with hydrogen.     
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Figure 4-15. 
1
H NMR spectra of AprD4/D3 reaction with a) paromamine, b) lividamine, 
c) [3'-
2
H]-paromamine, d) without any substrate. e) and f) are respectively 
1
H NMR 
spectra from the lividamine and paromamine standards at the same pH. 
 
 242 
4.4. CONCLUSION 
C3'-deoxygenation of aminoglycosides results in their decreased susceptibility to 
phosphorylation thereby increasing their efficacy as antibiotics. However, the 
biosynthetic mechanism of C3'-deoxygenation is unknown. To address this issue, the 
aprD4 and aprD3 genes from the apramycin gene cluster in Streptomyces tenebrarius 
were expressed in E. coli and the resulting gene products were purified and characterized 
in vitro. AprD4 was shown to be a radical S-adenosyl-L-methionine (SAM) enzyme, 
catalyzing homolysis of SAM to 5'-dAdo in the presence of paromamine. C3'-
deoxygenation of paromamine catalyzed by AprD4/D3 was confirmed by comparing the 
lividamine standard with reaction mixtures treated with FDNB and analyzed by HPLC. 
[4'-
2
H]-Paromamine was prepared and used to show that its C4'-H is transferred to 5'-
dAdo by AprD4, after which the substrate is dehydrated to a product consistent with 4'-
oxolividamine. In contrast, paromamine is reduced to a deoxy product when incubated 
with AprD4/AprD3/NADPH. The AprD4/D3 assay with [3'-
2
H]-paromamine showed that 
axial C3'-H is retained during the reaction, and the equatorial hydroxyl group is replaced 
with new hydrogen. These results provide evidence for the assignment of functions to the 
enzymes AprD4 and AprD3 in the biosynthesis of C3'-deoxyaminoglycosides. AprD4 
appears to be the first example of a radical SAM diol-dehydratase and catalyzes the 
radical-mediated dehydration of paromamine. AprD3 is shown to be a dehydrogenase 
that acts as the reductase counterpart to AprD4 in order to facilitate the net C3'-
deoxygenation of the pseudo-disaccharide substrates in the biosynthesis of apramycin and 
tobramycin. Enzymes LivW and LivY are expected to play analogous roles in the 
lividomycin biosynthetic pathway.  
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